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ABSTRACT 
Background: Liver cirrhosis is a global health problem and a national health 
problem in Egypt. There is a lack of literature on Health-Related Quality of Life 
(HRQOL) and symptoms experience of liver disease and cirrhotic patients in Middle 
East, particularly in Egypt. Aims: This PhD had three major aims: First aim: To 
describe HRQOL of Egyptian liver cirrhotic patients and to identify and evaluate the 
factors associated with (HRQOL) physical and mental health domains. Second aim: 
To explore and describe experienced symptoms (prevalence, severity and 
hindrance) in Egyptian cirrhotic patients and to identify and evaluate factors 
associated with symptoms severity and symptoms hindrance (distress). Third aim: 
To explore and describe how cirrhotic patients in Egypt perceive social support 
from spouse, family and friends and to identify and evaluate factors associated with 
general perceived social support. Method: A cross-sectional study with a 
convenience sample of 401 patients from three hospitals in Cairo, Egypt, was 
conducted between June and August 2011. Patients were interviewed to complete 
a background data sheet, Short Form-36v2 (SF-36), the Liver Disease Symptom 
Index (LDSI)-2.0 and the Multidimensional Scale of Perceived Social Support 
(MSPSS).  
Results:   
Findings for first aim: The findings showed that all domains and component 
summary scores [Physical component summary score (PCS) and mental 
component summary score (MCS)] of the generic SF-36 were below the norm (cut-
off score 50), suggesting that patients with liver cirrhosis in Egypt have poor 
HRQOL. About 87.2% of the patients rated their general health as poor or fair, 
which means the majority of these patients have low perceived general health. 
Many socio-demographic and medial factors were shown to be significantly 
associated with perceived HRQOL. Women, illiterate and unemployed people, and 
patients with frequent hospitalisation had poor PCS and MCS, while patients with 
advanced disease stage, increasing number of comorbidities and complications 
and those admitted to inpatients had significantly poorer PCS only. Perceived 
social support from a spouse had a statistically significant positive association with 
PCS and MCS, while perceived social support from family and friends had a 
statistically significant positive association with MCS only. Also, severity and 
hindrance of symptoms significantly correlated with PCS and MCS.  
Using stepwise multiple linear regression analysis, two models were developed to 
identify factors associated with PCS (Model 1) and MCS (Model 2) health. Model 1 
could significantly explain 19% of the variation in PCS (R2 = 0.190, R2adj = 0.180, p 
= 0.0005), and four factors (symptoms severity, disease stage, comorbidities and 
employment status) were significantly (p ≤ 0.02) associated with PCS. Model 2 
could significantly explain 31.7% of the variation in MCS (R2 = 0.317, R2adj = 0.308, 
p = 0.0005), and four factors (symptoms severity, employment status, perceived 
spouse support and perceived family support) were associated (p ≤ 0.04) with 
MCS. The key findings of this study were that severity of symptoms and social 
support from spouse and family were associated with HRQOL. Where patients with 
high symptoms severity were likely to report poor PCS and MCS; and patients with 
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low perceived social support were likely to report poor MCS. Symptoms severity 
contributed significantly in explaining 28.7% of the variation in PCS and 43.6% of 
the variation in MCS.  
Findings for second aim: This study found that the majority of patients had one or 
more of a wide range of symptoms and social problems. Two-thirds of patients 
reported joint pain (78.3%), decreased appetite (75.6%) and memory problems 
(77.3%). Joint pain and depression were reported to have the biggest impact on 
daily life. Symptoms severity and distress were significantly higher among patients 
who were: female, illiterate, unemployed, and who had advanced cirrhosis with 
more complications and comorbidities (p ≤ 0.006). Symptoms severity (r=-0.206) 
and symptoms distress (r=-0.205) were negatively associated with perceived social 
support (p=0.005). Stepwise regression analysis showed that the regression model 
could significantly explain 19.6% of the variation in symptoms severity (R2 = 0.196, 
R2adj = 0.180, p = 0.0005), and 14% of the variation in hindrance of symptoms (R
2 = 
0.140, R2adj = 0.132, p = 0.0005). Being female, having an increasing number of 
liver disease complications, and having low perceived support from spouse were 
significantly associated with high-perceived symptoms severity and hindrance 
(p≤0.01).  
Findings for third aim: This study found that social support score was relatively 
high among patients with cirrhosis in Egypt (total score mean of MSPSS was 2.02± 
standard deviation (0.537), while perceived support from spouse was the highest 
source of support. 67.5% of the patients felt their spouse is around when they need 
him/her and 71.7% of them share their joys and sorrows with their spouse. 
Likewise, 64.9% of married people feel their spouse cares about their feelings. In 
relation to the perception of adequacy of family support, it was observed that 52.6% 
felt that their families do not really try to help them. At the same time, 52.1% 
reported that they got the emotional help and support that they needed from their 
families. Regarding perceived support from friends, more than half of the patients 
reported that their friends do not really try to help them (57.9%), they cannot count 
on their friends when things go wrong (65.6%) and they cannot talk about their 
problems with their friends (56.4%). There was a significantly positive association 
between the perception of social support and general health perception (GHP), 
suggesting that when social support decreases GHP also decreases or and vice 
versa (r= 0.208, p = 0.0005). Stepwise regression analysis showed that the 
regression model could significantly explain 10.9% of the variation in perceived 
social support (R2 = 0.109, R2adj = 0.100, p = 0.0005). Marital status, gender, age 
and employment status were significantly associated with general perceived social 
support (p ≤ 0.01), while unmarried, females, unemployed and elderly cirrhotic 
patients were vulnerable groups that were likely to perceive low social support.  
Overall discussion and conclusion: This is the first study to investigate HRQOL, 
symptoms experience and perceived social support in patients with liver cirrhosis in 
Egypt. All aspects of HRQOL of Egyptian cirrhotic patients were poor, and they 
were experiencing various symptoms that can affect their daily life. However, social 
support was found to be related to perceived symptoms severity and perceived 
poor mental health. Hence, social support may alleviate suffering for certain 
cirrhotic patients. Nurses have a responsibility to assess and treat symptoms that 
cirrhotic patients experience, particularly such treatable symptoms as depression, 
pain and decreased appetite. Also, nurses should involve the patient’s family in any 
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plan of care. Future intervention studies that aim to develop programs to relieve 
treatable symptoms and enhance social support are also recommended. 
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1 CHAPTER 1- INTRODUCTION TO THE THESIS 
1.1 INTRODUCTION  
This chapter briefly states my rationale for selection of this area of study and 
summarises its major aims and research questions. It then outlines the overall 
organisation of the thesis.  
1.2 PERSONAL RATIONALE TO CONDUCT THIS STUDY  
Until coming to the United Kingdoms (UK) to undertake the PhD research here, I 
worked as a clinical instructor for six years and as an assistant lecturer for three 
years in the Faculty of Nursing, Cairo University in Egypt and my major task was to 
teach and train undergraduate students in nursing care for adults in medical and 
surgical departments. In this role, I observed the problems faced by many patients 
with different chronic conditions, but was aware that in the medically dominated 
world of healthcare, which focuses on a traditional medical model, patients received 
little advice on how to manage the symptoms they had or how to decrease their 
suffering by satisfying their psychosocial needs. As a nurse educator and from my 
experience with the patients, I am aware that a little information and psychological 
support can decrease patients’ suffering and improve their Health-Related Quality 
of Life (HRQOL). With my belief that chronic disease is not a bad experience in 
itself, but it can be a bad or good experience based on the quality of the supportive 
healthcare resources as well as quality of the supportive social environment. I know 
it is essential to care well for patients and to teach them how to care for themselves 
in order to improve their HRQOL. This personal belief and experience drove the 
topic of my research. 
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My long-term aim is to develop a self-care programme for patients with liver 
cirrhosis in Egypt that would help to decrease their suffering by providing the 
knowledge that they need to care for themselves and to help them improve their 
HRQOL. I started to search the literature to find existing research to get the basic 
knowledge and evidence that can answer these questions: what is the HRQOL of 
liver cirrhotic patients in Egypt? What are their biopsychosocial needs? What are 
the factors that influence their HRQOL? What symptoms do these patients 
experience? in order to use these studies as evidence to develop the self-care 
programme. There was no identified study could answer these questions.  
Assessing patients' needs is the key principle of developing educational or self-care 
programmes. Moreover, developing a programme has to be based on existing 
research explaining what the needs of these patients are and what will help them to 
improve their HRQOL. My observation and experience only are not enough to 
justify why I need to develop this programme and test its impact, without previous 
research to describe what their HRQOL and their needs actually are. Therefore, I 
decided to conduct the current study and based on its findings, the self-care 
programme will be developed (see section 3.10 definition of self-care), and its 
impact will be tested by developing other research in the future.  
1.3 AIMS OF THE STUDY AND RESEARCH QUESTIONS  
This study has three general aims and several research questions: 
The first aim is to describe Health-Related Quality of Life (HRQOL) of Egyptian 
liver cirrhotic patients and to identify and evaluate factors associated with (HRQOL) 
physical and mental health domains. 
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Research questions to achieve aim 1 
1.1. How do patients with liver cirrhosis in Egypt perceive their (HRQOL) physical 
and mental health? 
1.2. How do patients with liver cirrhosis perceive their general health? 
1.3. What is the relationship between individual characteristics (socio-
demographic characteristics) and perceived physical and mental health? 
1.4. What is the relationship between biophysical variables (medical data and 
disease stage) and perceived physical and mental health? 
1.5. Does symptoms severity influence physical and mental health? 
1.6. Does perceived social support influence physical and mental health? 
1.7. Do disease stage, symptoms experience (severity and hindrance), perceived 
social support, socio-demographic factors and medical data explain the 
perception of the physical health of patients with liver cirrhosis?  
1.8. Do disease stage, symptoms experience (severity and hindrance), perceived 
social support, socio-demographic factors and medical data explain the 
perception of the mental health of patients with liver cirrhosis?  
The second aim is to explore and describe experienced symptoms (prevalence, 
severity and hindrance) in Egyptian cirrhotic patients and to identify and evaluate 
factors associated with symptoms severity and symptoms hindrance (distress). 
Research questions to achieve aim 2  
2.1. What symptoms do patients with liver cirrhosis experience? 
2.2. Which of the reported symptoms limit the daily activities of patients with 
cirrhosis? 
2.3. What is the association between individual characteristics and symptoms 
experience (severity and hindrance of symptoms)? 
2.4. What is the association between biophysical variables and symptoms 
experience? 
2.5. What is the association between general health perception and symptoms 
experience? 
4 
 
2.6. Does perception of social support influence perception of symptoms 
experience? 
2.7. What are factors associate with symptoms experience among cirrhotic 
patients in Egypt? 
The third aim is to explore and describe how cirrhotic patients in Egypt perceive 
social support from spouse, family and friends and to identify and evaluate factors 
associated with general perceived social support. 
Research questions to achieve aim 3 
3.1 How do patients with liver cirrhosis in Egypt perceive the available social 
support? 
3.2 Do patients with liver cirrhosis perceive social support from spouse, family and 
friends to be adequate? 
3.3 Do patients’ socio-demographic characteristics and disease stage influence 
perceived adequacy of social support? 
3.4 What is the relationship between perception of general health and perception 
of social support among patients with liver cirrhosis? 
3.5 What are the factors associated with perceived adequacy of social support 
among liver cirrhotic patients in Egypt? 
1.4 STRUCTURE OF THE THESIS  
This thesis consists of eight chapters following this Introduction: 
Chapter 2  
The second chapter provides a background to liver cirrhosis epidemiology, a review 
of the literature on the concepts of Quality of Life (QOL), and HRQOL and social 
support and its relationship with health. 
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Chapter 3 
This chapter clarifies the search strategy that was used to find the relevant 
literature. Then it provides a review of the literature in three sections on HRQOL, 
symptoms experience and perceived social support among patients with liver 
cirrhosis.  
Chapter 4 
This chapter describes the philosophical paradigm and methodological approach 
that were adopted in this study, followed by illustrating and discussing the 
theoretical model of HRQOL outcomes that was used in this study. The research 
design, the population and sampling, and clinical settings are clarified as well as 
the data collection procedures. Finally, ethical approval and ethical considerations 
are discussed.  
Chapter 5 
This chapter provides details of the pilot study that was conducted before the main 
study. The results of the pilot study are presented in two sections: Section I 
describes the translation process findings and section II describes the pilot study 
findings.  
Chapter 6 
This chapter presents the findings from the main study analysis in three sections. 
Section I describes participant characteristics and the HRQOL of people with liver 
cirrhosis in Egypt. Section II presents factors associated with HRQOL using 
bivariate analysis. Section III presents factors associated with HRQOL using 
multivariate (stepwise multiple linear regression) analysis. 
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Chapter 7 
This chapter presents results related to the second and the third aims of the main 
study in two sections. Section I describes and analyse the symptoms experience of 
people with liver cirrhosis, how these symptoms affect their daily activities, and 
associated factors of overall symptoms severity and symptoms hindrance 
(distress). Section II presents how patients with liver cirrhosis in Egypt perceived 
available social support and factors associated with perceived social support.  
Chapter 8 
This chapter examines the psychometric properties of the three measures used in 
patients with liver cirrhosis: Liver Disease Symptom Index-2.0 (LDSI-2.0), 
Multidimensional Scale of Perceived Social Support (MSPSS) and Short Form-36v2 
(SF-36v2) using the main study data.  
Chapter 9 
The final chapter discusses the key findings of the study in relation to previous 
studies in three sections. Section I discusses HRQOL and its associated factors. 
Section II discusses symptoms experience and its associated factors. Section III 
discusses social support and its associated factors. The implications of the study 
findings in terms of theory, practice and research are outlined. Recommendations 
for improving the healthcare system in Egypt and for further research are stated. 
The strengths and weaknesses of the study are also acknowledged.  
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2 CHAPTER 2- LITERATURE REVIEW PART-1  
This chapter is presented in two sections. Section I considers liver cirrhosis; its 
epidemiology, causes and the epidemic of the hepatitis C virus (HCV) in Egypt and 
finally, complications and challenges of treating patients with cirrhosis.  
Section II addresses the nature of Quality of Life (QOL) in more detail, beginning 
with defining Quality of Life (QOL), then discussing the relationship between QOL 
and health. An examination of Health-Related Quality of Life (HRQOL) then follows 
relating to its definition, domains and the importance of measuring HRQOL. Finally, 
the relationship between HRQOL and social support is discussed.  
2.1 SECTION I: LIVER CIRRHOSIS 
2.1.1 Epidemiology of Liver Cirrhosis 
Liver cirrhosis is a serious disease associated with significant morbidity and 
mortality (Bosetti et al. 2007; Gutteling et al. 2007); it is considered one of the  
leading causes of death worldwide (Mathers 2008; Kochanek et al. 2011) and is the 
seventh leading cause of death in Egypt 2002 (World Health Organisation (WHO) 
2006). Cirrhosis can affect any individual; young and old, males and females (WHO 
2006; Bosetti et al. 2007).  
Liver disease and cirrhosis remains a major cause of death worldwide and a 
national problem in Egypt (WHO 2013). An estimated 800,000 deaths each year 
are attributed worldwide to cirrhosis (WHO 2006). However, Egypt has the highest 
prevalence of deaths due to liver disease and cirrhosis worldwide. For instance,  
the number deaths due to liver disease in 2007-2008 was 8908 in the United 
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Kingdoms (UK), 38964 in the United States of America (USA), 67 in Kuwait, and 24 
in Qatar, 165 in Jordan and 566 in Morocco, and in Egypt it was 42928 (WHO 
2012c). 
Mortality due to liver disease is still increasing in Egypt (WHO 2012c) (Figure 2-1). 
The total number of deaths due to liver disease and cirrhosis in 2010 was 51850. 
The majority of deaths was among those aged 55 to 74 (n = 29477); mortality 
among men was higher than among women (32884 vs. 18966 respectively) (WHO 
2012c) (Figures 2-1, 2-2). Figure 2-2 shows the number of deaths due to liver 
disease and cirrhosis in Egypt between years 2008 and 2010 among all ages 
group. The number of deaths rose steadily until age 35-54; then increased sharply 
until it reached a peak at age 55-74, and then it declined gradually. Although 
women and men had the same trend, the actual number of deaths is higher among 
males (WHO 2012c). 
It was estimated that three per cent of patients with chronic liver disease in Egypt 
die every year because of liver cirrhosis complications (Strickland et al. 2002). 
Hepatic dysfunction, oesophageal varices bleeding, ascites, and liver cancer are 
the most serious complications and are often fatal (Fujimoto and Kaneda 1999). 
Once complications of cirrhosis develop, the morbidity and mortality rates increase 
steeply (Dong and Saab 2009). 
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Figure 2-1: Trends of deaths due to liver disease, by gender group, in Egypt from 2008 
to 2010, (WHO 2012c) 
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Figure 2-2: Number of deaths due to liver disease, by age group, in Egypt from 2008 to 
2010, (WHO 2012c) 
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2.1.2 International and National Causes of Liver Cirrhosis  
The common causes of chronic liver disease and liver cirrhosis worldwide are 
hepatitis B and/or C (HBV, HCV) virus infection. Approximately 240 million people 
worldwide are chronically infected with HBV (WHO 2012); and up to 170 million 
people (3% of the global population) are chronically infected with HCV (WHO 
2010). It was estimated that about 3 to 4 million persons get infected each year with 
HCV (WHO 2012a). Up to 50% of people infected with HCV develop liver cirrhosis, 
liver failure and hepatocellular carcinoma (WHO 2010). In Western countries, the 
most common cause of liver cirrhosis is chronic alcohol abuse (Ramstedt 2001; 
Mandayam et al. 2004; Schuppan and Afdhal 2008), while in Egypt it is HCV 
(Darwish et al. 2001; Wasfi and Sadek 2011).  
2.1.3 Epidemic of Hepatitis C in Egypt from Past to Present  
Egypt has the highest prevalence of HCV worldwide (WHO 2006; Sievert et al. 
2011; WHO 2012a). Egypt also has higher rates of HCV infection than 
neighbouring countries and other countries in the world with comparable socio-
economic conditions and hygienic standards for invasive medical, dental, or 
paramedical procedures (Frank et al. 2000; Rao et al. 2002; WHO 2006). A 
systematic review conducted by Sievert et al. in 2011 shows that Egypt has a 
higher prevalence of HCV than other countries in Asia and Australia, e.g. Syria, 
Pakistan and China.   
Lehman and Wilson (2009) conducted a systematic review (using community-
based studies conducted in Egypt from 1990 to 2004) to calculate the fluctuating 
sources of HBV and HCV. They found that the HCV prevalence was 21.8% in 
1990-1994, then declined dramatically between 1995 and 1999 to 12.5%, then rose 
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slightly from 1999 to 2004 to 13.5%. Recently, El-Zanaty and Way (2009) 
conducted a Demographic and Health Survey (DHS) in 2008 on behalf of the 
Egyptian Health Ministry. They found that of the 11,126 respondents aged 15-59, 
10% had the active HCV. Accordingly, it seems that the rate of HCV infections 
declined from 13.5% to 10 % respectively in the period 2004 to 2008.  
Egypt has a history with the epidemic of Schistosomiasis (bilharziasis). It is a 
parasitic infection carried by snails living in the Nile River. A mass campaign 
providing intravenous therapy against Schistosomiasis in the period between 1960s 
and 1970s was conducted (Dalglish 2008). El Gohary (1995); Frank (2000); Rao et 
al. (2002) and Lehman and Wilson (2009) showed that Parenteral Antischistosomal 
Therapy (PAT) was the main cause for spreading the HCV among the Egyptian 
people, because contaminated syringes were used. Thus, there is a higher 
prevalence of HCV in people aged over 44 years than in younger ones (Sievert et 
al. 2011).  
Although the major cause for transmitting the HCV (PAT campaign) was abolished 
many decades ago, a strategy for preventing the spread of HCV by screening blood 
donations, sterilization techniques and avoiding unnecessary injections was 
implemented (Sievert et al. 2011). However, it seems that HCV continues to be 
transmitted in Egypt (Lehman and Wilson 2009). This may be due to the increase in 
infected people with the HCV, especially in geographical areas close to the Nile 
Delta, where there is a higher prevalence of infections than in Upper Egypt. Also, it 
seems there are other factors that may cause continuity of spreading HCV in Egypt. 
For example, household transmissions (spouse, father-offspring, sibling 
transmission), unsterilized equipment or techniques during surgery, blood 
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transfusions, tattoos, circumcision, acupuncture, public shaving by the village 
barber, ear piercings and drug injections may be important causes of spreading the 
HCV (Darwish et al. 2001; Sievert et al. 2011, ).  
In a recent study, El Feki et al. (2013) investigated the prevalence of HCV and its 
risk factors among a randomly selected sample of 400 participants from a rural 
area and 165 from an urban area in Egypt. They found that the prevalence of HCV 
was higher in the rural area than the urban area (36% versus 18.2%), with the 
number of the HCV positive patients in the rural area higher than the urban area 
(94% versus 63.3%). A significant risk factor for HCV infection in rural and urban 
areas among young people (≤30 years) was informal circumcision in rural areas, 
and blood transfusion in rural and urban areas. While a significant risk factor 
among older people (>30 years) were bilharziasis and endoscopy in rural area, and 
blood transfusion and parenteral treatment for bilharziasis in rural and urban areas 
(El Feki et al. 2013). Therefore, it seems that infected blood transfusion is the major 
risk factor for the increasing prevalence of HCV in different regions in Egypt.  
2.1.4 Complications of Liver Cirrhosis and Challenges of Management 
There is a clinical spectrum of liver cirrhosis; at one end, there are no obvious signs 
or complications (known as compensatory cirrhosis stage) and at the other end, 
there are severe signs and complications (known as decompensatory cirrhosis 
stage) (Everson 2005). Patients with decompensated cirrhosis are at risk of death 
from cirrhosis complications (Everson 2005) such as variceal bleeding, ascites, 
spontaneous bacterial peritonitis, hepatic encephalopathy, hepatic renal syndrome 
or/and hepatic carcinoma (Everson 2005; Dong and Saab 2009; Bjornsson et al. 
2009; Porth and Matfin 2009; Alazawi et al. 2010).  
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Patients with cirrhosis are the group most difficult to treat; particularly those with 
HCV genotype 4 (the genetic structure of HCV). The standard medical therapies for 
HCV are Interferon and Ribavirin. However, according to the recent systematic 
literature review the overall response rate of cirrhotic patients who were treated 
with antivirus therapy did not exceed 33.3% for all genotypes and 21% for genotype 
1 and 4 (Bota et al. 2011). Therefore, effective treatment for patients with liver 
cirrhosis (Alazawi et al. 2010) especially those infected with HCV genotype 4 (Bota 
et al. 2011) is not proven. In Egypt Genotype 4 is the most common type of HCV 
(93%) (Kamal and Nasser 2008; Sievert et al. 2011). Thus, people with chronically 
infected HCV will progress to liver cirrhosis, which will lead to an increasing number 
of people with liver cirrhosis in the future. 
Nowadays, medical intervention for patients with compensated cirrhosis has two 
dimensions. The first is to treat HCV infected people to clear the virus. Secondly, to 
temporarily control progression of cirrhosis complications among patients who do 
not respond effectively to antiviral therapy (Everson 2005). Once patients develop 
complications of cirrhosis the aim of any medical treatment is to treat these 
complications so they recover from the critical condition and their health status is 
stabilised (Everson 2005).  
Management of cirrhosis is still aimed at treating causative factors, such as 
stopping alcohol consumption, or managing complications according to type to 
alleviate any disabling or life-threatening problems (Dong and Saab 2009; Mayo 
Foundation for Medical Education and Research (MFMER) 2013). Also, periodic 
check-ups of the patients are essential for detecting early signs of hepatic 
encephalopathy or hepatic carcinoma (Heidelbaugh and Sherboundy 2006; 
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Cheney et al. 2012). A liver transplantation is the only available medical 
intervention for end-stage liver cirrhosis. However, this is impossible for many 
patients because either there are insufficient resources such as money or an 
appropriate donor (Allam et al.2010) or they are not eligible for this intervention. 
Patients with liver cirrhosis experience different complications with different signs 
and symptoms, which can affect their daily activities negatively. Studies conducted 
in Western countries where medical services of high quality are provided, found 
that patients with cirrhosis have a lower Health-Related Quality of Life (HRQOL) 
than the average population (Gutteling et al. 2006). They also experience a lower 
mental state of health than patients with other chronic diseases such as congestive 
heart failure and chronic obstructive pulmonary disease (Younossi et al. 2001). 
Patients with chronic diseases such as liver cirrhosis may need not only 
physiological treatment but also psychosocial support to improve their HRQOL 
(discussed in the next section) 
2.2 SECTION II: QUALITY OF LIFE AND HEALTH-RELATED QUALITY OF 
LIFE  
Many terms are utilized interchangeably with the term Quality of Life (QOL), and it 
is essential to differentiate between them (Haas 2007). One of these terms is 
HRQOL. There is indeed considerable overlap between QOL and HRQOL. The two 
terms have been used in previous research interchangeably, but they are not 
equivalent. Therefore, this section focuses on clarifying the following terms: What 
does QOL mean? What is the relationship between QOL and health? How was 
HRQOL generated? What are the definition and domains of HRQOL? Why is it 
important to measure HRQOL? Finally, the theoretical associations between social 
support and HRQOL are discussed.  
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2.2.1 Quality of Life  
The term 'Quality of Life' existed many centuries ago’ when Aristotle (384-322 BC) 
philosophically asked the questions “what does life mean” and “what is the best 
way of life” in order to explain the association between happiness, ‘well-being’ and 
a good life (Chung et al. 1997). According to Aristotle, happiness is developing a 
life goal and focusing one’s activities to achieve this goal (Chung et al. 1997). At 
the same time, happiness means different things to different people at different 
times, for example, when an individual falls sick he thinks health is happiness, but 
when he is poor, he thinks money is happiness. Due to this subjectivity, there have 
been long debates among researchers about the conceptualization and 
operationalization of QOL. There is also a difference of opinion as to whether QOL 
should have a valid place in reality, especially in health practice. Therefore, it is 
important to explore the relationship between health, ill health and QOL.  
2.2.1.1  Definition of Quality of Life 
Over the past two decades, numerous but not similar definitions of QOL have been 
provided. For example, the World Health Organisation QOL Group (WHOQOL-G) 
defined QOL as the 'individuals’ perceptions of their position in life in the context of 
the culture and value systems in which they live and in relation to their goals, 
expectations, values and concerns' (1998, p. 551). WHOQOL-G acknowledges that 
peoples’ perceptions about their life are subjective, shaped by their cultural 
background, life experiences, preferences and personal objectives. Therefore, 
QOL is a dynamic concept because values and evaluations of life are influenced by 
the individuals' reactions, emotions, physical health status and/or their experiences 
(Carr et al. 2003). It is also a multidimensional term that reflects the individual’s 
overall lives (Bowling 2001). 
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QOL can be divided into subjective and objective areas (Bowling 2001). A 
subjective perception of QOL reflects the individuals’ sense of well-being, which 
involves happiness and satisfaction with their overall life (Anderson and Burckhardt 
1999; Bowling 2001; Haas 2007), satisfaction with spirituality (Krupski et al. 2006) 
job, income, and feeling healthy, having happy social relationships and social 
support (Phillips 2006). Objective QOL measures what an individual is able to do 
(functional status) (Haas 2007); and materialistic objects (Fallowfield 1990) such as 
economic status (Shek 2005); although these are less common in health research 
(Haas 2007).  
The above discussion reflects that despite the inconsistency and complexity of 
defining QOL, there is a general agreement that QOL is a multidimensional concept 
(Bowling 2001; Bowling 2005; Haas 2007). It is a difficult and complex concept to 
define or to measure because there are cultural, ethical, and religious beliefs that 
influence an individual’s perceptions about QOL and its consequences (Zhan 
1992). 
2.2.1.2  The Relationship between Quality of Life and Health 
In 1948, the World Health Organisation (WHO) defined health as a 'state of 
complete physical, mental and social well-being and not merely the absence of 
infirmity and disease'. Thus, health can be considered in a multidimensional way, 
including physical, psychological and social health status and well-being in the 
context of disease (Fairclough 2002; Carr et al. 2003; Sirgy et al. 2006). As a result, 
the feeling of ‘good health’ may be with or without disease. For example, an 
individual may have a disease but as s/he is able to cope with difficult situations, 
s/he may still report a feeling of good health. Additionally, if this person has strong 
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social support s/he may be psychologically healthy (Bowling 2005). Therefore, 
satisfaction and happiness may be experienced not only with health but also with 
disease. 
Helman (2007) added that health is a state of physical and psychological balance 
of the individual with himself and with others. Therefore, a decline in any health 
domain is considered an illness mainly if this decline hampers the patients’ daily 
activities and social contacts (Helman 2007). Accordingly, health is a vital domain 
of overall QOL (Taylor 2000; Bowling 2001). Other domains include employment 
status, adequate income, education, housing and social relationships (Taylor, 2000; 
Bowling 2001). Thus, the WHO definition of health is considered to be the most 
basic definition that reflects the relationship between QOL and health (Fairclough 
2002; Carr et al. 2003), although it is complicated because it is difficult to 
distinguish between the terms QOL and health status (Haas 2007) sometimes in 
the literature. As a result, health researchers developed the term HRQOL to make it 
easier to measure QOL within the health domain (Sirgy et al. 2006; Gutteling et al. 
2007) and to discriminate between QOL as a general sense of well-being and 
HRQOL as a satisfaction with health status (Fayers and Machin 2007). 
2.2.2 Health-Related Quality of Life 
The HRQOL term was coined in 1980s by psychological and sociological 
researchers to help measure the health domains that influence an individual’s 
physical and mental health status and to avoid overlap with the broad term of QOL 
and its domains (McHorney 1999; Bowling 2001; Gutteling et al. 2007). Bowling 
(2001) confirmed that the term HRQOL is more limited than QOL, and relates to a 
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patient's subjective satisfaction with his/her health status, with medical intervention 
and/or the impact of any biopsychosocial changes on the patient's health status. 
2.2.3 Importance of measuring QOL in Health (HRQOL)  
The advancement in medical diagnostic procedures as well as medical and surgical 
interventions have given many patients a chance of survival and/or have increased 
their life expectancy (Fallowfield 1990; Sirgy et al. 2006; Haas 2007), particularly 
among patients with liver cirrhosis. Although a complete cure of liver cirrhosis is not 
yet possible, the available medical interventions can save patients’ lives and 
improve their longevity. However, a chronic disease can suddenly cause life 
threatening complications, e.g. bleeding, which can affect the patients' QOL 
negatively. It is therefore important to assess their QOL. Bowling (2005) maintained 
that a medical model is no longer enough; particularly in cases of chronic or life 
threatening diseases. 
Until recently, the medical model dominated the assessment of health conditions 
and the treatment outcome (Bowling 2005), e.g. a successful medical intervention 
was measured in terms of quantity of survival, mortality, morbidity, complications, 
biological tests, physical conditions, neglecting the quality of that survival, i.e. 
'HRQOL' (Fallowfield 1990; Bowling 2005; Phillips 2006). Using only clinical data to 
treat patients can be considered dehumanising, because healthcare providers 
forget to ask patients about their feelings of 'well-being' (Fallowfield 1990). Bowling 
(2005, p. 1) declares that ‘What matters is how the patient feels; rather than how 
professionals think they feel’. For example, feelings of pain and discomfort or 
perceptions of change in daily physical functioning or emotions are indicators of ill 
health, not only pathological abnormalities (Bowling 2005). Thus, the traditional 
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medical model that focuses on a clinical outcome becomes insufficient to 
understand the patients’ health problems because ‘there are multiple influences 
upon patient outcome, and these require a broad model of health to incorporate 
them’ (Bowling 2005, p. 1). 
Therefore, health researchers have started to shift their philosophy of treatment 
from just quantity of life to both quality and quantity of life. So, QOL measurements 
are used to assess the successful outcome of a medical intervention and as well as 
to investigate patients' satisfaction with their health or with the medical intervention 
(Fallowfield 1990).  
The measurement of QOL has become vital in healthcare, especially as a method 
of evaluating diseases and outcomes of interventions and their impact on the 
patient's life (Moore et al. 2005). Evaluating QOL helps to determine the individuals 
who perceive their health negatively to develop supported intervention programs to 
improve the health conditions of these individuals and to avoid complications 
(Taylor 2000) e.g. reducing symptoms, increasing functional performance and 
improving health perceptions, which will enhance their QOL (Anderson and 
Burckhardt 1999). The perceptions of  patients related to their QOL has become 
essential to evaluate the effectiveness of rehabilitation programs; as patients  are 
the best guides for healthcare providers to modify and improve their programmes 
(Fayers and Machin 2000; Bottomley 2002). Thus, QOL measurements are crucial 
to collect data about the problems that affect patients and to understand the impact 
of the illness and the side effects of treatment.  
Assessing how patients feel relating to their state of health will help healthcare 
providers to enhance the patients’ QOL (Fayers and Machin 2000; Bottomley 
20 
 
2002). Measuring HRQOL can provide unique data for tracking individuals’ physical 
and psychological health over time, and for identifying unmet health needs to 
improve their biopsychosocial health (Taylor 2000). Szende et al. (2003) argue that 
'Assessment of health-related QOL has become a recognized and important part of 
the evaluation of the health status of patients with chronic diseases' (p. 679). 
2.2.4 Definition and Domains of HRQOL  
There are numerous but similar definitions of HRQOL. For example, Anderson and 
Burckhardt in 1999 have stated that HRQOL is the patients’ subjective perception 
of the impact of their disease and/or its treatment on their daily life, and their 
physical, psychological and social functioning. Also, Bowling (2001) defined 
HRQOL as 'an optimum level of mental, physical, role (e.g. work, parent, career, 
etc.) and social functioning, including relationships, and perceptions of health, 
fitness, life satisfaction and well-being. It should also include some assessment of 
the patient's level of satisfaction with treatment, outcome and health status and with 
future prospects' (p. 6). Both these definitions clearly acknowledge that HRQOL is 
a multidimensional concept. It is theoretically based on the WHO definition of 
health, which integrates physical, psychological, social functioning and well-being 
(Bowling 2001) as well as the individuals' subjective perceptions about their health 
status, capacity and performance.  
Fayers and Machin (2000) added that the dimensions of HRQOL are physical 
health and symptoms, psychological and cognitive status, social role and social 
well-being or sexuality status. Helman (2007) argues that health is a holistic 
concept, which includes physical, psychological, social and spiritual health. 
Considering these various definitions, the common consistently shared domains of 
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HRQOL are physical, psychological and social health, although there may be other 
specific domains that differ from study to study based on its aims (Fayers and 
Machin 2000), such as sexual health.  
Different terms are used in HRQOL such as health status, functional status, well-
being and QOL, which are sometimes used interchangeably (Sirgy et al. 2006). 
QOL should not be used as a synonym for HRQOL because QOL is broader than 
HRQOL (Sirgy et al. 2006). However, there is considerable agreement that HRQOL 
and health status are similar. For example, health status consists of (1) functional 
capacity and (2) functional performance (Leidy 1994; Anderson and Burckhardt 
1999); and HRQOL consists of (1) the ability to perform daily life activities and (2) 
satisfaction with functioning levels (Fayers and Machin 2000). As a result, 
assessing the HRQOL reflects the individual's health status as well as well-being. 
Hence, both concepts: HRQOL and health status are used interchangeably in this 
thesis.  
2.3 SOCIAL SUPPORT 
2.3.1  Definition of Social Support  
Social support is a broad term that does not have a consistent or exact definition 
(Helgeson 2003; Lyyra and Heikkinen 2006) and this lack of agreement has 
resulted in a lack of consistency and comparability in research studies (Williams et 
al. 2004). As Hupcey (1998) states ‘social support is a multi-faceted concept that 
has been difficult to conceptualise, define and measure. Although this concept has 
been extensively studied, there is little agreement among theoreticians and 
researchers as to its theoretical and operational definition. As a result, the concept 
remains fuzzy and almost anything that infers a social interaction may be 
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considered social support’ (p. 1231). Thus, the definitions of social support that do 
exist fall into five theoretical categories: (1) type of support; (2) behaviour of 
provider of support; (3) reciprocity or exchange of resources between provider and 
recipient of support; (4) social network; and (5) perception of recipient of support 
(Hupcey 1998). 
Perceived social support reflects the individual's general expectations of available 
support (Tijhuis et al. 1995). Hlebec et al. (2009) define perceived social support as 
a ‘subjective evaluative assessment of support resources and behaviours’ (p. 156) 
and states that ‘perceived support is a person’s belief that some social support is 
available if needed’. Lakey and Cohen (2000) state that perceived social support is 
commonly measured by asking the respondent to evaluate the quality or availability 
different types of support. It was argued that an individual’s evaluation of social 
support is one of the indicators of the effectiveness of interpersonal relationships 
(Hlebec et al. 2009). 
2.3.2 Types of Social Support  
Social support is a tool that describes the nature of the social environment or 
people surrounding the individual (Helgeson 2003). Social support itself requires 
the existence of social relationships to provide supportive resources which include 
emotional, instrumental, informational (Williams et al. 2004) and companionship 
support (Wills and Shinar 2000). These types of support have been defined by Wills 
and Shinar (2000) as following: emotional support means availability of person who 
listens sympathetically and expresses caring, concern, love, and interest, especially 
during times of stress. Instrumental support means providing practical help such as 
helping with transportation, household duties and looking after children and/or 
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lending money. Informational support means helping in solving problems by 
providing required information such as information about available services and 
resources, and providing guidance during a specific action. Finally, companionship 
support means availability of persons with whom to participate in cultural, social 
and recreational activities.   
2.3.3 Source of Social Support  
Different sources of support have been found related to health outcomes including 
primary relationship (partner, families and friends) and professional or therapeutic 
relationship (nurses and doctors) (Wills and Shinar 2000). However, effectiveness 
of social support depends on the stressor demand (Lakey and Cohen 2000) and 
the provider of the support (Hlebec et al. 2009). Lakey and Cohen (2000) argue 
that according to the stress-support matching hypothesis, each stressor event 
requires a specific type of social support (demands of the stressor) that will be 
effective in promoting coping and reducing stress effect. For example, emotional 
support is helpful no matter where it comes from, including family, friends or 
healthcare providers (Helgeson 2003), particularly during illness. For example, 
DuPertuis et al. (2001) investigated the relationships between types, sources of 
support and frequency of contact from family and friends and perceived physical 
and mental health in 1,386 older men (median age = 62.7 years). They found that 
people with high perceived support from family and friends had better physical 
health and lower depression than people with low perceived support from family 
and friends. However, frequency of contact was not significantly associated with 
physical health. 
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Conversely, informational support should come from a specific source, like a 
professional person to be most effective (Helgeson 2003). For example, disease 
severity was perceived to be lower among patients with chronic HCV who reported 
hepatologists as a source of information than patients who reported other sources 
such as significant others, internet, television…etc. (Constant et al. 2005).  
2.3.4 Underlying Mechanism of Social Support  
The mechanism of relationship between social support and health outcomes is not 
completely understood and is still under empirical investigation. For instance, 
Cohen and Wills (1985); Tijhuis et al. (1995); Hlebec et al. (2009) state two 
possible hypotheses to describe the mechanism of social support in general: the 
‘main-effect’ hypothesis and the ‘buffering-effect’ hypothesis.  
The ‘main-effect’ hypothesis states that support influences behaviour and well-
being under normal situations. For example, the main-effect hypothesis indicates 
that social support has a positive influence at all times even if the individual is not 
under stress (Cohen and Wills 1985; Tijhuis et al. 1995). Thus, the main-effect 
hypothesis addresses the association between social support and QOL as a linear 
relation, which means more social support directly can lead to better QOL. 
Therefore, according to this model, the integration of an individual, for example, into 
social networks can decrease the susceptibility to psychological or physical 
problems (Cohen and Wills 1985). 
The ‘buffering-effect’ of social support states that social support is effective only 
during stressful situations like during illness. Thus supporting individuals during 
stressful situations can protect them from the diverse effects of that stress (Cohen 
and Wills 1985; Wills and Shinar 2000). Accordingly, the buffer-effect will occur 
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when a stressor to be buffered is present (Tijhuis et al. 1995; Wills and Shinar 
2000). The association between social support and health in the presence of a 
stressor (such as liver cirrhosis) was studied based on the buffer-effect hypothesis; 
see Diagram 2-1 that was proposed to illustrate this relationship. Accordingly, 
sufficient support can decrease or prevent a stress reaction that might result in a 
physiological or psychological illness (Cohen and Wills 1985), (Diagram 2-1). For 
example, providing support such as informational support from a healthcare 
provider can prevent a disease being perceived as highly severe (stressful) 
(Constant et al. 2005). Social support can enhance an individual’s perception in 
terms of his/her ability to cope by providing information that can lead to solving the 
problem and therefore decrease its significance (Cohen and Wills 1985). Thus, to 
support an individual coping with a stressful event, such as during disease, the 
appropriate resources from the surrounding people need to be provided in order to 
decrease the individual’s stress level, particularly with highly stressful events 
(Helgeson 2003).   
2.3.5 The Relationship between Social Support and HRQOL 
Several research studies have assessed the association between social support 
and HRQOL among patients with different chronic conditions. Social support has 
been found to be a vital factor in improving HRQOL among patients with chronic 
diseases, particularly mental health. For example, Arestedt et al. (2012) found that 
there was a significant positive association between perceived social support after 
controlling for age and gender among elderly patients with chronic heart disease 
and HRQOL. Social support was associated specifically with mental health but not 
associated with physical health. Furthermore, Karnell et al. (2007) showed that with 
increasing social support there was a decline in symptoms of depression and 
26 
 
improvements in mental health but there was no significant difference in the 
physical health of patients with head and neck cancer. Therefore, it appears that 
social support may be an important factor in perceived mental health in patients 
with chronic illness. 
The linkage between social support and survival rate has been investigated in 
numerous longitudinal studies, which showed that social support, especially 
perceived emotional support, is significantly related to improved psychological and 
physical health outcomes as well as a decrease in the mortality rate (Brummett et 
al. 2005; Lyyra and Heikkinen 2006). Cohen and Wills (1985) illustrate that lack of 
social support can cause psychological symptoms such as anxiety or depression, 
which may have a negative influence on an individual’s health status. Perceived 
social support has a significant effect on the HRQOL in patients with coronary 
artery disease, especially in female patients (Staniute et al. 2011). Therefore, when 
planning cardiac rehabilitation programs, special attention should be paid to 
patients with little social support (Staniute et al. 2011). However, little is known 
about perceived social support from different sources and its association with 
perceived physical and mental health in liver cirrhotic patients (more details in 
Chapter 3, section 3.5.2.3).  
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Diagram 2-1: Suggested theoretical framework of the association between stressor, social support and health status according to the buffer 
effect  
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2.3.6 Paradigms of Measuring Social Support 
Social support, particularly functional social support, can be assessed by two 
different methods; perceived support and received support. Perceived support is 
examined by asking individuals to what extent they perceive the people 
surrounding them are available to support them (Helgeson 2003; Sherbourne and 
Hays 1990). While received support is assessed by examining whether the people 
surrounding them are actually available and do provide the individual with the 
required support and coping skills (Helgeson 2003; Hlebec et al. 2009). Although 
both perceived and received support are measured through an individual’s 
perception (Helgeson 2003), the received support may be confused with the 
individual's needs and cannot reflect exactly the available amount of support 
(Sherbourne and Hays 1990). For that reason, the perceived availability of support 
is considered the most important aspect of measuring the adequacy of functional 
support (Sherbourne and Hays 1990). Also, assessing perceived support may be 
more feasible in research studies than assessing received support that requires 
direct observation, which may be difficult.  
Various measurements can be used to investigate social support. Structural 
instruments describe the existence of relationships e.g. marital status and network 
size. Functional instruments examine the quality of these relationships (Cohen and 
Wills 1985). Cohen and Syme (1985) suggest that for selecting the appropriate 
social support measurement to evaluate the perceived support it is essential to 
know whether a social support measurement examines a specific type of support 
(structure or function) or combines both, also whether it covers all or just some 
types of functional support. Therefore, these factors have to be considered when 
selecting a tool to investigate perceived adequacy of provided support.  
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2.4 CONCLUSION  
The literature has indicated that liver cirrhosis remains a leading cause of death 
worldwide and in Egypt in particular. Viral hepatitis C is the most common cause of 
cirrhosis in Egypt. There is significant evidence that liver cirrhosis is a chronic 
irreversible disease causing various complications, which can have negative effects 
on the patients’ health as well as their overall QOL. Although medical management 
of liver cirrhosis has advanced and can positively affect the patients’ longevity, 
morbidity has increased. There is also an expectation that the number of people 
with liver cirrhosis in the future will rise.  
Nowadays, the medical management of patients with liver cirrhosis is based on 
taking prescription drugs to avoid developing complications, continuous check-ups 
and a change in life style to decrease signs and symptoms in order to improve the 
patients’ HRQOL.  
Measuring HRQOL and the factors that influence it, such as symptom severity or 
perceived social support, has become an important area of health research in 
different populations with or without disease. Assessing HRQOL can be valuable in 
determining significant problems among a specific group of patients. This 
knowledge can be used to develop appropriate policies or programs of 
interventions to improve the population’s HRQOL.  
There has been a major effort in assessing HRQOL among patients with chronic 
liver disease or cirrhosis in Western countries, showing that patients with cirrhosis 
have a poorer HRQOL than the general population, and patients with other chronic 
diseases. Therefore, the next chapter will review previous studies that have 
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described HRQOL, symptom experience and social support and evaluated their 
associated factors among patients with liver cirrhosis.  
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3 CHAPTER 3- LITERATURE REVIEW PART 2 
This chapter aims to present the search strategy that was used to find relevant 
literature, and analyse and discuss the literature related to Health-Related Quality 
of Life (HRQOL), symptoms experience and perceived social support in liver 
disease patients. This literature review is structured in three sections. Section I 
describes HRQOL and aims to: (1) find the currently used HRQOL measurements 
in liver disease studies, (2) explore the HRQOL of liver disease patients compared 
with healthy people, (3) determine whether liver disease stage is related to 
perceived HRQOL, and (4) determine factors contributing to the understanding of 
HRQOL in cirrhotic patients. Section II describes symptoms experience and aims to 
identify: (1) instruments used to assess symptoms experience, (2) symptoms 
experience in cirrhotic patients and (3) self-care in cirrhotic patients. Section III 
explains social support, and aims to analyse the literature to find: (1) how liver 
disease patients perceived provided social support and (2) sources of support for 
liver disease patients. Finally, a summary is provided with an outline of the current 
study's aims.  
3.1 SEARCH STRATEGY AND SELECTING RELEVANT PAPERS  
3.1.1 Search Strategy  
Systematic searching of electronic databases [MEDLINE, CINAHL, PsychINFO and 
ASSIA] was conducted. Google scholar was also accessed as a public site for 
research. The search was not limited to publishing time or study design in order to 
find all the relevant papers up to April 2012. The following Medical Subject 
Headings (MeSH) and appropriate keywords were used separately and in 
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combination based on ‘‘AND’’ and ‘‘OR’’ terms: health-related quality of life’, ‘quality 
of life’, ‘well-being’, ‘functional status’, ‘health status’, ‘symptom, 'depression', 
'psychological status', 'fatigue', 'pain', ‘social support', 'social network', 
'psychosocial support', 'support system', 'perceived social support', 'liver disease', 
'liver cirrhosis', and 'hepatitis'. Appendix 3-1 details the search strategies used. 
Specific inclusion and exclusion criteria were used to find relevant paper (Table 3-
1).  
Table 3-1: Literature review inclusion and exclusion criteria  
Inclusion criteria Exclusion criteria 
1. Studied patients with liver cirrhosis,  
2. The study was written in English, 
3. The study reported a research-based 
study (no restriction on design), 
4. The study used HRQOL as a 
dependent variable, 
5. The study examined any symptom 
as a dependent or independent 
variable, 
6. The study examined social support,  
7. Psychometric studies  that reported  
relevant data  
 
 
1. A paper was excluded if any of these 
inclusion criteria was not met (1, 2 & 3). 
2. Participants with only primary biliary or 
alcoholic cirrhosis or fatty liver results, pre-
post transplantation, hepatic carcinoma, 
advanced hepatic encephalopathy, 
receiving interferon therapy, 
3. Clinical trials that only examined the impact 
of medical treatment or surgical procedure 
on QOL, HRQOL or symptom,  
4. Commentary, letter to editor or other 
papers not reporting original research 
results 
 
3.1.2 Database Search Results  
The database search yielded a total of 2924 publications (Diagram 3-1). 2636 
remained after removing duplicates. A further three screening stages took place: 
(1) The titles of the 2636 articles were screened; 2324 were excluded because they 
were irrelevant, duplicated or not written in English. (2) Abstracts of the remaining 
1312 articles were screened, of which 113 appeared to be relevant. (3) The full-text 
of the 113 papers was then reviewed to identify the papers that met the inclusion 
criteria. Forty-eight papers met the inclusion criteria.  
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3.1.3 Results of Google Scholar Search and Sites in Egypt 
The aim of this search was to find any relevant Egyptian studies that were not 
found in the searched databases. Google scholar was searched twice, limiting the 
timeframe to 1990-2012 and to studies in English. The first search was conducted 
to find papers that investigated HRQOL using the keywords: 'quality of life' AND 
'chronic liver disease' OR 'hepatitis C' in “Egypt” as commonly used terms in 
research studies. The search yielded a total of 4340 publications. Only the first 200 
papers were reviewed, because the remaining papers seemed irrelevant. The titles 
and abstracts of these 200 papers were read to identify those that met the inclusion 
criteria. If the title and abstract appeared to be relevant, the whole paper was read 
to decide if it met the inclusion criteria. Eight papers were reviewed but only five 
papers were relevant. One of these five papers had already been found in another 
database; therefore, only four new papers were included in the review.  
The second search was carried out using the key terms: 'fatigue' OR 'pain' OR 
'depression' AND 'chronic liver disease' OR 'hepatitis C' in 'Egypt', to find papers 
that investigated symptoms. The search yielded a total of 973 publications, but only 
the first 200 papers were reviewed as with the first search in Google scholar. One 
paper appeared to be relevant based on the title and abstract, and was reviewed 
fully. Another paper was found during reading irrelevant papers of literature and it 
was also reviewed. Additionally, a manual search was carried out in Egypt at the 
Libraries of the Faculty of Medicine, Faculty of Nursing, and Central Library in Cairo 
University, National Liver Institute, Academy of Scientific Research and Technology 
and Arab Journal of Gastroenterology. The search did not yield any new studies. 
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Diagram 3-1: Flow diagram of literature screening process  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total finding after deleted duplications  
2636 
Irrelevant  
2198 
Why? 
Other disease, paediatric, 
transplantation, PBC, Fatty 
liver, psychiatric, on interferon 
therapy, hepatic carcinoma, 
HIV, Prisons, Substance 
abuse, trial (medication), 
adolescent immunizations, 
advanced hepatic 
encephalopathy, alcohol 
abuser, rheumatoid arthritis, 
hereditary diseases.   
 
 
Excluded 
126 
Duplications = 93 
Language = 33 
 
 
Second review 
for abstract 
 
First review 
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Third review 
for full article 
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65 
Why? 
Language = 1 
Not available = 2 
Not met the inclusion criteria= 
62  
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44 
Language = 14  
Not available = 30 
 
 
Irrelevant  
155 
Why?  
On interferon therapy, hepatic 
carcinoma, other disease, on 
waiting list for transplantation, 
advanced encephalopathy, 
co-infected with HIV, 
Substance abuse, psychiatric, 
on caregiver, letter to editor or 
commentary paper. 
 
 
312 may be 
relevant 
 
 
113 may be 
relevant 
 
 
Total finding from all databases  
2924 
 
Duplications removed by 
ref-work program = 288 
 
Total of 54 relevant papers 
included  
48 relevant papers found in 
databases  
 
5 papers found by Google 
scholar. 
One found during reading 
irrelevant review papers 
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3.1.4 Summary of Search and Quality Appraisal  
A final total of 54 papers met the inclusion criteria and are included in this review. 
Forty-one papers studied HRQOL and QOL as the main outcome (Section I), and 
13 papers studied symptoms as the main outcome (Section II). The quality of the 
reviewed studies was assessed using the quality appraisal form (Appendix 3-2) that 
was developed based on the Critical Appraisal Skills Program (CASP) criteria and a 
checklist for assessment of methodological quality (Downs and Black 1998). All 
papers that met the inclusion criteria were used and no study was excluded due to 
its quality. The results of all studies are reported in tabular form based on data 
extraction tables using criteria suggested by Garrard (2007) for developing a 
research matrix. Data were extracted using the following headings: Author, year of 
publication, country, design, sampling method, measurements and key results. 
SECTION I: HEALTH-RELATED QUALITY OF LIFE (HRQOL) 
3.2 CHARACTERISTICS OF REVIEWED PAPERS THAT STUDIED HRQOL  
3.2.1 Publishing Year and Place  
Forty-one papers were all in English and published over 15 years period between 
1997 and 2012, see appendix 3-3 for methodological characteristics of 41 studies. 
Twenty-five of them were conducted in Europe from 2001-2011, with the 
Netherlands producing the highest number of studies: four in total. In Asia, six 
studies were conducted from 2005-2012; and 14 studies were conducted in 
America from 1997-2010, with the United States (US) producing the highest 
number of studies: 10 in total. In Africa, two studies were conducted in Egypt from 
2004-2011. This suggests that there is a growing interest worldwide in assessing 
HRQOL or QOL in patients with chronic liver disease and cirrhosis. Europe and 
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America have produced the highest number of these studies while in the Middle 
East it seems that studying HRQOL or QOL in people with liver disease or cirrhosis 
is uncommon. In 2007, Gutteling et al. argued that due to an increasing number of 
people with chronic disease in developed countries, assessing patients’ physical, 
psychological and social well-being (HRQOL) has become an important outcome 
measure. 
3.2.2 Methodological Limitations of Reviewed Papers that Studied 
HRQOL  
There are some important methodological limitations of studies identified in this 
review. First, there is often a lack of a theoretical basis in liver disease research, 
which can build a bridge between theory and practice, with none of the 41 studies 
using a theoretical model for the research. Secondly, there is a lack of consistency 
in the definitions of HRQOL or QOL, which results in overlapping between the two 
terms, as well as with other concepts such as functioning health (see section 3.3.3). 
Third, there is a lack of consistency in categorising liver disease according to cause 
(see section 3.5.3.1). Finally, there is a lack of consistency in the use of 
standardised measures to classify liver disease according to disease severity 
(stage) (see section 3.4.2). Despite these limitations, because of the shortage of 
liver disease research in the area of HRQOL, particularly in the Middle East, no 
study was excluded due to its quality. 
3.2.2.1 Design of Studies  
Of the 41 studies, 21 were observational, cross-sectional or survey studies, five 
were database cohort study or retrospective, two were prospective (Singh et al. 
1997; Taliani et al. 2007) and one was a quasi-experimental study (Zandi et al. 
2005). However, ten studies did not explicitly mention the study design. 
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Furthermore, two mentioned a prospective design (Haage et al. 2008; Svirtlih et al. 
2008). However, these 12 studies all seemed cross-sectional in nature. The only 
randomised controlled trial investigated the effects of a self-care program on 
cirrhotic Iranian patients’ HRQOL. Of the two prospective studies, one USA study 
had duration of 100 days for all participants and 18 months for patients after 
transplantations (Singh et al. 1997), and one Italian study aimed to assess and 
compare the change in HRQOL from baseline to 6 months among HCV patients 
treated with interferon and ribavirin therapy (Taliani et al. 2007).  
The survey, particularly the cross-sectional design, is therefore the most commonly 
used method in liver disease research. This limits the ability of studies to identify 
causal relationships between the studied variables and HRQOL.  
3.2.2.2 Studied Population  
The study sample sizes varied between 30 and 1175 patients in the 41 studies. 
Twenty-five studies had ≤ 200 patients (30-200 patients), and 16 studies had more 
than 200 patients (200-1175 patients); while three of these studies used the same 
sample in three separate papers (van der Plas et al. 2003; van der Plas et al. 2004; 
Gutteling et al. 2006). The liver disease causes and stages varied, with most 
studies focused on chronic liver disease due to various causes (n = 25), and only a 
few focused on cirrhosis stage (n = 13). Recruiting a low sample size (≤ 200) (e.g. 
Hauser et al. 2004; Karaivazoglou et al. 2010), studying a non-representative 
sample of liver disease or cirrhotic patients (e.g. Arguedas et al. 2003; van der Plas 
et al. 2004), recruiting participants from the community (e.g. van der Plas et al. 
2004) or outpatients’ clinic (e.g. Haag et al. 2008) made it difficult to generalise 
results from the studies to all liver cirrhotic patients, especially in clinical settings. 
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Using a convenience, retrospective or consecutive sampling method to recruit the 
participants (n= 26 studies) also limited generalisability of some results. Therefore, 
the findings from the reviewed 41 studies should be treated with caution. 
3.3 TOOLS USED TO ASSESS HRQOL IN LIVER DISEASE PATIENTS 
Out of the 41, 37 studies examined HRQOL and four studies examined QOL (Table 
3-2). These 37 studies were used to identify the commonly used HRQOL 
questionnaires. Several generic and liver disease specific HRQOL questionnaires 
were found, but generic tools were more commonly used (Figure 3-1).  
Table 3-2: Tools used to investigate HRQOL and QOL in liver disease patients   
Authors Country HRQOL and QOL tools  
Generic tools Liver disease 
specific tools 
1. Afendy et al. 2009 USA SF-36  
2. Arguedas et al. 2003 USA SF-36  
3. Bailey et al. 2009 USA Cantril's Ladder for 
measuring QOL. 
 
4. Bao et al. 2007 China SF-36 CLDQ 
5. Basal et al. 2011 Egypt SF-36  
6. Bianchi et al. 2005  Italy PGWBI  
7. Bondini et al. 2007 USA SF-36, HUI-II and HUI-III  CLDQ 
8. Dan et al. 2008 USA SF-6D, HUI-II  
9. Fritz and Hammer 2009 Austria SF-12  
10.Girgrah et al. 2003  Canada SF-36  
11.Gutteling et al. 2006  Netherlands SF-12 LDSI-2.0 
12.Haag et al. 2008 Germany SF-36  
13.Hauser et al. 2004 Germany SF-36 CLDQ 
14.Hilsabeck et al. 2005 USA SF-36  
15.Hsu et al. 2009  Canada SF-36, SF-12, HUI-II HQLO-v2 
16.Jover et al. 2005  Spain SF-36 CLDQ 
17.Kalaitzakis et al. 2006 Sweden SF-36  
18.Kalaitzakis et al. 2008 Sweden SF-36  
19.Karaivazoglou et al. 
2010 
Greece SF-36  
20.Kim et al. 2006  Korea QOLI  
21.Les et al. 2010  Spain SF-36 CLDQ 
22.Liu et al. 2012 Japan SF-12  
23.Marchesini et al. 2001 Italy SF-36, NHP  
24.Moyer et al. 2003 USA SF-36  
25.Schwarzinger et al. 
2004 
Egypt SF-12  
26.Singh et al. 1997 USA Self-assessed Rating of  
39 
 
Authors Country HRQOL and QOL tools  
Generic tools Liver disease 
specific tools 
Perceived QOL 
27.Sobhonslidsuk  et al. 
2006 
Thailand  SF-36 CLDQ 
28.Sumskiene et al. 2006 Lithuania  CLDQ 
29.Svirthlih et al. 2008  Serbia  SF-12  
30.Taliani et al. 2007 Italy  SF-36, WHOQOL-BREF CLDQ 
31.Teixeira et al. 2005 Brazil SF-36 part from LDQOL 
1.0 
LDQOL 1.0 
32.Teixeira et al. 2006 Brazil  SF-36  
33.Teuber  et al. 2008 Germany  SF-36  
34.Toda et al. 2005 Japan  SF-36  
35.van der Plas et al. 2003 Netherlands SF-36 LDSI-2.0 
36.van der Plas et al. 2004 Netherlands  SF-36 LDSI-2.0 
37.van der Plas et al. 2007 Netherlands SF-36 LDSI-2.0 
38.Wilson et al. 2010 USA SF-36  
39.Wunsch et al. 2011 Poland SF-36 CLDQ 
40.Younossi  et al. 2001 USA SF-36 CLDQ 
41.Zandi et al. 2005 Iran  CLDQ 
SF-36: Short Form 36,  
NHP: Nottingham Health Profile,  
LDSI-2.0: Liver Disease Symptom Index 2.0,  
CLDQ: Chronic Liver Disease Questionnaire,  
LDQOL 1.0: Liver Disease Quality Of Life 1.0,  
PGWBI: Psychological General Well-Being Index,  
SF-12: Short Form 12,  
QOLI: Quality Of Life Index, 
HUI-II: Health Utilities Index-Mark II, 
HUI-III: Health Utilities Index-Mark III,  
HQOL-v2: Hepatitis Quality of Life Questionnaire Version 2,  
QOL: Quality Of Life,  
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Figure 3-1: Studies using HRQOL tools  
 
 
 
 
 
 
 
3.3.1 Generic HRQOL Questionnaire  
Four generic HRQOL questionnaires were identified: Short-Form 36 (SF-36) was 
used in 29 studies; Short-Form 12 (SF-12) was used in six studies; Nottingham 
Health Profile (NHP) was used in one study and Health Utilities Index (HUI) [Mark II 
and Mark III] was used in three studies. Table 3-3 summarises the generic HRQOL 
tools and their components.  
The Short-Form (SF)-36 measures eight domains that commonly represent health 
status: physical functioning (PF), role limitations due to physical health problems 
(RP), bodily pain (BP), general health (GH), vitality (VT) (i.e. fatigue and energy), 
social functioning (SF), role limitations due to emotional problems (RE) and mental 
health (MH) (i.e. psychological well-being) (Ware 2000). The eight domains in the 
SF-36 can be integrated to form a physical component summary (PCS) score that 
indicates physical health, and a mental component summary (MCS) score that 
indicates mental health. The SF-36 scores from 0 to 100 where a lower score 
34 studies used SF-36, SF-
12, HUI-II/III and/or NHP. 
36 studies  
 
2 studies (5.40%) 
used a disease 
specific HRQOL tool 
only 
 
15 studies (40.54%) 
used generic and 
disease specific 
HRQOL tools 
 
19 studies (51.35%) 
used a generic 
HRQOL tool 
 
17 studies used CLDQ, 
LDSI-2.0, LDQOL-1.0 or 
HQOL-v2. 
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indicates a poorer health status. It also has a cut-off score of 50±10, meaning that 
scores lower than 50 indicate health below the mean. The cut-off score is used to 
make cross-cultural comparisons of HRQOL possible and when a normal 
comparative group is not available. Similarly, the SF-12 is a generic questionnaire 
that was developed to be a shorter alternative to the SF-36. It contains six domains 
of the SF-36: PF, BP, VT, SF, MH, and role limitations but without specifying 
whether role limitations are due to emotional or physical problems. 
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Table 3-3: Summary of generic HRQOL tools and their components  
Generic 
tools 
Tool components 
SF-36 8 domains 
 
Component summary scores 
Domains physical 
functioning 
role 
limitations 
due to 
physical 
health 
problems 
bodily 
pain 
general 
health 
vitality social 
functioning 
role 
limitations 
due to 
emotional 
problems 
mental health PCS MCS 
Generic 
tools 
Tool components 
NHP Part I 
 
Part II 
Domains physical mobility pain Social 
isolation  
emotional 
reactions 
energy sleep Paid 
employment 
Jobs 
around 
the home 
Social 
life 
Family 
relationships 
Sex 
life 
Interests 
and 
hobbies 
Holidays 
Generic 
tools 
Tool components 
HUI HUI-II HUI-III 
Domains sensation cognition  mobility  emotion  self-
care  
fertility  pain hearing vision emotion speech pain cognition ambulation  dexterity 
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The NHP is a generic HRQOL questionnaire that is used to investigate aspects of 
physical, emotional, and social health, and is divided into two parts. Part I involves 
six domains: physical mobility, pain, social isolation, emotional reactions, energy, 
and sleep. Part II assesses seven aspects of life that are most affected by health 
status (using Yes/No answers); NHP scores range from 0 to 100 where a lower 
score indicates a better health (Hunt et al. 1985). 
HUI-Mark II and Mark-III are preference-based generic HRQOL questionnaires that 
are used to investigate patients' preferences for a specific health state over a one-
week period. HUI contains 15 constructs, seven attributes form part of HUI-Mark II: 
sensation, cognition, mobility, emotion, self-care, fertility and pain, and eight 
attributes form part of HUI-Mark III: hearing, vision, emotion, speech, pain, 
cognition, ambulation and dexterity. HUI scores range from 0-1 where a score of 1 
means a healthy state (Feeny et al. 2002).  
There is therefore some inconsistency in conceptualization of HRQOL where 
different tools contain different domains that measure different aspects of health 
(Table 3-2) making it difficult to compare the findings of different studies 
systematically or to find evidence sometimes about the impaired domains of 
HRQOL. For example, the two generic HRQOL tools, SF-36 and NHP, were used 
in the study with Italian cirrhotic patients (Marchesini et al. 2001). Both tools 
indicated a significantly lower HRQOL of cirrhotic patients than the normal 
population. However, the SF-36 found that the largest differences were in the 
domains of role limitations, due to emotional and physical health problems, general 
health and bodily pain. The NHP found the largest differences in physical mobility 
and energy but no difference in pain between cirrhotic and healthy people. 
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Therefore, Marchesini et al. (2001) acknowledge that the SF-36 may be more 
sensitive than the NHP in finding differences between liver disease patients and 
healthy people. 
3.3.2 Liver Disease Specific HRQOL Questionnaires  
It has been argued that the generic HRQOL measures may not be sensitive to 
detect disease-related changes such as symptoms (Younossi et al. 1999; van der 
Plas et al. 2004). Therefore, liver disease specific HRQOL questionnaires have 
been developed and are used alone (Arguedas et al. 2003; Afendy et al. 2009; Fritz 
and Hammer 2009) or combined with generic HRQOL tools to capture sensitive 
disease issues (Hauser et al. 2004; Jover et al. 2005; Gutteling et al. 2006; Bao et 
al. 2007; Hsu et al. 2009). 
Four disease specific HRQOL questionnaires are used in included studies among 
liver disease patients to assess their health status: chronic liver disease 
questionnaire (CLDQ), Liver Disease Symptom Index 2.0 (LDSI-2.0), Liver Disease 
Quality Of Life 1.0 (LDQOL 1.0) and Hepatitis Quality of Life Questionnaire version 
2 (HQOL-v2). The CLDQ was used in 11 studies, LDSI-2.0 was used in four 
studies, LDQOL 1.0 was used in one study and HQOL-v2 was used in one study. 
However, while some are too narrowly focused (i.e. HQOL-v2), which focuses on 
patients with HCV, others are too long and do not address the extent to which 
symptoms affect patients' quality of life (i.e. LDQOL 1.0 and CLDQ)  
CLDQ was developed in the USA by Younossi et al. (1999) to evaluate the 
influence of liver disease on liver disease patients' health status. It contains 29 
items that produce six domain scores: abdominal symptoms, fatigue, systemic 
symptoms, activity, emotional function and worry. It can also give an overall 
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summary score. It was validated in patients with different types, causes and at 
different stages of liver disease, and it has adequate internal reliability (Younossi et 
al., 1999). Its validity and reliability have been established in several languages 
(Hauser et al. 2004; Sobhonslidsuk et al. 2004; Jover et al. 2005 Bao et al. 2007) 
but not in Arabic.   
LDSI-2.0 is the second most commonly used disease specific HRQOL tool that was 
developed in the Netherlands by van der Plas et al. (2004) to assess the symptom 
severity and impact of this symptom on daily life and social activities of liver 
disease patients due to different causes. It contains 24 items divided into two 
subscales: symptom severity and limitation of daily life due to symptoms (see more 
details about LDSI-2.0 and other liver disease specific HRQOL in Chapter 5). It was 
validated in patients with different types, causes and at different stages of liver 
disease, and it has adequate internal reliability (Unal et al. 2001; van der Plas et al. 
2004). Its validity and reliability have been established in English, Dutch (Hauser et 
al. 2004; Sobhonslidsuk et al. 2004; Jover et al. 2005 Bao et al. 2007) and Arabic 
(Youssef et al. 2012). The other measures (i.e. HQOL-v2 and LDQOL 1.0) are less 
commonly used. The HQLQ-v2 was developed in the USA by Bayliss et al. (1998). 
It contains 69 items combining the generic SF-36 domains with three additional 
generic scales and two hepatitis specific domains. It was validated in patients with 
viral hepatitis (Bayliss et al. 1998). It is available is several languages but not 
Arabic. However, it may have several disadvantages: (i) It is long, therefore it may 
be a problem with critically ill patients or to use with other questionnaires, and (ii) it 
was developed for patients with HCV, thus it may be not suitable for patients with 
different causes of disease. The LDQOL 1.0 was developed in the USA by Gralnek 
et al. (2000). It consists of 75 items combining the generic (SF-36) and disease-
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specific (12 items) scales. The LDQOL 1.0 is available in several languages such 
as Spanish and Brazilian Portuguese (Teixeira et al. 2005) but not in Arabic. 
However, it is very long.  
In conclusion, various HRQOL questionnaires such as generic, disease specific 
and patient-preference tools were used in liver disease studies. However, generic 
tools were the most commonly used to evaluate different aspects of health: 
physical, psychological and social as well as perceived well-being, with the SF-36 
the most commonly used. It is available in several languages such as English, 
German, Dutch and Arabic. Although there are several well developed and valid 
liver disease HRQOL tools, none were available prior to my pilot study in Arabic. 
There is, therefore, a need to develop a valid and reliable liver disease HRQOL 
questionnaire to investigate the impact of liver disease on Egyptian patients' lives. 
Details of the translation and psychometric properties of LDSI-2.0 are in Chapter 5.  
3.3.3 Theoretical and Operational Definitions of HRQOL  
None of the previous 37 studies used a theoretical framework to guide their study. 
Thirty-one (83.78%) of the 37 studies did not provide a definition of HRQOL, and 
only six (16.21%) attempted to define HRQOL. However, there was no consensus 
in these definitions. For instance, two studies used the WHO 1948 definition of 
health to define HRQOL (Sobhonslidsuk et al. 2006; Sumskiene et al. 2006) 
(Chapter 2, section 2.2.1.2: definition of health). Svirtlih et al. (2008) defined 
HRQOL as the patients’ subjective assessments of their physical, mental and social 
well-being. Gutteling et al. (2006) defined HRQOL as the impact of the disease 
and/or medical treatment on the patient’s physical, emotional and social 
functioning; Haag et al (2008) as an impairment of the physical and mental 
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functional status; and Hauser et al. (2004) as the assessment of symptoms, and 
the impact of the health status on psychological functioning and sense of well-
being.  
Although, these definitions share some aspects of HRQOL (physical, psychological 
and social) there is an inconsistency as to whether HRQOL refers to functional 
status, health status or well-being. There are also some overlaps in the theoretical 
definition of health and HRQOL. Sobhonslidsuk et al. (2006) and Sumskiene et al. 
(2006) used the WHO definition of health to define HRQOL, although the WHO 
definition is commonly known as a general definition of health itself. It appears that 
there is no agreement about what HRQOL in liver disease research means with a 
lack of theoretical and operational understanding of this concept. There was also 
inconsistency in using various generic and disease specific questionnaires to 
investigate HRQOL. Therefore, a conceptualization of HRQOL in liver disease 
research is recommended for future research to avoid its overlapping with other 
concepts such as well-being and functional status and to give a consistent 
interpretation of the study's findings.  
3.4 LIVER DISEASE PATIENTS' HRQOL  
This section aims to explain HRQOL among patients with liver cirrhosis and the 
factors associated with HRQOL using the 37 relevant studies (Table 3-2). The 
extent to which these studies focused on HRQOL of cirrhotic patients depended on 
the study's aim, disease stage and whether the authors investigated generic and/or 
disease specific HRQOL. 
Generally, patients with liver disease have been found to suffer from disease 
related stress that can influence their physical and mental health status. Liver 
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disease was perceived to be more stressful than diabetes and hypertension by 
patients with chronic HCV (Castera, et al. 2006). Some studies found that patients 
with chronic liver disease, particularly resulting from a viral infections had disease 
related worries about their family situation (van der Plas et al. 2004, Hauser et al. 
2004), depression and anxiety (Blasiole et al. 2006), fear of disease complications 
(van der Plas et al. 2004) and psychological distress (Kim et al. 2006). Cirrhotic 
patients due to viral hepatitis who had poor mental health were liable to experience 
social impairments such as poor emotional reaction (Marchesini et al. 2001), social 
isolation (Marchesini et al. 2001; Blasiole et al. 2006), limitations in their social 
functioning (Blasiole et al. 2006) and financial affairs (van der Plas et al. 2004).  
3.4.1 HRQOL of Liver Disease Patients Compared with Healthy People 
Evidence from observational studies found a significant difference in HRQOL 
between patients with liver disease and healthy people. For instance, in the US, 
patients with liver disease as a result of various causes (viral, cholestatic and 
hepatocelluer) and at different stages of liver diseases had a poorer HRQOL than 
the healthy population in domains of mental (MCS) and physical health (PCS) using 
SF-36 (Younossi et al. 2001). Similarly, Hauser et al. (2004) found that patients 
with chronic HCV had a poorer physical and mental health domains (SF-36) (PCS: 
40.94±12.06 and MCS: 43.21±11.98 respectively) than the healthy German 
population.  
Additionally, liver disease patients, particularly at the cirrhotic stage, had a 
significantly lower HRQOL in all domains of SF-36 than healthy Italian people. The 
largest differences were observed in role limitations due to physical and emotional 
problems (39% and 31% respectively), perceived general health (24%) and bodily 
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pain (6%) (Marchesini et al. 2001). Similarly, HRQOL in all domains of SF-36 was 
poorer in viral liver disease patients due to HCV and HBV than in the healthy Greek 
population (Karaivazoglou et al. 2010). The greatest impairments were in the 
domains of role limitation due to emotional problems (41.7%), perceived general 
health (67.9%) and mental health (52.4%) (Karaivazoglou et al. 2010). Girgrah et 
al. (2003) showed that cirrhotic patients in Canada had significant impairment 
(p≤0.01) in all domains and component summary scores (SF-36) except in the 
domain of bodily pain. It may be that the experience of physical pain may be low in 
liver disease patients, although the relatively small sample size may have 
contributed to the lack of finding a significant difference between liver disease 
patients and healthy people in the domain of bodily pain.  
Most of the reviewed studies from Western and Eastern countries, which used the 
validated generic HRQOL tool (SF-36), found significant differences in the HRQOL 
of liver disease patients and healthy controls people. Patients with liver disease had 
a poorer physical; psychological, social and well-being state than people without 
liver disease. These are the results of liver disease studies in developed countries 
with sufficient resources and a well-developed health system, what about results in 
developing countries, particularly Egypt? 
In Egyptian community-based study, 146 chronically infected people with HCV 
were compared with 1,140 non-infected people. Using the multivariable analysis, 
adjusting for confounding factors (such as age, gender, education and healthcare 
related risks), unexpectedly found that there was no significant difference in all 
domains and component summary scores of SF-12 (score from 0-100), supporting 
that the infected and non-infected people had the same HRQOL (p > 0.05) 
(Schwarzinger et al. 2004).  
50 
 
Many reasons may cause this contradiction in findings. First, the Western studies 
were conducted with liver disease patients who were aware of their disease, while 
in this Egyptian study the people did not know about their serological status. It may 
be that peoples’ awareness is a factor in their perceived health status. Further 
research is needed to find the association between serological awareness and 
perceived HRQOL.  
Secondly, the Western studies investigated patients at mixed stages of disease, 
who attended tertiary or referral hospitals (such as Younossi et al. 2001; Hauser et 
al. 2004) or were members of a liver disease group (van der Plas et al. 2007). In 
the Egyptian study, the researchers investigated a community-based population 
who might be asymptomatic of liver disease, as symptoms experience maybe a 
factor in the perceived HRQOL (Wilson and Cleary 1995).  
Third, the normal comparative group in the Egyptian study may not have been 
representative of Egyptian healthy people, as they were from rural areas and 
therefore likely to suffer from poverty and illiteracy which may be factors in 
perceived HRQOL. For instance, when Schwarzinger et al. (2004) compared the 
HRQOL of healthy rural people in Egypt with healthy people (norm-based sample) 
in the US; there was a significant deterioration in the physical and mental health 
domains (p < 0.0001) of rural Egyptian non-infected people compared to healthy 
US people (Schwarzinger et al. 2004).  
Fourth, although the researcher gave the background for the translation process of 
the SF-12 into Arabic, the SF-12 psychometric properties are unclear and 
questionable in the Schwarzinger et al. (2004) study that might affect the tool 
sensitivity in finding a significant difference. On the other hand, a study was 
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undertaken in three University Hospitals in Egypt to investigate HRQOL of 200 
chronic liver disease patients with HCV (Basal et al. 2011). They used the norm-
based cut-off score of SF-36 (50±10). The results showed that chronically infected 
patients with HCV without advanced decompensated cirrhosis (Child-A and B) had 
poor physical and mental health, with a mean PCS of 38.01 ± 15.78 and MCS of 
39.03 ± 15.05 (Basal et al. 2011).  
In general, literature found that patients with chronic liver disease had poorer 
HRQOL than healthy people. However, there is a difference between countries as 
to which domains of HRQOL patients perceived as worse. Additionally, little is 
known about the HRQOL of liver disease patients in Egypt.  
3.4.2 Criteria of Classifying Liver Disease into Stages 
There was inconsistency in classifying liver disease into stages across all 54 
studies. Figure 3-2 and Table 3-4 summarise the studies that used/did not use 
disease stage criteria. The Child-Pugh score is the most commonly used method to 
categorize liver disease into stages A (mild), B (moderate) or C (worse) based on 
laboratory and clinical data, to determine disease severity. It is a tool incorporating 
five laboratory and clinical variables: ascites, encephalopathy, prothrombin time, 
serum levels of bilirubin and albumin (Cholongitas et al. 2005).  
One study used only a Model of End-Stage Liver Disease (MELD) (Bajaj 2008). 
Three studies used both the Child-Pugh score and MELD to report disease severity 
(Kalaitzakis et al. 2006; Kalaitzakis et al. 2008; Wunsch et al. 2011). MELD is a tool 
that includes three laboratory variables: international normalized ratio, serum 
creatinine, and serum bilirubin. The Child-Pugh score and MELD are usually used 
to predict the survival rate in liver disease patients (Kamath and Kim 2007). 
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However, in a recent systematic review of the accuracy of MELD vs. Child-Pugh 
score in liver disease patients the results showed that MELD was not any more 
sensitive than the Child-Pugh score (Cholongitas et al. 2005).  
Other studies categorized cirrhosis according to the presence of liver disease 
complications during the year of data collection, as in compensated and 
decompensated cirrhosis (van der Plas et al. 2003; van der Plas et al. 2004; 
Gutteling et al. 2006; van der Plas et al. 2007; Hsu et al. 2009). This method does 
not need recent laboratory data, which may not be available during a cross-
sectional survey.  
A few studies used criteria that are based on invasive procedures to categorize 
disease stages, for example, the Ishak Fibrosis score (Svirtlih et al. 2008). The 
Ishak Fibrosis score is based on liver biopsies to categorize liver disease from early 
fibrosis to cirrhosis. It ranges from 0–6, with 5-6 being the cirrhosis stage (Everhart 
et al. 2010). Similarly, the histological fibrosis score according to the METAVIR 
scoring system (Constant et al. 2005; Hilsabeck et al. 2005) is also based on liver 
biopsies. However, 10 studies used no criteria to categorize liver disease into 
stages, and no explanations for this omission were given. Therefore, the 
discrepancy in the method made it difficult to compare the studies' findings. 
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Figure 3-2: Criteria for categorising liver disease into stages 
 
  
 
 
 
 
 
 
 
 
 
 
 
In conclusion, the Child-Pugh score is the most commonly used criteria for 
classifying cirrhosis into three stages, where Child-Pugh A is considered 
compensated cirrhosis and Child-Pugh B/C is considered decompensated cirrhosis. 
Therefore, the Child-Pugh score is most appropriate if recent laboratory and clinical 
data are available. Otherwise, other criteria that classify disease according to 
recent liver disease complications through the year of data collection are available.  
One study used the METAVIR 
scoring system. 
Three studies used the Ishak 
Fibrosis score. 
One study used the Fibrosis score 
without specifying its name.  
54 studies  
 
5 studies used liver disease 
complications: compensated or 
decompensated.  
 
29 studies used the Child-
Pugh score based on 
laboratory results: Child A, 
B or C. 
 
5 studies used criteria 
based on invasive 
procedures: liver 
biopsies.  
 
 
38 studies used criteria based 
on non-invasive procedures.  
44 studies used criteria  10 studies did not use 
criteria  
3 studies used both the Child-
Pugh score and MELD. 
 
One study used 
MELD. 
 
1 study used criteria based on 
non-invasive and invasive 
procedures: Child-Pugh and 
METAVIR. 
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Table 3-4: Criteria for categorising liver disease into stages  
Study Non-invasive criteria Invasive criteria Criteria not 
available Child-Pugh score Complications MELD Fibrosis score METAVIR 
1. Afendy et al. 2009 √      
2. Arguedas et al. 2003 √      
3. Bailey et al. 2009      × 
4. Bajaj 2008   √    
5. Bao et al. 2007 √      
6. Basal et al. 2011 √      
7. Bianchi et al. 2005 √      
8. Blasiole et al. 2006 √      
9. Bondini et al. 2007 √      
10.Constant et al. 2005     √  
11.Cordoba et al. 1998 √      
12.Dan et al. 2008 √      
13.Davis et al. 1998 √      
14.Dwight et al. 2000      × 
15.Elshahawi et al. 2011 √      
16.Erim et al. 2010      × 
17.Fritz and Hammer 2009 √      
18.Girgrah et al. 2003 √      
19.Gutteling et al. 2006  √     
20.Haag et al. 2008 √      
21.Hauser et al. 2004 √      
22.Hilsabeck et al. 2005 √    √  
23.Hsu et al. 2009  √     
24.Jover et al. 2005 √      
25.Kalaitzakis et al. 2006 √  √    
26.Kalaitzakis et al. 2008 √  √    
27.Karaivazoglou et al. 2007 √      
28.Karaivazoglou et al. 2010    Ishak Fibrosis   
55 
 
Study Non-invasive criteria Invasive criteria Criteria not 
available Child-Pugh score Complications MELD Fibrosis score METAVIR 
29.Kim et al. 2006 √      
30.Kim et al. 2006a √      
31.Kraus et al. 2000      × 
32.Les et al. 2010 √      
33.Liu et al. 2012       × 
34.Marchesini et al. 2001 √      
35.Moyer et al. 2003      × 
36.Rakoski et al. 2012      × 
37.Schwarzinger et al. 2004      × 
38.Singh et al. 1997 √      
39.Sobhonslidsuk et al. 2006 √      
40.Sumskiene et al. 2006 √      
41.Svirtlih et al. 2008    Ishak Fibrosis   
42.Taliani et al. 2007      × 
43.Teixeira et al. 2005 √      
44.Teixeira et al. 2006      × 
45.Teuber et al. 2008    Ishak Fibrosis   
46.Toda et al. 2005 √      
47.van der Plas et al. 2003  √     
48.van der Plas et al. 2004  √     
49.van der Plas et al. 2007  √     
50.Wilson et al. 2010    Fibrosis scale   
51.Wu et al. 2012 √      
52.Wunsch et al. 2011 √  √    
53.Younossi et al. 2001 √      
54.Zandi et al. 2005 √      
Total 33 5 4 4 2 10 
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3.4.3 Liver Disease Stage and Perceived HRQOL 
A considerable reduction of HRQOL with advanced liver disease has been reported 
in several observational studies (22 in total) (Table 3-5).  
The disease specific HRQOL questionnaire (LDSI-2.0) showed that cirrhotic 
(compensated and decompensated) patients had a higher probability of 
experiencing physical and psychosocial problems due to liver disease than non-
cirrhotic patients (van der Plas et al. 2003). Cirrhotic patients (compensated and 
decompensated) were more likely than non-cirrhotic to report personality changes, 
memory problems, itch, jaundice and sleepiness (p≤0.03). However, with advanced 
stage of cirrhosis, particularly with decompensated cirrhosis, patients had a higher 
probability of reporting worry about family situation, right abdominal pain, 
decreased appetite, financial problems, fear of disease complications, and 
depression (p≤0.01) (van der Plas et al. 2003).  
Furthermore, using the disease specific HRQOL tool (CLDQ), there was no 
significant difference in perceived disease specific HRQOL between Child-B and 
Child-C. Both had higher abdominal symptoms and fatigue compared to Child-A. 
However, Child-B had a higher worry compared to Child-A, while Child-C had 
higher systemic symptoms compared to Child-A (p<0.05) (Bao et al. 2007). This 
study contributed to the understanding of how patients with chronic liver disease 
perceived their generic and disease specific HRQOL according to disease stage. 
However, the discrepancy in findings caused difficulties to find the relevancy of 
disease stage to perceived fatigue between Child-B and Child-C cirrhosis. For 
example, the SF-36 found a significant reduction in vitality (i.e. increase in fatigue) 
with Child-C compared to Child-B, while CLDQ found a similar fatigue level. 
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However, using both tools, the results supported that with advanced stage of 
cirrhosis there was a reduction in physical health.  
Significant deterioration in physical health only (PCS/SF-36) with advanced 
cirrhosis has been identified in several studies (Younossi et al. 2001; Arguedas et 
al. 2003; Haag et al. 2008; Hsu et al. 2009; Les et al. 2010). For instance, 
decompensated cirrhotic patients (Child-C) had significantly poorer physical health 
domains, with higher limitations due to physical problems, bodily pain, poor 
perceived general health, and poor social functioning (p<0.04) compared to 
patients with compensated cirrhosis (Child-A) (Arguedas et al. 2003). Using 
multivariate analysis, the Child-Pugh score was significantly associated with the 
majority of physical health domains: PF, RP and GH (p<0.05) (Sobhonslidsuk et al. 
2006), and physical health (PCS ≤0.04), but it was not associated with mental 
health domains (MCS) (Kalaitzakis et al. 2006; Haag et al. 2008). It may be that 
disease stage influences physical health more than mental health in liver disease 
cirrhotic patients.  
In a recent study, Afendy et al. (2009) compared US and Italian liver disease 
patients. There was a significant difference in the perceived HRQOL between 
Italian and American cirrhotic patients. Italian cirrhotic patients had a significantly 
better HRQOL in the domains of BP, VT and PCS, whereas US cirrhotic patients 
had better HRQOL in the domains of RE, MH and MCS. This suggests that cirrhotic 
Italian patients had better perceived physical health while US cirrhotic patients had 
better mental health. Thus, the cultural background of the patient may be a factor 
related to perceived HRQOL. 
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In the light of these findings, it appears that disease stage can influence HRQOL 
from different aspects, particularly physical health. However, these findings may not 
be applicable to Egyptian patients as the cultural and environmental context is 
obviously different. Also, there is no available knowledge that could contribute to 
gaining insight into how cirrhotic patients in Egypt perceive their HRQOL, and 
whether the disease stage influences their HRQOL.  
The only identified study that examined HRQOL using SF-36 in liver disease 
patients in Egypt, Basal et al. (2011) showed opposite findings to the rest of the 
literature in terms of the association between disease stage and perceived physical 
and mental health. They found that there was no significant difference in HRQOL 
according to disease stage. However, these findings may be questionable, due to 
the relative sample size and the focus on the early stages of liver disease (Child-A 
and B). Therefore, this link between disease stage and perceived HRQOL of 
Egyptian liver disease patients, particularly with cirrhosis, needs to be investigated. 
It is important to find how patients with decompensated cirrhosis perceive their 
HRQOL compared to patients with compensated cirrhosis and compare them to 
normal population. Furthermore, the reviewed studies were observational studies 
with "snap shot" recruitment. Therefore, it is recommended to develop longitudinal 
studies with a reasonable sample size of cirrhotic patients, to find the evidence of 
any causal association between disease stage and perceived HRQOL. 
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Table 3-5: Studies investigating the influence of liver disease stage on HRQOL using SF-36 or SF-12 
Author/Country Methodology Key results 
Sample size (for comparison: sample size per 
group) 
Criteria of classifying 
disease stage 
 
Afendy et al. 2009 
USA 
1103 cohort sample-from databases of liver 
disease centres in US and Italy. 
Sample was divided into: Group (G)1: alcoholic 
=175, Group2: viral hepatitis =714, G3: 
autoimmune hepatitis =13, G4: cholestatic liver 
disease =119, G5: non-alcoholic fatty liver =67 
(number of patients with cirrhosis =761/69%) 
Mean age for all samples (54.2±12.0). All non-
alcoholic fatty liver disease was found in females. 
 
 
Child-Pugh score  Cirrhotic patients had poorer HRQOL than non-cirrhotic in all 
domains and component summary scores of SF-36 (delta 
score=6.6-34, p<0.05). Patients with Child-A had better 
HRQOL in all domains and PCS than Child-B cirrhosis and 
they had better MCS than Child-C. No significant difference in 
domains of component summary scores of SF-36 between 
Child-B and Child-C. Regression test, presence of cirrhosis 
predicted PCS and MCS. Significant difference in perceived 
HRQOL between Italian and American cirrhotic patients. Italian 
cirrhotic patients had significantly better HRQOL in domains of 
BP, VT and PCS. American cirrhotic patients had better 
HRQOL in domains of RE, MH and MCS.  
Bao et al. 2007 
China 
126: 20 chronic HBV, 28 Child-A, 78 Child-B/C 
 
Child-Pugh score  Disease severity associated with impaired HRQOL in all 
domains of SF-36 in patients with Child-B/C compared to 
Child-A (p<0.01). Disease severity related to poor disease 
specific HRQOL (CLDQ) in these domains (p<0.05): Child-B 
had poorer abdominal symptom, fatigue and worry compared 
to Child-A. Child-C had poorer abdominal symptom, fatigue 
and systematic symptoms compared to Child-A. Child-C had 
poorer HRQOL than Child-B in these domains of SF-36: RP 
and VT (p<0.05). 
Basal et al. 2011 
Egypt 
27 Child-A, 173 Child-B Child-Pugh score No significant difference in MCS and PCS between Child-A 
and Child-B cirrhosis.  
Dan et al. 2008 
USA 
140 patients with mixed disease stage: 88 non-
cirrhosis, 54 cirrhosis (28 Child A and 26 Child 
B/C), mean age 49.4±11.2, 42% females, 36% 
Child-Pugh score Cirrhotic patients had lower HRQOL in all domains than non-
cirrhotic patients (p<0.05). Child B/C had poorer HRQOL than 
Child-A cirrhosis  
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Author/Country Methodology Key results 
Sample size (for comparison: sample size per 
group) 
Criteria of classifying 
disease stage 
 
HBV, 29% HCV, 24% had cholestatic liver 
disease. 
Teixeira et al. 
2005 
Brazil  
103 patients (with liver cirrhosis) 
G1: 63 cirrhosis 
G2: 40 without cirrhosis, Cirrhotic group: mean 
age 46±9.2, 64.4% men. Child-A= 53.98%, B= 
22.22%, C= 23.80%.  
 
Child-Pugh score Cirrhotic patients had lower QOL than non-cirrhotic patients 
especially patients in the end stage of cirrhosis (Child-C). 
Decompensated cirrhotic patients had higher severity of 
concentration and memory problems, higher problems in 
sexual function, sleep, liver disease effect, quality of social 
interaction, loneliness, hopelessness, health distress and liver 
disease stigma than compensated cirrhotic patients. 
Fritz and Hammer 
2009 
Australia 
75 cirrhotic patients 
Disease severity: 37 Child-A, 34 Child-B and 4 
Child-C. Causes of cirrhosis: 68% alcohol, 10.7% 
viral B or C and 21.3% others. Mean age 57±1.4 
(range 24-82), 56% males. 
Child-Pugh score Child-A had similar HRQOL (PCS and MCS) to healthy people. 
Child-B had lower PCS than Child-A (p=0.006), no significant 
difference in MCS.    
Girgrah et al. 
2003 
Canada 
30 patients with cirrhosis,  
Disease stages: Child-A=12, Child-B/C=18 
Mean age 54.4±3.1, 93.3% males. 
Causes: 60% alcoholic, 30% HCV, 10% others. 
Child-Pugh score No significant correlation between disease severity (Child-
Pugh score or laboratory results) and PCS or MCS. Patients 
with Child-B or C (decompensated cirrhosis) had lower PCS 
and PF than Child-A (compensated cirrhosis) (p<0.01). No 
significant difference in MCS according to disease stage.  
Gutteling et al. 
2006 
Netherlands 
1175 patients with mixed disease stages: Disease 
severity: 42.5% non-cirrhosis 34% compensated, 
7.3% decompensated 16.2% liver transplant.  
Mean age 48±12, 42.3% males  
Causes: autoimmune 12.7% hepatitis, 24.6% 
HCV, 15.7% Primary Biliary Cirrhosis (PBC). and 
16.6% liver transplantation.  
Complications  Disease severity was strongly related to poor HRQOL among 
patients with HCV. With increasing disease severity there was 
more deterioration in HRQOL (Beta=-0.02, p<0.01). 
 
Haag et al. 2008 
Germany 
204 patients with chronic liver disease and 181 
patients with functional dyspepsia. 
Disease severity: 100 had cirrhosis (Child-A=39, 
Child-Pugh score Child-C cirrhosis had poorer PCS than Child-A and B (p=0.02). 
No significant difference in MCS according to disease severity. 
Disease severity associated with PCS (p=0.04) but not MCS. 
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Author/Country Methodology Key results 
Sample size (for comparison: sample size per 
group) 
Criteria of classifying 
disease stage 
 
B=28, C=33). Causes of liver disease: HCV & 
HBV=101, alcoholic= 63, autoimmune/PBC=12, 
idiopathic= 28. 
Chronic liver disease group: mean age 52.7±13.9, 
49% women,    
Functional dyspepsia group: mean age 44.7±14 
64% women.  
Hauser et al. 
2004 
Germany 
88 patients with chronic HCV. 
Disease stage: 70.4% non-cirrhosis, 17.0% Child-
A, 12.5% Child-B/C, 23.9% on interferon therapy. 
Mean age 48.6%±14.6, 50% females, 
Child-Pugh score Disease severity could not associate withPCS or MCS.  
Hsu et al. 2009 
Canada 
271 patients with chronic HCV. 
Disease severity: G1:197 had non-cirrhosis, G2: 
17 compensated and G3: 57 decompensated. 
Mean age 49.7±8.6, 62.4% males. 
Complications  Non-cirrhotic group had better HRQOL compared to cirrhotic 
groups in domains of: PF, RE and RP (p<0.005). 
Decompensated cirrhosis had the lowest domains of GH and 
PCS compared to non-cirrhosis and compensated cirrhosis 
(p<0.005).  
Compensated cirrhosis had the lowest RE compared to non-
cirrhosis and decompensated cirrhosis (p<0.005). 
Kalaitzakis et al. 
2006 
Sweden 
128 patients with cirrhosis  
Disease severity: 22% had Child-A cirrhosis and 
78% Child-B or C. causes: 43% alcoholic or 
mixed cirrhosis, 17% viral cirrhosis, 40% other 
causes. 9% hepatic carcinoma, 23% hepatic 
encephalopathy. Mean age 57.2±11.5, 61% 
males, 
Child-Pugh score, MELD Child-Pugh score and MELD were significantly associated with 
PCS, but not with MCS (p<0.005). Child-Pugh score could 
associate withPCS, p<0.05), but not MCS. 
Karaivazoglou et 
al. 2010 
Greece 
84 patients viral hepatitis, HBV=45 and HCV=39 
(matched in socio-demographic and disease 
severity). 
Mean age 46±16.7, 65.5% men. 
Fibrosis scale Fibrosis stage was associated with PCS (p=0.02), but not with 
MCS in HBV group. No significant association between fibrosis 
stage and HRQOL (PCS and MCS) in HCV group. 
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Author/Country Methodology Key results 
Sample size (for comparison: sample size per 
group) 
Criteria of classifying 
disease stage 
 
Les et al. 2010 
Spain 
212 sample with cirrhosis 
Causes: 30.5% alcohol, 16.5% mixed alcoholic 
and HCV, 11% others.  
Mean age 61.5±10.9, 74% males. 
Child-Pugh score All domains of HRQOL were significantly poor according to 
Child-Pugh except domains of general health and mental 
health.  
Marchesini et al. 
2001 
Italy 
544 patients with cirrhosis 
Stages: 38% Child-A, 62% Child-B/C. 
Causes: 64% HCV or HBV, 29% alcoholic, 2% 
PBC. Mean age 60±11 (17-91), 63.9% males. 
Child-Pugh score Using logistic regression: Child-Pugh score was associated 
with PCS but not with MCS. 
Sobhonslidsuk et 
al. 2006 
Thailand 
250 patients with chronic liver disease. Stage: 
23.6% Child-A, 22.4% Child-B/C. Causes: 58.8% 
viral hepatitis C or B, 17.2% alcoholic and 10.8% 
non-alcoholic fatty liver. Mean age 49.1±8.5, 64% 
males  
Child-Pugh score Perceived general health decreased with increasing disease 
severity. Increasing disease severity was significantly 
associated with poor HRQOL domains of: PF, RP, GH and RE. 
Severity of disease was positively predictive PF, RP, GH and 
RE. 
Sumskiene et al. 
2006 
Lithuania 
131 patients with cirrhosis. Stage: 24.6% Child-A, 
75.4% B or C. Causes: 40.5% viral hepatitis, 
38.2% alcoholic, and others.  
Age: 17.6% were <40years, 51.1% were 40-60 
years, 31.3% were > 60 years, 51.9% men. 
Child-Pugh score Disease severity was associated significantly with HRQOL. 
HRQOL was poorer among patients with advanced cirrhosis 
(Child-C) than patients in early stage of cirrhosis (Child-A) 
(p<0.01). 
 
 
Svirtlih et al. 2008 
Serbia 
227 patients with chronic liver disease. Stage: 
184 had chronic hepatitis and 43 had cirrhosis. 
G1: 167 HCV, mean age 39±11 (16-66), G2: 60 
HBV, age 42.5±12 (19-66).   
Ishak Fibrosis score Significant difference in PCS and MCS among patients with 
cirrhosis and patients without cirrhosis. Patients with cirrhosis 
had worse HRQOL. Cirrhosis predicted poor PCS and MCS 
(p=0.000). 
Teuber et al. 2008 
Germany 
215 untreated patients with chronic hepatitis C . 
Stage of fibrosis: 19.5% without fibrosis, 42.3% 
mild fibrosis, 21.4 moderate, 16.7% severe 
Ishak Fibrosis score Fibrosis was significantly predictive of PCS (P=0.01), but not of 
MCS. Patients with severe fibrosis or cirrhosis lower PCS than 
patients at early stage of cirrhosis. No significant association 
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Author/Country Methodology Key results 
Sample size (for comparison: sample size per 
group) 
Criteria of classifying 
disease stage 
 
fibrosis or cirrhosis. Mean age 46.7±13.4 (19-79), 
57% males 
 
between histological activity of the disease and the HRQOL 
(PCS and MCS). The main affected domains due to disease 
severity were PF, PR, and GH (p≤0.001). 
van der Plas et al. 
2003 
Netherlands 
 
1175 cohort sample of patients with chronic liver 
disease.  
G1: 489 non-cirrhosis, mean age 48±12, 43.8% 
males. G2: 391 had compensated cirrhosis, mean 
age 49±14, 41.4% males. G3: 84 
decompensated, mean age 50±12, 42.9% males. 
Viral hepatitis: G1: 36.3%, G2: 20.9%, G3: 30.3%, 
G4: 186 transplanted patients 
Complications  Decompensated cirrhotic patients had lower HRQOL than non-
cirrhotic patients. Fatigue was worse among decompensated 
cirrhotic patients. 
 
Wunsch et al. 
2011 
Poland 
77 patients with cirrhosis. 61% males 
Sample of patients with cirrhosis was divided into 
two groups: with and without minimal 
encephalopathy. There was no significant 
difference between 2 groups regarding to age, 
gender, education, cause or disease severity. 
Mean age 52.8±13.1, (22-84 years). 
Child-Pugh score, MELD Disease severity (using MELD score) was significantly 
associated with poor PCS and MCS (p≤0.03). Disease severity 
(using Child-Pugh score) was not significantly associated with 
poor HRQOL  
Younossi et al. 
2001 
USA 
353 patients with different causes of liver disease. 
G1: 133 viral disease, mean age 46±9, 64.7% 
males, Child-A=18.1%, Child-B/C = 24%. G2: 126 
cholestatic liver disease (PBC and others), 35.5% 
Child-A, 25.6% Child-B/C, mean age 54±11, 
30.2% males. G3: 94 hepatocellular disease 
(alcoholic, genetics and other), 43.6% Alcoholic, 
35% Child-A, 61.6% Child-B/C, cirrhosis mean 
age 52±13, 59.6% males 
Child-Pugh score HRQOL decreased with increasing disease severity, cirrhotic 
had lower HRQOL than non-cirrhotic. Cirrhosis significantly 
affected many domains of HRQOL according to causes of 
cirrhosis. Cholestatic cirrhosis had significantly poorer PF, RF, 
RE, GH and SF and PCS than patients with cirrhosis due to 
hepatocellular disease (p<0.01). 
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3.4.4 HRQOL of Egyptian Cirrhotic Patients  
Little is known about cirrhotic patients in the Middle East, particularly in Egypt. Out 
of the 37 identified studies, only two studies by Schwarzinger et al. (2004) and 
Basal et al. (2011) examined the HRQOL of Egyptian patients with chronic HCV. 
Basal et al. (2011) studied patients with chronic liver disease related to HCV at 
stage A and B according to the Child-Pugh score, but did not investigate the 
advanced stage of cirrhosis. Schwarzinger et al. (2004) investigated non-cirrhotic 
chronic liver disease related to HCV in people unaware of their serological status 
and in a rural community. Although these two Egyptian studies contributed to the 
understanding of perceived HRQOL of liver disease patients, the findings were 
inconclusive and may not be applicable to liver cirrhotic patients. The two studies 
investigated liver disease related to HCV and ignored other causes such as 
bilharzias and viral HBV, although the cause may lead to a different perception of 
HRQOL. Thus, there is a need to examine the HRQOL of patients with 
compensated and decompensated cirrhosis because of mixed causes in Egypt to 
find out how these people perceive their health status.  
3.5 FACTORS CONTRIBUTING TO THE UNDERSTANDING OF HRQOL 
Several studies examined factors associated with the HRQOL in liver disease 
patients. Most of these studies focused on patients with mixed chronic liver disease 
stages (van der Plas et al. 2004; Gutteling et al. 2006; Sobhonslidsuk et al. 2006; 
Afendy et al. 2009; Dan et al. 2008; Haag et al. 2008; Hsu et al. 2009; Liu et al. 
2012) with relatively small samples of cirrhotic patients (Younossi et al. 2001; 
Hauser et al. 2004; Toda et al. 2005; Teixeira et al. 2006; Bondini et al. 2007; 
Taliani et al. 2007; Svirtlih et al. 2008; Teuber et al. 2008; Wilson et al. 2010) or 
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without cirrhosis (Karaivazoglou et al. 2010). Other studies focused on investigating 
HRQOL and related factors only in patients with cirrhosis (11 in total). It is difficult 
to make comparisons of all the reviewed papers, because HRQOL is a 
multidimensional concept that can be measured by different tools. These tools 
involve different categories of domains, for example SF-36 and NHP. Thus, only 
the studies that (1) examined only patients with cirrhosis, (2) investigated perceived 
HRQOL as a main outcome and (3) used SF-36 or SF-12 were reviewed. However, 
other studies examining mixed disease stages were used to support the discussion 
about the association between independent variables and HRQOL, if they were 
relevant (Table 3-6 summarises these studies).  
In these studies several factors contributed to the perceived HRQOL in patients 
with cirrhosis. These factors include: (1) demographic characteristics and economic 
status, (2) environmental factors: social support, (3) bio-physiological factors and 
(4) symptoms experience. All these factors were analysed and discussed 
separately. Diagram 3-2 summarises all factors correlated with HRQOL in patients 
with liver cirrhosis.  
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Table 3-6: Studies investigating factors related to HRQOL in chronic liver disease and cirrhotic patients  
Author/Country Methodology Results 
Design, sample 
method 
Sample size 
Afendy et al. 2009 
USA 
 
 
Cohort study, 
sample from databases 
  
1103 from US and Italia, number of 
patients with cirrhosis=761/69%) 
 
Factors: Age associated with domains of SF-36 even after 
controlling confounding factors (i.e. gender, presence of cirrhosis, 
ethnicity). Females had poorer HRQOL than males in (PF, RP, 
BP, GH, VT and MH). Italians had better HRQOL than Americans 
in domains of BP, VT, and PCS. Americans had better HRQOL 
than Italians in domains of RE, MH and MCS. Regression test: 
age, presence of cirrhosis, ethnicity, gender, and cause of disease 
predicted PCS. Ethnicity, gender, presence of cirrhosis, cause of 
disease predicted MCS. 
Arguedas et al. 2003 
USA 
Cross-section, 
consecutive  
 
160 patients with cirrhosis 
 
 
 
Factors: PCS was significantly lower in patients with previous 
history of hospitalization due to hepatic encephalopathy and 
among patients with ascites. No significant difference in MCS 
according to disease severity, history of hospitalization and 
presence of ascites. Patients with grade 1 HE (overt) had 
significantly lower PCS and MCS than patients without 
encephalopathy. Patients with subclinical encephalopathy had 
lower MCS than patients without it. The most affected domains 
were RE, MH and SF. No significant difference in MCS and PCS 
according to age, gender, ethnicity and cause of cirrhosis. 
Bao et al. 2007 
China  
NA (seems cross-
section), NA 
126 patients with chronic liver 
disease divided into 20 with HBV and 
106 with cirrhosis 
 
Factors: Disease severity associated positively with increasing 
impaired domains of HRQOL in both SF-36 and CLDQ. Patients 
with decompensated cirrhosis (Child-B or C) had similar HRQOL 
in disease specific and generic HRQOL, with the exception of VT 
and RP. Significant difference between patients with minimal 
encephalopathy and patients without it on SF-36, and only a 
significant difference the domain of abdominal symptoms in 
CLDQ. 
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Author/Country Methodology Results 
Design, sample 
method 
Sample size 
Basal et al. 2011 
Egypt 
Descriptive cross-
section, Convenient 
200 patients with chronic liver 
disease, Child-A or Child-B  
 
Factors: Age and level of education were significantly associated 
with PCS, comorbidity and occupations significantly associated 
with MCS. No significant association between gender, marital 
status, income, severity of disease and both PCS and MCS. 
Dan et al. 2008 
USA 
Retrospective, cohort 
sample/from databases  
140 patients with chronic liver 
disease (38% had cirrhosis). 
Factors: Mental health was not significantly different in patients 
with cirrhosis and patients without. Cirrhotic patients had poor 
health utility and the worst domains were emotion, mobility, self-
care and sensation. Domains of cognition and pain were not 
significantly different between cirrhotic and non-cirrhotic patients.  
Females had poorer HRQOL, cognition and mobility than males. 
Older people had poorer PF and sensation. Regression test: 
gender (female) and having HCV significantly predicted poor 
HRQOL (SF-6D). Age and disease stage (cirrhosis) did not 
significantly associate withHRQOL, although cirrhosis significantly 
predicted health utility.     
Fritz and Hammer 2009 
Australia 
NA (seems cross-
section), consecutive 
75 patients with liver cirrhosis  
 
Factors: Disease severity associated significantly with poor 
HRQOL. No significant difference between patients with cirrhosis 
and the normal population in PCS and MCS. There was a 
significant difference between Child-B and Child-A and the 
HRQOL of the normal population, decompensated cirrhosis had a 
worse HRQOL. The most significant difference according to 
disease stage was PCS; but there was no significant difference in 
MCS. 
Girgrah et al. 2003 
Canada 
NA (seems cross-
section),, NA 
30 patients with cirrhosis 
 
Factors: No significant correlation between disease severity 
(Child-Pugh score or laboratory results) and PCS or MCS. 
However, patients with Child-B or C (decompensated cirrhosis) 
had lower PCS and PF than Child-A (compensated cirrhosis). 
Gutteling et al. 2006 
Netherlands 
NA (seems cross-
section), cohort sample 
from databases 
1175 patients in different liver 
disease stages. 42.5% non-cirrhosis 
34% compensated, 7.3% 
Significant association between experience of symptoms and 
HRQOL. Regression test: positive association between severity of 
symptoms (i.e. joint pain, depression, abdominal pain, decreased 
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Author/Country Methodology Results 
Design, sample 
method 
Sample size 
decompensated 16.2% liver 
transplant.  
appetite and fatigue) and HRQOL. With increasing disease 
severity there was more deterioration in HRQOL. Physical and 
psychosocial factors explained 53% of the variance in HRQOL. 
Demographic and medical factors explained 7% of the variance in 
HRQOL. A weaker significant association between daily time 
management, memory problems, change of personality, age and 
gender and HRQOL. Disease severity, depression, interferon 
therapy, fatigue, joint pain and limitations in financial affairs were 
strongly related to poor HRQOL among patients with HCV.   
Haag et al. 2008 
Germany 
 Prospective, 
consecutive 
204 patients with chronic liver 
disease and 181 patients with 
functional dyspepsia (liver cirrhosis= 
100).   
Factors: Severity of depression and anxiety symptoms and age 
were associated with HRQOL. Age was not associated with 
HRQOL. Regression test: PCS could be explained by disease 
severity, anxiety and age. MCS could be explained by depression 
and anxiety.  
Hsu et al. 2009 
Canada 
 Cross-
section/Comparative 
study, convenience 
271 patients with chronic HCV. (liver 
cirrhosis= 74)  
 
 
  
Factors: significant association between HRQOL and disease 
severity. Non-cirrhotic patients had lower hepatitis distress 
experiences than the cirrhotic patients. Married with a higher 
income had a better HRQOL. Female and older patients and 
those with history of substances abuse had lower MCS. Patients 
with comorbidities had lower HRQOL.  
Kalaitzakis et al. 2006 
Sweden 
Cross-section, 
consecutive 
128 patients with cirrhosis  
  
Factors: Patients with minimal encephalopathy had lower PCS 
and MCS than patients without it. Child-Pugh score predicted PCS 
and MCS. Encephalopathy predicted PCS. Aetiology of cirrhosis 
was not associated with HRQOL.   
Les et al. 2010 
Spain 
Cross-section, 
consecutive  
212 patients with cirrhosis 
 
Factors: Ascites, encephalopathy, low albumin level, prothrombin 
and haemoglobin, decreased mid-arm muscle circumference 
significantly correlated with disease specific HRQOL (CLDQ) and 
PCS. Beta-blockers, diuretics, spontaneous bacterial peritonitis, 
number of medications per day, low plasma, elevated levels of 
creatinine and bilirubin associated with PCS.  Non-alcoholic 
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Author/Country Methodology Results 
Design, sample 
method 
Sample size 
related disease significantly correlated with disease specific 
HRQOL (CLDQ). Sex or age had no significant association with 
PCS or CLDQ.  
Regression test: female sex, non-alcoholic cause of cirrhosis, 
current ascites and decreased albumin level could associate 
withHRQOL (CLDQ). Encephalopathy, ascites, and decreased 
haemoglobin could associate withPCS. Decreased haemoglobin 
and non-alcoholic cause could associate withMCS. 
Marchesini et al. 2001 
Italy 
Cross-sectional survey, 
Recruiting all patients 
who regularly are 
followed up in out-
patient clinic through 6 
months 
544 patients with cirrhosis 
 
Factors: No significant difference in HRQOL according to gender, 
cause of cirrhosis (alcoholic and non-alcoholic) and disease 
duration. Patients younger than 55 had poorer HRQOL. Recent 
admission to hospital, ascites, encephalopathy, daily therapy, 
diuretics, pruritus and muscle cramps correlated with poor PF. 
Muscle cramp and Pruritus associated with all domains of NHP 
(Sleep, energy, pain, emotional reaction, social isolation, physical 
mobility. Ascites, and muscle cramps associated with mental 
health. Hospitalization associated significantly with PF, BP, VT, 
and physical mobility. 
Sobhonslidsuk et al. 2006 
Thailand 
Cross-section, NA 
(seems consecutive) 
250 patients with chronic liver 
disease, (46% had cirrhosis) 
  
 
  
Factors: significant association between increasing disease 
severity and poor HRQOL especially in these domains: PF, RP, 
GH, RE and in all domains of CLDQ. Regression test: severity of 
liver disease was predictive of CLDQ and PF, RP, GH and RE 
(SF-36). Financial burden associated negatively with most of SF-
36 domains and CLDQ, and it predicted PF and RP. Perceived 
good health associated positively with all domains of (SF-36 and 
CLDQ). Cause of disease did not significantly associate with 
HRQOL. Female gender predicted poor PF, low education 
predicted low VT, type of work predicted RE, age predicted PF, 
RP and BP. 
Jover et al. 2005 Cross-section, 46 patients with cirrhosis  Factors: Patients with extra-pyramidal signs had worse PCS and 
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Author/Country Methodology Results 
Design, sample 
method 
Sample size 
Spain consecutive MCS and disease specific QOL. 
Kalaitzakis et al. 2008 
Sweden 
Cross-section, 
consecutive 
156 patients with cirrhosis 
 
Factor: Child-Pugh score was associated with PCS and MCS. 
Aetiology of cirrhosis was not associated with HRQOL. Child-
Pugh score and encephalopathy were associated with PCS.   
Liu et al. 2012 
Japan 
Cohort study/ collected 
data from databases 
stratified random sample 
from the main data in 
databases. 
 
306 patients with HCV After matching groups: all HRQOL of patients with HCV were 
lower than matched healthy group. Work productivity loss and 
healthcare resources use outcomes were worse among patients 
with HCV than matched group. The main affected domains were 
MCS, bodily pain, general health, mental health. Other domains 
were not significantly different between control and HCV groups. 
When controlling comorbidities the HRQOL was still impaired 
among patients with HCV particularly in domains of MH, GH and 
MCS. Domain of pain becomes insignificantly different. Then 
comorbidities may be a factor that may enhance pain perception. 
van der Plas et al. 2004 
Netherlands 
Survey, Consecutive  1175 patients with mix stages of liver 
disease in the main survey: Non-
cirrhotic 42.5%, compensated 
cirrhosis 34%, decompensated 7.3%, 
liver transplant 16.2%. group of 
clinical patients with liver disease in 
pilot study=69 
Significant positive association between symptoms experience 
(severity and hindrance) and HRQOL. Hindrance of symptom was 
strongly related to poor HRQOL more than the severity of 
symptoms. 
Wunsch et al. 2011 
Poland 
NA, consecutive 77 patients with cirrhosis.  Factors: Disease severity using the model of end-stage liver 
disease (MELD score) correlated significantly with poor HRQOL in 
most of the SF-36 subscales, and only with activity subscale of 
CLDQ. No association between disease severity (using Child-
Pugh score) and HRQOL. 
NA: not available  
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Diagram 3-2: Summary of factors that may contribute to explain HRQOL in patients with liver cirrhosis  
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3.5.1 Demographic Characteristics  
Several studies investigated the association between demographic characteristics 
and socio-economic status and HRQOL in cirrhotic patients. Table 3-7 summarises 
the studies that examined these variables in relation to HRQOL (i.e. physical and 
mental health) in cirrhotic patients.  
The studies had conflicting findings about the association between age and gender 
and HRQOL (Table 3-7). For example, Afendy et al. (2009) and Basal et al. (2011) 
found that age was significantly associated with physical health domains (SF-36), 
with elderly people more likely to experience poor physical health. Dan et al. 
(2008), similarly, showed that older patients had poorer physical functioning and 
sensation than younger ones. However, age was not significantly associated with 
mental health domains (Afendy et al. 2009; Basal et al. 2011). Kim et al. (2006) 
investigated QOL and psychological distress in cirrhotic patients, finding that age 
was not associated with perceived QOL (Quality of Life Index) or psychological 
distress. Therefore, it seems that age is more likely to be associated with physical 
health and less likely with mental health domains in cirrhotic patients.  
A few studies found that gender was related to perceived HRQOL in cirrhotic 
patients. Females were more likely than males to experience poor mental health 
domains (SF-36), and being female was associated with poor mental health 
domains (Afendy et al. 2009). However, in the Egyptian study, Basal et al. (2011) 
found that there was no significant different (p ≥ 0.2) between males and females' 
physical and mental health domains (SF-36). On balance, it appears that there is 
an association between age and gender and perceived HRQOL, without knowing 
whether physical or mental health domains are more affected. However, further 
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studies are needed to find the influence of gender and age on the HRQOL of 
cirrhotic patients.   
3.5.1.1 Socio-economic Status 
Employment status, occupation, level of education and income are the key 
indicators of socio-economic status. Although the association between socio-
economic status and HRQOL was investigated in cirrhotic patients (Table 3-8), 
different indicators of socio-economic status were used that making comparison 
difficult. For example, one study in Egypt investigated many indicators (type of 
work, education and income level) of socio-economic status and its association with 
HRQOL (Basal et al. 2011). The results showed that type of work (i.e. housewives, 
officers, teachers and farmers) was significantly associated with mental health, but 
not with physical health (Basal et al. 2011). Educational level was also significantly 
associated with physical health, but not with mental health. Congruent with these 
findings, education in the study by Kim et al. (2006) was not associated with the 
overall QOL or psychological distress in patients with cirrhosis due to mixed 
causes. This suggests that education may be related to perceived physical heath, 
but not mental health. However, further studies are required to develop the 
evidence of this association.  
Patients with decompensated cirrhosis had a higher probability of financial 
problems (van der Plas et al. 2003). About 33.3% of cirrhotic men reported that 
paid employment was the aspect most affected in their daily life (using NHP) 
(Marchesini et al. 2001). Also, 40% of patients less than 55 years old perceived 
their health status as a problem for employment (Marchesini et al. 2001). However, 
income was not significantly related to both physical and mental health domains 
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(Basal et al. 2011). This might be due to using invalid methods for assessing 
income, e.g. enough or not enough from the patients' perception. 
Unemployed cirrhotic patients were more likely to have a poorer QOL than 
employed patients. Employment status (current work or not) was associated with 
QOL (Kim et al. 2006), suggesting that cirrhotic patients who were unable to work 
were more likely to experience depression than patients who were able to work. 
These results suggest that liver cirrhotic patients are more liable to have poor 
socio-economic status, which consequently affects their health status and overall 
QOL. However, further research is required to assess socio-economic status in 
cirrhotic patients using valid tools to measure the influence of socio-economic 
status on perceived HRQOL.  
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Table 3-7: Studies investigating the association between demographic characteristics, socio-economic status and HRQOL in cirrhotic patients  
Study  Association between demographic variables and HRQOL 
 
Association between economic status variables and HRQOL 
Physical health Mental health 
 
Physical health  Mental health  
Age  Gender  Marital 
status  
Ethnicity  Age  Gender  Marital 
status  
Ethnicity  Income  Employment 
status 
Career 
type  
Education  Income  Employment 
status 
Career 
type 
Education  
Afendy et al. 
2009 
√ √ / / × √ 
 
/ / / / / / / / / / 
Arguedas et 
al. 2003 
× × / × × × / × / / / / / / / / 
Bao et al. 
2007 
/ / / / / / / / / / / / / / / / 
Basal et al. 
2011 
√ × × / × × × / × / × √ × / √ × 
Fritz and 
Hammer 
2009 
/ / / / / / / / / / / / / / / / 
Girgrah et 
al. 2003 
/ / / / / / / / / / / / / / / / 
Jover et al. 
2005 
/ / / / / / / / / / / / / / / / 
Kalaitzakis 
et al. 2006  
× × / / × × / / / / / / / / / / 
Kalaitzakis 
et al. 2008 
/ / / / / / / / / / / / / / / / 
Les et al. 
2010 
× × / / × × / / / / / / / / / / 
Marchesini 
et al. 2001 
√ √ / / × × / / / / / / / / / / 
Wunsch et / / / / / / / / / / / / / / / / 
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Study  Association between demographic variables and HRQOL 
 
Association between economic status variables and HRQOL 
Physical health Mental health 
 
Physical health  Mental health  
Age  Gender  Marital 
status  
Ethnicity  Age  Gender  Marital 
status  
Ethnicity  Income  Employment 
status 
Career 
type  
Education  Income  Employment 
status 
Career 
type 
Education  
al. 2011 
√…significant association  
×…not significantly associated  
/….association was not studied  
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3.5.2 Environmental Characteristics 
3.5.2.1 Ethnicity  
Only two studies investigated the association between ethnic background and 
perceived HRQOL in cirrhotic patients (Arguedas et al. 2003; Afendy et al. 2009). 
For example, in the study by Arguedas et al. (2003) in 160 cirrhotic patients there 
was no significant difference in physical and mental health domains according to 
their ethnicity (Caucasian/African, American and other). However, the large cohort 
study (n = 1103) by Afendy et al. (2009) assessed HRQOL according to the country 
of origin (i.e. Italian and American). The results showed that Italians had a better 
HRQOL than Americans in the domains of BP, VT, and PF. In the domains of RE, 
MH and MCS were better among Americans than Italians.  
Indeed, there were considerable discrepancies between these two studies to make 
them incomparable. For example, Afendy et al. (2009) studied patients in their own 
countries, while Arguedas et al. (2003) studied patients who were already living in 
the US. Therefore, it seems that the environment in terms of cultural and ethnic 
background may be a factor that can affect people’s perceptions about their health. 
Afendy et al.'s (2009) study contributed by showing the importance of cultural 
background and its relevance to specific domains of HRQOL.  
3.5.2.2 Marital status 
The association between marital status and perceived HRQOL is well documented 
in patients with other chronic diseases such as cardiac disease (Lee et al. 2005). 
However, little is known about this association in liver disease patients, particularly 
among cirrhotic patients. Few studies examined the association between marital 
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status and HRQOL (Hsu et al. 2009; Basal et al. 2011) and QOL (Kim et al. 2006) 
However, it appears that a relationship between marital status and HRQOL or QOL 
is not supported; the studies involved relatively small sample sizes with different 
disease stage and used different tools. For example, Basal et al. (2011) showed 
that marital status was not associated with HRQOL, as there was no significant 
difference in domains of physical and mental health between married and single 
patients. Similarly, in a study including 129 cirrhotic patients due to different causes 
(i.e. viral hepatitis and alcoholic), Kim et al. (2006) showed that there was no 
significant difference in QOL according to marital status. However, in a study of 271 
patients with mixed stages of HCV (without cirrhosis, compensated and 
decompensated cirrhosis) the results found that married people were more likely to 
have better physical and mental health, than singles (Hsu et al. 2009). 
Theoretically, marital status has been classified as a type of structured social 
support, which describes the existence of a relationship (Cohen and Syme 1985) 
as discussed in Chapter 2, Marital status as a source of support can work directly 
as a buffer against stress, especially during illness. Consequently, it can influence 
perceived physical and mental health. In the theoretical framework of HRQOL 
outcomes (Diagram 4-2), social support has been considered as a mediation factor 
between disease symptoms and perceived HRQOL. Therefore, there is a need for 
more research to establish whether social support (functional support) and marital 
status (structure support) are significant factors in perceived HRQOL in patients 
with cirrhosis.  
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3.5.2.3 Perceived Social Support  
Over the past years, the association between social support and HRQOL has been 
investigated among patients with different cardiac diseases (Bosworth et al. 2000; 
Kristofferzon et al. 2003; Graven and Grant 2012) and cancer (Lutgendorf et al. 
2012; Trevino et al. 2013). A lack of social support was associated with low 
physical and mental health domains (SF-36), and depression. However, little is 
known about the association between the perceived availability of social support 
from informal sources and the perceived HRQOL among patients with liver 
cirrhosis. Only three studies investigating social support in liver disease patients 
were found (Blasiole et al. 2006; Erim et al. 2010; Wilson et al. 2010).  
These studies aimed to assess mental health domains (SF-36) and depression 
(Wilson et al. 2010), coping and depression (Erim et al. 2010) and difficulties of 
social functioning and social support (Blasiole et al. 2006) as a mean outcome in 
patients with chronic HCV. Studies by Erim et al. (2010) and Wilson et al. (2010) 
included patients from outpatient clinics who were diagnosed with chronic HCV but 
not with cirrhosis (Erim et al. 2010; Wilson et al. 2010), while a study by Blasiole et 
al. (2006) included patients with HCV at various disease stages with a relatively 
small sample of cirrhotic patients (23.8%). The studies support the importance of 
social support for decreasing symptoms and improving social functioning. For 
example, patients with high social support had a high sense of coherence (i.e. 
coping with stressors), low depression and few anxiety symptoms (Erim et al. 
2010). Using the SF-36, Wilson et al. (2010) also found that liver disease patients 
with high social functioning had better mental health and lower depression. Based 
on these findings it appears that there is an association between the perceived 
availability of social support and mental health.  
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3.5.3 Biophysical Factors [Medical History and Clinical Data] 
Several biophysical variables were investigated in relation to HRQOL (using SF-
36): (1) cause of liver disease, (2) comorbidities (medical or psychiatric), (3) hepatic 
encephalopathy and (4) other biophysical factors.  
3.5.3.1  Cause of Liver Disease 
A comparison of HRQOL according to the causes of cirrhosis was made in several 
studies (Marchesini et al. 2001; Arguedas et al. 2003; Dan et al. 2008; Kalaitzakis 
et al. 2008; Les et al. 2010). Inconsistencies in categorising disease causes made 
difficulties in drawing conclusions regarding the impact of the cause of cirrhosis on 
perceived HRQOL. For example, Afendy et al. (2009) investigated whether the 
cause of cirrhosis (i.e. alcoholic liver disease, autoimmune hepatitis, viral hepatitis, 
non-alcoholic fatty liver disease and cholestatic liver disease) associated with 
HRQOL. They used a mixed cohort of cirrhotic patients from Italy and the USA. The 
results showed that the factors associated with poor physical health were non-
alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). However, 
NAFLD, autoimmune hepatitis and cholestatic liver disease were associated with 
poor mental health domains (Afendy et al. 2009). These results suggest that 
patients with non-alcoholic fatty liver disease have a poorer physical and mental 
health domains than patients with viral hepatitis, or with alcoholic liver disease.   
On the other hand, van der Plas et al. (2007) studied a large cohort of chronic liver 
disease patients with mixed stages and liver disease causes. The results showed 
that people with liver disease related to HCV had a poorer HRQOL and higher 
fatigue [Multidimensional Fatigue Index-20 (MFI-20)] than other causes (i.e. 
cholestatic, autoimmune, PBC, hemochromatosis, etc.) (van der Plas et al. 2007). 
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Viral hepatitis patients had a worse HRQOL, particularly in mental health, than 
other causes. They had more mental symptoms such as worry about the family 
situation, depression, and fear of liver disease complications. Patients with 
hemochromatosis had a poorer physical health, particularly bodily pain and role 
limitations due to emotional problems, and higher physical symptoms such as joint 
pain (ven der Plas et al. 2007). Having HCV was significantly associated with 
perceived poor HRQOL (SF-6D) (Dan et al. 2008).  
In contrast, mental and physical health was not significantly different according to 
the cause of liver cirrhosis (hepatocellular, cholestatic, alcoholic and hepatitis C 
cirrhosis) in the study by Kalaitzakis et al. (2008). Also, Kim et al. (2006) found that 
there was no significant difference in cirrhotic patients' QOL according to cause of 
cirrhosis (HCV, HBV and alcohol). As the studies compared different causes using 
various disease categorisations it is difficult to draw general conclusions about the 
association between HRQOL and cause of cirrhosis. 
Interestingly, Afendy et al. (2009) is the only study that investigated separately the 
association between cause of disease and HRQOL according to ethnicity 
(American and Italian patients) using regression methods. They found that in the 
American cohort, patients diagnosed with the NAFLD and ALD were more likely to 
report poor physical health, whilst those with NAFLD, PBC and primary sclerosing 
cholangitis were more likely to report poor mental health. In the Italian cohort, 
patients diagnosed with NAFLD were more likely to report poor physical health, 
however the causes of cirrhosis was not associated with mental health domains 
(Afendy et al. 2009). In Egypt, no study has investigated perceived HRQOL 
according to disease causes, only patients with liver disease due to HCV 
(Schwarzinger et al. 2004; Basal et al. 2011). Therefore, determining whether the 
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cause of cirrhosis is related to the perceived HRQOL in Egyptian cirrhotic patients 
is needed. 
3.5.3.2  Comorbidities 
Comorbidities are common in cirrhotic patients, particularly medical comorbidities, 
such as diabetes mellitus, hypertension, respiratory problems…etc. (Marchesini et 
al. 2001; Kalaitzakis et al. 2006; Firtz and Hammer 2009; Les et al. 2010; Basal et 
al. 2011). The association between the presence of comorbidities and HRQOL was 
investigated among cirrhotic patients (Marchesini et al. 2001; Basal et al. 2011), 
and chronic liver disease patients (Hauser et al. 2004; Hsu et al. 2009). However, 
Fritz and Hammer (2009) considered it as a confounding factor when investigating 
the association between severity of gastrointestinal symptoms and HRQOL. 
The relationship between the presence of comorbidities and HRQOL was 
inconsistent. For example, in a study by Hsu et al. (2009) into mixed disease 
stages, the number of present comorbidities (using index of Coexistent Disease) 
was strongly correlated with physical and mental health domains (SF-12). However, 
when Hsu et al. (2009) used another tool (Charlson Index) to assess comorbidities, 
there was a significant reduction in physical health but not in mental health. 
Similarly, Hauser et al. (2004) found that the number of medical comorbidities 
significantly predicted physical health but not mental health. However, in a recent 
Egyptian study by Basal et al. (2011), the HRQOL of patients with and without 
comorbidities were compared. Only the mental health domain was significantly 
reduced in patients with medical comorbidities (i.e. diabetes, peptic ulcer, 
hypertension and asthma) (p = 0.02). Interestingly, when using two generic HRQOL 
tools, the number of comorbidities was not significantly associated with HRQOL 
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(using SF-36). Nevertheless, the number of comorbidities was significantly related 
to the domains of energy, emotional reaction, social isolation and physical mobility 
(using NHP) (Marchesini et al. 2001). Accordingly, it seems that the presence of 
comorbidities can influence HRQOL, but the effect may be more on physical health. 
Therefore, the association between the presence of comorbidities and perceived 
HRQOL needs further research.  
3.5.3.3  Hepatic encephalopathy  
Hepatic encephalopathy has been found to be a factor in perceived HRQOL. 
However, there is a contradiction over which aspect of health is more affected, 
mental or physical health. For example, in a study by Bao et al. (2007) hepatic 
encephalopathy in cirrhotic patients was comprehensively investigated using 
psychometric tests (i.e. Number Connection test-A and Symbol Digit Test) and an 
electroencephalogram. The results showed that eight domains of SF-36 were 
significantly poorer among patients with hepatic encephalopathy than in patients 
without (p < 0.01) (Bao et al. 2007). Even using another tool for diagnosing hepatic 
encephalopathy, (i.e. Retain Test) physical and mental health domains were lower 
in patients with encephalopathy (p≤0.03) (Arguedas et al. 2003). However, using 
the regression test, encephalopathy significantly predicted physical health but not 
mental health (Les et al. 2010). In other studies, however, there was no significant 
difference in either physical or mental health domains due to the presence of 
hepatic encephalopathy (diagnosed by psychometric hepatic encephalopathy 
score) (Wunsch et al. 2011). Although it seems there is a relationship between 
hepatic encephalopathy and impaired HRQOL, there is no evidence which aspect 
of health is affected. Therefore, future research should diagnose encephalopathy 
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using a valid tool and investigate its effect on perceived HRQOL in cirrhotic 
patients.  
3.5.3.4  Other Biomedical Factors 
The reduction in HRQOL may be a result of other biomedical factors, including 
ascites, low albumen and haemoglobin levels, non-alcoholic cause (i.e. viral 
hepatitis) (Marchesini et al. 2001; Arguedas et al. 2003; Kalaitzakis et al. 2006; Les 
et al. 2010), type of medications (e.g. diuretics, beta blockers and lactulose) 
(Marchesini et al. 2001; Kalaitzakis et al. 2006; Les et al. 2010), number of daily 
medications (Marchesini et al. 2001; Les et al. 2010), spontaneous bacterial 
peritonitis (Les et al. 2010), neurological problems like extra pyramidal signs (i.e. 
tremor, difficulty to speak) (Jover et al. 2005), recent or previous hospitalizations 
(Marchesini et al. 2001; Arguedas et al. 2003) and a decrease in mid-arm muscle 
circumference (Les et al. 2010). These factors should be considered in future 
research of cirrhotic patients as well for the improvement of their HRQOL.  
3.5.4 Symptoms Experience 
Several studies of symptoms relating to liver disease were reviewed (Tables 3-6 
and 3-8). In these studies, various symptoms were examined in liver disease 
patients at different stages of the disease but few of them focused on cirrhotic 
patients. In addition, few of the symptoms were examined in relation to the HRQOL 
of cirrhotic patients (Table 3-6). The studies for the literature review were selected 
because they showed an association between symptoms and HRQOL of chronic 
liver disease patients at mixed stages, and in cirrhotic patients. However, the 
studies used cross-sectional designs, compared different symptoms, and were 
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inconsistent in their measurements (Table 3-6). It is therefore difficult to draw 
conclusions about the influence of general symptoms experience on HRQOL. 
The evidence from the observational studies suggests that symptoms such as  
depression, anxiety (Girgrah et al. 2003; Hauser et al. 2004; Haag et al. 2008; Fritz 
and Hammer 2009), erectile dysfunction, sexual interest, sexual activity (Toda et al. 
2005), fatigue (Girgrah et al. 2003; Teuber et al. 2008), gastrointestinal symptoms 
(Kalaitzakis et al. 2006; Fritz and Hammer 2009), pruritus, muscle cramps 
(Marchesini et al. 2001), overall symptom severity (van der Plas et al. 2004; 
Gutteling et al. 2006) and hindrances in daily life due to the presence of symptoms 
(van der Plas et al. 2004) may influence the HRQOL of patients with liver disease 
and cirrhosis.  
Fritz and Hammer (2009) studied the association between the number of 
experienced gastrointestinal symptoms and HRQOL in 128 patients with liver 
cirrhosis. They found that mental and physical health (SF-36) decreased 
significantly with an increasing number of gastrointestinal symptoms. Also, patients 
with high levels of gastrointestinal symptoms had poor HRQOL. This association 
remained significant even after controlling for age, gender and comorbidities. 
Similarly, Kalaitzakis et al. (2006) found that the severity of gastrointestinal 
symptoms associated significantly with both physical and mental health domains 
(SF-36). 
Gutteling et al. (2006) investigated physical and psychosocial factors using LDSI-
2.0 (15 items of symptom severity) in 1175 patients at different stages of liver 
disease (i.e. non-cirrhotic, compensated, decompensated and post transplanted). 
The authors controlled demographic (age, gender) and medical (use of antiviral 
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therapy, disease stage) variables to test the predictive ability of physical and 
psychosocial factors to HRQOL. Regression analysis identified that with increasing  
joint pain, depression, abdominal pain, fatigue, memory problems, change of 
personality and decreased appetite there was a strong reduction in HRQOL (SF-
12) (p < 0.05). Additionally, the majority of patients (49/53) reported they had 
erectile dysfunction (Toda et al. 2005). Erectile dysfunction was also identified 
among patients who had poor PF, SF and RP. Although the correlation supported 
the relationship between erectile dysfunction and HRQOL, this relationship 
disappeared with regression analysis. The authors considered erectile dysfunction 
as the main outcome, and HRQOL as an independent factor. Therefore, cirrhotic 
patients’ sexuality problems need further research to investigate this influence on 
their HRQOL.  
Psychological symptoms such as depression and anxiety may be shaped by 
patients’ perceptions and disease stage as well as physiological symptoms. Kim et 
al. (2006) studied overall symptoms experience in liver cirrhotic patients, but in 
relation to QOL. The results found that psychological distress was associated with 
disease severity (Child-Pugh score). Patients with decompensated cirrhosis were 
more anxious and depressed than patients with compensated cirrhosis. Depression 
is strongly associated with decreased vitality (Fatigue Assessment Inventory) (r = 
0.55, p < 0.001) (Girgrah et al. 2003), and sleep disorder (Bianchi et al. 2005) in 
cirrhotic patients. Depression and anxiety were significantly associated with mental 
(SF-36) (Hauser et al. 2004; Haag et al. 2008) and physical health (Hauser et al. 
2004) in liver disease and cirrhotic patients. Gutteling et al. (2006) found that 
physical and psychological factors could explain 53% of the variance in HRQOL, 
while the demographic and medical variables could only explain 7%.  
87 
 
Furthermore, symptom status has been investigated using the LDSI-2.0 which can 
be divided into two subscales, symptom severity and hindrance of daily life due to 
symptoms (van der Plas et al. 2004). The results showed that symptom severity 
and hindrance of symptoms were significantly associated with HRQOL. However, a 
reduction of HRQOL was more likely to occur with increasing hindrance of daily life 
due to symptoms than with increasing severity of symptoms. For example, 
hindrance of daily life due to symptoms of joint pain, depression, abdominal pain, 
decreased appetite, worry about family and sleepiness during the day were strongly 
associated with domains of PF, RP, BP, GH, SF, RE and MH. However, the 
severity of these symptoms affected HRQOL less (van der Plas et al. 2004). 
Therefore, it appears that the limitations of daily life due to the presence of 
symptoms are more important in predicting HRQOL than the severity of the 
symptoms themselves. No studies were found that examined symptoms experience 
and its influence on perceived HRQOL in liver disease and cirrhotic patients in 
Egypt. 
SECTION II: SYMPTOMS EXPERIENCE  
As seen in previous sections of this literature review, chronic liver disease and 
cirrhosis are a major cause of morbidity and mortality worldwide. Patients with liver 
cirrhosis may suffer from various physical and psychological symptoms that can 
affect their daily activities. Therefore, this section aims to review studies that 
assess the symptoms of patients with chronic liver disease and cirrhosis.  
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3.6 CHARACTERISTICS OF REVIEWED PAPERS THAT STUDIED 
SYMPTOMS 
Out of 54 papers, 31 papers investigated symptoms in liver disease and cirrhotic 
patients and were found to be mostly descriptive and cross-sectional in nature. 
Table 3-8 presents a summary of these studies. Of the 31 studies, 13 were 
conducted in Europe, with Germany conducting the highest number of studies: five 
in total, and one study was conducted in Australia. In Asia, six studies were 
conducted and 10 studies were conducted in America, where US conducted the 
highest number of the studies. In Africa, one study was conducted in Egypt in 2011. 
This suggests that there is a growing interest worldwide in assessing symptoms in 
liver disease patients. In Egypt, studying symptoms in liver disease patients is still 
uncommon.  
Most of the studies focused on patients with chronic liver disease at mixed stages 
(16 studies in total) (van der Plas et al. 2003, 2004 and 2007), with a relatively 
small sample of cirrhotic patients (Hauser et al. 2004; Teixeira et al. 2005) or 
without decompensated cirrhosis (Constant et al. 2005; Elshahawi et al. 2011). 
Other studies focused on investigating symptoms in cirrhotic patients only (13 in 
total) 
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Table 3-8: Studies investigating symptoms in liver disease patients  
Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
Bailey et al. 2009 
USA 
Cross-section, 
convenience   
126 patients with 
chronic HCV, mean 
age 53 (27-78 years), 
50.8% females 
 
Revised Piper 
Fatigue Scale 
(RPFS), Body pain 
was measured by 
using the SF-36 
(domain of pain). 
Centre for 
Epidemiology 
Studies Depression 
Scale (CES-D) 
Pain, depression, 
fatigue 
Patients had a moderate level of 
uncertainty-related liver disease, mild 
level of fatigue, mild level of 
discomfort/pain, not depressed. 
Regression test: Ambiguity subscale 
associated significantly with depression, 
QOL, pain and fatigue. Complexity 
subscale associated significantly with 
pain and fatigue. Unpredictability 
subscale associated significantly with 
pain. Education, age or gender did not 
associate with any of subscales of 
uncertainty. 
Bajaj 2008 
USA 
Cross-section, 
consecutive 
104 cirrhotic patients, 
70% of them males 
and their caregivers.  
For patients: 
Cognitive test battery  
MacArthur 
foundation socio-
demographic 
questionnaire, 
specific financial 
questions 
 
For caregivers: 
Perceived caregivers 
burden (PCB), 
Zarit Burden 
Interview (ZBI)-short 
form, Beck 
Depression among 
caregivers 
63% had financial affair problems after 
diagnosis with liver cirrhosis. 57% had 
work problems (i.e. decreasing work 
hours and income or losing work), 56% 
are still working after diagnosed with 
cirrhosis. 53% decreased their work 
time. 57% saw their work as an 
important source of support. White-collar 
workers significantly perceived their 
financial affairs better than blue-collar 
workers. Effect of medical expenses 
due to cirrhosis on the patients’ 
medical adherence (i.e. appointment, 
medications and procedures) for the 
previous year: 36% lost insurance, 
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Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
Depression 
Inventory, Beck 
Anxiety Inventory 
and Interpersonal 
Support evaluation 
List-Short Form 
(ISEL-SF) 
 
26% missed medical appointments, 12% 
do not take medications, 10% do not 
take all the prescribed medications and 
5% do not adhere to procedures. Effect 
of medical expenses due to cirrhosis 
on the family’s daily activities for the 
previous 3 years: 56% stopped saving, 
46% in debt, 16% no education, 15% 
late on paying bills, 11% no food (skip 
food) and 10% need to leave their home 
for a cheaper one. Family of cirrhotic 
patients had high score of perceived 
caregivers burden and Zarit Burden 
Interview. Family had personal health, 
schedule and financial problems. 
Severity of perceived burden in 
caregivers was higher among spouses 
than other caregivers. Spouses had a 
higher disruption of schedule, personal 
health, entrapment, but not financial nor 
abandonment. 23% of caregivers had 
mild to moderate depression, 5% had 
severe depression, 34% had mild-
moderate anxiety and 5% had severe 
anxiety. Factors: Severity of cirrhosis, 
previous hepatic encephalopathy and 
patients' cognitive profiles correlated 
positively with burden of the caregivers. 
Bianchi et al. 2005 
Italy 
Prospective cross-
section, consecutive  
165 cirrhotic patients, 
43 % females, age 
median 65 (37-87) 
Beck depression 
inventory (BDI), 
State Trait Anxiety 
Muscle cramp, 
somatic and 
psychological 
58% had muscle cramps in the last 
month. 56.7% had depression 40.7% 
mild-moderate depression, 10% 
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Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
 
 
Inventory (STAI) 
No specific tool for 
muscle cramp or 
sleeping symptoms  
depression, anxiety  moderate to severe depression, and 6% 
severe to extremely severe depression. 
Median of depression was 11 (normal 
range 0-37).  No significant association 
between socio-demographic 
characteristics and depression. 
Depression associated positively with 
encephalopathy, disease severity, sleep 
disorders, number of daily therapy. 
Domain of somatic depression 
associated with ascites, disease 
severity, sleep disorders, daily therapy. 
Depression (as measured by Well-being 
scale), global, somatic and 
psychological depression (as measured 
by BDI) were significantly higher among 
alcohol drinkers than abstaining. 
Somatic symptoms (i.e. sleep disorders, 
fatigue, loss of appetite and weight, 
body image, loss of libido and inability to 
work) were worse than psychological 
depression. Factors: disease severity 
associated with domains of self-control, 
general health, vitality and psychological 
well-being (PGWBI) and with depression 
(BDI) and somatic depression subscale 
(BDI). Sleep disorders associated with 
anxiety, depression, self-control, vitality 
and general psychological well-being 
(PGWBI) and depression and somatic 
depression (BDI). Muscle cramps 
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Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
associated with vitality and general 
psychological well-being (PGWBI). 
Regression test: sleep was associated 
with psychological well-being, and 
disease severity was related to poor 
psychological well-being and 
depression. 
Constant et al. 
2005 
France 
 NA, consecutive  185 patients with 
chronic HCV (17% 
compensated cirrhosis 
stage). mean age 
45±11 years, 60% 
males,  
Spielberger State-
Trait Anxiety 
Inventory (range 22-
80) 
Visual analogue 
scale for perceived 
severity of liver 
disease (0-100). 
Attention coping: 
Monitoring-Blunting 
Questionnaire.  
Trait anxiety  Patients perceived HCV as a severe 
illness (mean score=74±19). Mild 
anxiety (mean score=45±11) was similar 
to the community people. They were 
more likely to ask for information than 
ignoring (coping style). Factors using 
regression: age, hepatologist as a 
source of information and coping style 
predicted the variance in perceived HCV 
severity. Disease severity predicted 
perceived disease severity.  
Cordoba et al. 1998 
USA 
 Prospective, cross-
section, Study 1: 
consecutive, study 2: 
randomly selected, 
44 cirrhotic patients, 
50% males, mean age 
51±2 y (37-69). 
 
 
A sleep 
questionnaire (Sleep 
clinic at North 
Western Memorial 
Hospital), 
Horn and Ostberg’s 
questionnaire, 
Beck Depression 
Inventory (BDI), 
State Trait Anxiety 
Inventory (STAI) 
Sleep quality, 
depression and 
anxiety 
47.7% of cirrhotic patients had sleep 
disturbance and 38.6% of patients with 
chronic renal failure (CRF) had sleep 
disturbance. 4.5% of healthy people had 
sleep disturbance. Night time sleep: 
short sleep time night, difficulties falling 
asleep and more frequent nocturnal 
awakening were higher among two 
groups of patients than healthy group. 
Daytime activities were affected by 
higher episodes of undesired sleepiness 
and prolonged napping time.  
No significant difference in cognitive 
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Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
functioning, medical and demographic 
characteristics between cirrhotic patients 
who reported satisfactory sleep and 
cirrhotic who reported unsatisfactory 
sleep. 26% of cirrhotic had moderate 
depression and 20% of CRF had 
depression. Anxiety and depression 
were higher among patients who had 
unsatisfactory sleep than who had 
satisfactory sleep.     
Davis et al. 1998 
Israel 
Descriptive study, 
NA  
80 patients with 
compensated cirrhosis 
or chronic liver 
disease,  mean age 
45.9±13.9, 51.25% 
male 
 
Brief Symptom 
Inventory (BSI) 
Impact Event Scale 
(IES) assesses 
intrusive thinking 
(unwanted, recurrent 
and disturbing 
thoughts) 
Irritability, 
depression, 
aggression, fear, 
sensitivity, physical 
symptoms, appetite, 
concentration, 
anxiety and others by 
using the Brief 
Symptom Inventory 
(BSI).  
21.25% of patients stopped working 
because of liver disease. 50% of 
patients did not have severity of 
symptoms, 35% of patients had mild-
moderate severity of symptoms and 
15% of patients had severe symptoms 
experience. Factors: no significant 
difference in score of depression and 
Impact Event Scale according to gender, 
age, marital status, liver diseases 
duration and medical treatment. 
Significant association between 
depression and intrusive thinking. 
Depression and intrusive thinking were 
significantly higher among patients who 
stopped working due to liver disease 
than patients who were still working. 
Patients who stopped working due to 
liver disease were more likely to 
perceive high symptom severity 
compared to patients who were still 
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Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
working. Significant negative association 
between educational level and 
depression. Basic education had 
significantly higher levels of avoidance 
thought compared to highly educated 
patients. 
Teixeira et al. 2005 
Brazil 
Cross-section, NA 103 cirrhotic and non-
cirrhotic patients, 
mean age 46±9.2, 
64.4% men.  
 
 
Liver Disease Quality 
of Life 1.0 
(LDQOL1.0) second 
part (12 scales) 
 
Symptom of liver 
disease, effect of 
liver disease, 
concentration, 
memory, quality of 
social interaction, 
health distress, sleep 
problem, loneliness, 
hopelessness, 
stigma of liver 
disease, sexual 
functioning and 
sexual problems. 
Patients with decompensated cirrhosis 
had higher severity of concentration and 
memory problems and higher problems 
in sexual function, sleep, and liver 
disease effect, quality of social 
interaction, loneliness, hopelessness, 
health distress and liver disease stigma 
than patients with compensated 
cirrhosis.  
 
Dwight et al. 2000 
USA 
Cross-section, 
convenience  
50 patients with 
chronic HCV (18.2% 
had compensated 
cirrhosis), mean age 
44.7±8.32, 58% men.  
MAF Fatigue 
Questionnaire, back 
depression inventory 
(BDI). 
 Depression, fatigue  44% had history of major depression. 
16% had depression or anxiety 
disorders. Depression score was higher 
among patients with history of 
depression than without (p=0.009). 
Depressed were more likely to report 
many of somatic (physical) symptoms 
than non-depressed (p=0.004). No 
significant difference in fatigue score 
between depressed and none 
depressed. Depressed reported 
significant impairment of their daily 
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Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
activities due to fatigue. With controlling 
demographic characteristics and 
severity of disease, depression severity 
was associated with fatigue (beta=0.90, 
p<0.0001, R
2
=0.31). 
Elshahawi et al. 
2011 
Egypt 
Cross-section, case 
control study, 
convenient 
 200 patients with HCV 
(Child-A),  
Mini-International 
Neuropsychiatric 
Interview (MINI),  
Beck Depression 
Inventory (BDI) 
 Depression  Patients had higher depression than 
healthy control groups (n=200). Both 
groups of patients were receiving 
(n=100) and were not receiving (n=100) 
interferon therapy) had depression and 
no significant difference (MINI) between 
them. Depression symptom using BDI 
was higher among patients were 
receiving interferon than patients were 
not receiving (p=0.006).  
Erim et al. 2010 
Germany 
Cross-section 
survey, NA 
81 patients with HCV 
and not receive 
interferon therapy, 
mean age 47.1±11.9, 
63% males 
Beck Depression 
Inventory  
Hospital Anxiety and 
Depression Scale 
(HADS). 
Symptom Check List 
90-R 
Sense of Coherence 
Scale   
Depression, anxiety 
and emotional or 
psychological strain 
Depression and anxiety symptoms were 
higher among patients than healthy 
people (p<0.001). 11.1% had mild to 
moderate depression and 22.2% had 
severe depression. Recently diagnosed, 
women and singles had higher 
depression than who had longer known 
of disease, men and married (p≤0.05). 
These subscales of the general 
symptoms distress were higher among 
patients: somatization, compulsiveness, 
insecurity in social contact, aggression, 
phobic anxiety. Sense of coherence and 
gender was associated with severity and 
symptoms of depression.  
Fritz and Hammer  Cross-section, 75 patients with Bowel Disease Depression and No significant difference in depression 
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Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
2009 
Australia 
consecutive cirrhosis. 
Mean age 57±1.4 
(range 24-82), 56% 
males. 
 
Questionnaire, HAD 
 
anxiety, 
gastrointestinal  
(GIT) symptoms   
and anxiety among patients with Child-A 
and Child-B cirrhosis. According to the 
logistic regression: anxiety and 
depression were significantly associated 
with GIT symptoms.  
Depression and anxiety was higher 
among patients with dysphagia, while 
depression was higher among patients 
with bloating, dysphagia and diarrhea. 
Girgrah et al. 2003 
Canada 
 Cross-section, NA 
 
30 patients with 
cirrhosis, Mean age 
54.4±3.1, 93.3% 
males. 
 
 
Fatigue assessment 
inventory (FAI) 
Centre for 
epidemiology 
depression scale 
(CES-D) 
Cardiac assessment 
Fatigue and 
depression  
Patients with liver cirrhosis had higher 
levels of fatigue compared to healthy 
people. Fatigue was higher among non-
alcoholic related cirrhosis (i.e. HCV) 
than alcoholic related cirrhosis. 
Depression was higher among cirrhotic 
patients than healthy population. They 
had mild level of depression. Factors: 
there was no significant association 
between fatigue or depression and 
disease severity measuring by Child-
Pugh score. Depressive symptoms 
associated with increase fatigue and 
poor mental health.   
Haag et al. 2008 
Germany 
 Prospective, cross-
sectional study, 
consecutive   
204 patients with CLD 
(49.01% with 
cirrhosis), 181 patients 
with FD 
HADS Anxiety and 
depression  
Patients had higher anxiety and 
depression score compared to healthy 
blood donors and patients with 
functional dyspepsia.  
Hauser et al. 2004 
Germany 
 Cross-section, 
consecutive 
88 patients (70.4% 
non-cirrhosis), mean 
age 48.6%±14.6, 50% 
females, 70.4% had 
CLDQ 
HADS 
Anxiety and 
depression  
39.8% had depression; liver disease 
patients had higher depression than 
healthy people.  
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Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
non-cirrhosis 
Hilsabeck et al. 
2005 
USA 
Correlation study, 
consecutive 
94 patients (40.42% 
with cirrhosis, mean 
age 46.2±7.6, 57 
males, 40.4% had 
cirrhosis  
 
The revised version 
of Piper Fatigue 
scale, The back 
Depression 
Inventory-II 
Depression, anxiety  Patients had mild depression symptoms. 
Factors: gender, psychiatric problem, 
depression, PF, SF and pain were 
associated significantly with fatigue. 
While age, marital status, drug abuse 
and disease stage were not associated 
with fatigue.  Regression test: SF 
(variance=52%), PF (variance=10%), 
depression (variance=4%) and gender 
(variance=2%) were associated with 
fatigue 
Kalaitzakis et al. 
2006 
Sweden 
Cross-section, 
prospective  
128 patients with 
cirrhosis, mean age 
57.2±11.5, 61% males 
 
Gastrointestinal 
symptom rating scale 
(GSRS) 
Different 
gastrointestinal 
symptoms. 
Comorbidities did not associate with 
symptom severity. Increased age 
associated with poor abdominal pain. 
Gastrointestinal symptom severity 
associated with hospitalization, severity 
of cirrhosis, encephalopathy and ascites 
but not associated with cause of 
cirrhosis. Regression test: 
gastrointestinal symptoms associated 
with liver cirrhosis severity, daily 
lactulose intake, gastrointestinal 
comorbidities and HRQOL. 
Karaivazoglou et al. 
2010 
Greece 
Cross-section, 
consecutive  
 
84 patients with 
chronic viral hepatitis  
Mean age 46±16.7, 
65.5% men 
 
Beck depression 
inventory II, 
Functional 
Assessment of 
Chronic Illness 
Therapy Fatigue 
Scale (FACIT-F) 
Depression, fatigue. 14.3% of the patients had mild 
depression. Patients with HCV and 
patients with HBV had the same fatigue 
level. Depression was not significantly 
higher among patients with HCV than 
patients with HBV.  
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Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
Kim et al. 2006a 
Korea 
Cross-section, 
convenience 
129 cirrhotic patients, 
mean age 53.6±9.28, 
80% men 
 
Experience scale to 
investigate the three 
dimensions of 
symptom (frequency, 
intensity and degree 
of distress 
Disease specific 
symptoms (many 
symptoms) 
Overall symptoms experience was 
relatively low. Individual symptoms 
showed significant association with 
gender. Females had more severe 
muscle cramps, bleeding of the 
gum/bruising more than males. Cause of 
cirrhosis did not associate with overall 
symptoms experience. Some (n=18) 
individual symptoms had significant 
differences according to cause of 
cirrhosis such as: bleeding of the 
gum/bruising that was more among 
patients with HCV more than others. 
The number of hospitalizations 
correlated significantly with overall 
symptoms experience. Number of 
hospitalizations correlated significantly 
with some of individual symptoms such 
as: nausea/vomiting, muscle cramps, 
drowsiness, and decrease of 
concentration.  
Kim et al. 2006 
Korea 
Cross-section, 
convenience  
129 cirrhotic patients, 
mean age 53.6±9.28, 
80% men 
 
Profile of mood 
states (POMS), 
Experience scale to 
investigate the three 
dimensions of 
symptom (frequency, 
intensity and degree 
of distress). 
 
Different physical 
symptom (frequency, 
intensity and degree 
of distress). 
Psychological 
distress (Shin 1996). 
Depression, anxiety 
and anger. 
Patients with liver cirrhosis had mild to 
moderate psychological distress (anxiety 
and depression). Patients with advanced 
stage of cirrhosis (Child-C) had higher 
depression and anxiety than 
compensated cirrhosis (Child- A/B). 
Fatigue symptom had the highest score 
followed by muscle cramp, dry mouth, 
and change in appearance, decrease in 
memory, anorexia, itching, dyspepsia, 
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Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
drowsiness, abdominal pain, 
nausea/vomiting, bodily pain and urinary 
difficulty. Factors: only disease severity 
was associated with score of symptoms 
experience and psychological distress. 
Other factors were not associated 
significantly with symptoms experience 
or psychological distress, such as: age, 
gender, educational level, employment 
status, income, cause of cirrhosis and 
presence of hepatic carcinoma.  
Kraus et al. 2000 
Germany 
Cross-section, NA 113 patients with 
chronic HCV (15.9% 
had cirrhosis-none 
Child-B/C),  
 
HADS, State Trait 
Anxiety Inventory 
(STAI), Feiburg 
Questionnaire on 
Coping with Illness 
(FKV-FQCI) 
Emotional state: 
depression and 
anxiety, State and 
trait aspects of 
anxiety.  
22.3% had depression compared to 
healthy people, 3.2%.15.2% had high 
anxiety levels compared to healthy 
people, 6.8%.depression and anxiety 
were not significantly different between 
patients on drug use and patients did 
not. HCV genotype was not related to 
depression or anxiety scores. Patients 
above 50 years had higher depression 
than younger (p=0.02). Patients with 
early diagnosis (<6 months) had lower 
score of depression and anxiety than 
patients knowing their diagnosis more 
than 5 years (p≤0.003). Patients 
knowing their diagnosis more than 5 
years had lower score of problem 
solving behaviour than early diagnosed 
patients. Search for meaning and 
religiousness was higher in older 
patients than younger patients (p<0.01). 
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method  
Size and 
characteristic of 
sample   
Tools  
Marchesini et al. 
2001 
Italy 
Cross-section, 
consecutive  
 
544 cirrhotic patients, 
mean age 60±11 (17-
91), 63.9% males, 
 
Nottingham Health 
Profile (NHP): 
second part, No 
standardized tool to 
assess symptoms of 
pruritus or muscle 
cramp 
pruritus or muscle 
cramp in the last 
month. 
In men 40% had affected sexual life. In 
women 52.6% had affected home life 
and 39.2% had affected social life. The 
most affected aspect of daily life in men 
with cirrhosis was sexual life and paid 
work. Women perceived their social and 
home life were the most affected 
aspects of daily life. Factors: symptoms 
of muscle cramps and pruritus 
associated significantly with sleep, 
energy, emotional reaction, social 
isolation, and physical mobility (NHP) 
and with BP, GH, SF, VT, RE, RP and 
PF (SF-36). 
Moyer et al. 2003 
Michigan/USA 
Survey, consecutive  214 patients with HCV 
(27.6% had 
compensated 
cirrhosis), Mean age 
46.9±7.9 (20-69), 
59.3% males 
Brief Symptom Index 
(BSI) 
Questions to assess 
Optimism/Pessimism 
Emotional 
functioning 
(somatization, 
obsessive-
compulsive, 
interpersonal 
sensitivity, 
depression, anxiety, 
hostility, phobic 
anxiety, paranoid 
ideation and 
psychoticism.  
98 of the patients were realists, 17 were 
optimists, and 8 were pessimists. 
African Americans were more optimistic 
than Caucasians. Pessimists had higher 
level of emotional distress (BSI) than 
optimists and realists (p<0.05).Presence 
of cirrhosis and medical comorbidities 
were not related to optimism or 
pessimism. Psychiatric comorbidities 
was positively associated with 
pessimism (p=0.01).  
Singh et al. 1997 
USA 
Prospective  
100 days for all 
participants, 18 
months for patients 
after transplantation, 
81 cirrhotic patients, 
median age 47 (22-
68), 80 males 
 
Beck Depression 
Inventory  
Ways of Coping 
Scale 
Recent Events 
Depression  64.2% had depression; the majority of 
depressed patients had a viral infection. 
There was no significant demographic 
different between the patients with 
different causes. Depressed patients 
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Tools  
consecutive Inventory 
A self-assessed 
rating of Perceived 
Quality of Life  
Karnofsky 
Performance Score 
for rating physical 
functioning 
had poorer adaptive coping, quality of 
life and functional status than no 
depressed patients. Uncertainty about 
the future, loss of independency, fearful 
of being a burden on their care 
providers, having suicidal thoughts, 
having no future, being ill frequently and 
frequent pain were significantly more 
frequent among depressed patients. 
Quality of life was poor and depressive 
symptoms were higher among patients 
who died during the study than alive. 
Survival in patients was not 
transplantation was lower in depressed 
patients (there was no significant 
different between the depressed and 
non-depressed patients in medical or 
demographic characteristics). Serum 
bilirubin was significantly higher among 
non-depressed patients. 21 patients who 
had not received transplantation during 
follow up period, the depression and 
Child-Pugh score were significantly 
higher and QOL was lower among who 
died than the survival patients. 
Depression increased mortality among 
cirrhotic patients. 
Teuber et al. 2008 
Germany 
Cross-section, NA 215 untreated patients 
with chronic hepatitis 
C (16.7% had 
cirrhosis, Child-A/B), 
Fatigue impact scale 
(FIS) 
Fatigue No significant difference in fatigue 
between patients with and without 
cirrhosis. disease stage and gender 
predicted fatigue level (p≤0.04) 
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Design/sampling 
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Size and 
characteristic of 
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Tools  
mean age 46.7±13.4 
(19-79), 57% males 
Toda et al. 2005 
Japan 
 NA, NA 117 patients with 
chronic viral hepatitis 
(45.3% with cirrhosis), 
Age: 19% < 50 years, 
28% between 50-59 
years, 53% > 60 years. 
International index of 
erectile function 
(IILEF-5) 
Erectile dysfunction  85% of patients with chronic liver 
disease had erectile dysfunction. The 
incidence of erectile dysfunction among 
patients with liver cirrhosis was higher 
(92%) than patients with chronic liver 
disease (78%). Patients with chronic 
liver disease had higher incidence of 
erectile dysfunction than normal people 
with the same age (50-59 years). The 
incidence of erectile dysfunction among 
age group 50-59 years was not higher 
than the health group. Factors: age and 
disease stage (Child-Pugh score) 
associated positively with erectile. PF 
and SF (SF-36) associated with erectile 
dysfunction. Regression test: age and 
serum albumin level predicted erectile 
dysfunction. 
van der Plas et al. 
2003 
Netherlands 
 Survey, cohort 
sample 
 
1175 patients with 
mixed disease stages, 
mean age 48±12, 
43.8% males 
 
Liver Disease 
Symptom Index 
(LDS1 2.0), 
Multidimensional 
Fatigue Index-20 
(MFI-20) 
Different symptoms 
and fatigue symptom 
In comparison to healthy people, 
patients of the patients with chronic liver 
disease had worse pain. Fatigue was 
similar among different disease stages 
and liver transplant groups. Itch, pain in 
abdomen, sleepiness, and worry about 
the family situation, decrease appetite, 
depression, fear and jaundice were 
highest among patients with 
decompensated cirrhosis than non-
cirrhotic patients. Joint pain was similar 
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Size and 
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for all disease stages. Compensated 
and decompensated cirrhotic patients 
had higher memory problems and 
change in personality than non-cirrhotic 
patients. Only patients with 
decompensated cirrhosis had higher 
financial limitation due to liver disease 
than other groups of patients. Change in 
time use as a result of liver disease 
increased significantly with increasing 
disease stage. Decreased sexual 
interest was higher only among patients 
with decompensated cirrhosis but not 
significantly different between patients 
with compensated cirrhosis, non-
cirrhosis and transplantation. Patients 
with decompensated cirrhosis or 
transplantation had higher severity of 
decreased sexual activity than other 
groups. Symptom limitation: Patients 
with decompensated cirrhosis had 
higher perception of symptom limitations 
than non-cirrhotic patients.   
van der Plas et al. 
2004 
Netherlands 
Survey, 
Consecutive 
1175 patients with 
mixed disease stages, 
mean age 48±12, 
57.7% males. 
 
Liver Disease 
Symptom Index 
(LDS1 2.0), MFI-20 
Fatigue and all other 
symptoms 
Symptom severity: 71.2% sleepiness 
during day, 69.6% change of 
personality, 69.3% change in use of 
time, 57.5% joint pain, 56.3% memory 
problems, 51.4% decreased sexual 
activity, 50.5% worry about family 
situation, 47.5% depression,  46% 
decreased sexual interest, 44.8% 
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Size and 
characteristic of 
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financial affairs problems, 44.1% fear of 
liver disease complications, 39.6% itch, 
39.3% right abdominal pain, 32.3% 
decreased appetite and 9.9% jaundice. 
Hindrance of daily life due to 
symptoms: 85.1% sleepiness during 
day, 83.8% joint pain, 77.6% 
depression, 71.4% decreased appetite, 
66.6% worry about the family, 63.1% 
pain in right upper abdomen, 50.5% itch 
and 41.1% jaundice. 
van der Plas et al. 
2007 
Netherlands 
Cross-section, 
Observational study, 
cohort sample. 
918 patients with 
mixed stages of 
disease, mean age 
49±13, 58.5% women, 
 
Liver Disease 
Symptom Index 
(LDS1 2.0), MFI-20 
A list of symptoms 
and fatigue symptom 
All groups had worse scores for fatigue 
than healthy people. Patients with viral 
hepatitis had higher fatigue than other 
groups with other causes of disease. 
Patients with autoimmune hepatitis had 
lower scores in reduction of activity 
(subscale of fatigue scale), reduction in 
motivation than patients with viral 
hepatitis, but they had the same level of 
general, physical and mental fatigue.  
Using the Odd ratio patients with viral 
hepatitis had a significantly higher odds 
of reporting severe worry about the 
family situation than others patients with 
other causes, had severe depression 
and severe fear of complications. 
Severe fear was influenced by gender 
and comorbidities. Severity of joint pain 
was significantly higher among patients 
with hemochromatosis than other 
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groups. There was significant difference 
in severity of sleepiness during the day 
or severity of jaundice between different 
causes of liver disease. Hindrance of 
daily life due to symptoms: patients 
with viral hepatitis had higher severity of 
symptoms hindrance compared to other 
causes.  
Wilson et al. 2010 
USA 
Cross-section, 
consecutive 
65 patients with HCV 
(39% had grade IV 
fibrosis), Average age 
49 years 
Beck Depression 
Inventory II (BDI-II) 
Depression Regression test: Factors predicted 
depression (BDI-II): religious faith, 
ability to work, salary, social functioning 
and reaction to diagnosis, suicide 
attempt and vitality. 
Wu et al. 2012 
Taiwan 
Correlation study, NA 40 cirrhotic patients   
mean age 63.3±14.02 
(29-80 years), 77.5% 
males, 
 
Fatigue Symptom 
Inventory (FSI), 
Seven-day Physical 
Activity Recall 
(seven-day PAR) 
Fatigue: intensity, 
duration of fatigue 
and interference of 
fatigue on daily life 
(QOL). 
The total mean score of subscale of 
fatigue interference QOL was 
29.80±10.80 (possible scale score 0-
70). 50% of the patients suffered from 
afternoon fatigue more than morning 
time. Factors: no significant association 
between disease stage, cause and 
normality of laboratory tests and fatigue 
(level or interference with QOL). Men 
and married significantly had higher 
physical activity than women and 
unmarried. No significant difference in 
levels of physical activities between 
patients according to disease stage and 
cause of cirrhosis. Patients with normal 
haemoglobin, haematocrit and white 
blood cells level had higher levels of 
physical activity than patients with 
106 
 
Author Methodology Studied symptoms Results 
Design/sampling 
method  
Size and 
characteristic of 
sample   
Tools  
abnormal values. Fatigue was 
negatively associated with level of 
physical activity.   
Zandi et al. 2005 
Iran 
Quasi-experimental 
study control, 
Longitudinal cases 
register method 
random assignment 
to divide the sample 
into 20 control and 
20 study groups  
 
 
40 cirrhotic patients, 
Experimental group: 
age 40.8±12.5 (18-65 
years), males 50%, 
 
 
Self-Report 
Questionnaire, 
Need Assessment 
Questionnaire. 
 List of symptoms 
and needs  
Before the program: the most reported 
educational needs among cirrhotic 
patients were: 70% controlling of 
abdominal distension, curative ways in 
cirrhosis (treatable or not/uncertainty), 
65% ways of controlling fatigue, 60% 
principle of care and proper 
medications, 55% worry, 50% controlling 
pruritus and fatigue, ways to decrease 
muscle cramps, dry mouth, and 
dyspnoea, patterns of activity, rest, and 
sleep, 45% routes of transmission as 
well as diagnostic tests, 40% diagnostic 
procedures. Over three months of follow 
up these educational needs were 
reported by the patients higher than the 
other needs: 95% nutrition, 60% fatigue, 
anxiety and depression. 
NA: not available 
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3.7 INSTRUMENTS USED TO ASSESS SYMPTOMS EXPERIENCE  
Table 3-8 shows instruments that were used to assess a specific symptom such as 
depression; two related symptoms such as depression and anxiety or the full range 
of symptoms. A few studies assessed the full range of symptoms (Zandi et al. 
2005; Kim et al. 2006 and 2006a; van der Plas et al. 2003, 2004 and 2007), while 
three tools were used to measure the full range of symptoms experience among 
patients with cirrhosis. They were: (1) experience scale to investigate the three 
dimensions of symptoms (frequency, intensity and degree of distress) (Kim et al. 
2006 and 2006a), (2) Needs Assessment Questionnaire (Zandi et al. 2005). and (3) 
Liver Disease Symptom Index (LDS1-2.0) (van der Plas et al. 2003, 2004 and 
2007).  
The instruments vary in symptom content and extent of psychometric validation.  
Although the experience scale, which was developed and used by Kim et al. (2006) 
is a multidimensional tool that can measure the full range of symptoms experience 
from three aspects: frequency, intensity and distress, its psychometric properties 
are questionable. Kim et al. (2006) mentioned that the experience scale was 
developed based on the theory of unpleasant symptoms, without giving details 
about its development and construct validity. The second tool is the Need 
Assessment Questionnaire that was used to determine cirrhotic patients’ need to 
direct the development of a self-care educational program (Zandi et al. 2005). 
Although the Need Assessment Questionnaire was useful in finding many 
symptoms that cirrhotic patients experienced, question response was as "yes" or 
"no" only. This means that this tool could not determine the severity of the 
symptom. Also, its validity and reliability were not mentioned or how it was 
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constructed. On the other hand, the Liver Disease Symptom Index-2.0 is a 
psychometrically tested tool that was developed to assess liver disease specific 
HRQOL from two aspects: severity of symptoms and hindrance of daily activities 
due to symptoms (van der Plas et al. 2004). 
3.8 SYMPTOMS EXPERIENCE IN CIRRHOTIC PATIENTS 
The majority of the reviewed studies assessed only one symptom, two or three 
related symptoms, such as depression, anxiety, sleep and/or fatigue (Singh et al. 
1997; Cordoba et al. 1998; Marchesini et al. 2001; Girgrah et al. 2003; Bianchi et 
al. 2005; Wu et al. 2012). Two studies assessed the full range of gastrointestinal 
symptoms (Kalaitzakis et al. 2006; Fritz and Hammer 2009). One paper indirectly 
reported a list of symptoms but in terms of patients’ needs to assess the impact of a 
self-care program on improving cirrhotic patients’ QOL (Zandi et al. 2005). 
Interestingly, only one paper investigated the socio-economic and emotional 
burden due to cirrhosis and hepatic encephalopathy on elderly patients and their 
caregivers (Bajaj 2008). Only van der Plas et al. (2003, 2004, and 2007) and Kim et 
al. (2006 and 2006a) assessed the full range of physical and psychosocial factors.  
According to the reviewed studies, depression, anxiety and fatigue were the most 
commonly investigated symptoms. However, little is known about the full range of 
symptoms that patients with liver disease, particularly cirrhotic patients experience. 
Only the study by Kim et al. (2006 and 2006a) focused on exploring the full range 
of symptoms of cirrhotic patients. Van der Plas et al. (2003, 2004, and 2007) 
investigated the full range of symptoms but in mixed disease stages (non-cirrhotic, 
compensated, decompensated cirrhosis and post transplantation). Only one study 
examined symptoms of depression in patients with HCV (Child-A) and were on 
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antiviral therapy (Elshahawi et al. 2011). Therefore, there is a need to study the full 
symptoms experience in liver cirrhotic patients in Egypt and elsewhere.  
3.8.1 Types of Symptoms Experienced  
Research has demonstrated that patients with liver cirrhosis experience a variety of 
symptoms (Table 3-8). However, the majority of the reviewed studies focused on 
assessing the severity of the physical symptoms such as gastrointestinal symptoms 
(Kalaitzaki et al. 2006; Fritz and Hammer 2009), or psychosocial symptoms such as 
depression and anxiety or psychological distress (Singh et al. 1997; Cordoba et al. 
1998; Kim et al. 2006, Kim et al. 2006a; Fritz and Hammer 2009). Few of these 
studies assessed the general symptoms experience of patients with chronic liver 
disease (van der Plas et al. 2003, 2004 and 2007) and cirrhosis (Kim et al. 2006 
and 2006a) in terms of prevalence, severity and distress.  
3.8.1.1 Symptom Prevalence in Cirrhotic Patients 
There were discrepancies between the studies in terms of assessed symptoms, 
methods of reporting the findings (e.g. reporting the score of symptoms (Kim et al. 
2006 and 2006a) or reporting prevalence (van der Plas et al. 2004, Zandi et al. 
2005). Therefore, to identify symptom prevalence among patients with liver 
cirrhosis, studies that provided prevalence of one or more experienced symptom 
were given priority. The other studies will be used to support the discussion.  
The most commonly investigated symptom in liver disease patients is depression. 
Patients with liver disease were observed to have a high level of depression. 
Cirrhotic patients had a higher level of depression than healthy people (Girgrah et 
al. 2003), while patients with decompensated cirrhosis had a higher depression and 
anxiety level than patients with compensated cirrhosis (Bianchi et al. 2003; Kim et 
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al. 2006 and 2006a). Overall 56.7% of cirrhotic patients had depression, 40.7% had 
mild-moderate depression, 10% had moderate to severe depression and 6% had 
severe to extremely severe depression (Bianchi et al. 2005). Depressed patients 
were more likely to die than non-depressed patients in the longitudinal study on 
death rate among 81 American patients with advanced stage of liver cirrhosis who 
were waiting for liver transplantation (Singh et al. 1997). In relation to other 
symptoms, Bianchi et al. (2005) showed that somatic symptoms (i.e. sleep 
disorders, fatigue, loss of appetite and weight, body image, loss of libido and 
inability to work) were more debilitating than psychological depression in cirrhotic 
patients. Kim et al. in 2006 found that patients with cirrhosis had mild to moderate 
psychological distress (i.e. anxiety and depression), where decompensated 
cirrhotic patients were more likely to have psychological distress.  
Sleepiness during the day was found to be the most frequently reported symptom 
by two thirds of the patients (71.2%), while depression  was reported  by less than 
half of the patients (47.5%) (van der Plas et al. 2004). Cordoba et al. (1998) 
assessed the prevalence of sleep disturbance and its related factors in 44 cirrhotic 
patients without encephalopathy, comparing them to a matched group of patients 
with chronic renal failure. They found that patients with cirrhosis and patients with 
chronic renal failure had a higher prevalence of sleep disturbance. About 47.7% of 
cirrhotic patients had sleep disturbance, while 38.6% of patients with chronic renal 
failure had sleep disturbance but only 4.5% of healthy people had sleep 
disturbance. The most common problems related to sleep disturbance were short 
sleeping time at night, difficulties falling asleep and more frequent nocturnal 
awakening.  
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It has been found that depression and anxiety (using Beck Depression Inventory 
and State Trait Anxiety Inventory) were higher among patients with unsatisfactory 
sleep than with satisfactory sleep, although there were no significant differences 
between the two groups’ socio-demographic and medical characteristics or 
cognitive functioning (Cordoba et al. 1998). Similarly, Bianchi et al. (2003) found 
that depression was significantly associated with increased sleeping disorders in 
cirrhotic patients. This association between sleep disorders and depression needs 
further research to explain the relationship as well as the mechanism between 
depression and sleeping problems. However, the results from this study should be 
considered with caution as few details were given about the tools used to assess 
the symptoms of sleeping disorder so these findings may be unreliable and invalid. 
The cross-sectional design also limited assessment of causal associations.  
On the other hand, in the cross-sectional study by Kim et al. (2006 and 2006a) to 
assess symptoms experience and its association with psychological distress and 
QOL in 129 Korean patients with cirrhosis, the results showed that fatigue had the  
highest mean score followed by muscle cramp, dry mouth, change in 
appearance,…etc. Fatigue was also reported as being higher among cirrhotic 
patients than in healthy people, particularly in patients with non-alcoholic cirrhosis 
(i.e. HCV) (Girgrah et al. 2003). Half of the patients (20/40) suffered from afternoon 
fatigue and the average number of affected days due to fatigue was 3.15 (Wu et al. 
2012).  
In particular, the findings from the few observational cross-sectional studies that 
have examined general symptoms experience in patients with liver cirrhosis (van 
der Plas et al. 2004; Zandi et al. 2005; Kim et al. 2006) offer a valuable insight into 
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the importance of assessing symptom prevalence. However, there are 
inconsistencies relating to symptom prevalence in the studies by van der Plas et al. 
(2003); Zandi et al. (2005) and Kim et al. (2006a). These may be due to the 
different measurements used, which make it difficult to compare the results. Also, it 
is impossible to generalize these results across countries, particularly to Egypt, 
which is culturally different and has a different healthcare system. Therefore, 
investigating the symptom prevalence in Egyptian patients with liver cirrhosis is 
urgently needed.  
3.8.1.2  Hindrance of daily life due to symptoms  
Although assessing the prevalence of symptoms is important to determine those 
most experienced among a specific group of patients, assessing symptom distress 
is also essential; because it is the dimension of symptom experience that 
determines patient suffering. Studying symptom distress can provide important and 
complementary information to symptom frequency to gain more insight into 
symptom experience and its impact on the patient's daily life and social activities 
(Tishelman et al. 2007).  
In 2001, Marchesini et al. investigated 544 Italian patients with cirrhosis using two 
generic HRQOL tools (SF-36 and NHP).They found that the most affected aspect 
of daily life in men was sexual life and paid work. Women perceived their social and 
home life as the most affected aspect. It was also found that with an increased level 
of symptom severity such as muscle cramp and pruritus the impairment of social 
and daily activities also increased resulting in social isolation, sleeping problems, 
low vitality, emotional distress and physical disability (using NHP) (Marchesini et al. 
2001). Fatigue interference in the QOL was also reported in cirrhotic patients. The 
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total mean score of the subscale of fatigue interference QOL was 29.80±10.80 
(possible scale score 0-70). This means that the general fatigue interference in the 
QOL was low, although the two domains of interference of fatigue on activity level 
and on normal work activity were the highest scores (5.20 and 4.98 out of 0-10) 
(Wu et al. 2012). Cirrhotic patients also had limitations in their daytime activities as 
a result of higher episodes of undesired sleepiness and prolonged napping times 
(Cordoba et al. 1998).  
The study by van der Plas et al. (2004) was the only identified study that 
investigated prevalence of both severity and hindrance of symptoms in liver 
disease patients. They found that 71.2% of patients reported sleepiness during the 
day while 83.8% complained of joint pain hindering their daily activities. In the same 
study, the symptom of worry about the family situation was the third in symptom 
severity; and in hindrance of daily activities. While the symptom of itch was the fifth 
according to severity, however it became the seventh reported symptom that 
affected daily activities. Therefore, the prevalence of symptoms distress may be 
different to the prevalence of symptoms severity. In other words, symptoms may be 
severe but not affect the patients' daily life, while other symptoms may be mild but 
have a strong impact on the patients' daily activities. This suggests that although 
assessing prevalence of symptom severity is important, assessing prevalence of 
symptom distress is most important, as it reflects the most affected areas in 
patients’ social and daily activities. These findings on cirrhotic patients cannot be 
generalised because the studies had heterogeneous patients at different disease 
stages such as non-cirrhosis, compensated cirrhosis, decompensated cirrhosis and 
post transplantation. Also, the patients were recruited from the community where 
they were on databases for the liver disease association. Therefore, the prevalence 
114 
 
of symptoms experience in cirrhotic patients in a clinical setting needs further 
research.  
3.9 SELF-CARE AND SELF-MANAGEMENT  
3.9.1 What is Self-Care and Self-Management?  
Assessing and caring for symptoms is the responsibility of patients and healthcare 
providers. Two terms that are widely reported in the literature: self-care (SC) and 
self-management (SM) as essential for caring for patients with chronic diseases. 
SC and SM appear as increasingly key concepts in clinical, research and policy 
literatures (Jones et al. 2011, p. 175). However, there is no general census about 
their definition (Glasgow et al. 2003; Godfrey et al. 2011), although they are not 
similar (Jones et al. 2011).  
In brief, self-care is a broad concept that includes ‘the care of oneself’ it may be 
performed in response to illness, injury, longstanding chronic conditions, or 
disability, and for a myriad of different reasons such as recovery; maintenance of 
health, prevention; or in the case of personal care – the preservation of self. Self-
care can be self-instigated or follow a prescribed regime, and the process of care 
may be performed by individuals themselves or by a caregiver (professional, formal 
or informal)’’ (Godfrey et al. 2011, p. 3).However, self-management is ‘’simple 
patient education or skills training, in that they are designed to allow people with 
chronic conditions to take an active part in the management of their own condition’’ 
(Foster et al. 2007). Self-management refers to activities that are undertaken by 
individuals with chronic conditions with support from the health care providers 
(Health Department (HD), UK 2006). These activities are treating symptoms, 
coping with bio-psychosocial impacts of the disease to avoid deterioration in health 
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condition and changing one’s lifestyle to adapt to the chronic disease and to keep 
the illness under control (Barlow et al. 2002; Glasgow et al. 2003). 
Therefore, self-care is a very broad term, and self-management is a sub-set of the 
term self-care (Tomkins and Collins 2009). Tomkins and Collins (2009, p.5) 
suggest that “Outside hospitals or care homes, everyone self-cares all of the time 
but not everyone self-cares optimally”. Therefore, self-management strategies can 
support patients with chronic disease to improve their knowledge and skills that 
they need to maintain or promote their health condition and avoid deterioration 
under the supervision of healthcare professional.  
3.10 SELF-CARE AND SELF-MANAGEMENT IN CIRRHOTIC PATIENTS  
Depressed cirrhotic patients have poorer adaptive coping, QOL and functional 
status than non-depressed patients. They also face uncertainty about the future, 
loss of independence, fear of being a burden to their care providers; have suicidal 
thoughts, have no future, are ill frequently and frequently in pain (Singh et al. 1997). 
Therefore, because liver cirrhosis is a chronic and incurable disease it is important 
to look after these patients’ QOL by studying their health needs and symptoms 
experience in order to support them and provide the required care. The first step 
towards starting the caring process is to aim to improve these patients’ HRQOL and 
daily activities by assessing their symptoms experience and caring for it by 
improving their self-care strategies. 
There is a wide interest in studying and practising self-care or self-management 
among people with various chronic illnesses to improve their quality of life (DeWalt 
et al. 2006; Foster et al. 2007; Davies and Batehup 2010). However, exploring 
symptoms experience and caring for patients with liver cirrhosis is still in its infancy 
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and needs more attention from healthcare providers. The literature search yielded 
only one intervention study (Zandi et al. 2005) although there was no limit on 
design during the database search.  
Zandi’s study is the only research that has developed a self-care program for 
cirrhotic patients based on their preferences. Zandi et al. (2005) developed a tool to 
assess these patients’ needs in which they asked the patients about the information 
they wanted and the time at which it was offered to them. This educational self-care 
program took three months of demonstration and follow up. The results showed 
that there was no significant difference between the two groups before the program 
in socio-demographic and clinical characteristics and in the domains of HRQOL 
(CLDQ). However, the studied group had a significant improvement in abdominal 
symptoms, fatigue, systemic symptoms, activity, worry and emotional domains, 
without significant changes in disease severity after the program. Furthermore, the 
HRQOL of the control group had significantly declined three months later in these 
domains: activity, worry and emotional status. These findings suggest that the 
control group had significantly more emotional problems, anxiety and activity 
impairment than the studied group who received the self-care program (Zandi et al. 
2005). Therefore, studying symptoms experience and the patients' educational 
needs are essential for developing an intervention program to improve their 
HRQOL. 
SECTION III: SOCIAL SUPPORT  
Only three studies of social support among patients with liver disease were found 
(Blasiole et al. 2006; Erim et al. 2010; Wilson et al. 2010). These studies were 
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descriptive, cross-sectional designs, and conducted among patients with HCV in 
the USA and Germany. Table 3-9 summaries these studies.  
3.11  PERCEIVED SUPPORT IN LIVER DISEASE PATIENTS 
Although the studies had inconsistencies in terms of methodology, 
conceptualization of social support and wide differences in participants' 
characteristics, patients with HCV (73%) reported that they had a supportive 
environment (Blasiole et al. 2006). Similarly, Wilson et al. (2010) investigated 
patients (66% males) with chronic HCV using one question to assess their social 
support ''do you have one or more people in your life who provide support for you 
when you are having a bad day?''. They found that the majority of patients (64/65) 
had people available during hard times. Cohen and Syme (1985) classified social 
support into two categories: (1) structured support that refers to the existence of 
relationships (i.e. marital status and number of networks), and (2) functional 
support that refers to interpersonal relationships that focus on providing particular 
functions such as care, material support and/or emotional support. Wilson et al 
(2010) only assessed structural support, but not functional support. Therefore, only 
the quantity of people available during hard times was assessed, but not the type, 
source and quality of this social support. Whether the patients were satisfied with 
the available support was not measured.  
Erim et al. (2010) used a social support questionnaire (F-SOZU: 54 items, 4 scales 
and overall score) to examine the types of social support ''emotional support, 
instrumental support, social integration and social strain'' among patients with HCV 
(non-cirrhotic patients). Using overall score of perceived social support, the results 
showed that patients with HCV had higher levels of support than healthy people. 
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These results need further investigation in cirrhotic patients, since the majority of 
the patients were males (63%) in middle age (mean age 47.1±11.9) and were in the 
early stages of the disease and still able to do their work and daily activities. 
Unfortunately, the author did not give detailed results about how these patients 
perceived the different types of social support and which type of support was more 
beneficial for liver disease patients. Therefore, the representativeness of the results 
for the general population with liver disease, particularly with liver cirrhosis is 
uncertain. Besides, because culture and environment maybe important factors in 
perceived social support and their effects, it is essential to be cautious in 
generalizing these results to other cultures such as the Middle East. However, Erim 
et al's (2010) study contributed evidence about the relationship between anxiety 
and depression and perceived social support among patients with HCV. Low 
perceived support associated significantly with increasing severity and 
symptomatology of depression and anxiety; however, it did not associate any of 
them in multivariate analysis.   
3.12 FACTORS ASSOCIATED WITH PERCEIVED SOCIAL SUPPORT  
A few of the identified studies investigated factors associated with perceived social 
support among patients with liver disease (Blasiole et al. 2006; Erim et al. 2010). 
Many factors were associated with perceived social support including marital 
status, employment status, psychiatric comorbidities, time of interview (pre, during 
or post HCV-antiviral therapy) and method of getting infection (i.e. drug injection) 
(Blasiole et al. 2006). Age, gender (Blasiole et al. 2006; Erim et al. 2010), ethnicity, 
education, area of residence (rural vs. urban), cirrhosis and Child-Pugh score did 
not associate with social support (Blasiole et al. 2006). Therefore, it seems that 
marital status, employment status, hope in medical treatment and presence of 
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psychiatric comorbidities may be important factors in perceived social support. 
Therefore, these factors should be considered in future studies, to develop the 
evidence for associations between socio-demographic and medical characteristics 
and perceived social support in liver disease patients, particularly cirrhotic patients.    
3.13 SOURCES OF SUPPORT AMONG LIVER DISEASE PATIENTS  
No study had investigated the perceived social support from a partner, family and 
others. Social support, particularly from a partner, family and friends may be 
essential when living with a life threatening disease that also affects the patient’s 
social life and daily activities. Cohen and Syme (1985) stated that social support 
can work as a buffer against the effects of stressors such as chronic disease. 
Therefore, it is essential to measure the perceived social support in patients with 
liver cirrhosis in Egypt to increase the knowledge of healthcare providers of the 
main sources of support that can affect these patients' HRQOL.  
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Table 3-9: Studies examining social support in liver disease patients 
Authors/country Design/Aim Sample/Participants 
characteristic 
Tools Key results 
Erim et al. 2010 
Germany 
Design: cross-section 
survey 
  
Aim: to examine 
depression and other 
psychopathological 
symptoms in HCV patients 
and to analyse how sense 
of coherence and social 
support influence them. 
Hypothesis: 1) patients with 
HCV differ in depression 
and psychological 
symptoms from normal 
population. 2) Higher level 
of sense of coherence and 
social support would be 
related to lower levels of 
anxiety and depression. 
 
81 patients who met 
the inclusion criteria 
 
All had HCV, 63% 
males, mean age 
47.1±11.9 chronically 
infected with HCV 
mean of years= 
7.38±6.04. 25.9% had 
previous psychiatric 
therapy, 49.4% had 
co-morbidities, 49.4% 
had experience of 
receiving interferon 
therapy, and 30% had 
terminated interferon 
therapy due to side 
effects of anti-viral 
therapy. 
 Social support 
questionnaire (F-
SOZU) 
 
 Beck Depression 
Inventory  
 
 Hospital Anxiety 
and Depression 
Scale (HADS). 
 
 Symptom Check 
List 90-R 
 
 Sense of 
Coherence Scale   
Patients with HCV had higher social support than healthy 
people. No association between age, gender and social 
support.  Depressive and anxiety symptoms were higher 
among patients with chronic hepatitis C than norm. 
No significant association between socio-demographic 
characteristics, age, gender, marital and employment status 
and present of anxiety or depression. 
Sense of coherence was similar to norm. No association 
between sense of coherence and age and gender. These 
subscales of the general symptoms distress were higher 
among patients with CHV: somatization, compulsiveness, 
insecurity in social contact, aggression/hostility, phobic anxiety 
and psychoticism. Social support was significantly associated 
with depression and anxiety, but was not associated with them 
in the regression analysis. Sense of coherence (low) and 
gender (women) was associated with increasing depression 
severity and symptomatology. Employment status was not 
associated with depression severity or symptomatology in the 
regression analysis.   
 
Wilson et al. 2010 
USA 
Design: Cross-section 
 
Aim: to assess the 
prevalence of HCV related 
depression in outpatients 
setting; assess the 
importance of biological, 
psychological and social 
factors in predicting 
65 of consecutive 
sample 
 
All had HCV, 66% 
males, 55% married, 
17% see a mental 
health provider, 18% 
currently receiving 
 SF-36 (VT, SF 
and MH scales), 
 Beck Depression 
Inventory II (BDI-
II)  
 Social functioning 
was assessed by 
using (one item) 
98.5% of the patients said that they had social support. Social 
functioning, ability to work, income, and vitality could 
significantly associate with mental health. Religious faith, social 
functioning, reaction to diagnosis and vitality predicted 
depression. 
Age, gender, education and marital status did not associate 
with mental health domains (SF-36). 
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Authors/country Design/Aim Sample/Participants 
characteristic 
Tools Key results 
depression among patients 
with HCV. 
interferon therapy. 
39% had grade IV 
fibrosis. 
and Scale of 
social functioning 
in SF-36. 
 
Blasiole et al. 2006 
USA 
 
Design: cross-sectional 
mixed method (quantitative 
and qualitative) 
 
Aim: To assess the social 
support and cause of social 
difficulties using this 
hypothesis:  
Poor social support among 
patients with HCV is related 
to emotional and physical 
problems   
342 who met the 
inclusion criteria  
 
All had HCV, 62.6% 
males,  
Mean age 45.2±9.2, 
62.0% live with 
partner, 
35% currently 
unemployed, 64.3% 
rural residence, 26.4% 
had psychiatric co-
morbidity, 23.8% had 
cirrhosis and 62.3% 
had HCV due to drug 
injection.     
 HADS. 
 Sickness Impact 
Profile  
 
 Carlson 
Comorbidity 
Index 
 
 Child-Pugh score 
73% had supportive environment. 45% had loss of relationship 
due to HCV, 56% had problems with family interaction due to 
HCV, 12% lost at least one friend because of HCV, 8% had 
social isolation feeling negativity from others, 7% have decided 
to withdraw from social activities with family or friends. 
Financial burden due to loss of work, high cost of anti-viral 
therapy, without insurance. Causes of impaired social 
support: Afraid to infect others, feeling discrimination, disease 
stress (concern about family condition), and fatigue. Factors 
associated with perceived supportive environment (who 
perceived high support): marital status (married), current 
employment status (employed), interview to treatment status 
(after therapy), number of psychiatric comorbidity (low), route 
of infection with HCV (non-drugs injection), depression (low), 
anxiety (low), physical symptoms (low) and psychosocial 
disturbances (low).      
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3.14 CONCLUSION  
There is a growing interest in investigating the perceived HRQOL and QOL in 
patients with liver disease (various stages). Studies that have been carried out 
reached the same conclusion that patients with liver cirrhosis have a poorer 
generic and disease specific HRQOL than the normal population. However, the 
literature is not clear about which dimension of HRQOL are most affected, which 
may be related to differences in the cultural background and healthcare systems. 
Common factors that influence HRQOL have been identified, including 
demographic factors, socio-economic status, and clinical factors such as 
comorbidities. However, the heterogeneity of the participants in most of the 
previous studies is problematic regarding the generalisability of these studies' 
findings on patients with liver cirrhosis in Egypt particularly relating to perceived 
poor HRQOL. There is a concern regarding the composition of the samples in 
many of the studies, as most of the subjects were males, with a high standard of 
living and a high level of education. Ultimately, this makes generalisability of these 
findings to other groups of patients with liver cirrhosis and those from other cultural 
and educational backgrounds, for example patients in Egypt, questionable. 
Thus, based on the literature review this study aims to: (1) describe HRQOL of 
Egyptian liver cirrhotic patients and to identify and evaluate the factors associated 
with (HRQOL) physical and mental health domains, (2) explore and describe 
experienced symptoms (prevalence, severity and hindrance) in Egyptian cirrhotic 
patients and to identify and evaluate factors associated with symptoms severity 
and symptoms hindrance (distress) and (3) explore and describe how cirrhotic 
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patients in Egypt perceive social support from spouse, family and friends and to 
identify and evaluate factors associated with general perceived social support.  
This will help healthcare professionals and health policy makers in Egypt to 
recognize the psychosocial problems of these patients, in the hope that healthcare 
services in Egypt will shift from physician-centred to patient-centred care and will 
integrate both the biomedical and the psychosocial models together during care for 
these patients.  
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4 CHAPTER 4- METHODOLOGY  
This chapter presents justification for the philosophical paradigm, the 
methodological approach and the theoretical framework that were adopted in this 
study. Then, the research design, the population and sampling, and clinical settings 
are described as well as the procedures for data collection including an explanation 
of the measurements used and the recruitment strategy. Finally, ethical approval 
and ethical considerations are discussed.  
4.1 THE PHILOSOPHICAL PARADIGM AND RESEARCH APPROACH  
Although observing and explaining the world around us is part of human nature, 
daily observations are usually unsystematic and part of an aimless process that is 
carried out involuntarily. Observations carried out by researchers should be 
specific, objective, well focused and systematic to produce valid and replicable 
data (Black 1999). This study used a systematic research method to collect valid 
data in a systematic way in order to confirm existing knowledge and to create new 
knowledge (Langford 2001).  
The research Onion (Diagram 4-1) was adapted from Saunders et al. (2009). It 
consists of many layers that reflect the steps of the research process, which were 
followed in this study, (1) finding the philosophical paradigm, (2) selecting the 
research method, (3) selecting the research design, (4) determining the choices, 
(5) determining the time horizon according to the time allocated to the research, 
and (6) planning the data collection procedure and data analysis process. 
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4.1.1 Philosophical Paradigm 
The term paradigm refers to the general philosophical assumptions or view of an 
individual about the nature of the world and how its phenomena (i.e. experience or 
events) can be understood (Maxwell 1998; Broom and Willis 2007). Buetow (2007) 
claimed that research is a journey towards knowledge and understanding and a 
roadmap is essential to direct and guide this journey. Therefore, a paradigm is 
considered the roadmap that directs the research journey.  
There are different philosophical positions (paradigms) that represent very different 
ideas about reality and how knowledge can be gained, for example positivism and 
interpretivism (Saunders et al. 2009). Each of these paradigms includes a specific 
methodological strategy linked to the stated assumptions (Broom and Willis 2007). 
Therefore, the relationship between the research philosophy and the research 
method is essential; because it allows the researcher to decide the research 
approach and the research method. It is also useful for recognizing any limitations 
which may disrupt the research (Easterby-Smith et al. 2002). A positivist paradigm, 
also called logical positivism (deductive approach) was adopted in this study. 
Positivism is based on the logical objectivity of studying the phenomena of interest 
and withholding personal beliefs and biases to avoid contamination of the 
phenomena under investigation (Remenyi et al. 1998; Polit and Beck 2008). 
Remenyi et al., (1998, p.33) maintain that “the researcher is independent and 
neither affects nor is affected by the subject of the research”. The fundamental 
assumption of the positivist paradigm is that nature is basically ordered and 
phenomena are not random events, but rather have antecedent causes, e.g. more 
than one factor can potentially be the cause of a perceived poor health status.  
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Diagram 4-1: The “Research Onion” adapted from Saunders et al. 2009, p.108 
 
Philosophies 
Strategies /design 
Choices 
Approaches 
Time horizon 
Procedure of data 
collection and 
analysis 
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4.1.2 Research Approach  
Quantitative research has been defined as ‘a formal, objective, systematic process 
for generating numerical information about the world’, which ‘is conducted to 
describe new situations, events, or concepts; examine relationships among 
variables; and determine the effectiveness of treatments in the world’ (Burns and 
Grove 2011, p. 34). Quantitative research assumes that phenomena are stable and 
can be predicted, and therefore they can be measured (Topping 2010). The main 
outcomes in this study can be measured through measurements, like the Health-
Related Quality of Life (HRQOL) and symptoms; therefore, a quantitative approach 
was felt to be appropriate, primarily to find the frequency and association between 
factors, but also to develop a predictive model of factors that are related to these 
outcomes.  
Furthermore, with the quantitative approach it is easier to minimize bias and to 
maintain an objective view while studying the phenomena (Reichardt and Rallis 
1994) to develop valid and reliable results (Topping 2010). Grey (2009, p. 201) 
maintains that “quantitative research emanates from an objectivist position which 
holds that reality exists independently of the researcher the truth is ''out there''. 
Therefore, it is a highly structured method that can allow future replication of a 
study for comparison and confirmation, and development of inferences for future 
research (Gill and Johnson, 2002; Topping 2010).  
The quantitative approach is the most common research method and is an 
essential part of health services research (Meadows 2003). In Egypt, this approach 
is the dominant and best-known research approach among health researchers 
(nurses and doctors). Therefore adopting this approach to conduct this study was 
128 
 
most appropriate to communicate the results to healthcare providers as well as to 
health policy makers. 
4.2 THEORETICAL FRAMEWORK  
4.2.1 Importance of Using a Theoretical Framework    
Many researchers acknowledge the importance of using a theoretical model as a 
framework to develop a research study because it can assist in investigating a 
specific phenomenon in an organized context (Fawcett and Downs 1992; Vallerand 
and Payne 2003; Burns and Grove 2003; Sousa and Kwok 2006). Moreover, using 
a tested theoretical framework can help the researcher to specify research 
concepts, the definitions of these concepts and the appropriate measurements for 
investigating these concepts (Vallerand and Payne 2003), as well as to specify and 
direct the relationship between these concepts (Wilson and Cleary 1995). To my 
knowledge, the previous studies used the theoretical framework of HRQOL 
outcomes to clarify the predictors of HRQOL among patients with chronic disease 
(Sousa and Kwok 2006).  
In fact, the theoretical framework is a logical structure model of related concepts 
that can explain a specific phenomenon of interest by expressing assumptions and 
developing a philosophical view around this phenomenon (Burns and Grove 2003). 
Fawcett and Downs (1992) maintain that the theoretical model ‘seeks to identify a 
phenomenon, discover its dimensions or characteristics, or specify the relationship 
between the dimensions’ (p. 4). Vallerand et al. (1998) also state that using a 
tested theoretical model can enhance the applicability of the HRQOL concept as a 
reliable and valid outcome measure. As a result, it can improve the utilization of 
study findings in a particular area of health practice (Burns and Grove 2003).  
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4.2.2 The Conceptual Framework of HRQOL Outcomes   
The conceptual framework of HRQOL outcomes (Wilson and Cleary 1995) 
(Diagram 4-2) was used as a theoretical guide to: (1) write the research questions, 
(2) identify and define the variables, (3) identify the mediator variables, (4) direct 
the process of statistical analysis and (5) interpret the study findings. This 
framework integrates the two common models used for assessing health status: the 
biomedical model and the psychosocial model. The biomedical model focuses on 
assessing the aetiology of disease as well as physiological and clinical outcomes. It 
is useful to determine a medical diagnosis and medical treatment. The 
psychosocial model focuses on assessing different aspects of health status and 
overall quality of life (QOL/well-being). The framework addresses the difference 
between the clinical reported outcomes (CRO) and the patient reported outcomes 
(PRO), stressing the importance of investigating health status and QOL by using 
PRO. Therefore, patient preferences are the core of this framework and play an 
important role in understanding the HRQOL of patients.  
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Diagram 4-2: The original HRQOL outcomes model adopted from Wilson and Cleary 
(1995, p.60) 
 
 
4.2.3 Components of the HRQOL Outcomes Model 
The HRQOL outcomes model itself is quite complex. It acknowledges that health 
exists on a continuum from simple to complex outcomes with five determinants, 
each having multiple variables (Peterson and Bredow 2009). The five levels of 
health outcomes (Diagram 4-2) are:  
The first level focuses on the biophysiological variables such as biological factors, 
medical history, disease severity as well as medical diagnosis. The first level is 
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known as the CRO (or traditional clinical variables) that are commonly used in 
clinical practice.  
The second level focuses on symptom status such as physical and psychological 
symptoms. The physical symptoms relate to feelings about the physical status 
(body); while psychological symptoms relate to feelings of fear, worry and 
frustration (mind).  
There are many definitions of symptom. According to the model, a symptom is 
defined as "a patient's perception of an abnormal physical, emotional or cognitive 
status" (Wilson and Cleary 1995: 61). It is also defined as ‘a subjective experience 
reflecting changes in the biopsychosocial functioning, sensations or cognition” 
(Dodd et al. 2001, p. 669). Lenz et al. (1997) define symptom as a ‘perceived 
indicator of change in normal functioning as experienced by patients’. The common 
theme between these definitions is that a symptom is a subjective feeling which 
reflects a change in normal functioning that may be physical, psychological and 
social. Also, a symptom is characterized by subjectivity and multidimensionality 
(Armstrong 2003). 
Assessing symptom status is the first level of PRO; when healthcare providers 
assess a patient's symptom, the focus of caring shifts from caring for a specific part 
(organ) to caring for the person as a whole (holistic approach) (Wilson and Cleary 
1995). PRO is an umbrella term which covers single dimensional or 
multidimensional measures of symptom, HRQOL and overall satisfaction (Asadi-
Lari et al. 2004; Committee for Medicinal Products for Human Use (CHMP) 2005). 
Fallowfield (1990, pp. 22-23) confirmed that 'Healthy psychological functioning is a 
freedom from anxiety or depression and the ability to adapt and adjust to different 
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illness states, which is crucial for the maintenance of a good QOL'. Thus, 
evaluating symptoms is the essence of evaluating patients’ perceptions of their 
health status. Investigating symptom status by simply asking the patient what s/he 
feels can be a simple and convenient method of measuring the patient's 
perceptions about his/her functional health status (Fairclough 2002).  
The third level focuses on functional health status. Functional health status is 
defined as the patient's ability to perform particular defined tasks. The main 
domains include physical functioning, social functioning, role functioning, mental 
health, general health perception, vitality (energy/fatigue), cognitive functioning and 
pain. Many factors may be related directly or indirectly to functional health status, 
such as physiological factors, symptom status, individuals’ characteristics and 
environmental factors (i.e. social support).  
The fourth level is the perception of general health as defined by patients’ 
evaluations of their past and current overall health status. According to the model, 
symptom can be key predictor of general health perception. Therefore assessing 
the association between symptom status and general health perception is 
important. 
The fifth level looks at the overall QOL that is defined as the patients’ subjective 
well-being or satisfaction with their life as a whole. 
Wilson and Cleary in this framework declared that the concepts of HRQOL and 
QOL are used interchangeably. In this thesis only the term HRQOL was used to 
avoid overlapping between the two concepts that are conceptually different 
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(Section 2.2). Also, the two terms HRQOL and health status are used 
interchangeably.  
4.2.4 Justification of Using HRQOL Outcomes Model 
The theoretical framework of HRQOL outcomes has been chosen for many 
reasons. First, because the developers of the model were medical practitioners, 
they explained and defined the concepts and relationships between these concepts 
in such a way that this model can be understood and used in healthcare practice 
(Peterson and Bredow 2009). Second, HRQOL is a multidisciplinary concept and 
many factors that extend beyond nursing and doctor interventions can affect it. 
Therefore, this model is helpful in providing clear boundaries for research or clinical 
practice that can improve different dimensions of health outcomes. Furthermore, 
the scope of this model can have an individualized focus as well as a group focus 
(Peterson and Bredow 2009). Third, although the model is beneficial to predict the 
causal pathway associations between the biophysiological variables, symptom, and 
HRQOL, the arrows in the model do not prevent reciprocal relationships between 
the concepts (Wilson and Cleary 1995). Thus, this model is appropriate for guiding 
this study as it is a cross-sectional survey that investigates the associations 
between HRQOL and other factors without specifying the cause and effect.Finally, 
this model is a widely used theoretical framework to explore HRQOL among 
patients with different chronic conditions; such as cardiac conditions, cancer and 
end-stage renal diseases (Mathisen et al. 2007; Krethong et al. 2008, Kring 2008; 
Ulvik et al. 2008). It has also been used for people with comorbidities, HIV and 
chronic liver disease (Henderson 2007) but never used before for patients with liver 
cirrhosis. Therefore, this model is the theoretical framework that has been used to 
test HRQOL of cirrhotic patients. 
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The concept of HRQOL is not a commonly used term in Egyptian healthcare 
systems or in the community. Therefore, it was assumed that the patients might not 
be familiar with the types of questions that measure HRQOL. For that reason, face-
to-face interview was thought to be the most feasible method to complete the 
questionnaires so that unclear items could be probed, with caution to avoid 
affecting the patients’ response. However, face-to-face interviews with participants 
was expected to be longer than the consultation time, which might increase the 
chance of missing eligible participants during the recruitment process. Having 
numerous studied concepts is was also critical in that this would also be time 
consuming. For this reason, the model of HRQOL outcomes was adapted for the 
current study (see Diagram 4-3) to examine selected factors only: demographic and 
biophysiological factors, social support, symptom experience and HRQOL.  
 
Diagram 4-3: The revised HRQOL outcomes model adapted from Wilson and Cleary 
(1995) 
 
 
 
 
 
 
 
 
 
Clinician reported 
outcomes 
Patient reported outcomes/ Patients' perception 
 
 
Environmental characteristics: 
social support, marital status 
and socioeconomic status  
 
Biophysiological 
factors: disease 
stage, comorbidity 
etc.  
Symptom 
status: severity 
and distress 
HRQOL: 
physical 
and mental 
health 
health  
Individual’s (demographic) 
characteristics 
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4.3 RESEARCH METHODS  
4.3.1 Study Design  
The aim of this study is to describe HRQOL (health status) and symptoms 
experience of people with liver cirrhosis in Egypt as well as to identify a possible 
relationship between variables. Using a survey is a common research method in 
quantitative research, because it is a quick and inexpensive method that allows the 
collection of a significant amount of data from a sizeable population (Grey 2009; 
Jones and Rattray 2010). An epidemiological cross-sectional design obtains 
information from a single group of people at a single point in time: a ‘snapshot’ 
without any attempt to follow up over time (Ruane 2005; Mckenna et al. 2010).  
This epidemiological cross-sectional design was used to conduct this study to: (1) 
determine the characteristics of people with liver cirrhosis in Egypt; (2) describe 
HRQOL and patients’ symptoms, and explore the relationships between them and 
other independent factors such as socio-demographic characteristics, and to (3) 
find the prevalence of outcomes, such as these patients’ symptoms (Seers and 
Critelton 2001; Meadows 2003; Levin 2006; Nieswiadomy 2008). Mckenna et al. 
(2010) suggested that a descriptive cross-sectional design can be used to describe 
the characteristics of a particular population, their health status and measure the 
prevalence of health outcomes.  
A longitudinal study allows investigation of a causal link between independent and 
outcome factors (Mckenna et al. 2010). However, due to cost and time, it was 
decided to use a cross-sectional design for this study to also generate inferences 
and hypotheses (Levin 2006; Mckenna et al. 2010) and recommendations for future 
research in the area of HRQOL and symptoms experience among patients with 
136 
 
liver cirrhosis in Egypt. Levin (2006, p.25) suggests that "it is advisable to think 
carefully about what might be relevant because this is a good opportunity to gain a 
broad base of knowledge about subjects who have/do not have the outcome of 
interest". Therefore, the HRQOL outcome model (Diagram 4-2) was used as the 
basic theoretical framework for this cross-sectional study to set the boundaries for 
this study and to provide the structure for data analysis and presentation of results.  
4.3.2 Population  
4.3.2.1  Sampling Method  
A target population is a complete set of individuals who have the characteristics 
that the researcher is interested in studying, and to whom the study findings will be 
generalised or applied (Bruce et al. 2008; Nieswiadomy 2008). The target 
population in this study is all adults with liver cirrhosis in Egypt. Since it was 
impossible to recruit all people with liver cirrhosis from across Egypt or even one 
region, a study population was used (Procter et al. 2010). The study population is a 
subset of the target population from whom an accessible sample was taken over 
the three months’ period of data collection based on specific inclusion criteria. 
Because a sampling framework for these patients was not available, a convenience 
sampling method was used to identify the study participants. Convenience 
sampling is a non-probability sampling method that is widely used in exploratory 
studies (Procter et al. 2010). The following inclusion and exclusion criteria were 
specified  
Inclusion criteria 
1. Aged 18 years or older,  
2. Diagnosed with liver cirrhosis and so stated in the patient's medical records, and  
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3. Consented to take part in the study. 
Exclusion criteria 
1. Advanced stage of hepatic encephalopathy (≥ grade 2), 
2. Primary Biliary Cirrhosis (PBC), 
3. Post liver transplantation, 
4. Hepatic carcinoma or malignancy,  
5. Treatment with antiviral therapy, and 
6. Neurological or communication problems. 
The purpose of the criteria for this sampling strategy was to recruit a potential 
representative sample of people with liver cirrhosis. The age of 18 or above was 
decided, because the majority of patients with cirrhosis are above this age and 
capable to give consent. Patients in the advanced stage of hepatic encephalopathy 
(≥ grade 2) were excluded, because confused patients may have psychological as 
well as memory problems. Patients with PBC were excluded because they 
experience specific common types of disease related symptoms, such as jaundice 
and itching, more often than patients with liver cirrhosis resulting from other causes. 
PBC is also a more common cause of cirrhosis among women than men and 
among older people than younger ones (Younossi et al. 2001). Patients were also 
excluded if they had a liver transplantation, because they sometimes experience 
different symptoms and HRQOL (van der Plas et al. 2004). Patients who were 
diagnosed with hepatic carcinoma or any other malignancy were excluded because 
they sometimes undergo chemotherapy or radiotherapy that may lead to different 
symptoms experience. Similarly, patients who were on an antiviral therapy, such as 
hepatitis C anti-virus therapy were excluded because they usually experience 
severe fatigue and depression (Fried 2002). Finally, patients with any neurological 
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or communication problems were excluded because they were unlikely to be able 
to give informed consent. 
4.3.2.2  Sample Size  
How many subjects should the researcher include? It is a question that is frequently 
asked at the beginning of a study (Nieswiadomy 2008, Field 2009). Indeed, 
determining sample size and dealing with non-response bias is necessary during 
the development of a quantitative cross-sectional survey study (Bartlett et al. 2001). 
Therefore, many factors should be considered for the calculation of the required 
sample size, including number of independent variables, alpha level (alpha/α = 
0.05), expected effect sizes (how strong of the relationship between independent 
variable and dependent factor that is going to measure), and the power (size of 
power to detect this effect, beta/β=0.20) (Tabachnick and Fidell 2001).  
Filed (2009) suggests that the ratio of cases to the independent variables is a rule 
of thumb to calculate the required sample size, 10 to 15 cases for each 
independent variable in the model. However, this rule of thumb may not be helpful 
in finding the sample size that can identify the required effect size and the size of 
power to detect this effect. Thus, recruiting a larger sample size is better. 
Therefore, Field (2009) recommends these two rules of thumb to calculate the 
required minimum sample size based on the effect size. The first method is used to 
test the overall fit of the model (R2): N = 50 + 8 k (k is the number of independent 
variables). The second method is used to test the contribution of each individual 
independent variable to explain dependent factors: N = 104 + k.  
As there are 14 independent variables in this study (HRQOL is the outcome) the 
minimum required sample size is 162 to test the overall fit of the model, and 118 to 
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test the individual independent variable. This method assumes a medium effect 
size relationship between the independent variable and the dependent variable 
(outcome), alpha=0.05 and β=0.20 (Tabachnick and Fidell 2001) when data is 
normally distributed. Also, a priori sample size calculator for multiple regression 
showed that with anticipated effect size (f2) = 0.15, statistical power of 80%, 
probability level of 0.05 and with 14 independent variables, 135 was the required 
sample size (Soper 2012). Therefore, a sample size of 401 was enough for 
developing the regression models of HRQOL, symptom experience and perceived 
social support.  
4.4 ETHICAL APPROVAL AND ETHICAL CONSIDERATIONS  
4.4.1  Ethics Committee Approval 
The study was conducted in accordance with ethical approval granted by the 
internal Ethics Committee at the University of Stirling, the Department of Nursing 
and Midwifery Research Ethics Committee (DREC) (Appendix 4-1) and the 
Research Ethics Committee Board of the National Hepatology and Tropical 
Medicine Research Institute (NHTMRI) in Egypt (Appendix 4-2).  
4.4.2 Egyptian Educational Bureau Approval 
To get approval to conduct this study in Egypt, the research proposal, the 
questionnaires, a brief description of the study, ethical approval from DREC and the 
names and addresses of the data collection settings were sent to the office of the 
Egyptian Educational Bureau in London (the sponsor for Egyptian PhD students in 
the UK). Approval was granted to start the scientific mission for data collection (field 
work) after the submitted documents were considered and reviewed by all 
concerned institutions in Egypt. Following that, the research proposal and relevant 
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documents were submitted to the Internal Research Ethics Committee Board of the 
NHTMRI in Egypt to obtain ethical approval as described earlier. Data collection 
began once the necessary approvals had been obtained.  
4.4.3 Ethical Considerations  
The key principles of research ethics that the researcher must uphold are 
protection from harm, autonomy, privacy and confidentiality (Burns and Grove 
2003). A summary of the ethical considerations that were addressed in this study, 
relating to the patient population, are presented in the following discussion.  
4.4.3.1  Potential Risks  
There was no intervention in patient care in this study. The patients were simply 
interviewed to complete the study questionnaires. Therefore, there was no risk of 
physical or psychological harm in this study. Furthermore, there was no risk of 
social or economic harm because the patients who took part in this study were not 
attending specifically to take part in this study. They were recruited during their 
follow up visit or admission to an inpatients clinic.  
The researcher, who is a nurse, was alert to any suggestions of embarrassment 
from participants and checked at each stage that they were happy to continue with 
the interview. It was made clear, especially to less well educated patients, that their 
participation was voluntary, and that they could withdraw from the study at any time 
without giving a reason. As the interview started, patients were told that they could 
take breaks whenever necessary to avoid fatigue or exhaustion, and again, the 
researcher looked out for tiredness and checked with the participant that they were 
happy to continue. The patients were approached in a sensitive manner and were 
given a full description of what the study required.  
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Due to the religious and cultural background of the Egyptian population, there were 
two questions that the researcher assumed would be embarrassing, especially for 
unmarried patients, particularly women. These questions are the last two items in 
the LDSI-2.0 and they relate to sexual problems (desire and activity). Therefore, the 
researcher did not ask unmarried females these questions, and these questions 
were given zero score. Furthermore, for unmarried males these questions were 
asked after clarifying to them that these questions were optional and that they did 
not need to answer if they did not wish to. Therefore, the likelihood that the 
participants would experience any anxiety, stress, or embarrassment during their 
participation in this study was minimised.  
4.4.3.2  Autonomy, Confidentiality and Data Handling  
The researcher ensured that the patients had complete autonomy to decide 
whether to participate without any pressure. To ensure the participants’ autonomy, 
they were informed that their participation was entirely voluntary and that they could 
withdraw from the study at any time, without negatively affecting the treatment or 
care they received.  
The confidentiality of the participants was preserved throughout the study and 
participants were reassured that anything they said during the interview would be 
kept confidential and would be used for the study purpose only without mentioning 
the patients' identity in any documents (i.e. thesis and publishing paper). 
Identifiable information like telephone numbers, email and home addresses, and 
any other information that might identify them, were not collected during the 
interview as they were not required for this study. Because this was a cross-
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sectional (snapshot) study, the researcher did not need to contact the participants 
again.  
Respect for the participants’ privacy was secured by conducting the interview in a 
private area in the outpatient clinic. This was to ensure the patients' privacy and 
confidentiality, and to avoid disturbance as well. For the participants who were 
recruited from the inpatient clinics interviews were conduc ted in the patient’s 
admission room. If there was a relative with the patient, permission from the patient 
was obtained before conducting the interview as to whether her/his relative could 
be in the room during the interview.  
With respect to data handling, each participant was assigned a unique code 
(number) on the questionnaires during the study and all data were kept on a 
password-protected personal computer at the University of Stirling, and a personal 
Laptop used for fieldwork. The password was known only to the researcher. The 
questionnaires and research data on the computer did not contain any patient 
identifiable information. 
4.4.3.3  Informed Consent  
The principle of informed consent means that participants are provided with 
sufficient and understandable information about the aims of the study. It also 
means that participants are informed of the nature of the information that is being 
collected and how much time they will be required to contribute before giving 
consent. In fact, the usual way to provide information to participants is through a 
patient information sheet which provides a written record of what the study is about.  
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The participants were informed verbally and in writing using an information sheet 
(Appendix 4-3 and Appendix 4-4), which was developed with consideration for 
uneducated participants. Written information and consent sheets were provided, 
but the sheets were made more accessible through the use of pictures and 
illustrations. Furthermore, the study was explained verbally to patients who could 
not read. Written consent (Appendix 4-5 and Appendix 4-6) was obtained from the 
participants who could write and was obtained from an available witness if the 
participant could not write. A witness could be a family member (husband, wife, 
sister, brother, close relative like cousin); a nurse caring for the patient or the head 
nurse of the department. Some patients (21.6%) gave verbal consent and refused 
to write their name on the consent sheet (more details see section 5.4.2). 
4.5  DATA COLLECTION PROCESS 
According to Meadows (2003), the data collection process should be objective, 
systematic and replicable. Therefore, the key questions for designing the data 
collection procedure were as suggested by Nieswiadomy (2008): What? How? 
When? The revised theoretical framework of HRQOL outcomes (Diagram 4-3) was 
used to answer these questions systematically. 
4.5.1 Measurements  
Taillefer et al. (2003, p. 310) stated that ‘a failure to provide an a priori definition of 
the main concept is as serious and unacceptable as not providing hypotheses or 
research questions in an empirical study, and can lead readers to make inaccurate 
interpretations about a model, the results of a study, or the use and misuse of a 
model’. Therefore, it is essential to define the research concepts theoretically and 
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operationally. The following sections outline the theoretical definitions of the 
investigated variables and clarify how these concepts were measured.  
4.5.1.1  Theoretical Definition of Variables (What?) 
The theoretical definition is a conceptual definition which aims to clarify the 
theoretical meaning of a variable that may be derived from the theoretical 
framework or developed through concept analysis (Fawcett 1999). For this study 
the investigated concepts are defined theoretically as follows. 
Biophysical status  
This describes the patient's biophysical status because of liver cirrhosis in terms of 
disease stage, cause of liver cirrhosis, number of liver cirrhosis complications and 
number of comorbidities. 
Liver cirrhosis 
A patient with liver cirrhosis was defined as an individual who had been diagnosed 
by a physician as having cirrhosis, was not responding to antiviral therapy (i.e. 
Interferon), and had stopped it at least four months before data collection. In 
addition, patients who were not eligible for interferon therapy and requiring just 
conservative medical management were eligible for this study.  
Symptoms experience  
Symptoms experience is the patient's perception of the presence of physical or/and 
emotional problems that reflect the severity of their symptoms (Wilson and Cleary 
1995).  
Hindrance of symptoms  
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This means to what extent the symptom that the patient experiences limits or 
restricts his/her daily and social activities (van der Plas et al. 2004). 
General health perception 
General health perception describes a patient's perception of his/her current and 
past overall health status (Wilson and Cleary 1995).  
HRQOL 
HRQOL is the patient's subjective perception of the impact of their disease and/or 
its treatment on the various aspects of their daily life, including physical functioning, 
psychological status and social functioning (Anderson and Burckhardt 1999; Taylor 
2000). 
Environmental characteristics (Perceived social support)  
Environmental characteristics were defined as the perceived social support from a 
patient's perspective. Social support is ‘the extent to which an individual believes 
that his/her needs for support, information, and feedback are fulfilled’ (Procidano 
and Heller 1983, p. 2). 
4.5.1.2  Operational Definition of Variables (How?) 
The operational definition clarifies how the variable is measured. For measuring 
concepts that were defined theoretically, it was essential to define them 
operationally. An operational definition means the availability of valid and reliable 
tools that can be used to measure these concepts (Burns and Grove 2003). A valid 
measurement should have these characteristics: it measures what it is intended to 
measure, is clear, comprehensible, uses unambiguous wording, and is relevant and 
consistent (Fairclough 2002; Ruane 2005). In this study the instruments that were 
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already available in Arabic were given priority as translating questionnaires is costly 
and time-consuming. 
For data collection, a face to face structured interview technique was used. 
Although self-completion questionnaires are often sent by post, enabling large 
samples to be reached, response rates tend to be low and, this method is 
inappropriate for illiterate people. Hence, face-to face interview using short 
questions and simple language was used to avoid respondent misunderstandings 
(Meadows 2003). In this study one questionnaire and three scales were used to 
collect the study data in a structured and systematic manner. 
Background data sheet 
The background data sheet was used to collect the individual's characteristics and 
medical history (Appendix 4-7 and Appendix 4-8). This sheet was developed by 
reviewing previous studies that were conducted among people with liver disease. 
The sheet was divided into two parts, individual characteristics and medical history.  
Individual characteristics: Socio-demographic data (i.e. age, gender, marital status, 
educational level, area of residence, current employment status, cause of 
unemployment) were collected from the patients themselves, as this data is not 
usually recorded in the medical documents. 
All socio-demographic data were classified according to the Egyptian norm using 
the Egyptian census (Central Agency for Public Mobilization and Statistics 2011). 
For example, the categories for marital status were single (never married), married, 
and widowed / divorced / separated. The level of education was categorised into 
illiterate, primary, preparatory, secondary (public/technical) and higher education 
(students enrolled or graduated from university). Employment status was classified 
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into employed (working now), unemployed (not working now) and housewife 
(woman does not work at all). Causes of unemployment (not working) were 
classified into liver disease and other causes (i.e. retirement, age and no job 
available). These socio-demographic variables have all been shown to be important 
factors associated with HRQOL in patients with liver cirrhosis in previous studies 
(Kim et al. 2006; Sobhonslidsuk et al. 2006; Bjornsson et al. 2009; Hsu et al. 2009). 
It was also important to determine the cause of unemployment to investigate the 
impact of this disease on patients' ability to work which might cause a financial 
burden (Sobhonslidsuk et al. 2006). Financial burden was an item in LDSI-2.0 that 
was used to assess its severity as a result of liver disease. 
Medical history: This referred to the cause of cirrhosis, complications of cirrhosis, 
number of hospital admissions related to liver disease, causes of hospital 
admissions, comorbidity number and types, and disease stage. This part of the 
questionnaire was completed by accessing and reviewing the patient's medical 
records. However, the medical files of many patients were neither organized nor 
complete, particularly among patients attending the outpatient clinics. Because 
these medical files did not contain a history of previous hospitalizations related to 
liver disease, and co-morbidities, these two questions were addressed to the 
patients themselves. 
The stage of liver cirrhosis was classified into compensated and decompensated 
cirrhosis. Compensated cirrhosis means that the liver is coping with the damage 
and maintains its important functions. Thus, patients with compensatory liver 
cirrhosis do usually not have any complications of liver disease. In contrast, in 
decompensated cirrhosis, the liver is not able to perform all its functions 
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adequately, and patients often have serious complications such as splenomegaly, 
bleeding varices, ascites and/or encephalopathy (Smeltzer and Bare 2004; Porth 
and Matfin 2009).  
Therefore, participants who had cirrhosis but had not yet developed clinical de-
compensated complications (splenomegaly, ascites, oesophageal variceal bleeding 
or encephalopathy) in the year of data collection were classified as compensated 
cirrhosis. Participants who had developed any of the liver disease complications in 
the year of data collection were classified as decompensated cirrhosis (Cordoba et 
al. 2003; van der Plas 2003; Gutteling et al. 2006; Ong et al. 2008; Gutteling et al. 
2008).  
Comorbidity was assessed by asking the patients if they had been diagnosed with 
any disease other than liver disease. Comorbidities have been shown to be 
associated with perceived functional health status among patients with liver 
cirrhosis in prior studies (Marchesini et al. 2001; Cordoba et al. 2003; Kalaitzakis et 
al. 2006; Bjornsson et al. 2009; Hsu et al. 2009). Also, these variables are required 
to develop an individualized care plan to improve the perception of functional health 
among people with cirrhosis. 
HRQOL (perceived health status) 
The Medical Outcome Short-Form 36 version 2 (SF-36v2) is a generic HRQOL 
instrument that has been used widely to assess health status (Ware et al. 1993). 
The US version 2.0 of the SF-36 (SF-36v2) (Appendix 4-9) was developed in 1996 
to correct deficiencies identified in the original version (version 1.0) (Ware et al. 
2000). The SF-36 has been culturally adapted to different languages as part of the 
International Quality of Life Assessment (IQOLA) Project (Ware et al. 2008).   
149 
 
The SF-36 is a generic HRQOL tool used worldwide to assess health status among 
general and specific populations with different health conditions. Furthermore, 
evidence shows that the SF-36 is a more sensitive tool to assess changes in 
patients' health conditions over time than other generic health status measures like 
the Nottingham Health Profile, and the Sickness Impact Profile (Beaton et al. 1997). 
SF-36 is a tool that can be self-administered or completed with assistance in less 
than 10 minutes (El-Serafy et al. 2009). The psychometric properties (validity and 
reliability) of the Arabic version have been tested (Appendix 4-10) (Coons et al. 
1998; Sabbah et al. 2003; Mrabet et al. 2004) and it has been widely used among 
Egyptians patients with chronic conditions, such as liver transplantations and 
chronic hepatitis C infections (Tanamly et al. 2004; Kamal et al. 2006; El-Serafy et 
al. 2009). It was therefore judged that the SF-36v2 was the most appropriate 
measurement for this study. Permission to use the SF-36v2 in this study was 
granted by QualityMetric Incorporated (Appendix 4-11), and a license was obtained 
(license number: QM009535), (components of SF-36 see section 3.3.1)  
Kosinski (2009) argues that maintaining the data quality through accuracy of 
entering, coding and scoring is essential to ensure the study quality and giving valid 
results. QualityMetric Incorporated have developed software that can be used to 
enter patients' responses to the 36 items of the SF-36, to simplify the scoring 
process and to provide reliable results. This software has many advantages: it 
tracks the quality of the data entry process by giving an alert message to complete 
a missing item before starting the scoring operation; it provides a standardized 
scoring method, thereby avoiding errors (Kosinski 2009) and wasted time and 
effort; it yields less biased data and estimates the missing responses (Kosinski et 
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al. 2000). For these reasons, the scoring software was purchased from Quality 
Metric Inc for data entering and scoring SF-36. 
Ware et al. (2000) introduced a norm-based score (NBS), which uses a cut-off point 
of mean = 50 and standard deviation (SD) = 10. It is therefore possible to 
meaningfully compare scores for the eight-scale profile and the physical and mental 
summary measures with this cut-off score (Kosinski et al. 2000). It is also possible 
to interpret the SF-36 results without the need of a previous study to be used as a 
norm. A mean score below 50 indicates a poorer health status and a mean score 
above 50 indicates a better health status than the population average (Maruish and 
DeRosa 2009). For interpreting the SF-36 domains and the two component 
summary scores, the guideline suggested by Ware and Gandek (1998); Ware et al. 
(2000) was used (Appendix 4-12).  
General health perception  
The general health perception was assessed using item one in SF-36. Patients 
were asked to rate their general health on a 5-point ordinal scale ranging from one 
"excellent" to five "poor". This approach has been used in liver disease research 
(Sobhonslidsuk et al. 2006).  
Perceived symptom severity and hindrance of symptom  
Comprehensive and valid disease specific measurements of symptoms can be an 
excellent predictor of HRQOL (Wilson and Cleary 1995). Several questionnaires 
have been developed and used to measure disease specific HRQOL in patients 
with liver disease; these include the Hepatitis Quality of Life Questionnaire (Bayliss 
et al. 1998), the Chronic Liver Disease Questionnaire (Younossi et al 1999), the 
Liver Disease Quality of Life Instrument (Gralnek et al. 2000), the Hepatitis B 
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Quality of Life Instrument (Spiegel et al. 2007) and the Chronic Liver Disease 
Quality of Life Questionnaire (Lee et al. 2008). However, some are too narrowly 
focused (Bayliss et al. 1998; Younossi et al 1999; Gralnek et al. 2000; Spiegel et al. 
2007), and others are too long (Gralnek et al. 2000) and do not address the extent 
to which symptoms affect patients’ HRQOL (Younossi et al 1999; Lee et al. 2008).  
In contrast, the Liver Disease Symptom Index 2.0 (LDSI-2.0) (Appendix 4-13) is a 
psychometrically tested questionnaire that has been widely used among patients at 
different stages of chronic liver disease, mainly in the Netherlands (Unal et al. 
2001; van der Plas et al. 2003; van der Plas et al. 2004; Gutteling et al. 2008; 
Gutteling et al. 2008a; Kuiper et al. 2010). The index was designed by experts in 
liver disease (hepatologists) to help healthcare providers understand the 
experience of patients with liver disease and how their symptoms influence their 
daily life. Thus, not only does it assess symptom severity, it also addresses how 
symptoms influence patients’ daily living. Gutteling et al. (2007) maintains that the 
LDSI-2.0 is the best specific disease tool, because it is short, measures possible 
liver disease specific symptoms, and covers the impact of these symptoms on 
patients’ daily activities.  
In accordance with the scoring instructions provided by Gutteling et al. (2008), 
scores for all of the items on each subscale were added to obtain a value for the 
individual subscales. Possible scores for each subscale ranged from 0-60 for the 
severity of symptoms and 0-36 for hindrance of symptoms. A higher score on the 
symptoms severity subscale represents a higher perception of symptoms severity, 
and a higher score on the hindrance of symptoms subscale represents a higher 
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perception of the limitations of daily activities as a result of these symptoms. Table 
4-1 summarises the method used to report the result of LDSI-2.0.  
The LDSI-2.0 is available in English and is in public use. However, an Arabic 
version that could provide essential new information about patients with liver 
disease in Egypt did not exist before conducting the pilot study. The translation 
process and the testing of the validity and reliability of the LDSI-2.0 are discussed 
in detail in Chapter 5. 
Table 4-1: LDSI-2.0 scoring system  
Scale Total 
Items 
Subscales Subscales 
Items 
Response 
scale 
Score range 
(minimum and 
maximum  sum of 
responses) 
Sum of 
score 
for each 
category 
LDSI-
2.0 
24 Symptoms 
severity 
15 
 
 
0-4 Minimum=0 
(no symptom) 
Maximum =60 (very 
severe symptom) 
0-60 
Hindrance of 
symptoms 
9 0-4 Minimum=0 
(no debility in daily life 
as a result of 
symptoms) 
 
Maximum =36 (very 
severe debilities in 
daily life as a result of 
symptoms) 
0-36 
 
Perceived adequacy of social support  
Given the importance of choosing a measurement that can assess the perceived 
adequacy of social support that was specific to the research context, it was vital to 
identify an instrument which had been specifically designed to measure the 
perceived adequacy of social support from different sources of support. Searching 
the literature found that the multidimensional scale of perceived social support 
(MSPSS) (Appendix 4-14) is a commonly used instrument for measuring the 
adequacy of social support. The MSPSS was developed in the USA by Zimet et al.  
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(1988 and 1990). The three subscales assess the perception of the adequacy of 
social support from three specific sources: family, friends and significant others 
(Zimet et al. 1988; Zimet et al. 1990). Each subscale has four items that are rated 
on a seven point scale in the English version or are rated on a three point scale in 
the Arabic version. An increasing score represents increasing perceived adequacy 
of social support. 
The original MSPSS has an internal consistency reliability with Cronbach alpha’s 
for total MSPSS = 0.85 and for the sub-scales 0.85 or greater, as well as adequate 
construct validity. Although the MSPSS was originally developed to assess social 
support among university undergraduates, it has been translated and 
psychometrically tested in a number of studies worldwide among people with 
different illnesses (Nakigudde et al. 2009; Ramaswamy et al. 2009; Wongpakaran 
et al. 2011) including in Arabic (Aroian et al. 2010).  
The Arabic MSPSS (Appendix 4-15) was translated and back translated by a team 
of bilingual speakers following the protocol for translation to give a high quality 
translated version (Aroian et al. 2010). It is the most appropriate tool for measuring 
perceived social support among patients with liver cirrhosis in this study for many 
reasons. (1) It can assess the individuals’ subjective perceptions of the adequacy of 
social support from the main source of support (spouse, family spouse friends). (2)  
It is the shortest and simplest tool available (12 items); Zimet et al. (1988; 1990) 
stated that it can be used when time is limited and a number of questionnaires 
need to be used at the same time. (3) An Arabic version of MSPSS is available 
(Aroian et al. 2010) and has been widely used among Arabic people (Ramaswamy 
et al. 2009; Aroian et al. 2010). It showed good construct validity and internal 
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consistency reliability with Cronbach alpha’s for total MSPSS = 0.74 (Aroian et al. 
2010). Written permission to use the Arabic version of MSPSS was sought and 
granted by Professor Aroian as the translator for the tool and from Professor Zimet 
as the original author (Appendix 4-16).  
The MSPSS can be computed to give the total and subscale scores for each of the 
three sources of support (spouse, family and friends). The total score and subscale 
scores were calculated by adding up the participant's responses to give a total 
score. In accordance with the scoring instructions provided by Aroian et al. (2010), 
scores for all of the items on each subscale were added to obtain a value for the 
individual subscales. Possible scores for each subscale ranged from 12-36 
(adjusted score 1-3). Table 4-2 summarises the method of the MSPSS scoring that 
was used to report the result of MSPSS.  
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Table 4-2 : Scoring system of MSPSS  
 
 
 
 
 
 
 
Scale Items Subscales Items Response 
scale 
Score range 
(Sum of responses) 
Steps of scoring Categories Adjusted 
Scores 
MSPSS 12 Spouse support 4 1-3  
12-36 (Married) 
 
8-24 (Unmarried) 
 
Sum of responses 
 
Subtraction of sum of 
responses on the number 
of scale items 
 
Number of items: 
12 for married 
8 for unmarried 
 
Disagree 
Neutral 
Agree 
1 
2 
3 
Family support 
 
4 1-3 
Friends’ support 4 1-3 
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4.5.2  Overview of Clinical Settings  
The study was conducted in three hospitals in Cairo, Egypt. The National 
Hepatology and Tropical Medicine Research Institute (NHTMRI), the Section of 
Tropical Medicine in Kaser El-Ani Teaching Hospital, and the Centre Doctor Yassin 
Abdel Ghaffar Charity for Diseases of the Liver and Research (CDYCDLR). These 
hospitals were primarily considered because they offer both local and regional, 
inpatient and outpatient hepatic health services.  
4.5.2.1 Hospital 1: NHTMRI  
The NHTMRI is the largest specialist liver disease and tropical medicine institute 
not only in Egypt but also in the Middle East. The Institute is considered to be an 
international research centre, and was selected by the University of Maryland in the 
USA and the World Health Organisation to conduct clinical research in tropical and 
liver diseases. It was established in the era of King Fuad, first King of Egypt, in 
1931. The institute provides free services for all Egyptians with liver disease, 
including consultations, medical and surgical interventions, and antiviral therapy for 
hepatitis. Therefore, many patients from varies governorates in Egypt attend the 
outpatient clinic daily, both for consultation and admittance to the departments.  
4.5.2.2 Hospital 2: Section of Tropical Medicine  
Kaser El-Ani is a national teaching hospital that provides free healthcare services 
for Egyptians from varies governorates. The Section of Tropical Medicine is one of 
many sections in this hospital. It provides healthcare for patients with different 
medical health problems, especially gastroenterology and tropical illness. 
According to the annual statistics of Cairo University Teaching Hospital, 2285 
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patients were admitted with liver cirrhosis in the year 2004 to 2005 to Kaser El-Ani 
Teaching Hospital alone (Department of Statistics and Medical Documentation 
2005). 
4.5.2.3  Hospital 3: CDYCDLR 
The CDYCDLR was constructed and opened in 1999. It was created by Doctor 
Yassin Abdel Ghaffar, a Professor of liver disease, with contributions from other 
people who shared in funding this project. The centre is right in the middle of Nasr 
City, Cairo. It is a private hospital that provides healthcare for people with liver 
disease (adult and children) from different economic backgrounds. Many patients 
attend the centre daily for medical consultations in the outpatient clinics, while 
others are admitted to inpatient departments. According to the annual report the 
number of visitors to the centre and the beneficiaries of its services are around 
20,000 patients every year.   
4.5.2.4  Justification for Clinical Settings 
These hospitals were selected because many people with liver disease (men and 
women) come daily from different regions in Egypt (both rural and urban) to these 
hospitals to get inpatient and/or outpatient management. These patients have 
varied socio-economic, cultural and educational backgrounds. As a result, they 
provide a representative cross-section of the population, thus allowing 
generalization of the study results.  
4.5.3 Recruitment Process  
A sampling frame is a method of selecting people of interest in order to stratify the 
sample and contact them. A construct sampling frame that includes the whole 
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population of interest with their various characteristics such as age and gender is 
an ideal method to select the sample systematically, which can then be 
representative of the entire population (Bruce et al. 2008). However, this method 
(sampling frame) is impossible when the population's contact details (addresses 
and telephone numbers) and time of consultation in the clinic are not available. 
Therefore the following recruitment strategy was designed to facilitate systematic 
data collection from a large representative sample from three hospitals during the 
three months of field work (from June to August 2011).  
The feasibility of the recruitment method was tested by conducting a pilot study for 
a month in one of the selected hospitals. The three hospitals have little differences 
in the routine of work that might influence the recruitment process. Therefore, the 
following part clarifies the places of data collection and the methods of recruitment 
that were used in this study.  
4.5.3.1 Recruitment from Hospital 1: NHTMRI 
The work routine in the outpatient clinic and inpatient department in the NHTMRI is 
as follows. The outpatient clinic is open from 9am till 1pm daily except Friday. 
Therefore the recruitment process started in outpatients at 9am till 1pm to ensure 
that all the eligible patients who attended on that day had a chance to participate in 
this study. In the inpatient clinic the family’s visiting time is from 2pm till 5pm. 
Therefore, the admitted patients were recruited in the inpatient clinic after finishing 
the recruiting process in the outpatient clinic at 1 pm. Recruitment at the outpatient 
clinic was quite different to recruitment in the inpatient departments.  
Outpatient recruitment  
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The outpatient clinic has two liver consulting rooms worked at the same time by two 
physicians. After discussions with the staff, it was decided that the researcher 
would wait in one of the two rooms and the consultant would introduce her to 
eligible patients after finishing the consultation. Once the consultation was finished 
the interview started.  
It is important to highlight that in the pilot study interviews were conducted before 
the consultation. It was difficult to follow the same strategy in this setting because it 
was impossible to know which patients would be eligible before their consultation 
with the physician. Because the consultation time was less than 20 minutes, 
sometimes the consultation of the next patient was over before the interview with 
the last patient was finished. Therefore, to avoid missing any eligible patients, the 
physician helped the researcher by sending patients first to the pharmacy inside the 
institute to collect their prescribed medication. As this process takes time, patients 
who were willing to take part in the study could return to the researcher. The 
researcher wrote the patients name in a list before they left the consultation room to 
go to the pharmacy in order to record who was missed or did not return to 
participate in the study.  
Inpatient recruitment  
In the inpatient clinic there are two sides, one for females and one for males. The 
physician and the head nurse of each side helped the researcher to identify eligible 
patients who had been admitted.  
4.5.3.2  Recruitment from Hospital 2: Section of Tropical Medicine   
The Section of Tropical Medicine is an inpatient clinic, which has two sides, one for 
females and one for males. Each side can take at least 20 patients. Therefore, the 
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physician helped the researcher to find eligible patients and to write their names on 
a list.  
Kaser El-Ani Teaching Hospital is near the NHTMRI, around 15 minutes on foot. 
Therefore, it was easy for the researcher to go to Kaser El-Ani after finishing 
recruitment at the NHTMRI. Indeed, recruitment from the Section of Tropical 
Medicine in Kaser El-Ani Teaching Hospital was most appropriate in the afternoon 
to avoid interfering with routine work. Physicians make their ward rounds before 1 
pm and the family visits from 1 to 5 pm. Therefore recruitment after 4 pm was the 
most appropriate time. Eligible patients, who could not be interviewed that day 
because of a family visit or a critical condition, were recruited the next day, since 
their names were on the researcher's list. 
4.5.3.3  Recruitment from Hospital 3: CDYCDLR 
The routine of work in the outpatient clinic differs from the inpatient clinic at 
CDYCDLR. At the inpatient clinic, family visiting time is between 12am and 9pm. 
The outpatient consultation is from 9am till 4pm. Therefore, there were only two 
hours to recruit from the inpatients between 10am and 12pm, i.e. before visiting 
time. Recruitment from the outpatient clinic took place between 12pm and 4pm. 
Recruitment from the outpatient clinic was quite different to recruitment from the 
inpatient clinic. 
Inpatient recruitment  
In the inpatient clinic the names of all admitted patients were displayed on a board, 
together with the room numbers. The physician helped in identifying eligible 
patients and put their names on a list. This strategy ensured that as few patients as 
possible were missed. The researcher could recruit all the eligible admitted patients 
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on that day except those in a critical stage (bleeding or after an endoscopy) who 
could be recruited once their condition had stabilized. Some of these patients could 
not be recruited because they were either discharged before the next day or 
transferred to another hospital. If eligible patients could not be interviewed before 
visiting time, they could still be recruited the next day. 
Outpatient recruitment  
The outpatient clinic has two consultation rooms attended by two physic ians. The 
waiting area was crowded with patients waiting for a consultation, some of whom 
might have been eligible for the study.  
Initially, the researcher decided to compile a list of patients’ names one day before 
the consultation in order to recruit all eligible patients systematically. However, this 
turned out to be an inappropriate strategy because sometimes new cases were 
seen without registration while others cancelled their consultation. After discussion 
about the appropriate recruitment strategy with the staff, it was decided that the 
researcher wait in the outpatient clinic and the outpatient nurse administrator 
introduce her to eligible patients. This strategy ensured that both the researcher 
knew of the eligible patients attending the clinic that particular day, and that as few 
patients as possible were missed. The number of eligible patients per day during 
the recruiting month (pilot study) ranged from two to five patients and the time of 
consultation ranged from 15 - 30 minutes.  
The patients were interviewed before and/or after the consultation. For example, a 
patient might start the interview but was then called in to the consultant. When the 
patient returned he/she would complete the interview. In the pilot study, the majority 
(n = 23, 88.5%) of participants who were recruited from the outpatient clinic 
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completed their interview before the consultation. Others completed the SF-36 
before the consultation and afterwards the other instruments. The researcher was 
very keen to complete the interviews before patients were seen by the consultant 
as any news about the progress of the disease or a worsening status might have 
affected the patients’ perceptions and bias their responses. Table 4-3 illustrates the 
timetable of sample recruitment from the three hospitals. 
Table 4-3: Timetable of sample recruitment from the three settings 
Setting Day of visit Time of recruitment 
Outpatient Inpatient 
NHTMRI Sunday-Wednesday  9 am-1 pm 1.30 -3 pm 
Kaser-Elani Sunday-Wednesday N/A 4 -6 pm 
CDYCDLR Saturday and Thursday  12 am - 4 pm 10 - 12 am 
N/A: not applicable  
 
 
4.5.3.4  Interview Steps in the Inpatient Clinics 
A list of names of patients that might be eligible for the study was made available. 
1. The researcher went to the patient's room, introduced herself, explained the 
information sheet and asked the patient if s/he wanted to join the study. 
2. Written or verbal consent was taken before conducting the interview.  
3. The interview was conducted in the patient’s room. If other patients shared 
the same room, and the patient was unable to go to a separate place for the 
interview, the curtain was pulled around the patient’s bed to preserve his/her 
privacy. In my experience, there was enough space between the patients’ 
beds to avoid being overheard. If a relative was with the patient, the 
researcher asked the patient if her/his relative could remain in the room 
during the interview. Some of the participants agreed while others refused. 
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4.5.3.5  Data Collection Assistant  
Recruiting the sample from the three settings on the same day, especially from 
NHTMRI and CDYCDLR was impossible because the CDYCDLR is about an 
hour's travel time or more from NHTMRI. Therefore, a data collection assistant 
became essential. A nurse educator in the Faculty of Nursing, Cairo University with 
experience in data collection was found. In addition to her work at the faculty she 
was also studying for a Masters' degree and was able to assist in the data 
collection process on her days off, i.e. Thursday and Saturday. She recruited 
eligible patients from the NHTMRI on these two days and the researcher recruited 
from CDYCDLR on the same days. It was therefore essential to design a 
systematic recruitment strategy based on the hospital day work. A training protocol 
for the data collection assistant was used to avoid data collection bias (Appendix 4-
17). 
4.6 DATA ANALYSIS 
4.6.1 Checking Data Set Accuracy  
Before starting scale scores and data analysis it was vital to check the data 
accuracy. Therefore, initial analysis outputs were conducted to check for missing 
and extreme values that were out of the range of normal possible values (Pallant 
2007). 
The nominal and categorical data was inspected by running frequency tables, while 
continuous data were inspected by running descriptive statistics. The initial analysis 
outputs of frequency and descriptive tests were checked to correct any errors 
before starting data analysis. Some minor errors were noted and amended before 
any analysis was conducted. Following this, the data were again checked using 
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frequencies for non-numerical data and descriptive analysis for numerical data to 
confirm the accuracy of the data set.  
4.6.2 Computing Scales Scores 
Following the data accuracy check, scale scores were calculated. Three 
instruments were needed to compute the total and subscales scores; LDSI-2.0, 
MSPSS and SF-36. The computations were carried out for LDSI-2.0 and MSPSS by 
creating new variables using the transform option in SPSS following the scoring 
system that was explained. The SF-36 subscales and both component scores were 
computed using the QMI Software Program.  
4.6.3 Checking Data Normality and Outliers  
Continuous data were investigated for normality by observing the Q-Q Plot and the 
histogram. It was noted that the Q-Q Plot was straight and the histogram was 
normally distributed, suggesting normality of the data. The Skewness value for 
each continuous variable was checked. Variables were considered normally 
distributed if the Skewness value was between -1 and +1 (Pallant 2007). The 
Skewness value of all the continuous variables fell between -0.9 and + 0.4, 
suggesting that they were normally distributed. Additionally, the continuous 
variables were tested for linearity by checking the scatter-plots between each of the 
independent variables with the dependent variable (i.e. MCS and PCS).The data 
did not show any outliers. 
4.6.4 Statistical Analysis Procedure  
The IBM SPSS (Statistical Package for the Social Sciences) software (Edition 
Standard v18, United States) was used for data analysis. Descriptive statistics 
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including frequency for nominal and categorical variables; and mean ± standard 
division and median for continuous variables were computed. The Pearson product 
moment correlation coefficient (r) was used to assess the relationship between two 
parametric variables, and the Spearman's rank order correlation (rho) was used to 
assess the relationship between non-parametric variables.  
Parametric statistical techniques such as the independent sample t-test and the 
one way analysis of variance (ANOVA) test were used to assess the difference 
between group mean scores. Independent t-tests were used to compare and to find 
the differences between the mean scores of two groups. Otherwise, ANOVA was 
used for multiple group comparisons. If the ANOVA output was statistically 
significant, the post-hoc technique was used to find which of the three groups were 
statistically different. When there are multiple statistical comparisons to be made, 
this increases the risk of type 1 error. However, corrections were made for this by 
reporting the Bonferroni correction value for the ANOVA tests. 
A non-parametric statistical technique, chi-square for independence (cross table), 
was used to compare the frequencies of nominal variables for two groups, for 
example to find the difference between two groups, such as males and females 
symptoms experience. All statistical tests were two tailed with p < 0.05 as the 
significance level. 
To examine factors associated with physical and mental health domains, multiple 
linear regression analysis was used. This is a complex statistical technique based 
on numerous data assumptions such as adequacy of sample size, no-
multicollinearity, no-singularity, no-outliers, normality and no-homoroscedasticity 
(Pallant 2007; Field 2009). Therefore, these assumptions were investigated before 
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presenting the regression results and developing the regression model. There were 
no violations to these assumptions. Multiple regression analysis was conducted 
using the stepwise method, because it enabled finding variables that are most 
important in explaining the physical and mental health domains of people with liver 
cirrhosis. As a result, the stepwise method was useful in avoiding bias because 
there was no prior decision regarding the order of entering the variables in the 
model, especially as this was an exploratory study (Field 2009). 
4.7 CONCLUSION  
This chapter has presented the aims of the study and the research questions, and 
has discussed the philosophical paradigm underlying the research. Also, it has 
described in detail the method chosen to carry out this study, including an 
explanation of the study design, sample, measurements and recruitment strategy. 
A cross-sectional survey design and the convenience sampling method were 
selected to conduct this study.  
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5 CHAPTER 5- PILOT STUDY 
This chapter describes and justifies the pilot study that was conducted before the 
main study. Then, the process of translation and cross-cultural adaptation of the 
translated tool are clarified. Finally, results and discussion of the findings are 
presented at the end of the chapter.  
5.1 BACKGROUND  
A pilot or feasibility study is usually conducted to guide the researcher to evaluate 
the (1) appropriateness of the recruitment strategy; (2) appropriateness of the 
instruments; (3) estimating the needed sample size; (4) identifying confounding 
variables that need to be controlled; and (5) adequacy of the researcher’s skills and 
required training before the main study is carried out (Polit and Beck 2010). A pilot 
study is also a trial run to provide information regarding a measurement’s validity, 
reliability and the cross cultural adaptation of a translated instrument in order to 
reveal problems relating to the measurement’s content, administration and scoring 
(Guillemin et al. 1993; Fowler 1995; Litwin 1995; Waltz et al. 2010).  
Furthermore, conducting a pilot study of survey instruments is an essential step to 
assess the practical issues that may affect the study’s validity (Fowler 1995) such 
as (1) problems with the wording of the instructions or items of the questionnaire 
and (2) the length of the interviews (Fowler 1995; Waltz et al. 2010). The pilot study 
will also give the researcher a chance to find any unexpected errors, to avoid bias 
when collecting the main study data and to allow correction or redesigning of the 
study in advance before expending too much time or other resources (Litwin 1995).  
168 
 
There are two factors which may contaminate the main study as a result of the pilot 
study (1) including the pilot study data in the parent study; and (2) recruiting the 
same participants into the main study (van Teijlingen and Hundley 2001). It was 
therefore crucial to separate the pilot and parent studies’ data reports and the 
participants.  
5.2 JUSTIFICATION  
Using an existing valid and reliable measurement, which is psychometrically well 
tested, is better than using an instrument for which there is no psychometric 
evidence (Polit and Beck 2008). The Liver Disease Symptom Index-2.0 (LDSI-2.0) 
did not exist in Arabic before conducting this study; therefore it was essential to 
translate it into Arabic. However, tool translation alone cannot guarantee that the 
tool is valid and reliable.  
Parahoo (2006) claimed that the best method to assess an instrument’s quality is 
by carrying out a pilot study. Testing the psychometric properties of a tool before 
using it in a large study has many advantages such as (1) the participants' 
responses to an instrument's items will give an idea of whether they understood the 
items; (2) it is possible to evaluate the appropriateness of the tool's format for the 
population that will be studied; (3) it is possible to assess the relevancy of the tool's 
items to the population that will be studied; and (4) it is possible to find out whether 
the length of the tool and its structure are likely to affect the participants' way of 
response (Parahoo 2006). Thus, considering the respondents' views about the 
instrument was an important step that the researcher took to check the quality of 
the translated LDSI-2.0.  
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5.3  AIMS  
The aim of this pilot study was to make the first translation of the LDSI-2.0 English 
version into Arabic and to examine its psychometric properties among a sample of 
people with liver cirrhosis in Egypt.  
The specific objectives were to (1) assess the feasibility of using the trans lated 
LDSI-2.0 (Arabic version); (2) assess its construct convergent validity; and (3) 
examine its retest reliability. 
5.4 METHODS 
Permission to translate the LDSI-2.0 into Arabic and use it in the current study was 
granted by the original author (van der Plas et al. 2004) (Appendix 5-1).  
5.4.1  Permission from the Clinical Setting to Conduct the Study 
According to the policy of the Egyptian educational bureau, a PhD student must 
submit all the study documents (proposal, ethical approval and other relevant 
documents) to obtain formal approval for the research before travelling and 
collecting the study data. Accessing and recruiting patients is a critical and 
sensitive issue. It was therefore essential to personally contact the administrators of 
the chosen hospitals to obtain permission to carry out the pilot study in the clinical 
setting for one month.  
The CDYCDLR was the most suitable hospital (Section 4.5.3.3) for this pilot study 
because it is a specialized hospital caring for people with liver disease from all the 
different regions in Egypt as well as from different socio-economic and educational 
backgrounds. The variation in the characteristics of the participants was important 
when testing the translated LDSI-2.0 feasibility and its psychometric properties.  
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An email to explain the background of the study (the study’s aims, design, tools of 
data collection, recruitment strategy and consent) was sent to the Administrations 
Committee of CDYCDLR to obtain their permission to collect data for the pilot 
study. The Administrations Committee granted the required permission. 
5.4.2 Written Consent  
It is still a big challenge for Egyptian health researchers (Rashad et al. 2004; 
Ahmed and Dewedar 2011) to obtain written consent. The problem is that some 
ethical principles for conducting the research may be misunderstood by some 
Egyptians (Rashad et al. 2004), believing that they lose their right to change their 
mind and withdraw from the study if signing a consent form (Ahmed and Dewedar 
2011; Wazaify et al. 2009). As a result, they may be reluctant or refuse to give 
written consent although they are happy to support the research (Khalil et al. 2007).  
Therefore, providing the research participants with clear and understandable 
information about the importance and legality of their written consent was essential 
to enhance the trust between the participants and the researcher for an informed 
consent process (Khalil et al. 2007). Prior to enrolment, patients were given a 
verbal explanation of the written information sheet, which was developed with 
consideration for uneducated participants. The information (Appendix 5-2 and 
Appendix 5-3) and consent sheets (Appendix 5-4 and Appendix 5-5) were made 
more accessible by using pictures and illustrations.  
Unfortunately, due to the time constraints for data collection (one-month) patients 
who were happy to participate in this pilot study but refused to give written consent 
could not be excluded. Although the researcher clarified the process of participants’ 
anonymity and confidentiality, many insisted that they would only give verbal 
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consent. Therefore, for patients who wanted to participate in this pilot study but did 
not want to give written consent, verbal consent was acceptable.  
5.4.3  Process of Translation and Cultural Adaptation of LDSI-2.0 
The international standardized guidelines for the cross-cultural adaptation of 
instruments (Guillemin et al. 1993), consisting of five  steps (1) translation; (2) back 
translation; (3) committee review; (4) pre-testing; and (5) weighting of scores  were 
followed (Diagram 5-1).  
5.4.3.1  Forward Translation 
The LDSI-2.0 was translated by two independent bilingual translators who were 
native Arabic speakers and proficient in English. One of these translators 
(Translator 1: T1) was aware of the underpinning concepts and objectives of the 
questionnaire while the other translator (Translator 2: T2) was not. This was useful 
to elicit unexpected meanings from the original version and helped to detect errors 
and divergent interpretations of ambiguous items in the original tool. 
5.4.3.2  Back Translation 
Two qualified translators who were native English speakers (T3 and T4) and 
proficient in Arabic carried out the back translation. The back translators were not 
aware of the underpinning concepts and objectives of the questionnaire. This was 
to ensure they were free from bias. 
5.4.3.3  Face and Content Validity 
To assess the face and content validity of the translated LDSI-2.0, a review 
committee of five experts (Appendix 5-6), was asked to review the content of the 
Arabic version by comparing it with the original version, considering 
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appropriateness, adequacy and validity. All committee members were native Arabic 
speakers highly qualified in English. The committee members received the original 
LDSI-2.0 as well as the Arabic version and a guidance sheet (Appendix 5-7) 
designed by the researcher. The researcher incorporated the feedback from the 
committee in the development of the penultimate version of the Arabic LDSI-2.0. 
5.4.3.4  Field Pre-Testing  
To complete the steps of cross-cultural adaptation and to check the quality of the 
translated LDSI-2.0 it was necessary to pre-test the questionnaire in a pilot study 
(Guillemin et al. 1993; Fowler 1995).  
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Diagram 5-1: Translation process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Original LDSI-2.0 Questionnaire in English 
LDSI-2.0 Arabic (T1) LDSI-2.0 Arabic (T2) 
 
Return to T1 and T2 to resolve the 
discrepancy and produce one Arabic copy 
T 1-2 
Is there a discrepancy between the two translations (T1 and T2)? Yes  
 
No 
One T 1-2 Arabic version 
Two native English speaking 
Translators 
 (Translator 3: T3) (Translator 4: T4) 
LDSI-2.0 English 
(T3) 
LDSI-2.0 English 
(T4) 
Is there a discrepancy between the two back-translations (T3 and T4)? 
No Yes  
 
Return to T3 and T4 to resolve the discrepancy and 
to produce one copy T 3-4  
Email the final T 3-4 to the original author to get his approval on the similarity of the translated and 
original versions 
Stage 1: Forward 
translation 
Stage 2: Back- 
translation 
One T 3-4 English version 
Committee review for both Arabic (T 3-4) and original 
English version of LDSI-2.0 to ensure equivalence  
 
Stage 3: Committee 
review 
Pilot study to test the feasibility, validity and 
reliability of the Arabic version (T 3-4)  
 
 
Stage 4 and 5: 
pretesting and 
piloting 
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5.4.4 Data Collection  
5.4.4.1  Recruitment Process 
Data were collected between December 2010 and January 2011 over a one month 
period. During the pilot study, the researcher elected to be present at the hospital 
for four days per week to ensure the appropriate identification of eligible 
participants and to explain the study’s purpose and pilot stage. Physicians working 
in the hospital identified the patients who met the inclusion criteria and gave 
permission to ask them to participate in the study.  
An interview with the participants at time 1 (T1) was carried out to complete the 
tools and to ascertain whether: (1) the words in the questionnaire were clear;  (2) 
patients could understand the questions and answer them; and (3) no difficulties 
were encountered in completing these instruments. Patients were interviewed for 
approximately 45 minutes in a private place in the hospital. A series of instruments 
(SF-36v2, LDSI-2.0 and background sheet) were administered to the participants 
once, while the LDSI-2.0 was administered twice with a maximum of three days in 
between. 
5.4.4.2  Instruments  
Three instruments were used for data collection: the background data sheet, the 
translated LDSI-2.0 and SF-36. Additionally, an observation sheet was utilized to 
evaluate the feasibility of Arabic LDSI 2.0 (Appendix 5-8). The observation sheet 
was completed by the researcher while patients completed the translated LDSI 2.0. 
It consisted of open ended questions to clarify what patients meant when they 
answered each question. The observation sheet was designed to assess the 
content validity and translation quality of the Arabic LDSI-2.0.  
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5.4.4.3  Interview Procedure 
The researcher interviewed all the participants according to the sequential steps 
formulated in section 4.5.3.4 and additionally received consent from the participants 
who agreed to be interviewed for a second time (T2) (for test-retest reliability).  
5.5 DATA ANALYSIS 
The IBM Statistical Package for Social Sciences (SPSS), Edition Standard v18 was 
used for data analysis and tabulation. 
5.5.1 Psychometric Properties of the Translated LDSI-2.0 
5.5.1.1 Testing the Feasibility of the Translated LDSI-2.0 
Testing the translated LDSI-2.0 for readability and comprehension was an 
important factor before conducting the main study. Therefore, the administration 
time (time taken to complete the questionnaire) and the questions deemed difficult 
to answer were recorded during the interview. 
An item was defined as difficult if the patient (1) did not provide a specific answer; 
(2) gave an open ended answer; or (3) gave a misunderstood answer. Additionally, 
after each question answered on the translated LDSI-2.0 the patient was asked to 
clarify what was meant by each answer. This ‘probe technique’ was used to 
encourage the participants to explain their understanding of the questions to 
determine whether they had understood the questionnaire items correctly 
(Guillemin et al. 1993; Kitapcioglu et al. 2004). 
The feasibility of the translated LDSI-2.0 was tested in terms of administration time 
and the percentage of questions considered difficult to answer. Descriptive 
statistics were used to describe the range of completion times. If less than 5% of all 
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the items in the translated LDSI-2.0 were misunderstood, it was judged feasible to 
administer (Unal et al. 2001; van der Plas et al. 2004).  
5.5.1.2  Testing the Initial Validity of the Translated LDSI-2.0  
Construct validity investigates to what extent the measurement assesses what it is 
intended to measure (Litwin 1995), which is the most important characteristic of an 
instrument. Convergent validity is a subtype of the construct validity that examines 
the general agreement between measurements that theoretically are assumed to 
be similar or interrelated. Polit and Beck (2010) argue that ‘Construct validity is 
essentially a hypothesis testing endeavour, which is typically linked to a theoretical 
perspective about the construct’ (p. 379).  
The SF-36 is a generic HRQOL that does not contain any disease specific items 
such as sleep adequacy, cognitive functioning, sexual functioning, health distress, 
family functioning, self-esteem, eating, recreation/hobbies, communication, and 
symptoms/problems (Ware et al. 1993) as compared to the LDSI-2.0 that is a 
disease specific HRQOL questionnaire. However, there are similar items 
addressed in both the generic and the disease specific HRQOL questionnaires (SF-
36 and LDSI-2.0). Therefore, to assess the construct validity of the Arabic LDSI-
2.0, the top 10 correlations with the highest magnitude between items of the LDSI-
2.0 and domains of SF-36 were identified in van der Plas’s study (van der Plas et 
al. 2004) (see Table 5-1). For example, it was hypothesised that the mental health 
domains in SF-36 could moderately correlate with items of depression and 
hindrance of depression in the LDSI-2.0, suggesting that the item of depression 
and the domain of mental health measure similar construct. These associations 
were tested in the pilot study.  
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Table 5-1: Association between SF-36 and LDSI-2.0 items that produced correlations 
of the highest magnitudes in study by van der Plas’s et al. (2004) 
SF-36 domains LDSI-2.0 items (r value) 
 
BP Joint pain 1 (-0.67)
 *
 
Hindrance joint pain 2 (-0.67)
 *
 
MH Depression 3 (-0.61)
 *
 
Hindrance depression 4 (-0.59)* 
SF Hindrance depression 5 (-0.59)* 
Depression 8 (-0.55)* 
 
VT Hindrance depression 6 (-0.55)* 
Depression 7 (-0.55)* 
Hindrance sleep 9 (-0.54)* 
RE 
 
Hindrance depression 10 (-0.54)* 
 
Note: it was hypothesized that there would be a relationship between the listed items of LDSI-
2.0 and the domains of SF-36. 
*
P < 0.0002,  
 
To examine the convergent validity of the LDSI-2.0, Spearman’s rho rank 
correlation coefficient (rs) test was utilized. The Spearman’s correlation matrix 
examined the convergent relationship between the LDSI-2.0 items and the eight 
subscales of SF-36. It was also used to test the convergent relationship between 
specific symptom severity items and their accompanying symptom hindrance items, 
based on data obtained at T1. The Spearman’s correlation coefficient scale from (-
1 to +1) was used to assess the level of correlation, with particular attention paid to 
those judged most likely to be correlated. A Spearman’s correlation value < 0.40 
was considered as low, 0.40-0.70 as moderate and > 0.70 as high (Fayers and 
Machin 2000). 
5.5.1.3  Testing the Reliability of the Translated LDSI-2.0  
The test-retest reliability was examined using data obtained from the participants (n 
= 27) who completed the translated LDSI-2.0 at both T1 and T2 (van der Plas et al. 
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2004; Waltz et al. 2010). A short interval of maximum three days was selected to 
decrease the potential variation in symptom severity that might lead to 
disagreement between the test and retest results (van der Plas et al. 2004).  
To evaluate the retest reliability the statistical test weighed Kappa (K) was utilized. 
The Kappa (K) test assesses the proportion of chance of agreement between first 
time and second time measures (Viera and Garrett 2005; McDowell 2006; Waltz et 
al. 2010). Interpretation of the K result was as follows: Kappa < 0.20 poor, 0.21-
0.40 fair, 0.41-0.60 moderate, 0.61-0.80 good and 0.81-1.00 very good reliability 
(Fayers and Machin 2000; van der Plas et al. 2004; Viera and Garrett 2005).  
To test the internal consistency of the translated LDSI-2.0's multi-item scales, 
Chronbach's alpha coefficients were used; alpha ≥ 0.70 was considered an 
acceptable level of internal consistency (Nunnally and Bernstein 1994).  
5.6 RESULTS 
5.6.1 Translation Result 
5.6.1.1  Forward Translation 
In Arabic, many synonyms have the same meaning. Therefore, the main difference 
between the two forward translations was the actual Arabic words used, although 
their meanings were similar. A member of the research team (an Arabic native 
speaker qualified in English) and the two translators discussed the two versions of 
the forward translation, to give one Arabic version (T 1 - 2).  
5.6.1.2  Back Translation 
The main discrepancies between the two back translations were small words, 
although the translations were similar. The two back translators carried out a 
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reconciliation of these minor differences to give the final back translation LDSI-2.0 
(T 3 - 4) which was emailed to the original author for his feedback and approval.  
5.6.1.3  Face and Content Validity 
Modifications to the wording of some items were made to ensure clarity for an 
Arabic speaking person (Egyptians). For example, in item 12 the phrase “with 
respect to mortgaging or insurance” was removed, as this is not relevant to Arabic 
people. A clear instruction is one of the most important characteristics of instrument 
(Parahoo 2006). Thus, a brief introduction was added to the Arabic LDSI-2.0 to 
show participants how they could respond to questions (Appendix 5-9). 
5.6.2 Pilot Study Result 
Forty-three patients met the inclusion criteria and were invited to participate in the 
pilot study. Three patients refused to participate and two did not complete the 
interviews (Diagram 5-2).  
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Diagram 5-2: Pilot study sample flow diagram and consent 
 
 
 
Table 5-2 shows the characteristics of the participants: 38 patients with liver 
cirrhosis enrolled in the study; 26 (68.4%) in-patients and 12 (31.6%) outpatients. 
There was a reasonable balance between men and women and those living in 
urban and rural areas. For the majority of the sample (78.9%), hepatitis C caused 
their cirrhosis, and 82% had decompensated cirrhosis. 
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Table 5-2: Characteristics of the participants (demographic and medical data)  
Characteristics n = 38 100 (%) 
Gender Men 
Women 
26 
12 
68.4 
31.6 
Age Mean (±SD)     50.21 (8.40)    age  ranged from 21 - 66 years 
Education level Illiterate 
Can read and write 
Basic education 
Higher education 
9 
11 
11 
7 
23.7 
28.6 
28.9 
18.4 
Current employment status Employed 
Unemployed 
17 
21 
44.7 
55.3 
Reason for unemployment Liver disease 
Retirement 
No specific reason 
7 
2 
29 
18.4 
5.3 
76.3 
Place of Residence  Rural  
Urban  
20 
18 
52.6 
47.4 
Medical fees Patient or Relatives  
Insurance  
Zaka (charity) 
23 
10 
5 
60.5 
26.3 
13.2 
Marital status Single (never married or 
Widowed)  
Married  
3 
 
35 
7.9 
 
92.1 
Setting of data collection Outpatient  
Inpatient  
26 
12 
68.4 
31.6 
Cause of cirrhosis Hepatitis C 
Hepatitis B 
Bilharzias  
Hepatitis C & Bilharzias 
30 
1 
4 
3 
78.9 
2.6 
10.5 
7.9 
Cirrhosis stage Compensated  
Decompensated 
7 
31 
18.4 
81.6 
Previous hospital admission Yes  
No  
19 
19 
50 
50 
Number of comorbidities  Without comorbidities  
With one comorbidities 
With >1 comorbidities  
17 
15 
6 
44.7 
39.5 
15.8 
 
5.6.2.1  Translated LDSI-2.0 Feasibility  
The LDSI-2.0 was completed in a face-to-face interview lasting 5-15 minutes, with a 
median completion time of 10 minutes and a mean of 9.6± (standard deviation (SD) 
1.88) minutes. 89.4% of participants completed the questionnaire in less than or 
equal to 10 minutes. The interview time to complete all the instruments did not 
exceed 45 minutes. The items were clear and understandable for all participants 
and there were no unanswered questions.  
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During the interviews of the first five patients, direct responses were hard to elicit 
for three items and more clarification was required. For example, for item 1 
“severity of itch”, three of the participants gave irrelevant responses such as eye 
itch or gum itch. The item was therefore modified to “severity of skin itch”. Although 
item 8, “Fear of complications” was clear to the majority of participants, it elicited 
unspecific responses such as “I do not know” or “only Allah (God) knows that”. This 
kind of response is culturally and religiously appropriate, as developing 
complications are seen as in “God’s hand”. It was therefore decided that such a 
response did not necessarily mean that the respondent had misunderstood the 
item. For item 10 “remembering things”, some participants, especially those who 
were illiterate, gave a response which suggested that they did not understand the 
question. This item was therefore changed to “to what extent did you have difficulty 
in remembering things since liver disease”. To ensure that participants understood 
the question, they were then asked to give an example. 
The LDSI-2.0 response scale  
The original LDSI-2.0 is an index scored on a 5-point scale ranging from zero ‘not 
at all’ to 4 ‘to a high extent’. This scale was unclear for a minority of the 
participants, especially the uneducated ones. With input from the patients, the scale 
was not changed but clarified by adding the terms "0. Not at all, 1. Mild, 2. 
Moderate, 3. Severe, 4. Very severe". These terms (mild, moderate, severe and 
very severe) were only used with patients who found it difficult to understand the 
original scale. They were not added to the questionnaire to avoid confusion in 
future use.  
Finally, an open-ended question was added at the end of the LDSI-2.0 (Are there 
any other symptoms you experienced during the last week?) to ensure that all 
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symptoms that participants could have suffered from were recorded. Twenty-six 
(68.42%) participants indicated that the tool covered all symptoms which hindered 
their daily activities but nine added muscle cramp, two added insomnia, five added 
dark skin colour or brown colour and one added constipation. All these participants 
indicated that these symptoms affected their daily activities and their social 
interaction to a high extent.  
5.6.2.2  Translated LDSI-2.0 Validity  
Table 5-3 and Table 5-4 present the Spearman’s rho correlation coefficient (rs) that 
was used to examine the convergent relationships between items of the LDSI-2.0 
and eight domains of the SF-36. The result showed that there were no high 
correlations between LDSI-2.0 and SF-36, but there was moderate correlation 
between some of LDSI-2.0 items and SF-36 (rs ranged from 0.40 to 0.61). As was 
hypothesised, hindrance of depression in the LDSI-2.0 was convergent with many 
domains of SF-36 such as role limitation due to emotional problems (rs = -0.54) and 
vitality (rs = -0.41). Hindrance of depression item was expected to correlate 
moderately with the domains of MH and SF in SF-36 (Table 5-1). However, the 
level of correlation was lower than the previous study (van der Plas et al. 2004).  
The LDSI-2.0 depression item was expected to correlate moderately with the 
domains of VT, MH and SF in the SF-36 (Table 5-1). The results showed that 
depression item was convergent with the domain of MH in the SF-36 (rs = - 0.40), 
as expected. However, the association between the depression item and the 
domain of vitality showed low correlation (rs = - 0.36). On the other hand, the items 
of joint pain, hindrance of joint pain and hindrance of sleepiness during the day 
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were not correlated with any of the SF-36 domains, despite the previous study 
identifying associations.  
Interestingly, only the item of abdominal pain (LDSI-2.0) had a moderate 
convergent correlation with the domain of bodily pain (SF-36) (rs = - 0.45), in 
contrast to the previous study (van der Plas et al. 2004) that found a moderate 
convergent correlation between the LDSI-2.0 items of joint pain and abdominal 
pain, and the SF-36 domain of bodily pain (Table 5-1).  
Unexpectedly, the hindrance of a decreased appetite showed a moderate 
convergent association with four domains of SF-36 (PF, RE and GH). The items of 
decreased sexual interest and sexual activity were moderately correlated with two 
domains in the SF-36: PF and VT. These items seem to be important disease-
related symptoms that might interfere with the HRQOL of patients with liver 
cirrhosis.  
The result also showed that symptoms and hindrance of itch on activity and 
sleeping, joint pain, sleepiness during the day and jaundice had a low correlation 
with all of the SF-36 domains, suggesting that these items had divergent 
relationships with SF-36.  
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Table 5-3: Convergent validity of the translated LDSI-2.0 by means of Spearman’s rho correlation (rs) between its items and the SF-36 domains 
(n = 38) 
SF-36 Itch HITC IHS JP HJP ABP HAP SLD HSLD WOR HWOR DAP HDAP DEP HDEP FDC J HJ 
PF -0.07 -0.33* -0.20 -0.15 -0.22 -0.46** -0.47** 0.06 -0.09 -0.33* -0.50** -0.45** -0.50** -0.56** -0.61** -0.24 -0.11 -0.12 
RP -0.07 -0.14 -0.01 -0.04 0.06 -0.32* -0.31 -0.06 -0.06 0.14 -0.01 -0.25 -0.35* -0.22 -0.29 -0.22 -0.10 -0.07 
RE 0.08 -0.02 0.12 0.06 -0.13 -0.25 -.031 0.15 0.03 -0.10 -0.26 -0.26 -0.55** -0.33* -0.54** -0.36* -0.16 -0.19 
BP -0.00 -0.14 -0.15 -0.08 -0.06 -0.45** -0.38* -0.09 -0.28 -0.22 -0.39* -0.41** -0.42** -0.17 -0.25 -0.02 -0.02 -0.04 
VT -0.07 -0.04 -0.03 0.05 0.02 -0.23 -0.28 -0.06 -0.13 -0.29 -0.36* -0.28 -0.42** -0.36* -0.41** -0.39* 0.18 -0.01 
MH -0.07 -0.14 -0.12 -0.18 -0.21 -0.30 -0.30 -0.14 -0.21 -0.29 -0.37* -0.37* -0.43** -0.40* -0.33* -0.15 -0.10 0.001 
SF -0.04 -0.01 0.02 0.17 0.08 -0.16 -0.19 0.01 -0.07 -0.21 -0.30 -0.19 -0.31 -0.10 -0.23 -0.28 0.04 -0.05 
GH -0.15 -0.30 -0.26 -0.16 -0.15 -0.25 -0.25 -0.17 -0.27 -0.13 -0.25 -0.59** -0.59** -0.38* -0.47** -0.40* 0.03 -0.11 
*Correlation is significant at the p value < 0.05, ** Correlation is significant at the p value ≤ 0.001 (2- tailed) 
Spearman’s (rs) value < 0.40 low correlation (slight information overlapping between LDSI item and SF-36 domains), rs value ≥ 0.40 and < 0.70 moderate 
correlation (moderate information overlapping), rs ≥ 0.70 (strong information overlapping) 
The bold values in the table are items with rs ≥ 0.40 (moderate correlation or overlapping) 
The underlined values are the results according to the 10 hypotheses in Table 5.1 
LDSI 2.0’S items: 
Itch: severity of itch, HITC: hindrance of itch in daily activities, HIS: hindrance of itch in sleeping, JP: severity of joint pain, HJP: hindrance of joint pain in daily 
activity, ABP: severity of right abdominal pain, HAP: hindrance of abdominal pain in daily activities, SLD: severity of sleepiness during the day, HSLD: 
hindrance of sleepiness during the day in daily activities, WOR: severity of worry about the family situation, HWOR: hindrance of worry about the family 
situation in daily activities , DAP: severity of decreased appetite, HDAP: hindrance of decreased appetite in daily activities , DEP: severity of depression, 
HDEP: hindrance of depression in daily activities or social contact, FDC: severity of fear disease complications, J: severity of jaundice, HJ: hindrance of 
jaundice in daily activities or social contact 
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Table 5-4: Convergent validity of the translated LDSI-2.0 (extra six items) by means of 
Spearman’s rho correlation (rs) between these items and the SF-36 domains (n = 38)  
SF-36 Memo PersoCh Time Financial Sex.Int Sex.Act 
PF -0.39* -0.47** -0.39* -0.27 -0.47** -0.52** 
RP -0.05 -0.35* -0.49** -0.17 -0.27 -0.31 
RE -0.06 -0.21 -0.34* -0.14 -0.36* -0.44** 
BP -0.25 -0.19 -0.24 -0.10 -0.28 -0.16 
VT -0.10 -0.45** -0.51** -0.28 -0.55** -0.54** 
MH -0.37* -0.23 -0.24 -0.12 -0.36* -0.32 
SF -0.02 -0.37* -0.36* -0.18 0.54** 0.38* 
GH -0.32* -0.40* -0.43** -0.25 0.33* 0.30 
*Correlation is significant at the p value < 0.05, ** Correlat ion is significant at the p value ≤ 0.001 
(2- tailed) 
The bold values in the table are items with rs ≥ 0.40 (moderate correlation or overlapping) 
LDSI-2.0’s extra items:  
Memo: severity of remembering, PersoCh: severity of changing personality, Time: severity of 
using and managing time, Financial: hindrance in financial affairs, Sex.Int: severity of 
decreasing sexual interest and Sex.Act: severity of degreasing sexual activity.  
 
Table 5-5 displays the Spearman’s rho correlation between paired items (items of 
symptom severity and accompanying symptom hindrance) of the LDSI-2.0. The 
results showed that correlation coefficients ranged from medium to high (rs ranging 
from 0.44 to 0.93). In general, symptom severity items correlated strongly with their 
accompanying hindrance symptom item rather than with other items. However, only 
three items, joint pain, abdominal pain and sleep day, had a high correlation with 
their accompanying items (0.89, 0.93 and 0.84 respectively).  
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Table 5-5: Construct convergent validity of the translated LDSI-2.0 by means of 
spearman’s rho correlation between symptom items and their accompanying symptom 
hindrance items (n = 38) 
Severity and hindrance item pairs Inter item Spearman’s correlation (rs value) 
Itch (3) Itch hampered activity 0.44** 
Itch hampered sleep 0.65** 
Joint pain (2) 0.89** 
Abdominal pain (2) 0.93** 
Sleepiness during the day (2) 0.84** 
Worry (2) 0.56** 
Decreased appetite (2) 0.74** 
Depression (2) 0.73** 
Jaundice  (2) 0.74** 
**Correlation is significant at the 0.001 level (2 tailed); p value ranged from (0.001-0.0005). The 
bold rs values are the values of items that have low to moderate correlation with their paired 
items. 
 
 
5.6.2.3  Translated LDSI-2.0 Test-Retest Reliability 
The test-retest reliability of the translated LDSI-2.0 was examined using the Kappa 
test with the 27 patients who gave consent to take part in a second interview. 
Seventeen items of LDSI-2.0 showed a moderate to very good retest reliability 
(Kappa value 0.62 - 0.94). Seven items did not produce Kappa values because of 
an inequality of response. To solve this problem, a non-parametric marginal 
homogeneity test was used to examine the retest reliability of these seven items, 
with p value ranging from 0.13 to 0.76 (p > 0.05) indicating that there was no 
significant change in the participants’ second responses (Table 5-6). 
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Table 5-6: Test-retest reliability of the translated LDSI-2.0 by kappa test and 
nonparametric, marginal homogeneity test (n = 27) 
LDSI items Kappa value Non Par, Marginal 
homogeneity test 
P-value 
Itch 0.84  
Itch hampered activity - 0.31 
Itch hampered sleep - 0.16 
Joint pain 0.84  
Joint hampered 0.94  
Abdominal pain 0.74  
Abdominal pain hampered 0.74  
sleepiness during the day 0.73  
Sleepiness during the day Hampered 0.79  
worry - 0.12 
Worrying hampered 0.62  
Decrease appetite 0.89  
Decrease appetite hampered - 0.76 
Depression 0.67  
Depression hampered - 0.13 
Afraid complication - 0.18 
Jaundice 0.80 0.14 
Jaundice hampered - 0.43 
Memory  0.76  
Personality change  0.80  
Financial 0.81  
Use time differently 0.94  
Sexual interest 0.94  
Sexual activity 0.67  
 
5.6.2.4  Translated LDSI-2.0 Internal Consistency  
Chronbach’s alpha coefficient for multi-items scales ranged from 0.73 to 0.96. 
Alpha ≥ 0.70 is considered the acceptable level of internal consistency (Nunnally 
and Bernstein 1994) (Table 5-7). 
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Table 5-7: Internal consistency reliability of the translated LDSI-2.0 by means of alpha 
coefficient between symptom items and their accompanying symptom hindrance items 
(n=38) 
Severity and hindrance item 
pairs concerning Items (N) 
Alpha coefficient 
(α value) 
Itch (3) 0.84 
Joint pain (2) 0.95 
Abdominal pain (2) 0.96 
Sleepiness during the day (2) 0.90 
Worry (2) 0.73 
Decreased appetite (2) 0.87 
Depression (2) 0.86 
Jaundice (2) 0.81 
 
5.6.2.5 Sample Size  
With a sample size of 38, this study had 90% power to identify a Pearson's 
correlation of 0.5 (and lower with Spearman's correlation co-efficient), with 
statistical significant at p ≤ 0.05. 
5.7 DISCUSSION  
Before this research was undertaken, valid and reliable short Arabic disease-
specific tools to assess symptoms related to liver disease and hindrance of these 
symptoms on patients’ daily activities (disease specific HRQOL tool) did not exist. 
Therefore, in this pilot study, an Arabic version of the LDSI-2.0 was developed, its 
psychometric properties were tested and its administration showed that it has 
acceptable validity and retest reliability.  
5.7.1 Translation Process 
The translation process is the most common method of preparing instruments for 
cross-cultural research (Sperber 2004; Cha et al. 2007). The process of translating 
a tool into a different language can be difficult and requires a considerable 
investment of time and money (Sperber 2004; Acquadro et al. 2008). For this 
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reason, the translation process was funded by the School of Nursing, Midwifery and 
Health, University of Stirling, and it took around three months to complete before 
the pilot study could commence.  
Sperber 2004, (p. S124) claimed that questionnaire translation is 'often an 
afterthought, treated as an unimportant part of the study protocol and implemented 
without attention to the critical issues involved’. However, appropriate translation of 
the instrument can enhance research quality and validity (Sperber 2004). Selecting 
the proper translation technique and procedure was a vital step to maintain the 
equivalence between the two versions of the tool (Cha et al. 2007). The guideline 
for standards of questionnaire translation (Guillemin et al. 1993) was used to carry 
out the translation process to maintain the conceptual and semantic equivalence of 
the translation with the original LDSI-2.0. The translation process was carried out 
by highly qualified translators (Sperber 2004) to prevent difficulties that might result 
from tool translation that might threaten the study’s validity. Although the back-
translation was time consuming and expensive, it is important to keep the 
equivalence of semantic words (meaning), idiomatic expressions and grammatical 
form between the translated questionnaire and its original source (Guillemin et al. 
1993; Sperber 2004).  
Finally, the original author of the LDSI-2.0 and the review committee approved the 
quality of the translation. The review committee also approved the face and content 
validity of the Arabic LDSI-2.0. Field testing (piloting) was recommended in the 
international guidelines. Therefore, the translated LDSI-2.0 was used with a sample 
of people with liver cirrhosis in Egypt to complete the cross-cultural adaptation of 
the Arabic LDSI-2.0.  
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5.7.2 Pilot Study Key Results 
5.7.2.1  Arabic LDSI-2.0 Feasibility  
The LDSI-2.0 is a multidimensional short questionnaire that consists of 24 items. 
The findings indicate that the Arabic version of the tool can be completed quickly in 
clinical settings through interviews, even with illiterate patients or those with more 
advanced disease. In this study, the median completion time of the translated 
LDSI-2.0 was 10 minutes, which is a little higher than in a previous study which 
recorded a median completion time of 6 minutes (Unal et al. 2001). This 
discrepancy may have arisen because different completion methods were used, as 
participants in the earlier study completed the questionnaire themselves, whilst in 
this study the participants were interviewed. It could also be that to read the 
questions in Arabic takes longer than in English. 
Although the majority (68.42%) of the participants indicated that the tool covered all 
symptoms that hindered their daily activities, a number of other symptoms like 
muscle cramp, difficulty with sleeping at night, dark skin colour (brown) and 
constipation, were added by a few of the participants as they affected their daily 
activities and social interaction to a high extent. It is therefore recommended that 
the open ended question be kept in the Arabic version to collect all relevant 
symptoms experienced by these patients.  
5.7.2.2  Arabic LDSI-2.0 Construct Validity  
Validity means the degree to which an instrument measures what it is intended to 
measure (Fowler 1995; Litwin 1995; Liobiondo-Wood and Haber 1994; McDowell 
2006). The foundation of all rigorous research designs is the use of measurement 
tools that are psychometrically sound (DeVon et al. 2007). Validity is one of the 
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most essential characteristics of an instrument and is a prerequisite for quantitative 
tools and for assuring the integrity of study findings (Polit and Beck 2008). Knowing 
what type of psychometric properties to look for can be a very important step in 
proving the tool’s validity, such as convergent construct validity (DeVon et al. 
2007). 
Convergent construct validity is used to determine the extent to which two or more 
instruments measure the same construct (item) after administration to the same 
individuals at the same time and under the same conditions (Liobiondo-Wood and 
Haber 1994; Litwin 1995; McDowell 2006). Convergent construct validity is 
measured by using correlation tests. Correlations indicate whether there is an 
overlapping between the measurements’ items, establish whether the tested 
scale’s items measure the same concept, and give either redundant or 
complementary information depending on the magnitude of the association (van 
der Plas et al. 2004). As the SF-36 questionnaire is validated in Arabic it was used 
as the gold standard instrument to test the convergent validity of the LDSI 2.0, 
which is a disease specific HRQOL questionnaire. Thus, both measurements 
(LDSI-2.0 and SF-36) were completed during patient interview. 
The result showed that there was a moderate correlation between a minority of 
LDSI-2.0 items and SF-36. According to the stated hypotheses (see Table 5-1), the 
results have shown that there were specific items of LDSI-2.0 that moderately 
correlated with specific domains of SF-36 as was expected (in total three 
correlations). For example, hindrance of depression in the LDSI-2.0 was 
convergent with role limitation due to emotional problems in the SF-36. Additionally, 
the item of depression was convergent with the domain of mental health in the SF-
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36, and hindrance of depression was convergent with the domain of vitality. This 
result means there is moderate overlapping between the provided information by 
the two tools regarding these items and domains. Also, as was expected, the item 
of depression correlated with the domain of vitality and the item of hampered 
depression correlated with domain of mental health, although r’s value of both 
correlations was less than 0.40, suggesting only slight overlapping.  
However, r’s values of the remaining five correlations that were expected for Table 
5-1 were ≤ 0.23, suggesting that these items in LDSI-2.0 had divergent 
relationships with the SF-36. For example, there was a divergent association 
between the item of joint pain in the LDSI-2.0 and the domain of bodily pain in the 
SF-36, suggesting that joint pain as a specific type of pain is complementary to the 
bodily pain.  
For instance, in this study, the item of abdominal pain (LDSI-2.0) showed a 
convergent correlation with the SF-36 domain of bodily pain, while the prior study of 
van der Plas et al. in 2004 found a convergent relationship between joint pain and 
abdominal pain as well as the domain of bodily pain (SF-36). This result suggests 
that the domain of bodily pain in the SF-36 assesses a general pain, while the 
items of pain in the LDIS-2.0 (joint pain and abdominal pain) examine specific types 
of pain. Therefore, the items of the LDSI-2.0 as a specific disease index can give 
complementary information to the generic SF-36.  
Furthermore, the results show that disease specific items such as itch, hindrance of 
itch on daily activity, hindrance of itch on sleeping, jaundice, hindrance of jaundice 
and hindrance in financial affairs showed a divergent association with all domains 
of SF-36. These results are consistent with the previous study of van der Plas et al. 
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in 2004. This result supports the hypothesis that the SF-36 does not examine 
disease specific items. Thus, there was a slight to moderate overlapping 
information between the two measurements, suggesting that the disease specific 
HRQOL questionnaire (LDSI-2.0) can be used to complement the generic HRQOL 
measurement (SF-36), and it is, therefore, important to use both tools when 
investigating HRQOL. 
Interestingly, the items of hindrance of decreased sexual interest and sexual 
interest unexpectedly had a convergent moderate association with multiple 
domains of vitality and PF (SF-36); that suggested moderate overlapping. Indeed, 
the association is logical, and it means that patients with low vitality or low PF are 
more likely to have low sexual interest or sexual activity. Furthermore, sexual 
activity had a moderate correlation with role limitation due to emotional problems, 
and sexual interest had moderate correlation with social functioning. These findings 
supported the construct validity of the Arabic LDSI-2.0 because sexuality 
theoretically can reflect the individual’s vitality, physical functioning and relationship 
with their partner. For instance, in 2005, Toda et al. found that significant predictors 
of erectile dysfunction among patients with cirrhosis were PF, SF and RP. 
However, it is worth noting that this study investigated sexual health in terms of 
erectile function among males, but not desire or activates therefore the study’s 
findings cannot be generalised to females’ sexual health. Therefore, based on 
these findings, there is a need for future research to investigate the association 
between sexuality and HRQOL among patients (males and females) with cirrhosis. 
It is important to highlight that difference in the results between the current study 
and prior study (van der Plas et al. 2004) may be due to differences between the 
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Egyptian and Dutch populations and differences in symptoms of concern that may 
be relevant to their HRQOL.  
All the items of symptoms, such as joint pain and hampered of joint pain had a 
moderate to high correlation with their accompanying items of hindrance of these 
symptoms. This finding is similar to the previous study by van der Plas in 2004 
which found that the correlation value ranged from 0.52 to 0.80. These results 
suggest information overlapping between these items and their accompanying 
items. However, van der Plas et al. (2004) found that hindrance of symptoms had a 
higher negative influence on HRQOL than increasing symptoms severity. 
Therefore, the items of symptoms severity and items of symptoms hindrance 
measure different aspects of HRQOL (van der Plas et al. 2004).  
Additionally, the convergent relationships between all symptom severity items and 
their accompanying symptom hindrance items showed a strong relationship, rather 
than with other symptom hindrance items. This result is very similar to the study of 
van der Plas et al. in 2004, suggesting construct validity and internal items 
consistency of the LDSI-2.0.  
5.7.2.3  Arabic LDSI-2.0 Reliability  
High reliability of a measurement is not evidence of its validity, but unreliability is 
evidence of its invalidity (Polit and Beck 2008). However, reliability and validity are 
interrelated criteria for the tool (Polit and Beck 2008). A measuring tool cannot 
assess what it is intended to measure if it is inconsistent (unreliable) (Polit and 
Beck 2008). Reliability means to what extent the instrument gives consistent results 
over time (Liobiondo-Wood and Haber 1994), and whether it is free from 
measurement error with repeated measures (Waltz et al. 1991; Litwin 1995).  
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Test-retest reliability 
The test-retest reliability is the most common type of reliability procedure that is 
used to assess an instruments’ reliability (stability over time) (Litwin 1995). The 
test-retest reliability procedure is conducted by administering the same instrument 
to the same individuals under the same conditions on two or more separate times 
to evaluate whether the measurement gives the same results (Liobiondo-Wood and 
Haber 1994; Litwin 1995; McDowell 2006; Waltz et al. 2010). The time interval 
between the repeated measures depends on the phenomena being measured 
(Waltz et al. 1991; Liobiondo-Wood and Haber 1994; Waltz et al. 2010). Therefore, 
test-retest reliability was carried out using data obtained from the participants (n = 
27) who completed the translated LDSI-2.0 at both times 1 and 2.  
Internal consistency reliability 
The results of the current study show that the alpha coefficients for the subscales 
exceeded the acceptable value > 0.70 (Nunnally and Bernstein 1994) indicating 
that the Arabic LDSI-2.0 subscales are internally consistent. This confirms the 
result of an earlier study, which found all alpha values > 0.78 (range 0.79 - 0.86) 
(Unal et al. 2001). 
5.8 LIMITATIONS AND RECOMMENDATIONS  
Although this is the first study to use an Arabic version of LDSI-2.0, which is 
available for future use, its limitations must be acknowledged. 
The study design was cross-sectional in nature; which involves the collection of 
data at one time. The participants were predominately patients with liver cirrhosis. 
The disease stage was categorised as patients with compensated or 
decompensated cirrhosis according to liver disease complications during the year 
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of data collection. However, the strength of the current study is the heterogeneity of 
the study participants, which included patients from both outpatient and inpatient 
clinics, as well as males and females from both rural and urban areas in Egypt. 
Therefore, the translated LDSI-2.0 can be used with a wide range of patients with 
liver cirrhosis in Egypt. 
The small sample size, from only one hospital, limited the validation that could be 
carried out, although the initial validity was good. It is therefore recommended that 
further research will continue the psychometric validity testing of the translated 
LDSI-2.0 among Arabic patients at different chronic liver disease stages; to 
evaluate the construct known group validity and to carry out factor analysis that 
was not done in the original LDSI-2.0. 
5.9 CONCLUSION  
The pilot study was a particularly useful stage for translating and testing the 
feasibility, validity and reliability of the LDSI-2.0. The translated LDSI-2.0 was found 
to be feasible, valid and reliable with patients at different stages of cirrhosis, 
suggesting that the Arabic LDSI-2.0 is a satisfactory tool for future research of 
symptoms or QOL related liver disease in the Egyptian population.   
The pilot study was also useful to confirm the feasibility of daily recruitment rates 
(minimum and maximum), and the expected sample size for the main study. 
Additionally, it was helpful in identifying issues of concern for the main study such 
as time of interviews, recruitment strategy and whether three months of field work 
would be enough to recruit a large enough sample for the main study. This study 
reinforced the importance of the researcher attending the clinic settings daily and 
being systematic in the recruitment of a large sample size during the three months. 
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In particular, the pilot study helped to confirm that the daily rate of recruitment 
would range from 2 to 7 eligible participants from one setting. It is also important to 
acknowledge that the pilot phase findings were strengthened by the diverse range 
of patients that were recruited. For example, the participants were from a wide age 
range, males and females from rural and urban regions and with different social 
backgrounds, allowing a range of perceptions to be obtained. 
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6 CHAPTER 6- RESULTS  
6.1 INTRODUCTION  
This chapter presents the findings from the cross-sectional survey (main study) 
analysis. The study had three aims as stated in section 1.3. This chapter addresses 
the first aim of the study:  
First aim: To describe Health-Related Quality of Life (HRQOL) of Egyptian liver 
cirrhotic patients and to identify and evaluate factors associated with (HRQOL) 
physical and mental health domains. The chapter is structured in three sections. 
Section I describes: (a) participant characteristics and (b) HRQOL of people with 
liver cirrhosis in Egypt. Section II presents factors associated with HRQOL using 
bivariate data analysis: (a) socio-demographic characteristics; (b) medical data; (c) 
symptoms experience and (d) perceived adequacy of social support. Section III 
presents factors associated with HRQOL using multivariate (stepwise multiple 
linear regression) analysis, followed by a summary of the chapter.  
6.2 PARTICIPANT CHARACTERISTICS  
Participants were recruited from three clinical settings in the biggest city in Egypt 
(Cairo), from both inpatient and outpatient clinics if they had been diagnosed with 
compensated or decompensated liver cirrhosis.  
Recruitment rates were monitored and recorded on a daily basis and were 
accurately maintained through the study. The reasons why patients refused to take 
part in the study, or indeed withdrew from the interview were recorded. The 
recruitment phase in the study lasted three months and was conducted from June 
200 
 
to August 2011. During this time, 415 patients were identified as being eligible to 
participate in the study; two of them were not approached because their consultant 
advised that these patients were too anxious to participate. The total number of 
participants who gave consent and participated in the study was 401 (Diagram 6-1).  
The researcher obtained permission from the patient before conducting the 
interview as to whether her/his relative could be in the room during the interview. 
The majority of the patients who participated in the study preferred to be 
interviewed alone. Data collection time lasted between 20-40 minutes per 
participant and was dependent on the patients' health status and as well as their 
ability to provide further details about their experience with the disease. 
Whilst interviewing the participants to complete the questionnaires  some of them 
felt the need to "explain" their answer. Therefore this information not used as data, 
but used as quotes for illustration. Illustrative quotes from qualitative quotes are 
seen as a way of illuminating the quantitative results and thus are treated as part of 
discussion. Therefore, these quotes are not really being treated as data in this 
study. The participants were Arabic speakers so as a result their quotes were 
translated into English. 
The following quote illustrates the interest of the participants to talk about their 
health status.  
‘I need to talk and express my feelings because I cannot say this to anyone … I am 
feeling comfortable to talk...there is no one who can understand me’. Female (303) 
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Diagram 6-1: Sample flow diagram  
 
 
 
 
 
  
 
 
 
 
 
 
 
6.2.1 Socio-Demographics Characteristics and Medical Data 
Just over half of the participants were female (56.6%), 77.3% were married with 
mean age 53.25 ± (standard deviation-SD) 9.0 that ranged from 22 to 76 years 
(Table 6-1). The mean age of males was 52.44±8.804 and mean age of females 
was 53.87±9.185 and age did not differ significantly between males and females, t 
(1, 399) = 0.1579. Only 17% of participants in this study were currently employed, 
although the majority (90%) were less than 65 years old. 53.4 % of the participants 
12 persons refused to participate in 
the study 
Three did not give any reason 
(Two males and one female) 
One had a hearing problem 
(Female) 
One had a speech problem 
(Male) 
Seven did not have time 
(Males=5 and Females=2) 
415 patients were identified as being eligible to 
participate in the study 
Two were not approached because 
they were too anxious to participate 
(Male and Female) 
413 persons were invited to take part in 
the study 
401 participants gave consent and participated in 
the study 
Response rate 96.6% 
 
 
202 
 
were housewives, while 39.0% were unemployed (stopped working) due to their 
inability to work as a result of liver disease. 
The majority of the participants (80.3%) were recruited from outpatient departments 
and were equally distributed between compensated and decompensated stages of 
liver cirrhosis (50.1% and 49.0%) respectively. There was no significant different 
between males (compensated = 81, decompensated = 93) and females 
(compensated = 120, decompensated = 107) disease stage X2 (1, n = 401) = 
1.570, p = 0.210. 62% of the patients reported suffering from at least one additional 
chronic disease (comorbidities) such as diabetes (27.7%) and hypertension 
(20.2%). Liver cirrhosis complications such as splenomegaly (64.6%) were 
prevalent. 153 (38.2%) of the patients had experienced hospital admission at least 
once as a result of liver disease. Ascities (23%) and bleeding (13.2%) were the 
most common causes of hospital admission (Table 6-2).  
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Table 6-1: Participants’ socio-demographic characteristics, n=401  
Demographic data N (%) 
 
Age  Mean ± SD 53.25 ± 9.0 
Age categories 22-44 
45-64 
65+ 
55 (13.7) 
306 (76.3) 
40 (10.0) 
Gender 
 
Males  
Females  
174 (43.4) 
227 (56.6) 
Marital status Married 
Single (never married, widowed, 
divorced)  
310 (77.3) 
91 (22.7) 
Education  
 
Cannot read and write 
 Basic education  
(Primary, preparatory, secondary) 
Higher education  (university) 
219 (54.6) 
163 (40.0) 
 
19 (4.7) 
Residence  
 
Urban  
Rural 
255 (63.6) 
146 (36.4) 
Medication fees The patient 
Relatives or family 
Complete insurance 
Insurance and the patient 
Charity/Zakat 
Combined (Treatment at state 
expense and the patient) 
39 (9.7) 
29 (7.2) 
7 (1.7) 
6 (1.5) 
2 (0.5) 
318 (79.3) 
 
House occupation  Own  
Rent  
260 (64.8) 
141 (35.2) 
Type of work  Employee (officers with stable 
salary) 
Worker (manual work without stable 
salary) 
Housewife (women do not work) 
farmer 
56 (14.0) 
 
136 (33.9) 
 
178 (44.4) 
31 (7.7) 
Current employment status  Employed  
Unemployed  
68 (17.0) 
333 (83.0) 
Cause of unemployment 
(n=333 unemployed) 
Housewives  
Liver disease 
Other reasons  
(Retirement, no job available) 
178 (53.4) 
130 (39.0) 
25 (7.5) 
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Table 6-2: Participants’ medical data, n = 401 
Medical data                               Variables N (%) 
 
Setting of data collection  Outpatient  
Inpatient  
322 (80.3) 
79 (19.7) 
Disease Stage  
 
Compensated cirrhosis 
Decompensated cirrhosis 
201 (50.1) 
200 (49.9) 
Cause of cirrhosis 
 
Hepatitis C virus (HCV) 
HCV and Bilharzias 
Bilharzias 
Cryptogenic (unknown cause)  
Hepatitis B virus (HBV) 
HCV and HBV 
Autoimmune 
Portal vein thrombosis 
217 (54.1) 
151 (37.7) 
14 (3.5) 
7 (1.7) 
5 (1.2) 
4 (1.0) 
2 (0.5) 
1 (0.2) 
Complications of cirrhosis 
  
Splenomegaly  
Ascities  
Oesophageal Varices (OV) with bleeding  
OV without bleeding 
Portal hypertension 
Hepatic encephalopathy (Grade 1)    
259 (64.6) 
179 (44.6) 
57 (14.2) 
82 (20.4) 
47 (11.7) 
19 (4.7) 
Number of hospital 
admissions related to liver 
disease 
Never admitted 
Admitted 1-5 times 
Admitted >5 times  
248 (61.8) 
69 (17.2) 
84 (20.9) 
Cause of hospital admission 
 
Ascities and/or edema 
Gastrointestinal Bleeding 
Hepatic coma 
Abdominal pain 
Jaundice  
Fever 
Spontaneous bacterial peritonitis 
Anemia 
91(23) 
53 (13.2) 
31 (7.7) 
29 (7.2) 
8 (2) 
7 (1.7) 
6 (1.5) 
4 (1) 
Comorbidities  
 
Without comorbidities   
≥1 comorbidities 
151 (38) 
249 (62) 
Types of comorbidities  
 
Diabetes Mellitus  
Hypertension  
Gastrointestinal disease 
Musculoskeletal disease 
Renal disease 
Heart disease 
Asthma 
111 (27.7) 
81 (20.2) 
53 (13.2) 
52 (12.96) 
30 (7.5) 
24 (6) 
18 (4.5) 
 
6.3 HRQOL OF CIRRHOTIC PATIENTS AND ASSOCIATED FACTORS  
6.3.1 HRQOL of Egyptian Cirrhotic Patients 
The Means (± SD) of the eight subscales of SF-36 and the two component 
summary scores are provided for the entire sample (n = 401) then broken down by 
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demographic characteristics, medical data and symptoms experience, in order to 
identify the factors associated with HRQOL.  
No Egyptian study so far has used the SF-36 to establish a norm-based standard of 
comparison between people with cirrhosis and the normal population in Egypt. 
Ware et al. (2008) suggest using a norm-based or cut-off score of a mean of 50 
and a standard deviation of 10 to interpret the results of SF-36. A mean score 
below 50 indicates a poor HRQOL and a mean score above 50 indicates a better 
HRQOL (Maruish and DeRosa 2009).  
Table 6-3 shows that the mean scores of the eight domains of the SF-36 for the 
total sample ranged from 28.93 to 36.29, suggesting that these patients had poor 
perceived health. Role limitations due to physical health problems (RP) and mental 
health (MH) were the lowest rated domains (Mean = 28.37 and 28.93 
respectively), while vitality (VT) and physical functioning (PF) were the highest 
rated domains (Mean = 36.29 and 35.20 respectively). Additionally, the mental 
component summary score (MCS) was lower than the physical component 
summary score (PCS) (Mean = 31.55 and 35.56 respectively).  
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Table 6-3: Means of SF-36 domains of patients with liver cirrhosis in Egypt 
 
 
 
SF-36 Domains 
n = 401 
Egyptian people with liver 
cirrhosis 
 (out of cut-off score 50) 
Egyptian people with 
liver cirrhosis 
 (Out of score 0-100) 
Mean ± SD Mean ± SD 
 
Physical 
health  
PF  35.20±11.78 48.13±27.98 
RP 28.37±11.28 27.31±28.81 
BP 34.94±13.50 35.68±31.96 
GH 34.80±11.02 38.95±23.12 
 
Mental health  
VT  36.29±11.98 30.86±23.99 
SF 33.01±14.76 45.36±33.82 
RE 31.11±16.41 46.90±35.18 
MH 28.93±15.73 37.58±27.94 
PCS 35.56±10.43 
MCS 31.55±14.42 
 
 
6.3.2 General Health Perception among Egyptian Cirrhotic Patients 
The perception of patients’ general health was assessed using a single question 
(item 1 in SF-36) that asked the patients to rate their health in general. This 
question was rated on the 5-point ordinal scale ranging from one "Excellent" to five 
"Poor". For statistical analysis, the 5-point scale order was reversed during the 
analysis process using the transform option in SPSS to be from one "Poor" to five 
"Excellent" without affecting the actual meaning of the scale.  
Table 6-4 summarises the description of patients' general health perception. The 
results show that 183 (45.6 %) of the patients rated their general health (GH) as 
fair followed by 168 (41.6) who rated their general health as poor. Very few 
patients rated their general health as good or excellent.  
 
 
207 
 
Table 6-4: Perceived general health as rated by liver cirrhotic patients 
n = 4 01 
Rating scale of perceived general 
health 
n (%) 
Poor 168 (41.9) 
Fair 183 (45.6) 
Good 41(10.2) 
V. good 6 (1.5) 
Excellent 3 (0.7) 
 
Compared to one year ago, patients were asked to rate how they perceive their 
health in general now. Results show that 67.8% of the patients in general perceived 
their health was worse than one year ago (Table 6-5).  
Table 6-5: Perceived general health compared to one year ago as rated by liver 
cirrhotic patients 
n = 401 
Rating scale of health transition n (%) 
Much better now than one year ago 12 (3.0) 
Somewhat better now than one year ago 70 (17.5) 
About the same as one year ago 47 (11.7) 
Somewhat worse now than one year ago 169 (42.1) 
Much worse now than one year ago 103 (25.7) 
 
6.3.3 Factors Associated with HRQOL among Cirrhotic Patients  
Various factors associated with HRQOL (physical health and mental health 
domains) were examined. These factors were socio-demographic characteristics, 
medical data, disease stage, symptoms experience and perceived adequacy of 
social support.  
6.3.3.1 Socio-Demographic Characteristics  
To explore the association between socio-demographic factors and HRQOL, as 
measured by the SF-36, the study sample was divided into two groups according to 
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gender, marital status and employment status; and into three groups according to 
age and education. 
Table 6-6 shows the difference in HRQOL according to age, gender and marital 
status. In relation to the difference between the age groups, RP [f (2, 398) = 3.03, p 
= 0.04] was the only domain that was statistically significant, with much higher RP 
for the 22-44 year age group (38.47) than for the 65+years (25.75) group. Using 
Post-hoc statistical analysis Tukey Bonferroni identified a statistically significant 
difference between the two age groups [mean difference = - 5.58, Std Error = 2.33, 
p = 0.04]. 
When investigating gender, women had lower mean scores than men in all eight 
domains, as well as in the two component summary scores of SF-36. All results 
were statistically significant. PF, bodily pain (BP), VT and MH were the poorest 
rated domains among women [t (399) = 5.18, 4.09, 4.42 and 4.95 respectively] 
(Table 6-6).  
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Table 6-6: HRQOL stratified by age, gender and marital status 
SF-36 Age Gender Marital status 
Domains 22-44 years 
N=55 
45-64 years 
N=306 
65+ years 
N=40 
f (p) Men 
N=174 
Women 
N= 227 
t (p) Single 
N= 91 
Married 
N=310 
t (p) 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
PF 38.47±11.45 34.47±11.63 33.25±12.79 2.82(0.06) 38.58±12.00 32.61±10.89 5.18(0.0005) 32.68±12.11 35.94±11.59 2.33 (0.02) 
RF 31.34±11.67 28.18±11.23 25.75±10.58 3.05(0.04) 30.70±12.52 26.58±9.89 3.68(0.0005) 27.44±11.16 28.64±11.32 0.90(0.37) 
BP 35.54±13.89 34.71±13.47 35.83±13.50 0.18(0.83) 38.03±14.0 32.56±12.64 4.09(0.0005) 32.47±12.17 35.66±13.81 1.99 (0.04) 
GH 34.98±11.73 34.35±10.95 37.97±10.19 1.92(0.14) 36.54±10.69 33.46±11.10 2.79(0.0005) 35.00±11.15 34.74±11.00 0.20 (0.83) 
VT 39.03±12.15 35.62±11.91 37.57±11.96 2.15(0.11) 39.24±12.67 34.02±10.92 4.42(0.0005) 34.32±11.32 36.86±12.12 1.85(0.07) 
SF 34.54±15.40 32.68±14.64 33.40±14.98 .38(0.68) 34.66±14.70 31.74±14.71 1.96(0.050) 32.64±14.31 33.12±14.90 0.27(0.78) 
RE 32.13±16.69 31.23±16.25 28.77±17.39 .52(0.59) 33.29±16.73 29.44±15.99 2.34(0.02) 29.57±16.09 31.59±16.50 1.03(0.30) 
MH 28.15±14.88 29.00±16.07 29.52±14.57 0.09(0.90) 33.26±16.27 25.62±14.49 4.95(0.0005) 25.72±13.84 29.88±16.14 2.42(0.02) 
Component summary scores 
 
PCS 38.27±11.48 35.11±10.22 35.25±10.21 2.17(0.11) 37.93±10.96 33.75±9.64 4.05(0.0005) 34.39±9.80 35.91±10.60 1.27(0.22) 
MCS 31.48±13.69 
 
31.52±14.58 31.86±14.45 0.01(0.99) 34.34±15.20 29.40±13.43 3.44(0.001) 29.68±12.38 32.09±14.93 1.55(0.16) 
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In relation to the association between marital status and HRQOL, singles had a 
poorer HRQOL than married people, particularly in the domains of PF, BP and MH 
[t (399) = 2.33, 1.99 and 2.42, p < 0.05], but not in the summary scores. 
Table 6-7 demonstrates the association between the level of education and 
HRQOL domains. There was a statistically significant difference between the 
educational groups in PF, RP, BP, VT and MH [f (398) = 4.05, 6.58, 6.99, 9.14 and 
6.31 respectively, p < 0.02], and in the two component summary scores. Post hoc 
Tukey Bonferroni tests showed that illiterate people had significantly lower scores 
than educated people in PF, RP , BP, VT and MH, and in the two component 
summary scores (p < 0.04) (Table 6-8). 
Table 6-7: HRQOL studied by education level  
SF-36 Education level 
Domains Illiterate 
N=219 
Basic 
education 
N=163 
Higher 
education 
N=19 
f (p) 
Mean ± SD Mean ± SD Mean ± SD 
PF 33.72±11.06 36.80±11.96 38.53±15.80 4.05 (0.01) 
RP 26.62±9.92 30.17±12.28 33.14±13.78 6.58 (0.002) 
BP 32.70±12.62 37.44±13.92 39.27±15.50 6.99 (0.001) 
GH 34.44±10.99 34.82±10.81 38.73±12.84 1.32 (0.26) 
VT 34.64±10.37 37.38±12.97 45.85±15.25 9.14 (0.0005) 
SF 32.15±14.55 33.90±15.08 35.32±14.36 0.90 (0.40) 
RE 30.16±16.58 31.82±15.89 36.03±18.41 1.37 (0.25) 
MH 27.27±14.89 29.88±15.96 39.93±18.78 6.31 (0.002) 
Component summary scores 
 
PCS 34.02±9.95 37.35±10.46 37.90±13.07 5.36 (0.0005) 
MCS 30.49±14.08 31.98±14.21 40.06±17.49 4.03 (0.01) 
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Table 6-8: Statistically significant differences between groups according to education 
level using Post Hoc test  
SF-36 
 
Education level Mean 
difference 
p value 
PF Illiterate Lower educated -3.08 0.03 
RP Illiterate Lower educated 
Higher educated 
-3.55 
-6.52 
0.006 
0.03 
BP Illiterate Lower educated -4.74 0.002 
VT Illiterate Higher educated -11.20 0.0005 
MH Illiterate 
Lower educated 
Higher educated 
Higher educated 
-12.65 
-10.04 
0.002 
0.02 
PCS Illiterate Lower educated -3.32 0.006 
MCS Illiterate Higher educated -9.56 0.01 
Only the significant result that were reported 
 
Table 6-9 shows the association between employment status and HRQOL. The 
eight domains and the two component summary scores were poorer among 
unemployed than employed people (p = 0.0005). There were no statistically 
significant differences between people living in rural and urban regions in Egypt.  
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Table 6-9: HRQOL stratified by residential area and current employment status  
SF-36 
 
Residence area Current employment status 
Domains Rural 
N=146 
Urban 
N=255 
t (p) Employed 
N=68 
Unemployed 
N=333 
t (p) 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
PF 35.05±11.95 35.29±11.70 0.19(0.84) 43.35±11.61 33.54±11.11 6.58(0.0005) 
RP 28.34±11.47 28.39±11.20 0.04(0.96) 36.61±12.18 26.69±10.33 6.99(0.0005) 
BP 35.10±14.18 34.84±13.13 0.17(0.85) 41.04±14.12 33.69±13.05 4.17(0.0005) 
GH 35.73±10.73 34.26±11.16 1.30(0.19) 40.08±9.89 33.72±10.94 4.43(0.0005) 
VT 36.05±11.08 36.42±12.49 0.30(0.76) 44.19±12.09 34.67±11.31 6.24(0.0005) 
SF 34.70±14.73 32.04±14.71 1.73(0.08) 39.93±13.43 31.59±14.63 4.33(0.0005) 
RE 31.44±16.25 30.92±16.53 0.30(0.76) 40.96±15.76 29.10±15.82 5.63(0.0005) 
MH 28.48±16.04 29.19±15.58 0.43(0.66) 37.67±15.82 27.15±15.13 5.18(0.0005) 
Component summary scores 
 
PCS 35.79±10.79 35.43±10.24 0.32(0.74) 41.53±11.99 34.34±9.66 5.34(0.0005) 
MCS 31.88±14.30 31.36±14.51 0.34(0.72) 46.22±14.96 29.78±13.66 5.64(0.0005) 
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6.3.3.2  Disease Stage and Medical Data  
To explore the association between disease stage and medical data and HRQOL 
as measured by the SF-36, the study sample was divided into two groups 
according to disease stage and hospital setting, and was divided into three groups 
according to cause of liver disease, number of complications, comorbidities and 
hospitalization.  
Table 6-10 shows that the domain of physical health (i.e. PF and RP) and the PCS 
[t (399) = 3.10, 2.68 and 3.52 respectively, p < 0.009] were lower among patients 
with decompensated cirrhosis than among patients with compensated cirrhosis. 
Causes of liver cirrhosis, on the other hand, were not significantly related to 
HRQOL domains.  
 
 
 
214 
 
Table 6-10: HRQOL stratified by disease stage and cause of cirrhosis 
SF-36  Disease stage Cause of liver cirrhosis 
 
 
 
Domains 
Compensated 
N= 201 
Decompensated 
N= 200 
t (p) Viruses 
(B or C) 
N= 226 
Mix 
(Viruses and 
Bilharzias) 
N=151 
Others causes 
N=24 
f (p) 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
PF 37.00±11.74 33.39±11.56 3.10(0.002) 34.58±11.384 36.56±12.054 32.48±13.204 1.96(0.141) 
RP 29.87±11.98 26.87±10.35 2.68(0.008) 28.60±11.261 28.52±11.495 25.22±10.134 0.99(0.370) 
BP 36.08±13.08 33.79±13.86 1.70(0.08) 34.77±13.501 35.56±13.744 32.55±12.251 0.54(0.578) 
GH 35.76±11.18 33.82±10.79 1.76(0.07) 34.52±11.043 35.48±11.049 33.07±10.798 0.64(0.523) 
VT 37.33±11.66 35.23±12.23 1.76(0.07) 36.16±12.434 36.54±11.527 35.83±10.854 0.06(0.938) 
SF 31.55±15.61 30.67±17.20 1.50(0.13) 32.79±14.808 33.95±14.607 29.13±15.165 1.16(0.313) 
RE 34.11±14.73 31.90±14.73 0.53(0.59) 30.10±16.527 32.81±16.313 29.96±15.704 1.30(0.272) 
MH 29.05±15.79 28.82±15.71 0.14(0.88) 28.30±15.658 29.87±16.035 29.01±14.878 0.44(0.640) 
Component summary scores 
 
PCS 37.37±10.09 31.48±14.72 3.52(0.0005) 35.59±10.341 36.02±10.715 32.34±9.293 1.29(0.274) 
MCS 31.61±14.14 31.48±14.72 0.08(0.92) 30.85±14.567 32.65±14.022 31.21±15.654 0.71(0.489) 
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Table 6-11 summarises the association between the number of liver cirrhosis 
complications and HRQOL. Four domains of physical health (PF, RP, BP and GH), 
one domain of mental health (i.e. VT) and the PCS were significantly related to the 
number of liver cirrhosis complications. Post-hoc statistical analysis using Tukey 
Bonferroni identified that patients without any or with only 1-2 liver disease 
complications had a higher score of HRQOL than people with 3-4 complications 
(Table 6-12).   
Additionally, Table 6-11 shows the difference in HRQOL between patients who 
were in inpatient departments and patients who were in outpatients. Three domains 
of physical health (PF, RP and BP) [t (399) = 4.22, 2.63 and 3.72 respectively, p ≤ 
0.009], two domains of mental health (i.e. VT and Social functioning (SF)) [t (399) = 
3.00 and 3.12 respectively, p < 0.004] and the PCS [t (399) = 4.48, p = 0.0005] 
were lower among patients in inpatient clinics than patients in outpatient clinics. 
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Table 6-11: HRQOL stratified by hospital setting and number of liver cirrhosis complications  
SF-36  Hospital setting Complications of liver cirrhosis 
 
Domains Outpatients 
N= 322 
Inpatients 
N=   79 
t (p) Without 
complications 
N=74 
With 1-2 
complications 
N=244 
With 3-4 
complications 
N=83 
f (p) 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
PF 36.41±1158 30.29±11.37 4.22(0.0005) 37.38±10.54 35.37±12.00 32.77±11.85 3.09(0.04 ) 
RP 29.10±11.53 25.39±9.74 2.63(0.009) 29.49±12.03 28.98±11.56 25.58±9.28 3.29(0.03 ) 
BP 36.16±13.77 29.95±11.11 3.72(0.0005) 33.37±10.40 36.48±14.33 31.79±12.87 4.42(0.01 ) 
GH 34.99±11.14 34.00±10.53 0.74(0.47) 36.03±11.20 35.37±10.91 32.01±10.83 3.48(0.03 ) 
VT 37.17±12.13 32.69±10.70 3.00(0.003) 36.10±10.98 37.43±12.22 33.09±11.66 4.12(0.01 ) 
SF 34.14±14.6 28.41±14.50 3.12(0.002) 33.63±14.47 33.36±14.90 31.42±14.66 0.61(0.54 ) 
RE 31.11±16.20 31.13±17.33 0.01(0.99) 32.56±15.37 31.28±16.95 29.32±15.69 0.79(0.45 ) 
MH 29.35±16.09 27.23±14.16 1.16(0.28) 30.68±16.32 29.26±15.69 26.43±15.20 1.56(0.21 ) 
Component summary scores 
 
PCS 36.69±10.38 30.95±9.37 4.48(0.0005) 36.02±8.90 36.41±11.05 32.67±9.36 4.12(0.01 ) 
MCS 31.77±14.36 30.64±14.71 0.62 (0.53) 32.64±14.20 31.87±14.67 29.63±13.84 1.00(0.36 ) 
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Table 6-12: Statistically significant differences between groups according to liver disease 
complications using Post Hoc test  
SF-36 Liver disease complications Mean 
difference 
p value 
PF Without complications  With 3-4 complications  
 
4.61 0.03 
RP With 1-2 complications  
 
With 3-4 complications  
 
3.40 
 
0.04 
 
BP With 1-2 complications  
 
With 3-4 complications  
 
4.69 0.01 
GH With 1-2 complications  
 
With 3-4 complications  
 
3.35 0.04 
VT With 1-2 complications  
 
With 3-4 complications  
 
4.33 0.01 
PCS With 1-2 complications  
 
With 3-4 complications  
 
3.73 0.01 
Only the significant result that were reported 
 
Table 6-13 shows the association between the number of comorbidities and HRQOL. 
All domains of physical health, two domains of mental health (VT and SF) and the 
PCS were significantly associated with the number of co-morbidities. Post-hoc 
statistical analysis using the Tukey Bonferroni identified that patients without 
comorbidities had a higher HRQOL score than patients with comorbidities (p < 0.05) 
(Table 6-14). 
 
 
218 
 
Table 6-13: HRQOL stratified by the number of comorbidities and the number of hospital admission 
SF-36  Number of Comorbidities Number of Hospitalization related to liver disease 
 
Domains Without 
comorbidities 
N=152 
With 1-3 
comorbidities 
N=235 
With 4-6 
comorbidities 
N=14 
f (p) Never 
admitted 
N=248 
Admitted 1-
5 
N=125 
Admitted 
>5 
N=28 
f (p) 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
PF 38.24±12.13 33.51±11.35 30.58±7.27 8.92(0.0005) 37.18±11.37 32.32±12.02 30.50±10.55 9.91(0.0005) 
RP 31.49±12.88 26.65±9.80 23.27±8.00 10.43(0.0005) 29.99±12.02 25.62±9.20 26.24±10.59 6.96(0.001) 
BP 37.52±14.77 33.65±12.43 28.40±11.91 5.60(0.004) 36.81±13.86 32.62±12.83 28.70±9.52 7.42(0.001) 
GH 36.46±11.24 33.99±10.76 30.26±10.69 3.60(0.02) 35.63±11.01 34.23±10.82 30.00±10.97 3.56(0.02) 
VT 38.90±13.25 34.91±10.73 30.90±12.67 6.77(0.001) 37.97±11.77 33.86±12.14 32.24±10.55 6.78(0.001) 
SF 36.07±15.76 31.34±13.84 27.63±13.29 5.84(0.003) 34.18±14.38 32.76±15.09 23.74±13.59 6.49(0.002) 
RE 33.25±17.52 29.83±15.48 29.50±17.85 2.08(0.12) 32.62±16.10 28.79±16.66 28.11±16.98 2.78(0.06) 
MH 31.33±16.34 27.48±15.25 27.28±14.71 2.87(0.058) 30.65±16.29 26.26±14.47 25.67±14.40 3.93(0.02) 
Component summary scores 
 
PCS 38.30±11.39 34.17±9.46 29.16±8.01 10.41(0.0005) 37.15±10.53 33.46±9.93 30.89±8.788 8.49(0.0005) 
MCS 33.72±15.25 30.25±13.86 29.73±12.18 2.80(0.06) 32.89±14.25 29.84±14.48 27.24±14.40 3.23(0.04) 
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Table 6-14: Statistically significant differences between groups according to 
comorbidities using Post Hoc  
SF-36 
 
Comorbidities Mean 
difference 
p value 
PF Without comorbidities    With 1-3 comorbidities 
With 4-6 comorbidities      
4.73 
7.66 
0.0005 
0.04 
RP Without comorbidities    With 1-3 comorbidities 
With 4-6 comorbidities    
4.84 
8.22 
0.0005 
0.02 
BP Without comorbidities    With 1-3 comorbidities 
With 4-6 comorbidities    
3.86 
9.12 
0.01 
0.03 
VT Without comorbidities    With 1-3 comorbidities 
With 4-6 comorbidities    
3.99 
7.99 
0.004 
0.04 
SF Without comorbidities    With 1-3 comorbidities 4.73 0.006 
MH Without comorbidities    With 1-3 comorbidities 3.85 0.04 
PCS Without comorbidities    With 1-3 comorbidities 
With 4-6 comorbidities    
4.12 
9.13 
0.0005 
0.004 
Only significant results were reported 
 
Table 6-13 presents the association between the number of admissions to the 
hospital (hospitalization) and HRQOL. There was a statistically significant 
difference between the three groups of hospital admissions in all domains of SF-36, 
except for the domain of role limitations due to emotional problems (RE). Post-hoc 
statistical analysis using the Tukey Bonferroni identified seven domains of HRQOL 
(PF, RP, BP, GH, VT, SF and MH) and two component summary scores which 
were higher among patients who were never admitted to hospital than among 
patients who had experienced  hospitalization (p < 0.05) (Table 6-15).  
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Table 6-15: The statistically significant difference between groups according to the 
number of hospital admissions using Post Hoc test  
SF-36 
 
Number of hospital admissions Mean 
difference 
p value 
PF Never admitted Admitted 1-5 times  
Admitted above 5 times    
4.86 
6.68 
0.0005 
0.01 
RP Never admitted   Admitted 1-5 times  4.36 0.001 
BP Never admitted   Admitted 1-5 times  
Admitted above 5 times      
4.18 
8.10 
0.01 
0.007 
GH Never admitted   Admitted above 5 times       5.62 0.02 
VT Never admitted   Admitted 1-5 times  
Admitted above 5 times      
4.10 
5.72 
0.0005 
0.04 
SF Never admitted 
Admitted 1-5 times  
   
Admitted above 5 times       10.44 
9.02 
0.001 
0.009 
MH Never admitted   Admitted 1-5 times  4.38 0.03 
PCS Never admitted   Admitted 1-5 times  
Admitted above 5 times      
3.68 
6.25 
0.003 
0.007 
Only the significant results were reported 
 
6.3.3.3  Symptoms Experience  
Because the data from the LDSI-2.0 subscales included in the analysis was 
continuous, the parametric test of correlation (Pearson product moment correlation 
coefficient, r) was used to test for statistically significant associations between 
patients’ perceptions of severity of symptoms and the extent to which they were 
hampered by these symptoms, and HRQOL (Table 6-16).  
Table 6-16 shows the correlation between symptoms experience and HRQOL. It 
was noted that both LDSI-2.0 subscales of symptom severity and hindrance of daily 
life due to symptoms had a statistically significant negative association with all 
domains of SF-36 (r ≤ -0.519, p < 0.001). Symptoms severity had a highly 
significant association with the domains of VT and MH and the MCS (r = -0.494, -
0.492 and -0.519 respectively, p < 0.001), but the magnitude of the association was 
low with the domain of PF (r = -0.382, p < 0.001).  
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Similarly, hindrance of daily life due to symptoms (the extent to which the patients 
were hampered by these symptoms) had a highly significant correlation with the 
domains of VT and MH and the MCS (r = -0.435, -0.424 and -0.462 respectively, p 
< 0.001), but it had a lower association with the domain of SF (r = -0.350, p < 
0.001).  
6.3.3.4  Social Support  
As explained before, the MSPSS contains the total score for the perceived 
adequacy of social support but also contains three subscales that represent three 
sources of social support: spouse, family and friends. As in previous analysis of 
symptoms experience, the Pearson product moment correlation coefficient (r) test 
of correlation was used to assess the association between perceived social support 
and HRQOL. 
Table 6-16 shows that perceived social support (total score) had a statistically 
significant positive association with all domains and the MCS of SF-36 (r = 0.270, p 
< 0.001), but not with PCS (r = 0.061). Perceived social support from a spouse had 
a statistically significant positive association with all domains and the two 
component summary scores of SF-36. It has a high correlation with GH, VT and 
MH and the MH (r = 0.270, 0.261, 0.338 and 0.292 respectively, p ≤ 0.001). 
Perceived social support from the family had a statistically significant positive 
association with only four domains of mental health (VT, SF, RE and MH) (r = 
0.128, 0.125, 0.132 and 0.190, p ≤ 0.01) and the MCS (r = 0.200, p < 0.001). 
Perceived social support from friends had a statistically significant positive 
association only with the domain of MH and the MCS (r = 0.122 and 0.105 
respectively, p <0.01). The results showed that the highest correlation was between 
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perceived spousal support and the domain of MH and the MCS (r = 0.338 and 
0.292 respectively, p < 0.001). 
Table 6-16: Association between HRQOL and symptoms experience and perceived 
social support by Pearson's correlation 
 n = 401 
SF-36  
Domains 
Symptoms 
severity 
Hindrance 
of 
Symptoms 
Perceived 
social 
support 
Perceived 
spouse 
support 
N=311 
Perceived 
family 
support 
Perceived 
friends 
support 
r value r value r value r value r value r value 
PF -0.382
**
 -0.386
**
 0.139
**
 0.150
**
 0.071 0.048 
RP -0.442
**
 -0.388
**
 0.120
*
 0.132
*
 0.054 0.061 
BP -0.431
**
 -0.421
**
 0.125
*
 0.219
**
 0.062 0.009 
GH -0.455
**
 -0.385
**
 0.144
**
 0.270
**
 0.089 0.012 
VT -0.494
**
 -0.435
**
 0.221
**
 0.261
**
 0.128
*
 0.076 
SF -0.392
**
 -0.350
**
 0.152
**
 0.176
**
 0.125
*
 0.034 
RE -0.431
**
 -0.422
**
 0.160
**
 0.165
**
 0.132
**
 0.061 
MH -0.492
**
 -0.424
**
 0.295
**
 0.338
**
 0.190
**
 0.122* 
Component summary scores 
 
PCS -0.366
**
 -0.349
**
 0.061 0.123
*
 0.003 0.011 
MCS -0.519
**
 -0.462
**
 0.270
**
 0.292
**
 0.200
**
 0.105* 
Correlation is significant at 2 tailed 
*P<0.01 **P<0.001   
 
Table 6-17 and Diagram 6-2 summarise the factors that are significantly associated 
with the physical and mental health domains (HRQOL) of people with liver cirrhosis 
using bivariate analysis. Many factors were significantly associated with the two 
component summary scores of SF-36. Factors that were significantly associated 
with physical health were gender, education, employment status, disease stage, 
complications of liver disease, comorbidities, symptoms severity and hindrance of 
daily life due to symptoms. Physical health domains (PCS) was most highly 
correlated with comorbidities, the number of hospitalizations, educational level and 
employment status [f (398) = 10.41 and 8.58, t (399) = 5.36 and 5.34 respectively, 
p ≤ 0.0005]. 
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Factors that were significantly associated with mental health domains (MCS) were 
gender, educational level, employment status, number of hospitalisations, social 
support and symptoms severity. MCS was most highly correlated with employment 
status and educational level [t (399) = 5.64 and 4.03 respectively, p ≤ 0.01]. 
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Table 6-17: Summary of factors associated with HRQOL (PCS and MCS) among Egyptian cirrhotic patients  
Variables Classifications N HRQOL 
PCS MCS 
Mean ± SD t or f (p) Mean ± SD t or f (p) d 
Gender Male 
Female 
174 
227 
37.93±10.96 
33.75±99.64 
4.05(0.0005) 34.34±15.20 
29.40±13.43 
3.44(0.001) 
Marital status Single  
Married 
91 
310 
34.39±9.80 
35.91±10.60 
1.27(0.22) 29.68±12.38 
32.09±14.93 
1.55(0.16) 
 Residential area Rural 
Urban 
146 
255 
35.79±10.7 
35.43±10.249 
0.32(0.74) 31.88±14.30 
31.36±14.51 
0.34(0.72) 
Educational level Illiterate 
Basic education 
High education 
219 
163 
19 
34.02±9.95 
37.35±10.46 
37.90±13.07 
5.36(0.0005) 30.49±14.08 
31.98±14.21 
40.06±17.49 
4.03(0.01) 
Employment status Employed 
Unemployed 
68 
333 
41.53±11.99 
34.34±9.66 
5.34(0.0005) 
 
46.22±14.96 
29.78±13.66 
5.64(0.0005) 
Disease stage Compensated 
Decompensated 
201 
200 
37.37±10.09 
31.48±14.72 
3.52(0.0005) 31.61±14.14 
31.48±14.72 
0.08(0.92) 
Cause of cirrhosis Viruses 
Bilharzias and viruses 
Others 
226 
151 
24 
35.59±10.341 
36.02±10.715 
32.34±9.293 
1.29(0.274) 30.85±14.567 
32.65±14.022 
31.21±15.654 
0.71(0.489) 
Hospital setting Outpatient 
Inpatient 
322 
79 
36.69±10.38 
30.95±9.37 
4.48(0.0005) 31.77±14.36 
30.64±14.71 
0.62(0.53) 
Complications Without complications 
1-2 complications 
3-4 complications  
74 
244 
83 
36.02±8.90 
36.41±11.05 
32.67±9.36 
4.12(0.01 ) 32.64±14.20 
31.87±14.67 
29.63±13.84 
1.00(0.36 ) 
Comorbidities  Without comorbidities    
1-3 comorbidities   
4-6 comorbidities   
152 
235 
14 
38.30±11.39 
34.17±9.46 
29.16±8.01 
10.41(0.0005) 33.72±15.25 
30.25±13.86 
29.73±12.18 
2.80(0.06) 
Hospitalization  Never admitted 
Admitted 1-5 times 
Admitted >5 times 
248 
125 
28 
37.15±10.53 
33.46±9.93 
30.89±8.78 
8.49(0.0005) 32.89±14.25 
29.84±14.48 
27.24±14.40 
3.23(0.04) 
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Association is significant at the p level < 0.05 (2 tailed) 
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Diagram 6-2: Summary of factors associated with HRQOL (PCS and MCS) among Egyptian cirrhotic patients  
 
 
 
 
 
 
 
 
 
 
 
 
 
Only the significant results are presented, all associations were significant at p level < 0.05 (2 tailed) 
Disease stage 
Symptom 
experience  
Social support 
(MSPSS) 
 
MCS 
PCS 
t=5.64 
f=4.03 t=3.44 
t=4.05 
 
f=5.36 t=5.34 
 
Comorbidities  
Complications 
Employment status Education  
f=4.12 
Severity: r= -0.52 
Severity r=-0.37 
r=0.270 
f=10.41 
t=3.52 
HRQOL 
Hospitalization  
f=8.49 
 
Gender  
Hindrance: r= -0.35 
Hindrance: r= -0.46 
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6.3.4 Multivariate analysis: Factors associated with HRQOL (PCS and 
MCS)  
As we have seen, HRQOL was measured using the SF-36 that gave two 
component summary scores, physical health (PCS) and mental health (MCS) 
domains. Stepwise regression method was used to find factors associated with 
HRQOL (PCS and MCS). The PCS and MCS were considered two dependent 
variables. Therefore, it was essential to develop a regression model for each of 
these dependent variables independently.  
The socio-demographic characteristics, medical data, symptoms experience and 
social support (independent variables) that correlated significantly with the PCS 
and MCS (dependent variables) were combined and tested by multivariate analysis 
(multiple linear regression).  
The following variables were entered all together into the regression analysis to 
develop Model 1 for physical health and Model 2 for mental health. (1) symptoms 
severity, (2) hindrance of symptoms, (3) perceived spouse support, (4) perceived 
family support, (5) perceived friends support, (6) disease stage (dummy code), (7) 
number of comorbidities, (8) number of liver cirrhosis complications and (9) socio-
demographic characteristics (age, gender, marital status, employment status, 
education and area of residence (dummy code)). The significance limit to enter and 
leave the multiple regression steps was set at p = 0.05 (Field 2009).  
6.3.4.1 Factors Associated with Physical Health domains (PCS) 
Table 6-18 presents the multiple regression analysis (Model 1) that was 
constructed using the stepwise method to answer the sub-research question 2.1. 
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An initial investigation was conducted to ensure the non-violation of the regression 
assumptions of multicollinearity, normality, linearity, and homoscedasticity.  
The first model (Model 1) included symptoms experience (severity and hindrance), 
the three subscales of perceived social support (spouse, family and friends), socio-
demographic factors and medical data. Physical health (PCS) was the dependent 
variable. 
The results show that the Model 1 could significantly explain 19% of the variation in 
PCS (R2 = 0.190, R2adj = 0.180, p = 0.0005) (Table 6-18). Four variables were 
significantly associated PCS [symptoms severity (b = -0.287, p = 0.0005), 
employment status (b = -0.152, p = 0.005), number of comorbidities –b = -0.134, p 
= 0.01) and disease stage (b = 0.122, p = 0.02)]. This means that patients with high 
severity of symptoms, unemployed, with increasing number of comorbidities and 
with advanced disease stage are more likely to report low perceived PCS. 
Symptoms severity has the strongest contribution (28.7%) to explain PCS, while 
disease stage has the lowest contribution (12.2%).  
Although Model 1 could significantly explain the PCS (p = 0.0005), around 81% of 
the variation in PCS could not be explained by the model, suggesting that there are 
other associated factors that have an influence on physical health domains, which 
need further research to be explored  
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Table 6-18: Summary of factors associated with physical health (PCS) using multivariate analysis  
Model 1 df F  R R
2
 R
2
adj. Sig. 
Collinearity Statistics 
4/306  17.987 0.436 0.190 0.180 0.0005 
Factors Unstandardized 
coefficient 
B 
Standardized 
coefficient 
Beta 
t Sig. 95% CI of beta 
Lower Upper 
Tolerance 
VIF 
Constant  46.554  24.775 0.0005 42.857 50.252   
Symptoms severity -0.228 -0.287 -5.285 0.0005 -0.313 -0.143 0.897 1.115 
Employment status  -4.215 -0.152 -2.816 0.005 -7.160 -1.269 0.911 1.098 
Number of comorbidities  -1.241 -0.134 -2.554 0.011 -2.197 -0.285 0.961 1.041 
Disease stage 2.548 0.122 2.324 0.021 0.391 4.705 0.956 1.046 
VIF: Variance inflation factor  
Dummy codes: gender: 0 males, 1 females, disease stage: 0 decompensated, 1 compensated, employment status: 0 employed, 1 unemployed, marital 
status: 0 single, 1 married, educational level: 0 educated, 1 uneducated, area of residence: 0 rural, 1 urban 
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6.3.4.2  Factors Associated with Mental Health domains (MCS) 
Table 6-19 presents the multiple regression analysis (Model 2) that was 
constructed using the stepwise method to answer the sub-research question 2.2. 
The second model (Model 2) included the two subscales of symptoms experience 
(severity and hindrance) and the three subscales of perceived social support 
(spouse, family and friends), socio-demographic factors and medical data as the 
independent variables (variables used in model 1); and mental health (MCS) as the 
dependent variable.  
It was discovered that Model 2 significantly predicted 31.7% of the variation in MCS 
(R2 = 0.317, R2adj = 0.308, p = 0.0005). Four variables significantly predicted MCS 
[symptoms severity (b = -0.436, p = 0.0005), perceived spouse support (b = 0.135, 
p = 0.007), employment status (b = -0.116, p = 0.02) and perceived family support 
(b = 0.097, p = 0.046)]. This means that patients with high severity of symptoms, 
unemployed, with low perceived support from spouse and family are more likely to 
report low perceived MCS. Symptoms severity made the strongest contribution 
(43.6%) to explain MCS, while perceived family support made the lowest 
contribution (9.7%).  
Although Model 2 could significantly predict the MCS (p = 0.0005), around 68.3% of 
the variation in MCS could not be explained by the model, suggesting that there are 
other factors that have an associate with mental health domains and need further 
research to be explored.  
In conclusion, symptoms severity made the strongest contribution in explaining 
both aspect of HRQOL, PCS (28.7%) and MCS (43.6%). However, hindrance of 
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symptoms did not associate with any of them. Many of somatic variables 
associated with PCS while psychosocial variables associated with MCS. For 
example, disease stage and number of comorbidities were associated with only 
PCS, while perceived social support, from spouse and family, was significantly 
associated with MCS but not PCS.  
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Table 6-19: Summary of factors associated with mental health (MCS) using multivariate analysis  
 
Model 2 
 
df 
 
F  
 
R 
 
R
2
 
 
R
2
adj. 
 
Sig. 
Collinearity Statistics 
4/306  35.427 0.563 0.317 0.308 0.0005 
Factors Unstandardized 
Coefficients 
B 
Standardized 
coefficient Beta 
t Sig. 95% CI of beta 
Lower Upper 
Tolerance VIF 
Constant  40.911  9.944 0.0005 32.815 49.007   
Symptoms severity -0.478 -0.436 -8.585 0.0005 -0.587 -0.368 0.868 1.152 
Perceived spouse 
support 
2.573 0.135 2.705 0.007 0.702 4.445 0.896 1.116 
Employment status -4.447 -0.116 -2.330 0.020 -8.202 -0.692 0.903 1.107 
Perceived family 
support 
1.873 0.097 2.008 0.046 0.038 3.709 0.961 1.041 
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6.4 CONCLUSION  
The study shows that Egyptians with liver cirrhosis have poor HRQOL. Using 
bivariate analysis, many factors had a significant correlation with HRQOL, including 
socio-demographic characteristics, medical data, symptoms experience and 
perceived social support. Females, illiterate people and the unemployed had the 
worst PCS and MCS. Patients with decompensated cirrhosis, comorbidities and 
complications of liver cirrhosis had the worst PCS. Additionally, the results suggest 
that PCS and MCS decrease with increasing severity of symptoms and hindrance 
of daily life due to symptoms. Also, perceived social support had a statistically 
significant positive relationship with MCS, with patients with perceived low levels of 
social support, particularly from spouse and family, having the worst MCS.  
Finally, multiple regression analysis showed that symptoms severity was the main 
factor that was associated with both PCS and MCS. Disease stage and the number 
of comorbidities were associated with PCS, while perceived social support from 
spouse and family was associated with MCS.  
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7 CHAPTER 7- RESULTS  
7.1 INTRODUCTION  
This chapter presents further results from the cross-sectional study (main study) 
analysis. The study has three aims as stated in section 1.3. Chapter 6 covered the 
first aim of this study. This chapter will cover the second and the third aims of this 
study: 
Second aim: To explore and describe experienced symptoms (prevalence, 
severity and hindrance) in Egyptian cirrhotic patients and to identify and evaluate 
factors associated with symptoms severity and symptoms hindrance (distress).  
Third aim: To explore and describe how cirrhotic patients in Egypt perceive social 
support from spouse, family and friends and to identify and evaluate factors 
associated with general perceived social support. 
Therefore, the chapter is divided into two sections. Section I describes the 
symptoms experience of people with liver cirrhosis and how these symptoms affect 
their daily activities. It also presents factors that are associated with and predicted 
symptoms experience. Section II describes the perceived social support and factors 
associated with perceived availability of social support. Finally, a summary of this 
chapter is presented.  
7.2 SYMPTOMS EXPERIENCE 
Experienced symptoms were investigated by using the LDSI-2.0 that contains 24 
items, which describe the disease specific HRQOL. The LDSI-2.0 is divided into 
two subscales. One subscale assesses the severity of various physical and 
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psychological symptoms as well as the social dysfunctional experience over the 
previous week, which consists of 15 items. The other subscale examines how 
much people’s daily or social activities are affected by some of these symptoms 
and it contains 9 items. 
7.2.1 Symptoms Experience among Egyptian Cirrhotic People  
The Means (± SD) of the total score (disease specific HRQOL) and the two 
subscales (symptoms severity and hindrance of daily activities due to symptoms) of 
the LDSI-2.0 are provided for the entire sample (n = 401). Additionally, the 
prevalence of symptoms severity and the prevalence of the impact of symptoms on 
daily or social activities in patients with cirrhosis are presented. 
Results in table 7-1 show that the mean score of the overall LDSI-2.0 was 46.16 ± 
SD (20.75); the high score indicates a poor disease-specific HRQOL as a result of 
liver disease. The mean score of the symptoms severity subscale was higher than 
the mean score of the symptoms hindrance subscale, suggesting that symptoms 
severity was higher than hindrance of daily life due to these symptoms among 
these patients.  
Table 7-1: Symptoms experience by total and subscales scores of LDSI-2.0  
Variables n=401  Instrument 
possible range LDSI-2.0 Mean ± (SD) Median Percentiles 
 
Disease specific HRQOL 
 
 
46.16 ± (20.75) 49.00 25 
50 
75 
30.00 
49.00 
61.00 
 
0-96 
Symptoms severity 
 
 
32.61 ± (13.15) 35.00 25 
50 
75 
24.00 
35.00 
43.00 
 
0-60 
Symptoms hindrance  13.54 ± (8.54) 13.00 25 
50 
75 
7.00 
13.00 
20.00 
 
0-36 
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7.2.2 Prevalence of Experienced Symptoms 
In order to assess the prevalence of reported symptoms among patients with liver 
cirrhosis, it was essential to transform the scale responses to "Yes" for those who 
answered 1 to 4 (have symptoms) and "No" for those who answered not at all (no 
symptoms). Table 7-2 shows the prevalence of the 15 symptoms that were 
reported by the patients who answered yes. The majority of the patients had one or 
more of a wide range of physical and psychosocial symptoms (Table 7-2). Joint 
pain was reported by 78.3% of the whole sample, decreased appetite by 75.6%, 
memory problems by 77.3%, difficulty of using time effectively as a result of liver 
disease by 90% and financial affairs resulting from liver disease by 80%. On the 
other hand, jaundice was the only symptom that few of these people experienced 
(27.2%).  
Table 7-3 shows the additional symptoms that were not measured in the LDSI-2.0 
but were reported by the patients. Indeed, to explore all the symptoms that these 
patients experienced, an additional question was added to the LDSI-2.0, which 
asked if other symptoms had been experienced over the last week. Muscle cramp 
was the most frequent additionally reported symptom (37.15%) followed by difficulty 
in sleeping at night (26.68%).  
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Table 7-2: Percentage of patients reporting symptom severity and hindrance of 
symptom by answering yes  
 
LDSI-2.0 items 
n = 401 (100%) 
Prevalence of people 
reported Symptom 
severity 
n (%) 
Prevalence of people reported 
hindrance of daily activities 
due to symptom 
(Among symptomatic) 
n (%) 
Itch 210 (52.4) Activity: 103 (25.7) 
Sleep: 125 (31.2) 
Joint pain 314 (78.3) 282 (70.3) 
Right abdominal pain 259 (64.6) 208 (51.9) 
Sleepiness during the day 290 (72.3) 213 (53.1) 
Worry about the family 
situation  
300 (74.8) 231(57.6) 
Decreased appetite 303 (75.6) 237 (59.1) 
Depression 291 (72.6) 246 (61.3) 
Fear disease complications 281 (70.1) N/A 
Jaundice 109 (27.2) 65 (16.2) 
Memory problems 310 (77.3) N/A 
Changing personality  283 (70.6) N/A 
Hindrance in financial affairs  321 (80) N/A 
Difficulty managing time  361 (90) N/A 
Decreasing sexual interest 256 (63.8) N/A 
Decreasing sexual activity 255 (63.6) N/A 
N/A: Not applicable 
 
Table 7-3: Prevalence of additional symptom severity and hindrance of symptom  
 
Additional symptoms 
n = 401 (100%) 
People reported 
Symptom severity 
n (%) 
Prevalence of people 
reported hindrance of daily 
activities due to symptom 
(Among symptomatic) 
n (%) 
Difficulty in sleeping at night 107 (26.68) 95 (23.69) 
Muscle cramp 149 (37.15) 122 (30.42) 
Heart burn  62 (15.46) 40 (9.97) 
Constipation  11 (2.74) 11 (2.74) 
These additional reported symptoms were not combined with the LDSI-2.0 score 
 
7.2.3 How Symptoms Affect Daily Activities of People with Liver Cirrhosis  
The mean score of the impact of symptoms on daily and social activities (hindrance 
of symptoms) was 13.54 ± SD (8.54) with a median of 13 (Table 7-1). The 
increased score means impaired daily and social activities as a result of symptoms. 
Some of the patients had one or more of a wide range of physical and psychosocial 
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symptoms that impacted on their daily and social activities (Tables 7-2 and 7-3), 
such as hindrance of daily life due to joint pain (70.3%), and depression (61.3%). In 
other words, joint pain and depression were the symptoms that influenced these 
people’s activities in their daily life most. Itching was the symptom that interfered 
least with their daily life (27.2%).  
7.2.4 Factors Associated with Experienced Symptoms  
To assess the factors associated with the severity of symptoms and the impact of 
these symptoms on daily life, the sample (n = 401) was broken down into groups 
according to socio-demographic characteristics and disease stage, as discussed in 
Chapter 6.  
7.2.4.1  Socio-Demographic Characteristics  
As can be seen from Table 7-4, the means of symptoms severity was significantly 
higher among females, illiterate people and the unemployed (p ≤ 0.002). This 
suggests that gender, educational level and employment status have a significant 
impact on the perceived severity of symptoms. Moreover, the limitation in their daily 
activities because of symptoms was higher in those same groups (i.e. females, 
illiterates, unemployed) and married (p ≤ 0.04). Therefore, further statistical 
analyses (chi-square test) were done to compare these groups. 
Table 7-5 shows the prevalence of symptoms severity and hindrance of daily life 
due to symptoms among males and females. There was a significant difference in 
the types of symptoms experienced between men and women. Women were more 
likely than men to report symptoms of joint pain, right abdominal pain, decreased 
appetite, depression, jaundice, memory problems, changing personality and 
difficulty in managing time (p ≤ 0.02). On the other hand, men were more likely than 
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women to report symptoms of sexuality problems (decreased sexual interest and 
activity) (p = 0.0005). However, males and females have the same symptoms of 
worry about the family situation, itching, fear of disease complications and 
problems in financial affairs.  
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Table 7-4: Association between socio-demographic characteristics and symptoms experience  
Variables Classifications N Symptoms experience, n = 401 
Symptoms severity Symptoms hindrance  
Mean ± SD t or f (p) Mean ± SD t or f (p) 
Gender Male 
Female 
174 
227 
29.11±13.48 
35.29±12.25 
4.79(0.0005) 10.65±8.15 
15.76±8.19 
6.20(0.0005) 
Age  22-44 
45-64 
65+ 
55 
306 
40 
33.40±15.33 
32.74±12.65 
32.61±13.15 
0.015(0.54) 14.11±9.32 
13.35±8.20 
14.20±10.07 
0.31(0.73) 
Marital status Single 
Married 
91 
310 
30.70±11.58 
33.17±13.54 
1.57(0.11) 15.15±8.73 
13.07±8.45 
2.05(0.04) 
Residential area Rural 
Urban 
146 
255 
31.68±13.40 
33.14±12.99 
1.06(0.28) 13.26±8.87 
13.70±8.37 
0.49(0.61) 
Educational level Illiterate 
Basic education 
Higher education 
219 
163 
19 
34.48±11.83 
30.64±14.15 
27.89±15.56 
5.39(0.0005) 14.84±8.16 
12.15±8.76 
10.42±8.81 
6.11(0.002) 
Employment status Employed 
Unemployed 
68 
333 
24.84±14.44 
34.20±12.30 
5.54(0.0005) 9.16±7.50 
14.44±8.48 
4.75(0.0005) 
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Table 7-5: The proportion of symptom severity and hindrance of symptom among 
males and females  
phi 
coefficient 
p value Chi-square 
(X
2
) 
Gender (n) Symptom severity 
Females 
N=227 
n (%) 
Males 
N= 174 
n (%) 
0.06 0.25 1.27 125(55.06) 85(48.85) Itch 
0.37 0.0005 52.88 208(91.62) 106(60.91) Joint pain 
0.25 0.0005 23.24 170(74.88) 89(51.14) Right abdominal pain 
0.04 0.45 0.56 168(74.08) 122(70.11) Sleepiness during the 
day 
0.09 0.07 3.17 178(78.41) 122(70.11) Worry about the family 
situation  
0.17 0.001 10.73 186(81.93) 117(67.24) Decreased appetite 
0.17 0.001 11.12 180(79.29) 111(63.79) Depression 
0.02 0.75 0.09 161(70.92) 120(67.95) Fear disease 
complications 
0.15 0.004 8.39 75(33.03) 34(19.54) Jaundice 
0.15 0.004 8.35 188(82.81) 122(70.11) Memory problems 
0.11 0.02 5.18 171(75.33) 112(64.36) Changing personality  
0.02 0.76 0.09 180(79.29) 141(81.03) Hindrance in financial 
affairs  
0.16 0.002 9.45 214(94.27) 147(84.48) Difficulty managing 
time  
0.20 0.0005 16.58 125(55.06) 131(75.28) Decreased sexual 
interest 
0.26 0.0005 27.08 119(52.42) 136(78.16) Decreased sexual 
activity 
phi 
coefficient 
p value Chi-square 
(X
2
) 
Females 
N=227 
n (%) 
Males 
N= 174 
n (%) 
Hindrance of 
symptom 
 
0.06 0.23 1.43 64(28.19) 39(22.41) Itch hindrance  activity 
0.035 0.55 0.35 74(32.59) 51(29.31) Itch hindrance  sleep 
0.34 0.0005 46.34 191(84.14) 91(52.29) Hindrance  of joint pain  
0.20 0.0005 15.87 138(60.79) 70(40.22) Hindrance  of right 
abdominal pain  
0.11 0.02 4.86 132(58.14) 81(46.55) Sleep hindrance 
0.08 0.11 2.48 139(61.23) 92(52.87) Hindrance  of worry  
0.11 0.03 4.48 145(63.87) 92(52.87) Hindrance of 
decreased appetite  
0.16 0.002 9.94 155(68.28) 91(52.29) Hindrance  of 
depression 
0.11 0.03 4.43 45(19.82) 20(11.49) Hindrance  of jaundice  
 
In terms of the hindrance of symptom, women were more likely than men to 
experience limitations in their daily and social activities due to symptoms of joint 
pain, right abdominal pain, decreased appetite, depression, sleepiness during the 
day and jaundice (p ≤ 0.03) (Table 7-5).  
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Although there was no significant difference between men and women in reporting 
sleepiness during the day, there was a significant difference between them in terms 
of the impact of sleepiness on their daily lives. Women were more likely than men 
to have limitations in their daily life due to this symptom. Therefore, the assessment 
of symptoms experience showed to include not only the severity of the symptom 
but also the effect of this symptom on daily life.  
Table 7-6 presents the prevalence of symptom severity and hindrance of daily 
activities due to symptom among single and married people. There was a 
significant difference in the types of symptoms experienced between married and 
single people. Singles were more likely than married people to report symptoms of 
joint pain and worry about the family situation (p ≤ 0.04). In contrast, married 
people were significantly more likely to report a decrease in sexual interest and 
activity (p = 0.0005). In terms of the impact of symptoms on daily life, single and 
married people were likely to experience a similar level of impact of symptoms on 
their daily activities. 
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Table 7-6: The proportion of symptom severity and hindrance of symptom among 
unmarried and married   
phi 
coefficient 
p value Chi-square 
(X
2
) 
Marital status (n) Symptom severity 
Married 
N=310 
n (%) 
Single 
N=91 
n (%) 
0.008 0.97 0.001 163 (52.58) 47(51.64) Itch 
-0.14 0.008 7.14 233(75.16) 81(89.01) Joint pain 
-0.09 0.09 2.81 193(62.25) 66(72.52) Right abdominal pain 
-0.07 0.15 2.00 230(74.19) 60(65.93) Sleepiness during the 
day 
-0.109 0.04 4.15 224(72.25) 76(83.51) Worry about the family 
situation  
-0.073 0.18 1.72 229(73.87) 74(81.31) Decreased appetite 
-0.066 0.23 1.42 220(70.96) 71(78.02) Depression 
0.036 0.55 0.34 220(70.96) 61(67.03) Fear disease 
complications 
-0.08 0.12 2.38 78(25.16) 31(34.06) Jaundice 
0.0005 1.00 0.00 240(77.41) 70(76.92) Memory problems 
-0.036 0.55 0.35 216(69.67) 67(83.51) Changing personality  
0.042 0.48 0.49 251(80.96) 70(76.92) Hindrance in financial 
affairs  
-0.021 0.81 0.05 278(89.67) 83(91.20) Difficulty managing time  
0.596 0.0005 139.48 246(79.35) 10(10.98) Decreased sexual 
interest 
0.592 0.0005 137.75 245(79.03) 10(10.98) Decreased sexual 
activity 
phi 
coefficient 
p value Chi-square 
(X
2
) 
Married 
N=310 
n (%) 
Single 
N=91 
n (%) 
Hindrance of 
symptom 
-0.049 0.39 0.72 76(24.51) 27(29.67) Itch hindrance  activity 
-0.047 0.42 0.65 93(30.00) 32(35.16) Itch hindrance  sleep 
-0.065 0.24 1.38 213(68.70) 69(75.82) Hindrance  of joint pain  
-0.081 0.13 2.25 154(49.67) 54(59.34) Hindrance  of right 
abdominal pain  
0.004 1.00 0.00 165(53.22) 48(52.74) Sleep hindrance 
-0.043 0.45 0.55 175(56.45) 56(61.53) Hindrance  of worry  
-0.015 0.86 0.03 182(58.70) 55(60.43) Hindrance of decreased 
appetite  
-0.088 0.10 2.67 183(59.03) 63(69.23) Hindrance  of 
depression 
-0.020 0.80 0.059 49(15.80) 16(17.58) Hindrance  of jaundice  
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Table 7-7 shows the prevalence of symptom severity and hindrance of symptom 
among the employed and unemployed. The proportion of symptoms of right 
abdominal pain, depression, changing personality, difficulty managing time and 
jaundice was significantly higher among the unemployed than the employed (p ≤ 
0.01). In terms of the impact of symptom on daily life, the prevalence of the impact 
of joint pain, right abdominal pain, decreased appetite and depression on daily and 
social activities was higher among the unemployed than the employed (p ≤ 0.01).  
 
Table 7-7: The proportion of symptom severity and hindrance of symptom among 
employed and unemployed  
phi 
coefficient 
p value Chi-square 
(X
2
) 
Employment status Symptom severity 
Unemployed 
N=333 
n (%) 
Employed 
N=68 
n (%) 
0.075 0.17 1.85 180(54.05) 30(44.11) Itch 
0.10 0.06 3.44 267(80.18) 47(69.11) Joint pain 
0.152 0.004 8.40 226(67.86) 33(48.52) Right abdominal pain 
0.003 1.00 0.0005 241(72.37) 49(72.05) Sleepiness during the 
day 
-0.017 0.84 0.03 248(74.47) 52(76.47) Worry about the 
family situation  
0.083 0.13 2.28 257(77.17) 46(67.64) Decreased appetite 
0.169 0.001 10.46 253(75.97) 38(55.88) Depression 
0.009 0.96 0.002 234(70.27) 47(69.11) Fear disease 
complications 
0.127 0.01 5.70 99(29.72) 10(14.70) Jaundice 
0.088 0.10 2.59 263(78.97) 47(69.11) Memory problems 
0.146 0.006 7.68 245(73.57) 38(55.88) Changing personality  
0.074 0.19 1.71 271(81.38) 50(73.52) Hindrance in financial 
affairs  
0.182 0.001 11.74 308(92.49) 53(77.94) Difficulty managing 
time  
0.047 0.42 0.65 216(64.86) 40(58.82) Decreased sexual 
interest 
0.045 0.44 0.57 215(64.56) 40(58.82) Decreased sexual 
activity 
phi 
coefficient 
p value Chi-square 
(X
2
) 
Unemployed 
N= 333 
n (%) 
Employed 
N= 68 
n (%) 
Hindrance of 
symptom 
0.08 0.13 2.28 91(27.32) 12(17.64) Itch hindrance  
activity 
0.103 0.054 3.70 111(33.33) 14(20.58) Itch hindrance  sleep 
0.157 0.003 9.03 245(73.57) 37(54.41) Hindrance  of joint 
pain  
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0.150 0.004 8.23 184(55.25) 24(35.29) Hindrance  of right 
abdominal pain  
-0.038 0.52 0.40 174(52.25) 39(57.35) Sleep hindrance 
0.016 0.85 0.03 193(57.95) 38(55.88) Hindrance  of worry  
0.124 0.01 5.53 206(61.86) 31(45.58) Hindrance of 
decreased appetite  
0.160 0.002 9.39 216(64.86) 30(44.11) Hindrance  of 
depression 
0.091 0.10 2.66 59(17.71) 6(8.82) Hindrance  of 
jaundice  
 
7.2.4.2 Disease Stage and Medical History  
As can be seen, the mean score of symptoms severity was significantly higher 
among patients with decompensated cirrhosis than patients with compensated 
cirrhosis (p = 0.009) (Table 7-8). In other words, it seems that the perceived 
severity of symptoms increases with the progressive stage of cirrhosis. Besides 
that, the mean score of perceived symptoms severity extensively increased with the 
increasing number of complications and comorbidity (p ≤ 0.008). This means that 
there was a significant positive correlation between the number of both 
comorbidities as well as liver disease complications and severity of symptoms.  
Table 7-8 shows that severity of symptoms also had a significant positive 
association with the number of admissions to hospital because of liver disease. For 
example, whereas the mean score of symptoms severity for those never admitted 
to hospital was 30.59, the mean score for those admitted <5 times was much lower 
(35.22) than the mean score for those admitted >5 times (38.82) (p = 0.0005). On 
the other hand, the severity of symptoms did not have a significant association with 
the causes of cirrhosis. Furthermore, the mean score of the impact of the 
symptoms on daily activities significantly increased with the advanced stage of 
cirrhosis, comorbidities, complications and hospitalizations (p < 0.05). 
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The data in Table 7-8 identifies that a significant difference was found in the mean 
score of the LDSI-2.0 related subscales between the groups in terms of disease 
stage. The disease stage has a relationship with the type of symptoms experienced 
similar to those found in prior studies. For example, Bjornsson et al. (2009) found 
that the proportion of depression and pain symptoms were higher among patients 
with decompensated cirrhosis than in patients with compensated cirrhosis. 
Therefore, it was important to run further statistical analyses (chi-square test) to 
compare the two groups of disease stages (compensated and decompensated 
cirrhosis). 
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Table 7-8: Association between disease stage and medical history and symptoms experience  
Variables Classifications N Symptoms experience, n = 401 
Symptoms severity Hindrance of symptoms 
Mean ± SD t or f (p) Mean ± SD t or f (p) 
 
Disease stage Compensated 
Decompensated 
201 
200 
30.91±14.06 
34.32±11.95 
2.61(0.009) 12.44±8.70 
14.65±8.27 
2.59(0.01) 
Cause of cirrhosis Viruses 
Viruses & Bilharzias  
Others 
226 
151 
24 
32.40±13.70 
32.60±12.45 
34.58±12.39 
0.29(0.74) 13.81±8.56 
12.77±8.59 
15.79±7.90 
1.55(0.21) 
Hospital setting Outpatient 
Inpatient 
322 
79 
32.10±13.37 
34.68±12.04 
1.67(0.11) 13.42±8.61 
14.03±8.30 
0.56(0.57) 
Complications Without complications 
With 1-2 complications 
With 3-4 complications 
74 
244 
83 
29.86±13.27 
32.21±13.25 
36.22±12.07 
4.94(0.008) 12.36±8.47 
13.14±8.48 
15.76±8.52 
3.81(0.02) 
Comorbidities  Without comorbidities  
With 1-3 comorbidities 
With 4-6 comorbidities 
152 
235 
14 
29.17±13.79 
34.55±12.28 
37.29±12.86 
8.99(0.0005) 12.22±8.84 
14.29±8.32 
15.36±7.72 
3.07(0.048) 
Hospitalization  Never admitted 
Admitted 1-5 times 
Admitted >5 times 
248 
125 
28 
30.59±13.40 
35.22±11.74 
38.82±13.21 
8.85(0.0005) 12.56±8.50 
14.83±7.85 
16.43±10.61 
4.72(0.009) 
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There was a significant difference in the types of symptoms experienced between 
patients with decompensated cirrhosis and patients with compensated cirrhosis. 
For instance, patients with decompensated cirrhosis were more likely than patients 
with compensated cirrhosis to have sexual problems (decrease in desire and 
activity) and difficulty in managing time (P ≤ 0.002). Moreover, in terms of the 
symptom hindrance, the impact of right abdominal pain, sleepiness during the day 
and decreased appetite on daily and social activities was higher among patients 
with decompensated cirrhosis than in patients with compensated cirrhosis  (p ≤ 
0.03) (Table 7-9). 
Table 7-9: The proportion of symptom severity and hindrance of symptom among 
compensated and decompensated patients  
phi 
coefficient 
p value Chi-square 
(X
2
) 
Disease stage (n) Symptom severity 
Decompensated 
N=200 
n (%) 
Compensated 
N=201 
n (%) 
0.043 0.45 0.56 109(54.5) 101(50.24) Itch 
-0.092 0.08 2.96 149(74.5) 165(82.08) Joint pain 
0.071 0.18 1.74 136(68) 123(61.19) Right abdominal pain 
0.082 0.12 2.34 152(76) 138(68.65) Sleepiness during the 
day 
0.050 0.37 0.79 154(77) 146(72.63) Worry about the family 
situation  
0.068 0.21 1.56 157(78.5) 146(72.63) Decreased appetite 
0.043 0.45 0.56 149(74.5) 142(70.64) Depression 
0.064 0.24 1.36 146(73) 135(67.16) Fear disease 
complications 
0.018 0.79 0.06 56(28) 53(26.36) Jaundice 
-0.007 0.97 0.001 154(77) 156(77.61) Memory problems 
0.053 0.34 0.91 146(73) 137(68.15) Changing personality  
-0.039 0.51 0.422 157(78.5) 164(81.59) Hindrance in financial 
affairs  
0.166 0.002 9.92 190(95) 171(85.07) Difficulty managing 
time  
0.159 0.002 9.49 143(71.5) 113(56.21) Decreased sexual 
interest 
0.195 0.0005 14.45 146(73) 109(54.22) Decreased sexual 
activity 
phi 
coefficient 
P value Chi-square 
(X
2
) 
Decompensated 
N=200 
n (%) 
Compensated 
N=201 
n (%) 
Hindrance of 
symptom 
0.076 0.16 1.96 58(29) 45(22.38) Itch hindrance  activity 
0.061 0.26 1.23 68(34) 57(28.35) Itch hindrance  sleep 
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-0.062 0.26 1.26 135(67.5) 147(73.13) Hindrance  of joint 
pain  
0.112 0.03 4.62 115(57.5) 93(46.26) Hindrance  of right 
abdominal pain  
0.138 0.008 7.04 120(60) 93(46.26) Sleep hindrance 
0.069 0.20 1.61 122(61) 109(54.22) Hindrance  of worry  
0.201 0.0005 15.36 138(69) 99(49.25) Hindrance of 
decreased appetite  
0.085 0.10 2.56 131(65.5) 115(57.21) Hindrance  of 
depression 
0.048 0.40 69 36(18) 29(14.42) Hindrance  of jaundice  
 
7.2.4.3 Social Support and General Health Perception  
Table 7-10 presents the association between perceived social support and 
symptoms experience. The correlation between the total score of the LDSI-2.0 
related subscales and the total score of the MSPSS identifies that there was a 
significant inverse relationship between symptoms experience and perceived 
adequacy of social support (p ≤ 0.006). This result suggests that with a perceived 
high social support there is a low perception of symptoms severity or vice versa. 
These results agree with the theory of unpleasant symptoms, which indicates that 
with insufficient social support there is a potential increase in the severity of 
symptoms (Lenz et al. 1997). 
Table 7-10 shows the correlation between the LDSI-2.0 related subscales and the 
MSPSS related subscales. It was found that the severity of symptoms was 
negatively associated with the perceived availability of social support, particularly 
support from spouse and family (r = 0.27, p = 0.0005 and r = 0.16, p = 0.001, 
respectively). On the other hand, the severity of symptoms does not have a 
significant relationship with the perceived availability of friends’ support among 
these patients.  
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Moreover, Table 7-10 presents the association between symptoms experience and 
perceived general health. There was a significant negative association between 
perceived symptoms severity and general health perception. This suggests that the 
increase of symptoms severity and hindrance of daily activities due to symptoms  
worsens the perceived general health and vice versa (r=-0.288, p = 0.0005 and r=-
0.304 p = 0.0005, respectively).  
Table 7-10: Association between perceived social support and general health 
perception and symptoms experience 
MSPSS LDSI-2.0 
Symptoms severity 
r (p value) 
Hindrance of symptoms 
r (p value) 
Social support total score   
-0.206
 
(0.0005) 
 
-0.205 (0.0005) 
Spouse Support 
N=311 (married patients) 
-0.272 (0.0005) -0.237
 
(0.0005) 
Family support -0.166
 
(0.001) -0.137
 
(0.006) 
Friends support -0.048 (0.335) -0.055 (0.275) 
General health perception -0.288 (0.0005) -0.304 (0.0005) 
Correlation is significant at the p level < 0.05 (2 tailed) 
 
 
7.2.5 Multivariate analysis: Factors associated with Symptoms 
Experience  
Tables 7-11 (Model 1) and 7-12 (Model 2) show the multiple regression models that 
were constructed using the stepwise method to explore factors associated with 
symptoms severity and hindrance of symptoms. To develop the regression model 
for each of the dependent factors (i.e. symptoms severity and hindrance of 
symptoms), all the socio-demographic and medical variables (used in deveoping 
model 1 and 2 in HRQOL, section 6.3.4) and social support from three sources 
(spouse, family and friends) were entered into the regression analysis together.  
Related to the factors associated with symptoms severity (Table 7-11 - Model 1) 
the results show that the model significantly explained 19.6% of the variation in 
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symptoms severity (R2 = 0.196, R2adj = 0.180, p = 0.0005). Six variables significantly 
associated with symptoms severity [spouse support (b = -0.207), marital status (b = 
0.181), gender (b = 0.175), number of liver cirrhosis complications (b = 0.154), 
employment status (b = 0.148) and family support (b = 0.124), p ≤ 0.01). Low 
perceived spouse support, being married, females, increasing number of liver 
cirrhosis complications, being unemployed, and low perceived family support were 
significantly associated with increasing symptoms severity among this group of 
patients with liver cirrhosis. Perceived spouse support, marital status and gender 
made the strongest contribution in explaining severity of symptoms (20.7%, 18.1% 
and 17.5% respectively). This suggests that these psychosocial variables are most 
important in explaining severity of symptoms among these patients. On the other 
hand, somatic factors such as number of liver disease complications made less 
contribution although this explained about 15.4% of the variation in severity of 
symptoms.  
Perceived social support particularly from a spouse (b = -0.207, p =0.0005) was the 
highest associated source of support, followed by perceived family support (b = -
0.124, p = 0.01), while friends’ support was not significantly associated with 
symptoms severity. People with a high perception of social support from spouse 
and family were more likely to have a low perception of severity of symptoms. 
Although model 1 (Table 7-11) could significantly explain the overall severity of 
symptoms (p = 0.0005), around 80.4% of the variation in severity of symptoms 
could not be explained by the model, suggesting that there are other factors that 
have an influence on perceived severity of symptoms, which need to be explored 
further.  
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Table 7-11: Summary of factors associated with symptoms severity using multivariate analysis  
Model 1 df  F  R R
2
 R
2
adj. Sig. 
Collinearity Statistics 
6/304 12.333 0.442 0.196 0.180 0.0005 
Independent factors Unstandardized 
Coefficients 
β 
Standardized 
coefficient 
Beta (b) 
t Sig. 95% Confidence interval for B 
 
Lower Upper Tolerance 
 
VIF 
Constant  31.276  8.095 0.0005 23.673 38.878   
Gender   4.638 0.175 2.930 0.004 1.523 7.753 0.741 1.349 
Marital status  5.684 0.181 3.327 0.001 2.322 9.047 0.891 1.123 
Perceived spouse 
support 
-3.590 -0.207 -3.777 0.0005 -5.461 -1.720 0.884 1.131 
Employment status  5.175 0.148 2.593 0.010 1.248 9.101 0.814 1.229 
Perceived family support  -2.188 -0.124 -2.379 0.018 -3.999 -0.378 0.973 1.028 
Number of liver cirrhosis 
complications 
1.888 0.154 2.931 0.004 0.621 3.156 0.962 1.040 
VIF: Variance inflation factor  
Dummy codes: gender: 0 males, 1 females, disease stage: 0 decompensated, 1 compensated, employment status: 0 employed, 1 unemployed, marital 
status: 0 single, 1 married, educational level: 0 educated, 1 uneducated, area of residence: 0 rural, 1 urban 
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In terms of the impact of symptoms on daily activities (symptom hindrance) (Table 
7-12 - Model 2) the results show that the model significantly predicted 14% of the 
variation in hindrance of symptoms (R2 = 0.140, R2adj = 0.132, p = 0.0005). Three 
variables were significantly associated with the hindrance of daily activities due to 
symptoms: gender (b = 0.259, p = 0.0005), perceived social support from spouse (b 
= -0.169, p = 0.002) and number of liver cirrhosis complications (b = 0.167, p = 
0.002). Being female, low perceived support from spouse and increasing number of 
liver cirrhosis complications were associated with more limitations in daily life due 
to symptoms. Gender made the strongest contribution (25.9%) in explaining 
hindrance of daily life due to symptoms, while number of liver cirrhosis 
complications and perceived spouse support made a similar level of contribution in 
explaining hindrance of symptoms (16.7% and 16.9% respectively).   
Interestingly, only gender, perceived spouse support and number of liver cirrhosis 
complications were significantly associated with both dimensions of symptoms 
experience, severity and hindrance. Therefore, healthcare providers should 
consider these factors during the development of intervention programs to treat 
symptoms among cirrhotic patients. However, many variables associated with 
severity of symptoms but did not associate with hindrance of symptoms such as 
marital status, perceived family support and employment status (Tables 7-11 and 7-
12).  
Although model 2 (Table 7-12) predicted the overall hindrance of symptoms 
significantly (p = 0.0005), around 86% of the variation in hindrance of symptoms 
could not be explained by the model, suggesting that there are other factors that 
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have an influence on perceived hindrance of daily life due to symptoms, which 
need further research to be explored.  
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Table 7-12: Summary of factors associated with hindrance of daily activities due to symptoms using multivariate analysis  
Model 2 df F  R R
2
 R
2
adj. Sig. 
Collinearity Statistics 
3/307  16.672 0.374 0.140 0.132 0.0005 
Independent factors Unstandardized 
coefficient  
β  
Standardized 
coefficient 
Beta (b) 
t Sig. 95% Confidence interval for B 
Lower 
Upper Tolerance 
VIF 
Constant 13.560  6.995 0.0005 9.745 17.374   
Gender 4.458 0.259 4.665 0.0005 2.578 6.339 0.910 1.099 
Number of liver cirrhosis 
complications  
1.334 0.167 3.147 0.002 0.500 2.168 0.994 1.006 
Perceived spouse support -1.910 -0.169 -3.052 0.002 -3.142 -0.679 0.913 1.096 
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7.3 PERCEIVED SOCIAL SUPPORT  
The third aim of this study was to explore and describe how cirrhotic patients in 
Egypt perceived social support from spouse, family and friends and to identify the 
predictive factors of general perceived social support. Social support was 
investigated by using the Multidimensional Scale of Perceived Social Support 
(MSPSS) that contains 12 questions, which assess the availability of social support 
generally. The MSPSS is divided into three subscales, which assess the availability 
of social support from a spouse, family and friends. An increasing score shows 
there is increasing perceived availability of social support. 
7.3.1 Social Support among Egyptian Cirrhotic People  
Table 7-13 presents the means ± SD for the total MSPSS and the three subscales. 
The means were as follows: total MSPSS (2.02), spouse (2.45), family (1.93), and 
friends (1.83). As can be seen, the mean score of perceived spouse support was 
the highest; while the mean score of perceived friends’ support was the lowest. 
This result suggests that Egyptians patients with liver cirrhosis perceive the spouse 
as the main source of social support followed by family and friends respectively. 
Table 7-13: Perceptions of social support among people with liver cirrhosis  
Variables n = 401 (100%) Instrument 
range MPSS Mean ± SD Median 
Total score 
 
2.02±0.537 2 1-3 
Spouse subscale (n=311 married) 
 
2.45±0.757 3 1-3 
Family subscale  
 
1.93±0.745 2 1-3 
Friends subscale  1.83±0.732 1.75 1-3 
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7.3.2 Perceptions of Social Support from Spouse, Family and Friends  
Table 7-14 shows the perceptions of patients with liver cirrhosis about the social 
support from spouse, family and friends. Married people agreed that their spouse 
(husband or wife) provided them with different kinds of support. For instance, 
67.5% of them feel their spouse is around when they need him/her and 71.7% of 
them share their joys and sorrows with their spouse. Likewise, 64.9% of married 
people feel their spouse cares about their feelings.  
In relation to the perception of adequacy of family support, it was observed that 
52.6% felt that their families do not really try to help them. At the same time, 52.1% 
reported that they get the emotional help and support that they need from their 
families. Compared with patients' perceptions about the adequacy of friends’ 
support, 65.6 % of patients reported that they cannot count on their friends during 
hard times, and 57.9% claimed that their friends do not really try to help them. 
However, 51.1% of the patients said that they could share their joys and sorrows 
with their friends (Table 7-14). These results suggest that the majority of the 
patients see a partner to be more helpful than family and friends, and the main 
source of instrumental and emotional support. Furthermore, the family was found to 
be more supportive than friends. However, most of the patients perceive their 
friends as a source of sharing their joys and sorrows but not as a source for 
tangible support (like providing services or money). 
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Table 7-14: Perceptions of patients with liver cirrhosis about social support from a spouse, family and friends 
Items n (%) Frequency, n (%) 
1. Disagree  2. Natural  3. Agree  
Spouse subscale  
My spouse is around when I am in need 
311 (100%)  
79(25.4) 
 
22(7.0) 
 
210(67.5) 
My spouse with whom I can share my joys and sorrows 64(20.5) 24(7.7) 223(71.7) 
My spouse is a real source of comfort to me 68(21.8) 31(9.9) 212(68.1) 
My spouse in my life who cares about my feelings  82(26.3) 27(8.6) 202(64.9) 
Friends subscales 
My friends really try to help me 
401 (100%) 232(57.9) 31(7.7) 138(34.4) 
I can count on my friends when things go wrong 263(65.6) 20(5.0) 118(29.4) 
I have friends with whom I can share my joys and sorrows 161(40.1) 35(8.7) 205(51.1) 
I can talk about my problems with my friends 226(56.4) 32(8.0) 143(35.7) 
Family subscale 
My family really tries to help me 
401 (100%) 
 
 
211(52.6) 29(7.2) 161(40.1) 
I get the emotional help and support I need from my family 153(38.3) 39(9.7) 209(52.1) 
I can talk about my problems with my family 199(49.6) 39(9.7) 163(40.6) 
My family is willing to help me make decisions 228(56.9) 31(7.7) 142(45.4) 
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7.3.3  Factors Contributing to Perceptions of Adequacy of Social Support  
To determine the factors which are associated with a perceived low or high social 
support among people with liver cirrhosis in Egypt; the sample (n=401) was broken 
down into groups according to socio-demographic characteristics and disease 
stage, as discussed in Chapter 6.  
7.3.3.1  Socio-Demographic Characteristics  
Table 7-15 presents the comparison of perceived social support of the entire study 
group according to gender. An independent sample t-test was conducted to 
compare the mean score of perceived social support among males and females. 
There was a statistically significant gender difference in the total MSPSS score (t = 
4.822, p = 0.0005) and spouse subscale score (t = 5.412, p = 0.0005). Females 
were more likely than males to perceive a low availability of support in general and 
from the husband in particular. 
Table 7-16 shows the comparison of the perception of social support between the 
study entire groups according to age. There was a statistically significant 
association between age and perceived social support (total score) ((f = 5.13, p = 
0.006). In addition, the mean score of the subscale of perceived family support was 
significantly higher among younger than elderly patients ≥ 45 (f = 3.19, p = 0.04).  
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Table 7-15: Perception of social support according to gender 
Variables n = 401 
Gender n Mean ± SD t P value 
MPSS 
Total score  Males  174 2.17±0.50 4.822 0.0005 
Females  227 1.91±0.53 
Spouse subscale  Males  161 2.66±0.63 5.412 0.0005 
Females  150 2.22±0.80 
Family subscale Males  174 1.99±0.74 1.569 0.117 
Females  227 1.88±0.74 
Friends subscale Males  174 1.91±0.73 1.954 0.051 
Females  227 1.76±0.72 
Table 7-16: Perception of social support according to age  
Variables n = 401 
Age group n Mean ± SD f p value 
MPSS 
Total score 22-44 55 2.21±0.48 5.13 0.006 
45-64 306 2.01±0.53 
65+ 40 1.87±0.56 
Spouse subscale 22-44 49 2.53±0.73 0.48 0.61 
45-64 242 2.44±0.76 
65+ 20 2.34±0.76 
Family subscale 22-44 55 2.16±0.73 3.19 0.04 
45-64 306 1.90±0.74 
65+ 40 1.84±0.76 
Friends subscale 22-44 55 1.97±0.738 2.29 0.10 
45-64 306 1.83±0.74 
65+ 40 1.64±0.63 
 
Table 7-17 presents the difference in perception of social support according to 
educational level. The results show that there was a significant association 
between perceived social support and level of education. The mean score of 
MSPSS was statistically significant lower among illiterates than other groups (f = 
5.83, p = 0.003). The mean score of perceived family support was also lower 
among illiterates than other groups (f = 7.28, p = 0.001).  
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Table 7-17: Perception of social support according to educational level 
Variables n = 401 
Education level n Mean ± SD f p 
value MPSS 
Total score Illiterate 219 1.96±0.54 5.83 0.003 
Basic  education 163 2.08±0.52 
Higher education 19 2.33±0.50 
Spouse subscale Illiterate 155 2.39±0.77 1.52 0.22 
Basic  education 138 2.48±0.74 
Higher education 18 2.68±0.64 
Family subscale Illiterate 219 1.82±0.72 7.28 0.001 
Basic  education 163 2.02±0.76 
Higher education 19 2.39±0.56 
Friends subscale Illiterate 219 1.81±0.73 0.61 0.54 
Basic  education 163 1.83±0.74 
Higher education 19 2.00±0.61 
 
Tables 7-18 and 7-19 present the perception of social support according to marital 
status and area of residence. There was a statistically significant relationship 
between the total MSPSS score and both marital status and area of residence. In 
terms of general perceived social support (total score), married people and those 
living in rural areas had higher general perceived social support than unmarried 
people (t = 4.51, p= 0.0005) and those living in urban areas (t = 2.41, p= 0.01). 
However, there was no statistically significant difference according to the source of 
support between married and single people and rural and urban areas. 
Table 7-18: Perception of social support according to marital status 
Variables n = 401 
Marital status N (%) Mean ± SD t p value 
MPSS 
Total score Single   91 1.81±0.63 4.51 0.0005 
Married   310 2.09±0.49 
Family subscale Single   91 1.84±0.76 1.20 0.22 
Married   310 1.95±0.73 
Friends subscale Single   91 1.73±0.73 1.46 0.14 
Married   310 1.86±0.73 
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Table 7-19: Perception of social support according to area of residence 
Variables n = 401 
Residence area n Mean ± SD t p value 
MPSS 
Total score Rural  146 2.11±0.53 2.41 0.01 
Urban  255 1.98±0.53 
Spouse subscale Rural  117 2.54±0.73 1.67 0.10 
Urban  194 2.39±0.76 
Family subscale Rural  146 2.00±0.72 1.41 0.16 
Urban  255 1.89±0.75 
Friends subscale Rural  146 1.90±0.71 1.61 0.10 
Urban  255 1.78±0.73 
 
Table 7-20 shows the perception of social support according to employment status. 
There was a statistically significant difference between employed and unemployed 
peoples’ perception about available social support. Employed patients had a higher 
mean score of general perceived social support than the unemployed (t= 4.348, p = 
0.0005). Also, perceived social support from three sources, spouse, family and 
friends, was higher among employed than unemployed (t ≤ 2.137, p ≤ 0.03). 
Table 7-20: Perception of social support according to employment status 
Variables n = 401 
Employment 
status 
n Mean ± SD t p value 
MPSS 
Total score Employed 68 2.28±0.509 4.348 0.0005 
Unemployed  333 1.97±0.529 
Spouse subscale Employed 61 2.78±0.579 3.925 0.0005 
Unemployed 250 2.36±0.774 
Family subscale Employed 68 2.10±0.713 2.137 0.03 
Unemployed 333 1.89±0.748 
Friends subscale Employed 68 2.05±0.731 2.755 0.006 
Unemployed 333 1.78±0.725 
 
7.3.3.2  Disease Stage  
Table 7-21 presents the perception of social support according to disease stage by 
comparing compensated and decompensated cirrhotic patients. Results show that 
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there was a statistically significant difference only in the subscale of perceived 
family support between the two disease stages (t = 2.11, p = 0.03). Patients with 
decompensated cirrhosis had a higher mean score of perceived social support than 
patients with compensated cirrhosis. This result suggests that with advanced 
disease stage, social support particularly from the family increases 
Table 7-21: Perception of social support according to disease stage 
Variables n = 401 
Disease stage n Mean ± SD t p value 
MPSS 
Total score Compensated  201 1.98±0.50 1.51 0.13 
Decompensated  200 2.06±0.56 
Spouse subscale Compensated  158 2.43±0.74 0.245 0.80 
Decompensated  153 2.46±0.77 
Family subscale Compensated  201 1.85±0.70 2.11 0.03 
Decompensated  200 2.01±0.77 
Friends subscale Compensated  201 1.81±0.68 0.56 0.57 
Decompensated  200 1.85±0.77 
 
7.3.3.3  General Health Perception  
Table 7-22 presents the association between the perception of social support and 
general health perception. There was a significant positive association between the 
perception of social support and general health perception, suggesting that when 
social support decreases the general health perception also decreases or vice 
versa (r= 0.208, p = 0.0005). The mean score of the spouse support subscale 
reporting the highest correlation with the general health perception (r= 0.209, p = 
0.0005). This means that the social support from a spouse influences the general 
health perception more than the support of family and friends. However, because 
this study is a cross-sectional design it is not possible to infer a causal relationship. 
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Table 7-22: Association between perception of social support and general health 
perception  
MSPSS General health 
perception 
rho value 
P value  
Social support total score  0.208 0.0005 
Spouse Support (n=311/married 
patients) 
0.209 0.0005 
Family support 0.137 0.006 
Friends support 0.093 0.64 
 
7.3.4 Multivariate analysis: Factors Associated with Perceived Social 
Support  
Table 7-23 shows the multiple regression model that was developed using the 
stepwise method to explore factors associated with perceived social support [i.e. 
MSPSS total score (depended factor)]. To develop the regression model, all the 
socio-demographic characteristics [age, gender, marital status, educational level 
and employment status, area of residence (dummy code)], and medical variables 
[disease stage (dummy code), number of comorbidities and number of liver 
cirrhosis complications] were entered into the regression analysis together as 
independent factors.  
The results in Table 7-23 show that the model significantly explained 10.9% of the 
variation in perceived social support (R2 = 0.109, R2adj = 0.100, p = 0.0005). Four 
variables were significantly associated with overall perceived social support 
[Gender (b = -0.135, age (b = -0.117), Marital status (b = 0.136) and employment 
status (b = -0.124), p ≤ 0.01]. The findings suggest that females, unmarried, 
unemployed and elderly patients had low perceived social support. Marital status 
made the strongest contribution (13.6%) followed by gender (13.5%) to explain 
perceived social support in patients with liver cirrhosis.  
265 
 
Although model 1 (Table 7-23) significantly (p = 0.0005) predicted the overall 
perceived social support, around 89 % of the variation in perceived social support 
could not be explained by the model, suggesting that there are other Independent 
factors that have an influence on perceived social support, which need further 
research to be explored.  
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Table 7-23: Summary of factors associated with perceived social support (MSPSS total score) using multivariate analysis  
Model 1 df  F  R R
2
 R
2
adj. Sig. 
Collinearity Statistics 
4/396  12.083 0.330 0.109 0.100 0.0005 
Independent factors Unstandardized 
Coefficients 
B 
Standardized 
coefficient 
Beta 
t Sig. 95% Confidence interval for B 
Lower 
Upper Tolerance 
VIF 
Constant 2.490  13.842 0.0005 2.137 2.844   
Gender -0.146 -0.135 -2.510 0.012 -0.260 -0.032 0.780 1.282 
Age -0.007 -0.117 -2.394 0.017 -0.013 -0.001 0.935 1.070 
Marital status 0.174 0.136 2.667 0.008 0.046 0.303 0.863 1.158 
Employment status -0.177 -0.124 -2.383 0.018 -0.323 -0.031 0.836 1.197 
VIF: Variance inflation factor  
Dummy codes: gender: 0 males, 1 females, disease stage: 0 decompensated, 1 compensated, employment status: 0 employed, 1 unemployed, marital 
status: 0 single, 1 married, educational level: 0 educated, 1 uneducated, area of residence: 0 rural, 1 urban 
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7.4 CONCLUSION  
This chapter aimed to explore symptoms experience and its predictive factors by 
using the LDSI-2.0. The analysis of the LDSI-2.0 identified that the patients in this 
study experienced severity of various symptoms and hindrance in their daily 
activities because of these symptoms. The most commonly reported symptoms 
among these patients were the difficulty of managing time as a result of liver 
disease, financial problems because of liver disease and memory problems. It was 
also noted that some symptoms could influence daily activities of these patients 
more than others could for example; joint pain and depression. Therefore, these 
symptoms need more attention from healthcare providers when caring for these 
patients.  
Bivariate analysis showed that there was a significant association between 
symptoms experience related subscales and gender, education, employment 
status, disease stage, complications of liver cirrhosis, and comorbidities. Women, 
uneducated and unemployed people, and patients with decompensated cirrhosis, 
multiple complications and comorbidities were more likely to perceive a high 
severity of symptoms and hindrance in their daily activities due to these symptoms. 
Singles were more likely to report more hindrance on their daily activities than 
married patients as a result of symptoms.  
Moreover, numerous factors significantly influenced the type of symptoms 
experienced, suggesting that different patients experience different of symptoms. 
For example, there was a significant difference in the type of symptoms 
experienced by women and men. Women were more likely than men to suffer from 
joint pain, right abdominal pain, decreased appetite, depression, jaundice, memory 
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problems and personality change, while men were more likely than women to suffer 
from sexual problems. In relation to the association between social support and 
symptoms experience, there was a significant inverse relationship between them. 
Perceptions of symptoms severity and hindrance of daily activities due to 
symptoms were significantly associated with social support, particularly from 
spouse and family. Furthermore, symptoms experience (i.e. severity and hindrance 
of daily activities due to symptom subscales) was negatively associated with 
general health perception.  
Finally, the stepwise multiple regression analysis was used to evaluate factors 
associated with symptoms experience for two subscales of LDSI-2.0, severity and 
hindrance of symptoms, among this population. Gender, perceived spouse support 
and number of liver cirrhosis complications were associated with symptoms 
severity and hindrance of daily activities due to symptoms.  
The third aim of this study was explore and describe how cirrhotic patients in Egypt 
perceive social support from spouse, family and friends and to identify and evaluate 
factors associated with general perceived social support using the MSPSS. The 
analysis of the MSPSS identified that patients with liver cirrhosis in Egypt perceived 
their spouse as the greatest source of social support followed by family and friends. 
A comparison of social support according to the socio-demographic characteristics 
found that females were more likely than males to perceive low social support from 
their partner as well as from friends. In addition, elderly, illiterate and unemployed 
were more likely to report low perceived social support. Using multiple regression 
analysis found that age, gender, marital status and employment status were 
significantly associated with overall perceived social support. 
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8 CHAPTER 8- PROPERTIES OF INSTRUMENTS  
8.1  INTRODUCTION  
As acknowledged in Chapter 4, this is the first time that the Arabic Liver Disease 
Symptom Index-2.0 (LDSI-2.0) and Multidimensional Scale of Perceived Social 
Support (MSPSS) have been used among Egyptian patients in general and among 
patients with liver cirrhosis specifically. In addition, the MSPSS has not been used 
in Arabic men; it has been only used in Arabic immigrant women in the USA. 
Therefore, this chapter aims to evaluate the psychometric properties of the three 
measures: LDSI-2.0, MSPSS and Short Form-36v2 (SF-36v2) in patients with liver 
cirrhosis using the dataset. Table 8-8 summarises the concepts studied, the 
measures used, and the psychometric properties.  
Griffiths and Rafferty (2010) argued that researchers should evaluate the 
psychometric properties of instruments and not simply believe the claims of others 
that the tool is valid. Reliability and validity are the key indicators of the quality of an 
instrument (Kimberlin and Winterstein 2008). Reliability (internal consistency) 
means that the items within a scale are theoretically homogeneous and are 
measuring the same construct (DeVellis 2003). A commonly used statistical 
method for estimating the internal consistency is Cronbach's alpha coefficient (α). 
Therefore, the alpha coefficient was investigated for the three instruments used in 
this study. Alpha coefficients range from 0.00 to 1.00 (Kimberlin and Winterstein 
2008), with a value of 0.70 or higher indicating an acceptable level of reliability 
(Nunnally and Bernstein 1994; DeVellis 2003). Validity reflects the extent to which 
the instrument measures what it is intended to measure. Therefore, the validity of 
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the three instruments used in this study (LDSI-2.0, MSPSS and SF-36) was also 
investigated.  
8.1.1 Background about Factor Analysis  
Factor analysis (FA) is a statistical technique that is commonly used to develop or 
evaluate an instrument structure. As suggested by de Vet et al. (2005) factor 
analysis is an essential step in the validation of multi-item questionnaires. It aims to 
evaluate the factor structure (dimensions of the questionnaires). Factor analysis is 
a sophisticated statistical technique that can reveal whether or not the pattern of 
responses on a number of items can be explained by a smaller number of 
underlying factors.  
There are two different methods of factor analysis (exploratory or confirmatory). 
The two methods make different assumptions about the data and how they should 
be handled and it is crucial to select the most suitable method to provide answers 
to different research questions (de Vet et al. 2005). Floyd and Widaman (1995) 
suggest that exploratory factor analysis (EFA) should be used when there is no 
previous hypothesis about the instrument's factor structure (number of dimensions 
and associations between items). Confirmatory factor analysis (CFA) is appropriate 
if the instrument has a prior hypothesis that is based on a theory or previous 
analysis, and it can be used to test the fitness of the hypothesized model (the 
measurement’s factor structure).  
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8.2  VALIDITY AND RELIABILITY OF ARABIC LDSI-2.0  
In 2004, van der Plas et al. investigated the psychometric properties of LDSI-2.0 in 
terms of feasibility, validity (construct and known group / discriminant validity) and 
reliability (internal consistency and test-retest reliability). Its construct validity was 
evaluated in terms of convergent and divergent validity with SF-36 among Dutch 
people with chronic liver disease and cirrhosis (van der Plas et al. 2004). Similarly, 
construct validity of the Arabic LDSI-2.0 was investigated among a sample of 38 
patients with liver cirrhosis in Egypt (Youssef et al. 2012) (in the pilot study-Chapter 
5). The pilot study could not be used for additional validity tests such as factor 
analysis or known group validity as they usually require a large sample size 
(Tabachnick and Fidell 2007). Therefore, to complete the validation process the 
main study sample (n = 401) was used to investigate the construct validity and the 
internal consistency reliability of the Arabic LDSI-2.0.  
8.2.1 LDSI-2.0 Construct Validity 
8.2.1.1  LDSI-2.0 Discriminant Validity  
Known group validity aims to assess the ability of the LDSI-2.0 to discriminant 
between subgroups that differ for example by gender or disease stage. Based on 
the reviewed literature, it was hypothesized that the mean scores of the symptoms 
severity and hindrance of symptoms subscales of, for example, women and 
patients with decompensated cirrhosis would be higher than those of men and 
patients with compensated cirrhosis (Armstrong 2003; van der Plas et al. 2004). 
Results in Chapter 7 confirmed these hypotheses, suggesting the discriminant 
validity of the Arabic LDSI-2.0 to find significant differences between patients 
according to gender and disease stage.  
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8.2.1.2  LDSI-2.0 Exploratory Factor Analysis  
Exploratory factor analysis is the appropriate test if the tool does not have a prior 
structure hypothesis and has not been used before in a specific group of patients or 
language (de Vet et al. 2005). Factor analysis (FA) for LDSI-2.0 has not previously 
been investigated; thus exploratory factor analysis was most suitable according to 
Field’s suggestion (2009). There is no previous study with which to compare the 
results. However, van der Plas et al. (2004) hypothesized that the LDSI-2.0 has two 
subscales that are related (symptom severity and hindrance of symptom), and an 
additional six items as discussed in section 4.5.1.2. Based on van der Plas et al. 
(2004) suggestions, it was hypothesized that the two related items (e.g., depression 
severity and depression hampered daily life) should be loaded together because 
these items measure a related concept (depression).  
The following steps were followed according to Pallant (2007): 
1. Suitability of data for factor analysis was checked by determining the 
adequacy of the sample size and the strength of items intercorrelation. De 
Vet et al. (2005) suggest that before conducting any type of factor analysis a 
sufficient sample size is required to give reliable results. There is no general 
agreement about the minimum required sample. However, the ratio of the 
number of cases to the number of variables is helpful to decide whether the 
sample is sufficient. Four to ten cases per item is the rule of thumb to decide 
the required sample size (de Vet et al. 2005). Therefore, for LDSI-2.0 (24 
items), 10 cases x 24 items = 240 subjects would be enough to give reliable 
factor structure. Therefore, a sample size of 401 (without missed data) is 
sufficient to give a reliable factor structure. For instance, strength of items 
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intercorrelation was tested using the Kaiser-Meyer-Olkin (KMO) measure. 
KMO ranges from 0.0 to 1.0, with 0.6 the minimum required value to give 
reliable factor analysis and indicating adequacy of sample to give strong 
intercorrelation among items (Tabachnick and Fidell 2007).  
2. The next step was to select the factor extraction technique, in other words 
determine the smallest number of factors that could be used to measure the 
interrelations among the variables. Principal component analysis, the most 
commonly used technique, was used. 
3. The Orthogonal rotation (varimax) method was also selected as a factor 
rotation method because its solution is usually easier to interpret and report 
and is the most commonly used (de Vet et al. 2005). 
A principal component analysis (PCA) was used to compute the 24 items factor 
loading with orthogonal rotation (varimax). The KMO measure verified the sampling 
adequacy for the analysis. Overall KMO value was 0.77 and all KMO values for 
individual items were greater than 0.62; that is above the acceptable limit of 0.60 
(Tabachnick and Fidell 2007). Chi-Square = 5374.930, df = 276, p < 0.0001, 
indicates that correlations between items were sufficiently large for PCA. An initial 
analysis was run to obtain eigenvalues for each component in the data. Only 
factors with an eigenvalue > 0.7 explaining the maximum cumulative variance were 
interpreted as suggested by Field (2009). Eleven components had eigenvalues 
over Jolliffe's criterion of 0.7 and in combination, explained 84.46% of the variance. 
To assess the most significant loadings in interpreting the factor solution, items that 
had value ≥ 0.50 was considered significant (Hair et al. 2010). Most items showed 
the highest factor loadings on the original factors (Tables 8-1 and 8-2).  
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Table 8-2 shows the factor loading after rotation. Items that cluster on the same 
components suggest that they are measuring related concepts. Table 8-3 
summarises the 11 factors related to a relevant symptom component. For example, 
Factor 1 included three items related to itching (i.e. itch severity, itch hampered 
sleep, itch hampered daily life). Factor 2 included three items (depression severity, 
depression hindrance and afraid of complications), which may indicate mental 
health. Factor 3 included two items: sexual interest and sexual activity that related 
to sexual health. These results support the hypothesis that LDSI-2.0 is a 
multidimensional tool, and items that were assumed to be structurally related were 
loaded together.  
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Table 8-1: Exploratory factor analysis for 24 items of Arabic LDSI-2.0 (n = 401) 
Rotated Component Matrix
a
 
Items Component/Factors  
1 2 3 4 5 6 7 8 9 10 11 
Itch hampered sleep 0.856    0.116 0.170      
Itch 0.851  0.104        0.168 
Itch hampered   0.843 0.145  0.145        
Depression 0.104 0.825  0.138  0.206 0.144 0.110  0.208  
Depression hampered  0.817  0.158 0.166 0.148 0.162 0.120 0.118 0.137  
Afraid of complications 0.125 0.621 0.156     0.344   0.183 
Sexual interest  0.107 0.945         
Sexual activity  0.127 0.939       0.104  
Joint pain 0.146   0.919       0.117 
Joint hampered 0.101 0.152  0.905 0.140 0.126     0.106 
Abdominal pain hampered  0.104 0.180 0.108 0.100 0.907   0.131    
Abdominal Pain 0.120   0.144 0.900 0.134    0.132 0.114 
Decreased appetite  0.150    0.871 0.116 0.151    
Decreased appetite hampered  0.142 0.143 0.102 0.131 0.863  0.102    
Sleepiness during the day  0.105 0.107    0.924     
Sleepy hampered 0.122 0.109  0.125 0.122  0.895     
Worry  0.165    0.115  0.890  0.165  
Worry hampered  0.220  0.105 0.126 0.145  0.840    
Yellow skin hampered         0.911   
Yellow skin       0.139   0.900   
Financial problems 0.104 0.158   0.110  0.106 0.114  0.879 0.136 
Use time differently   0.296 0.197 0.121  0.305  0.239 0.121 0.622 0.101 
Difficult memory  0.135   0.123 0.113      0.871 
Personality change  0.422 0.169 0.160 0.108  0.102   0.157 0.609 
Extraction Method: Principal Component Analysis.  
Rotation Method: Varimax with Kaiser Normalization. 
Rotation converged in 6 iterations. 
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Table 8-2: Summary of the exploratory factor analysis for the loaded factors for the Arabic LDSI-2.0 (n = 401) 
Rotated Component Matrix 
Items Component/Factors 
1 2 3 4 5 6 7 8 9 10 11 
Itch hampered sleep 0.856           
Itch 0.851           
Itch hampered   0.843           
Depression  0.825
 a
          
Depression hampered  0.817
 a
          
Afraid of complications  0.621
 a
          
Sexual interest   0.945         
Sexual activity   0.939         
Joint pain    0.919        
Joint hampered    0.905        
Abdominal pain hampered      0.907       
Abdominal Pain     0.900       
Decreased appetite      0.871      
Decreased appetite hampered      0.863      
Sleepiness during the day       0.924     
Sleepy hampered       0.895     
Worry        0.890    
Worry hampered        0.840    
Yellow skin hampered         0.911   
Yellow skin          0.900   
Financial problems          0.879  
Use time differently           0.622  
Difficult memory             0.871 
Personality change  0.422         0.609 
Eigenvalues 6.88 2.02 1.81 1.65 1.47 1.38 1.22 1.19 0.96 0.90 0.81 
% of variance 28.65 8.41 7.53 6.89 6.14 5.73 5.08 4.94 3.98 3.75 3.36 
Internal consistency / α 0.84 
a
 3 items 0.90 0.94 0.91 0.91 0.84 0.90 0.84 0.83 0.70 0.61 
a: Reliability of the three items 
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Table 8-3: Factorial structure of the Arabic LDSI-2.0 (24 items)  
Factor 
number 
Number of 
items 
Name of items Suggested 
factor name 
1 3 Itch severity, itch hampered sleep and itch hampered daily life Itching  
2 3 Depression severity, depression hindrance and afraid of complications  Mental health   
3 2 Sexual interest* and sexual activity* Sexual health  
4 2 Joint pain and Joint hampered Joint pain 
5 2 Abdominal pain and abdominal pain hampered Abdominal pain 
6 2 Decreased appetite and decreased appetite hampered Appetite change 
7 2 Sleepiness during the day and Sleepy day hampered Sleepiness  
8 2 Worry and Worry hampered Worry  
9 2 Jaundice and jaundice hampered Jaundice  
10 2 Financial problems as a result of liver disease* and use time differently as a result of liver 
disease* 
Extra items 
11 2 Difficult memory* and personality change* Extra items 
*Bolded items: are the items that are considered extra according to van der Plas et al. 2004 
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8.2.2 LDSI-2.0 Reliability  
The internal consistency reliability was investigated for each subscale of the LDSI-
2.0. The results in Table 8-2 revealed Cronbach’s alpha value ranged from 0.70 to 
9.4, suggesting internal consistency reliability of the Arabic LDSI-2.0 in liver 
cirrhotic patients.  
8.3 VALIDITY AND RELIABILITY OF ARABIC MSPSS  
8.3.1 MSPSS Construct Validity 
The studies that developed and reported validity of the MSPSS (Zimet et al. 1988; 
Aroian et al. 2010) were used to develop the following two hypotheses that helped 
to test the factorial and construct validity of MSPSS in liver cirrhotic patients: (1) the 
factor structure was assumed to give three independent factors for support from 
family, spouse and friends and (2) the discriminant validity was investigated by 
testing the following theoretical hypotheses: 
I. Social support would be negatively associated with perceived symptom 
severity (Lenz et al. 1997), and with increasing social support there would 
be fewer symptoms of depression and anxiety (Zimet et al. 1988). 
II. According to the model of HRQOL outcomes, perceived social support 
would be positively associated with general health perceptions (Wilson and 
Cleary 1995). 
Therefore, the construct validity of the MSPSS was tested using confirmatory factor 
analysis to test the first hypothesis, and discriminant validity to test the second 
hypothesis. 
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8.3.1.1  MSPSS Confirmatory Factor Analysis   
De Vet et al. (2005) stated that if the aim of the analysis is to confirm the existing 
factor structure; then confirmatory factor analysis is more appropriate. The MSPSS 
has a hypothesized factor structure that was supported by previous studies (Zimet 
et al. 1988; Aroian et al. 2010). Therefore, to test the construct validity of the 
MSPSS, confirmatory factor analysis was used. 
The more appropriate technique for CFA is Structural Equation Modelling (SEM) 
(Tabachnick and Fidell 2007). SEM is a specific statistical technique that is used to 
test hypotheses about the relationships between observed variables (measured 
items) and unobserved factors (latent variables). SEM needs a formal model to be 
estimated (Field 2009). Consistent with the original MSPSS (Zimet et al. 1988 and 
1990) and the MSPSS-AW (Aroian et al. 2010) we anticipated obtaining a three-
factor structure for the MSPSS. Thus, the SEM was developed where the three 
factors in circles and the items in boxes, see Figure 8-1. To assess this proposed 
factor structure, CFA was performed.  
As discussed in section 8.2.1.2, a large sample size is a crucial requirement for 
conducting factor analysis. Using the rules of thumb method of ratio of cases to 
items, 120 cases are sufficient to give reliable results (de Vet et al. 2005). 
Therefore, a sample size of 401 was sufficient to give a reliable factor structure.  
A proposed model that represented the 12 items and the three factors of MSPSS 
was developed (Figure 8-1) using Analysis of Moment Structures (AMOS) Version 
19. Fitting of the model was based on criteria that were suggested by Tabachnick 
and Fidell (2007), where these criteria indicate a significant fitting model:  
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Comparative Fit Index (CFI) > 0.95 and Root Mean Square Error of Approximation 
(RMSEA) ≤ 0.06.  
Figure 8-1 shows the standardized factor loadings using the Maximum Likelihood 
Estimates obtained with the total sample for the three subscales of the MSPSS. 
The standardized factor loadings for the 12 items ranged from 0.62 to 1.0, and all 
were statistically significant (p < 0.0001). The result exceeds the stated criteria, 
suggesting that the overall fit of the CFA model was good: a Chi-square (X2) = 
109.47, df = 51, p < 0.0001, CFI = 0.995 and RMSEA = 0.054. This finding is 
consistent with previous studies that investigated MSPSS using factor analysis and 
confirmed that MSPSS has three independent factors or sources of support (Zimet 
et al. 1988; Nakigudde et al. 2009; Aroian et al. 2010; Wongpakaran et al. 2011). 
The results of correlations between the subscales reveal that there is a weak 
association (r = 0.06) between the subscales of spouse and friends (Figure 8-1). 
However, Zimet et al. (1988) found that there was a moderate association (r = 0.63) 
between the two subscales of friends and significant other, which was modified in 
the Arabic MSPSS to be spouse (i.e. Husband) (Aroian et al. 2010). Participants in 
Zimet et al.'s (1988) study were undergraduate healthy students (mean age = 
18.6±0.88) who were studying away from their families. Thus, Zimet and colleagues 
considered it to be logical that these students could not separate between their 
friends and significant others, e.g. girl/boyfriend, spouse, physician…etc. In 
contrast, participants in this study were adult patients (mean age 53.25 ± 9.0) from 
a different cultural background; also the subscale of significant other was clearly 
defined (i.e. spouse) in the Arabic MSPSS. As a result, the patients could 
differentiate between support from friends and spouse.  
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Figure 8-1: A proposed model and standardized estimation of the MSPSS 
 
Arrows in the model indicate the hypothesized relationships, and coefficients above each arrow 
are estimated standardized regression weights. Squares represent observed variables (MSPSS 
items), and circles represent latent variables. 
 
8.3.1.2  MSPSS Discriminant Validity  
To test the stated hypotheses, Pearson's test was used to obtain the correlation 
between MSPSS and related subscales, and general health perception, symptoms 
severity and symptoms hampered. Also, perception of social support according to 
area of residence (rural vs. urban) was tested using the non-parametric 
independent t-test (see Chapter 7). As was noted, there was a statistically 
significant relationship between age and perceived social support. The mean score 
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of the subscale of perceived family support was statistically significantly higher 
among younger than elderly patients (f = 5.13, p = 0.006) (Table 7-16). It was also 
found that the severity of symptoms was negatively associated with the perceived 
availability of social support, particularly support from spouse and family (r = 0.27, p 
= 0.0005 and r = 0.16, p = 0.001, respectively) (Table 7-10). There was a 
significant positive association between perceptions of social support and general 
health (r= 0.208, p = 0.0005), particularly from the spouse and family (r= 0.209, p = 
0.0005; r = 0.136, p = 0.006) (Table 7-22). In terms of the relationship between 
perceived social support and area of residence, people in rural areas perceived 
higher social support than people in urban areas (t = 2.41, p = 0.01). These findings 
confirmed the stated hypotheses and suggested known group validity of the 
MSPSS in the liver cirrhotic population in Egypt.  
8.3.2 MSPSS Reliability  
MSPSS demonstrated high internal consistency with an alpha of 0.80 (Table 8-4). 
Also, the Cronbach's alpha for the three subscales of MSPSS was > 0.78 with the 
spouse subscale having the highest alpha value (alpha = 0.97). This indicates 
acceptable internal consistency of this measurement as a whole and for its related 
subscales (Nunnally and Bernstein 1994).  
The point rating scale of 1-3 that was suggested by Aroian et al. (2010) was used 
to present this study's results. According to Aroian et al. (2010) suggestion, the 
three point rating scale (1-3) was transformed into a seven point rating scale 1-7 
(disagree = 1, neutral = 4 and agree = 7) to maintain the comparability with 
previous studies that used the MSPSS. Table 8-4 shows the means, standard 
deviations and alpha coefficients of the MSPSS among patients with liver cirrhosis 
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in Egypt compared with the original study (Zimet et al. 1990) and the study that 
translated it (Aroian et al. 2010). As was noted, the spouse subscale had the 
highest mean score (mean = 6.27 ± SD = 1.898), followed by the family and friends 
subscales.  
Table 8-4: Means, standard deviations and alpha coefficient of the MSPSS for current 
study and prior studies  
MSPSS Current study Aroian et al. 2010 Zimet et al. 1990* 
Mean ± 
SD 
Reliability 
Alpha 
coefficient 
Mean ± 
SD 
Reliability 
Alpha 
coefficient 
Mean ± SD Reliability 
Alpha 
coefficient 
Total 
scale 
6.47±1.50 0.80 5.51±1.10 0.74 6.01±0.90 0.90 
Spouse 6.27±1.89 0.97 6.43±1.36 0.89 6.39±0.88 0.90 
Family 5.22±2.55 0.79 5.75±1.63 0.73 6.02±1.16 0.90 
Friends 4.70±3.13 0.79 4.34±2.04 0.80 5.64±1.27 0.94 
Note: Total scale and subscale scores are averaged over items ranged from 1 to 7 
* The reported result for pre-partum (pregnant women) 
 
  
8.4  VALIDITY AND RELIABILITY OF ARABIC SF-36V2  
SF-36 has been used among patients with different health conditions in Egypt over 
a long period. However, its validity and reliability have not yet been investigated in 
Egypt. In psychosocial and medical sciences, a construct such as HRQOL is 
usually measured by means of a multi-item health status tool. Therefore, it is 
important to investigate these questionnaires extensively before using them (de Vet 
et al. 2005). 
Testing the validity of the SF-36 focuses on assessing the related hypothesis (Ware 
et al. 2008). As explained in Chapter 4, the SF-36 has a standardized software 
program that was used to compute the scales score. Furthermore, this software 
gives an analytical report that is called ''Data Quality Evaluation Report''. This 
report is useful in explaining the reliability and validity of SF-36 among the studied 
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group. Therefore, this report is used to present the validity and reliability of SF-36 
among patients with liver cirrhosis in Egypt. 
8.4.1 SF-36 Construct Validity  
The following steps that were suggested by McHorney and colleagues (1994) were 
followed to investigate the construct validity and internal consistency of the SF-36 
among patients with liver cirrhosis in Egypt.  
1. Item validity (convergent and discriminant validity)  
2. Scale validity 
3. Internal consistency 
8.4.1.1 SF-36 Item Level Validation 
For testing the SF-36 items validity, the hypotheses that were developed by Ware 
et al. (2008) were followed.  
Hypothesis-1: Correlations between items and their hypothesized scale scores 
should equal 0.40 or greater (Item convergent validity). Table 8-5 shows that 97.1% 
of items had a correlation coefficient of 0.40 or greater with their hypothesized 
scale, showing that SF-36 has satisfactory convergent validity. 
Hypothesis-2: The correlation between each item and its hypothesized scale 
should be significantly higher than the correlation between that item and other 
scales (Items discriminant validity). Table 8-6 shows that after correcting 
overlapping between items, 98.4% of items correlated significantly higher with their 
hypothesized scale than with other competing scales score, suggesting scaling 
success of SF-36. However, the items of PF01, GH01 and SF02 seemed to fail in 
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discriminate validity because they were not more highly correlated with their 
hypothesised scale items than with alternative scales. However, these correlations 
were not significant (Table 8-6), suggesting that their discriminant validity is 
acceptable.  
Table 8-5: Multi-trait / multi-item correlation matrix (convergent validity/success rate)  
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = PF - Physical Functioning 
PF01 0.50* 0.52 0.29 0.25 0.38 0.32 0.26 0.22 
PF02 0.66* 0.60 0.35 0.31 0.48 0.37 0.40 0.24 
PF03 0.65* 0.48 0.31 0.22 0.38 0.36 0.27 0.22 
PF04 0.65* 0.53 0.45 0.33 0.51 0.32 0.39 0.28 
PF05 0.65* 0.40 0.31 0.21 0.38 0.28 0.29 0.27 
PF06 0.64* 0.49 0.42 0.35 0.48 0.37 0.31 0.32 
PF07 0.72* 0.57 0.43 0.34 0.49 0.42 0.28 0.35 
PF08 0.79* 0.56 0.42 0.30 0.49 0.39 0.23 0.33 
PF09 0.68* 0.44 0.31 0.26 0.37 0.34 0.18 0.25 
PF10 0.52* 0.36 0.28 0.19 0.25 0.29 0.23 0.20 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = RP - Role Physical 
RP01 0.62 0.80* 0.39 0.35 0.55 0.41 0.46 0.37 
RP02 0.61 0.83* 0.42 0.36 0.54 0.42 0.46 0.37 
RP03 0.62 0.81* 0.41 0.33 0.58 0.41 0.42 0.37 
RP04 0.56 0.71* 0.40 0.37 0.51 0.40 0.44 0.37 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = BP - Bodily Pain 
BP01 0.46 0.39 0.82* 0.38 0.50 0.46 0.24 0.40 
BP02 0.48 0.48 0.82* 0.42 0.55 0.48 0.32 0.46 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = GH - General Health 
GH01 0.41 0.41 0.38 0.45* 0.49 0.39 0.34 0.38 
GH02 0.18 0.24 0.23 0.43* 0.26 0.28 0.25 0.30 
GH03 0.32 0.32 0.33 0.57* 0.41 0.32 0.23 0.38 
GH04 0.13 0.15 0.22 0.38* 0.30 0.22 0.27 0.31 
GH05 0.35 0.32 0.34 0.59* 0.44 0.34 0.30 0.33 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = VT - Vitality 
VT01 0.42 0.44 0.38 0.38 0.53* 0.35 0.34 0.35 
VT02 0.40 0.44 0.38 0.37 0.59* 0.36 0.34 0.48 
VT03 0.56 0.57 0.47 0.47 0.59* 0.44 0.44 0.46 
VT04 0.41 0.45 0.45 0.41 0.56* 0.34 0.38 0.54 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = SF - Social Functioning 
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SF01 0.31 0.33 0.38 0.35 0.32 0.49* 0.32 0.33 
SF02 0.52 0.47 0.47 0.40 0.52 0.49* 0.33 0.41 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = RE - Role Emotional 
RE01 0.35 0.44 0.27 0.34 0.43 0.33 0.83* 0.48 
RE02 0.36 0.47 0.29 0.35 0.46 0.34 0.87* 0.49 
RE03 0.37 0.49 0.25 0.38 0.46 0.38 0.76* 0.42 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = MH - Mental Health 
MH01 0.17 0.23 0.26 0.27 0.25 0.25 0.28 0.44* 
MH02 0.29 0.36 0.34 0.37 0.49 0.35 0.45 0.72* 
MH03 0.24 0.26 0.35 0.37 0.49 0.34 0.33 0.66* 
MH04 0.38 0.38 0.40 0.42 0.55 0.38 0.49 0.71* 
MH05 0.37 0.42 0.42 0.46 0.55 0.38 0.42 0.72* 
Note: * Item-scale correlation corrected for overlap (relevant item removed from its scale for the 
correlation). Starred correlations are hypothesized to be highest in the row of correlations. 
 
Table 8-6: SF-36 item-level discriminant validity tests (scaling success) 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = PF - Physical Functioning 
PF01 ** -1 2 2 2 2 2 2 
PF02 ** 1 2 2 2 2 2 2 
PF03 ** 2 2 2 2 2 2 2 
PF04 ** 2 2 2 2 2 2 2 
PF05 ** 2 2 2 2 2 2 2 
PF06 ** 2 2 2 2 2 2 2 
PF07 ** 2 2 2 2 2 2 2 
PF08 ** 2 2 2 2 2 2 2 
PF09 ** 2 2 2 2 2 2 2 
PF10 ** 2 2 2 2 2 2 2 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = RP - Role Physical 
RP01 2 ** 2 2 2 2 2 2 
RP02 2 ** 2 2 2 2 2 2 
RP03 2 ** 2 2 2 2 2 2 
RP04 2 ** 2 2 2 2 2 2 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = BP - Bodily Pain 
BP01 2 2 ** 2 2 2 2 2 
BP02 2 2 ** 2 2 2 2 2 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = GH - General Health 
GH01 1 1 1 ** -1 1 2 1 
GH02 2 2 2 ** 2 2 2 2 
GH03 2 2 2 ** 2 2 2 2 
GH04 2 2 2 ** 1 2 2 1 
GH05 2 2 2 ** 2 2 2 2 
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Items Scales 
PF RP BP GH VT SF RE MH 
Scale = VT - Vitality 
VT01 2 1 2 2 ** 2 2 2 
VT02 2 2 2 2 ** 2 2 2 
VT03 1 1 2 2 ** 2 2 2 
VT04 2 2 2 2 ** 2 2 1 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = SF - Social Functioning 
SF01 2 2 2 2 2 ** 2 2 
SF02 -1 1 1 1 -1 ** 2 1 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = RE - Role Emotional 
RE01 2 2 2 2 2 2 ** 2 
RE02 2 2 2 2 2 2 ** 2 
RE03 2 2 2 2 2 2 ** 2 
Items Scales 
PF RP BP GH VT SF RE MH 
Scale = MH - Mental Health 
MH01 2 2 2 2 2 2 2 ** 
MH02 2 2 2 2 2 2 2 ** 
MH03 2 2 2 2 2 2 2 ** 
MH04 2 2 2 2 2 2 2 ** 
MH05 2 2 2 2 2 2 2 ** 
Levels of Scaling Success Presented in the Table mean the following  
2 = Item-scale correlation is significantly higher (2 standard errors or more) for the hypothesized 
scale than for the competing scale.  
1 = Item-scale correlation is higher for the hypothesized scale than for the competing scale, but 
not significantly.  
-1 = Item-scale correlation is lower for the hypothesized scale than for the competing scale, but 
not significantly.  
-2 = Item-scale correlation is significantly lower (2 standard errors or more) for the hypothesized 
scale than for the competing scale.  
 
8.4.1.2 SF-36 Scale Level Validity  
Two hypotheses were examined to assess the scale level validity of SF-36: 
Hypothesis-1: Scales measuring physical health (PF, RP, and BP) should have 
higher correlations with each other than with the other scales that measure mental 
health domains (MCS).  
Hypothesis-2: Scales measuring MCS (MH, RE, and SF) should have higher 
correlations with each other than with the other scales that measure physical health 
domains (PCS).  
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Furthermore, SF-36 scales measuring PF, RP, and BP were expected to be more 
highly correlated with an empirically derived PCS than with MCS. Also, SF-36 
scales measuring SF, RE, and MH were expected to be more highly correlated with 
an empirically derived MCS than with PCS; while the two scales measuring GH and 
VT were expected to overlap between MCS and PCS (Ware et al. 1994). The 
results that are presented in (Table 8-7) supported these hypotheses, and suggest 
validity of the SF-36 dimensionality into the two summary components.  
Table 8-7: Construct validity and internal reliability of SF-36  
Domains Number 
of Items 
Correlation (rs) Internal 
Reliability 
Item-total 
correlation MCS PCS 
PF  10 0.334
*
 0.815
*
 0.89 0.49-0.78 
RP 4 0.448
*
 0.726
*
 0.90 0.71-0.82 
BP 2 0.393
*
 0.708
*
 0.87 0.78-0.78 
GH 5 0.511
*
 0.505
*
 0.71 0.38-0.58 
VT 4 0.661
*
 0.563
*
 0.76 0.53-0.58 
SF 2 0.602
*
 0.471
*
 0.65 0.49-0.49 
RE 3 0.806
*
 0.145
*
 0.90 0.76-0.86 
MH 5 0.858
*
 0.180
*
 0.84 0.43-0.72 
* P < 0.0005, p value significant at 2-tailed 
 
 
8.4.1.3 SF-36 Reliability 
The QualityMetric report using the data of the current study identified that 87.5% of 
scales had Cronbach's alpha coefficients ≥ 0.70, suggesting good reliability. SF 
scale (2 items) was the only scale that had alpha coefficients less than 0.7 (α = 
0.65) (Table 8-7). The alpha coefficient is quite sensitive to the number of items on 
the scale, with scales consisting of less than 10 items commonly having low values 
of alpha (i.e. 0.5) (Pallant 2007). Therefore, alpha coefficients of 0.50 or 0.60 
suggest satisfactory reliability (Nunnally, 1978).  
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Table 8-8: Summary of the studied concepts and used measures and their psychometric properties  
Studied 
concepts 
Measures Psychometric properties of  English and Arabic versions 
Name Structure Scoring English: Validity/ Reliability Arabic: validity and reliability 
HRQOL: physical 
and mental 
health domains  
 
SF-36v2 Eight domains and two 
components summary 
score 
The past 4 weeks 
Old a logarithm 
score from 0-100 
Cut-off score: 
mean= 50 ± 
standard division 
10) 
Reliability ranged from 0.68 
(social functioning)-0.93 
(physical functioning) (Ware 
et al. 1994) 
content, concurrent, criterion, 
construct and predictive 
validity establised  
(Ware 2000) 
 
Internal consistency: alpha coefficient 
ranged  
from 0.57-0.88 
retest reliability 
ranged from 0.29-0.80  
(Coons et al. 1998) 
 
Internal reliability: alpha coefficient 
ranged  
from 0.65-0.90 (in the current study) 
Symptoms 
experience: 
Frequency, 
severity and 
hindrance 
(distress) 
LDSI-2.0 Total score: Disease 
specific HRQOL 
Two subscales: 
Symptom severity and 
symptom distress 
The past week 
Index scored on a 
5-point scale 
ranging from zero 
‘not at all’ to 4 ‘to a 
high extent’ 
 
Construct validity: low to 
moderately correlated with 
the SF-36 
Retest reliability (Kappa 
value 0.32–0.91) 
(van der Plas et al. 2004) 
 
 
Construct validity: moderate to high 
correlated with the SF-36 
Retest reliability (Kappa value 0.62–
0.94). 
Chronbach’s alpha 
coefficient for the multi-item scales 
ranged from 0.73 to 0.96 
(Youssef et al. 2012) 
Social support 
from different 
sources 
 
MSPSS Total score: general 
perceived social support 
Three subscales: 
Spouse support 
Family support 
Friends support 
English version 
scored on a 7-point 
Likert scale  
Arabic version 
scored on a 3-point 
Likert scale  
  
Alpha coefficient of MSPSS= 
0.90 and for subscales=0.90-
0.94 
(Zimet et al. 1990) 
 
 
Alpha coefficient of MSPSS= 0.74, for 
subscales=0.73-0.89 
 (Aroian et al. 2010) 
 
Alpha coefficient of MSPSS= 0.80, for 
subscales=0.79-0.97 (in the current 
study) 
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8.5 CONCLUSION  
This chapter aimed to test the psychometric properties of measures used in this 
study using the main study data. Exploratory factor analysis confirmed that the 
Arabic LDSI-2.0 is a valid multidimensional tool that can discriminate between 
known groups. It also has satisfactory internal consistency reliability.  
The confirmatory factor analysis result showed that the Arabic MSPSS has three 
subscales (spouse, family and friends), which were replicated within this sample of 
patients with cirrhosis, providing support for the construct validity of the MSPSS. 
Furthermore, the overall MSPSS and its subscales have high internal consistency 
reliability. 
The data Quality Evaluation report of the SF-36 software was summarised and 
confirmed that the Arabic SF-36 has construct validity and it has high internal 
consistency reliability in patients with cirrhosis in Egypt. However, future research is 
suggested to test its validity in healthy people to develop the norm-based standard.  
In conclusion, in this study the results revealed that the three Arabic measures: 
LDSI-2.0, MSPSS and SF-36v2 are valid and have high internal consistency 
reliability. Thus, these tools can be used in future research in patients with liver 
cirrhosis in Egypt. 
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9 CHAPTER-9: DISCUSSION AND CONCLUSION  
This chapter discusses the key findings in order to answer the research questions 
in three separate sections: Section I: Health-Related Quality of Life (HRQOL) and 
its associated factors. Section II: symptom experience and its associated factors 
and section III: perceived social support and its associated factors. It also presents 
the theoretical, practical and research implications of this thesis. Recommendations 
for improving healthcare practice in Egypt and future research are explained, 
followed by discussing the internal and external strengths and limitations of the 
study. Finally, a conclusion is provided. 
SECTION I: HRQOL AND ITS ASSOCIATED FACTORS  
The first aim of this study was to describe HRQOL of Egyptian liver cirrhotic 
patients and to identify and evaluate the factors associated with (HRQOL) physical 
and mental health domains. Table 9.1 presents the major research questions and 
the key findings. To the best of my knowledge, this is the first study investigating 
HRQOL and its psychosocial associated factors among liver cirrhotic patients in 
Egypt. It is also the first study that has used both generic and disease specific 
questionnaires to investigate HRQOL (Power of sample, section 4.3.2.2). 
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Table 9-1: Research questions and key findings  
Discussed points  Research questions Findings 
HRQOL of 
Egyptian cirrhotic 
patients 
 
1.1 How do patients with liver 
cirrhosis in Egypt perceive 
their (HRQOL) physical and 
mental health? 
 
All the domains and the physical 
and mental health summary scores 
of generic SF-36, are poor, 
suggesting that patients with liver 
cirrhosis in Egypt have a 
significantly worse perceived 
HRQOL. 
General health 
perception  
1.2 How do patients with liver 
cirrhosis perceive their 
general health? 
 
 
45.6% of the patients rated their 
general health as fair; 41.6% rated 
their general health as poor. Very 
few patients rated their general 
health as good or excellent. 
67.8% of the patients perceived 
their health as worse than one year 
ago 
Factors associated 
with (HRQOL) 
physical 
health/PCS and 
mental health/MCS 
in cirrhotic 
patients  
 
1.7 Do disease stage, 
symptoms experience 
(severity and hindrance), 
perceived social support, 
socio-demographic factors 
and medical data explain the 
perception of the physical 
health of patients with liver 
cirrhosis?  
 
1.8 Do disease stage, 
symptoms experience 
(severity and hindrance), 
perceived social support, 
socio-demographic factors 
and medical data explain the 
perception of the mental 
health of patients with liver 
cirrhosis?  
 
 
 
Model 1 could significantly explain  
19% of the variation in PCS. Four 
factors were significantly associated 
with PCS: symptoms severity, 
disease stage, comorbidities and 
employment status.  
 
 
 
 
Model 2 could significantly explain 
31.7% of the variation in MCS. Four 
variables significantly predicted the 
variations in MCS: symptoms 
severity, employment status, 
spousal support and family support.  
 
Symptoms severity made the 
strongest contribution to explain 
PCS and MCS. Social support from 
spouse and family was significantly 
associated with  MCS only. 
 
9.1 HRQOL OF EGYPTIAN CIRRHOTIC PATIENTS 
The study findings show that all the domains, and the physical and mental health 
summary scores of generic Form-36v2 (SF-36v2) in liver cirrhotic patients in Egypt 
are under the norm (cut-off score 50) (Table 6-3). This suggests that patients with 
liver cirrhosis in Egypt have poor physical, mental and social health status . These 
findings are consistent with those from several international observational studies in 
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cirrhotic patients in comparison with healthy people (Marchesini et al. 2001; 
Arguedas et al. 2003; Hauser et al. 2004; Bao et al. 2007) and with non-cirrhotic 
patients (Younossi et al. 2001; Svirtlih et al. 2008). The results, also, are similar to 
the Egyptian study among patients with chronic HCV (Child-Pugh A/B) (Basal et al. 
2011). Similarly, using SF-12 HCV patients with mixed disease stages (non-
cirrhosis and compensated and decompensated cirrhosis) had lower HRQOL in all 
domains than the standardised cut-off score (Hsu et al. 2009).  
Summary scores for physical (PCS) and mental health (MCS) showed that 
although both aspects of health were poor, the MCS was lower than the PCS. This 
suggests that Egyptian cirrhotic patients may experience more deterioration in their 
mental health domains than in their physical health domains. In contrast, reviewing 
liver and chronic disease studies across countries showed that PCS was usually 
lower than MCS (Table 9-2). Hopman et al  (2009) reviewed data of 10 studies 
including 2418 patients (rate of participation > 77%) with different chronic 
conditions, including renal failure, osteoarthritis, multiple sclerosis, heart failure, 
and chronic leg ulcers to determine the association between disease, age, and 
HRQOL (using SF-36 or SF-12). They concluded that all chronic diseases had a 
significant negative impact on the physical aspects of health; although mental 
health domains remained relatively unaffected (Hopman et al. 2009). However, 
Egyptian cirrhotic patients had poorer MCS than Western people with liver and 
other chronic diseases. There is no clear reason for this. One possible explanation 
is that psychotherapy and support groups available to people in the West are not 
available in Egypt, which may be a factor that influences the perceived HRQOL.  
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For instance, in England guidelines give essential information for healthcare 
providers to implement the HCV Action Plan (Department of Health 2004). The 
Scottish Intercollegiate Guidelines Network (SIGN) also recommend that healthcare 
professionals treating patients with liver disease, particularly with HCV are directed 
to observe and assess signs of depression using the hospital anxiety and 
depression scale (HADS).for all patients receiving anti-HCV therapy before, during 
and after the process of treatment. Communication and psychological support for 
patients without therapeutic treatment like cirrhotic patients should be provided. 
Patients with depression are referred to specialists for treatment (SIGN 2006).  
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Table 9-2: HRQOL of Egyptian cirrhotic patients compared to Western liver disease patients and other chronic conditions  
HRQOL Current 
study 
Arguedas et 
al. 2003 
Younossi et 
al. 2001 
Hauser et al. 
2004 
Teuber et al. 
2008 
Reviewed 5 studies by Hopman et al. 2009  
Liver 
cirrhosis 
Advanced 
cirrhosis 
HCV/HBV HCV Advanced 
cirrhosis 
Renal 
Failure 
Osteoarthritis Heart 
Failure 
Chronic 
wound 
Multiple 
Sclerosis 
Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD 
PCS 35.56±10.43 28±11 41±13 40.94±12.06 42.3±11 33.2±11.8 25.3±7.3 30.9±8.6 33.8±0.2 33.5±10.6 
MCS 31.55±14.42 43±13 46±12 43.21±11.98 44.5±13.7 50.1±11.2 50.2±12.5 48.4±0.9 48.7±11.5 46.0±12.2 
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9.1.1 General Health Perception Among Egyptian Cirrhotic Patients 
General health perception (GHP) has been reported as an essential health indictor 
that can predict survival rate (Wilson and Cleary 1995). In this study, patients with 
liver cirrhosis were asked to self-rate how they perceive their general health using a 
single question (item 1) in the SF-36. The results showed that 87.2% of patients felt 
their general health was poor or fair, while only a very few felt it was good. This 
indicates that the majority of Egyptian cirrhotic patients have low perceived health 
in general. In comparison with the only identified study that assessed perceived 
general health in liver disease patients using a similar scale, Sobhonslidsuk et al. 
(2006) found that only 25.6% of 250 cirrhotic and non-cirrhotic patients in Thailand 
reported poor general health, which shows that Egyptian cirrhotic patients have a 
poorer perception of their general health than Thai patients (South East Asia). 
However, more than half of the patients in Sobhonslidsuk's study were non-
cirrhotic, while all the patients in this study had cirrhosis, which might explain the 
inconsistency in the results. Sobhonslidsuk et al. (2006) also observed that health 
perception decreased with increasing disease severity. 
Comparing health over the last 12 months about 68% of the patients perceived 
their health as worse than a year ago [using the second item in the SF-36 (item 2: 
health transition)]. Marchesini et al. (2001) showed that only 45.7% of cirrhotic 
Italian patients felt their health had deteriorated in the last year. This study findings 
suggest that may be due to the low healthcare resources, as well as the low quality 
of care that Egyptian patients receive, they have low perceived general health 
(recommendations, see section 9.8.1).  
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According to the model of HRQOL outcomes, evaluating the link between symptom 
status and GHP can explore an essential finding (Wilson and Cleary 1995). In this 
study, GHP was associated negatively with perceived symptom severity and 
hindrance of symptoms (see section 7.2.4.3), suggesting that patients with high 
perceived symptoms severity and hindrance of symptoms  are more likely to have 
poor perceived general health. Due to the cross-sectional nature of the study, it 
was impossible to identify the direction of the association between symptoms and 
GHP. However, this finding supports the hypothesis that symptoms are important 
factors in perceived general health (Wilson and Cleary 1995). Treating symptoms 
and teaching patients how to care for these symptoms (self-management 
programs) may improve these patients GHP. There is a line of evidence that self-
management can improve perceived health status, knowledge, self-efficacy, as well 
as decrease the number of hospital admission among patients with various chronic 
conditions (Lorig et al. 1999; Barlow et al. 2002).  
9.2 FACTORS ASSOCIATED WITH HRQOL IN EGYPTIAN CIRRHOTIC 
PATIENTS  
9.2.1 Demographic Characteristics  
In current study, many demographic factors were shown to be significantly 
associated with perceived HRQOL (section 6.3.3.1), as hypothesised by Wilson 
and Cleary’s model (1995). Women, the illiterate and the unemployed significantly 
experienced lower physical and mental health. However, there was no significant 
difference regarding marital status and area of residence (rural vs. urban). This 
suggests that the disease itself affects people's HRQOL in rural or urban areas 
similarly, particularly if healthcare services for liver disease patients from the two 
regions are the same. 
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The reason for showing no significant difference in perceived HRQOL according to 
marital status is possibly that singles in Egypt usually live with their families, who 
are the main source of support. Although, marital status was not associated with 
physical or mental health, it was significantly associated with social support that is 
significantly associated with mental health. A longitudinal study (baseline and 12 
months follow up) conducted in US for 1,817 chronically ill people found that marital 
status indirectly affected mental health through social support but did not affect 
physical or mental health directly (Sherbourne and Hays 1990). 
Although, female and illiterate Egyptian cirrhotic patients had poorer physical and 
mental health, gender and level of education were not associated with HRQOL. 
This may be due to the sample size. Likewise, the current study results are in line 
with the findings of several Western and Eastern liver studies that investigated the 
association between socio-demographic variables and HRQOL using bivariate 
analysis. For example, it was found that women were more likely to have poor 
HRQOL, particularly in physical health (Sobhonslidsuk et al. 2006; Afendy et al. 
2009; Karaivazoglou et al. 2010), RP, BP, GH, VT, MH (Afendy et al. 2009) and RE 
(Teuber et al. 2008). However, gender was not associated with physical or mental 
health domains in Spanish cirrhotic patients (Les et al. 2010), or among German 
patients at different stages of liver disease (Haag et al. 2008), or with chronic 
hepatitis C (Hauser et al. 2004). 
In this study, there was no significant difference in perceived physical and mental 
health domains according to age, although there was a significant decrease in 
perceived RP among elderly people. Basal et al. (2011) and Haag et al. (2008) 
found that age was significantly associated with PCS but not with MCS. Similarly, 
299 
 
Dan et al. (2008) found that older patients had poorer PF than younger ones. 
Based on these findings it seems that there is a discrepancy between this study 
and previous studies regarding the association between age and HRQOL. 
However, it is worth noting that the domains of RP and PF are two elements of the 
PCS. This means that age is associated with physical health, but it is not 
associated with mental health domains in liver disease and cirrhotic patients. 
Nevertheless, age was not independently associated with physical and mental 
health domains in this study when it was entered in the regression analysis. 
Likewise, Bondini et al. (2007) and Hauser et al. (2004) showed that age was not 
associated with physical and mental health domains in patients with chronic HBV 
and HCV. Theoretically, it is hypothesised that socio-demographic characteristics 
have a smaller influence on perceived health status and well-being than symptoms, 
and it could be confounders, which affect HRQOL indirectly but may not be 
important factors like symptom status (Wilson and Cleary 1995). 
9.2.2  Socioeconomic Factors 
In this study, employment status and level of education were examined as key 
indicators of socioeconomic status. Illiterate and unemployed people had 
significantly lower PCS and MCS than those educated and employed. However, 
using regression analysis, only the employment status was significantly associated 
with PCS and MCS. Cohen and Wills (1985) argue that poverty, work overload, 
unemployment and chronic diseases are examples of general stressors that can 
affect physical and mental health. Thus, the inability to work or the loss of a job, 
which is the main source of economic support for the majority of Egyptian people, is 
an important factor that might affect their PCS and MCS. This finding is consistent 
with previous studies of liver disease patients whatever the disease stage. The 
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ability to work, salary and social functioning positively predicted the perceived 
mental health and depression symptoms in patients with chronic HCV in US, more 
than other biological and socio-demographic (i.e. laboratory results, age and 
gender) factors (Wilson et al. 2010). 
Hannon (2012, p. 17) suggests that "Work and employment play a central role in 
people’s lives and are essential factors in social inclusion and well-being". 
Employment is an important requirement to meet the basic needs of life, and work 
is not only to cover physical needs but is also essential for mental health (Linn et al. 
1985). Therefore, the unemployed are more likely to experience psychological and 
physical symptoms such as anxiety and depression, particularly if they do not have 
other sources of economic support (Linn et al. 1985). In the current study, more 
than half of the participants were housewives and 39% were unemployed, which 
means they were more vulnerable to low socioeconomic status. Using the disease-
specific HRQOL tool (LDSI-2.0), unemployed cirrhotic patients were also more 
likely to report right abdominal pain, depression and a perceived change in their 
personality (Table 7-7).  
The following are examples of translated (from Arabic to English) quotes from 
patients who participated in this study, which reflect how an insecure social life and 
the loss of economic support affect their health status:  
‘I am living with my son, he is 24 years old and is mentally retarded; my husband 
left the house because he was afraid to get the infection. I cannot work and my 
second son is married and  cannot support me. So, I do not know how I can live 
and I am continually thinking about my son, how he will live without me, I am 
worried, depressed and sad. I cannot work like before the disease to cover needs 
of my daily life; I do not have any power…I want to live with dignity… I do not have 
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money to do the required lab investigation to follow up my health condition’ Women 
44 years. 
‘I am ill with an incurable disease and my wife is young and we do not have 
children, my wife wishes to be a mum. Also, I am an employee in the private sector 
and there is no consideration for my health condition because I have to work like 
my healthy colleagues’ Man 36 years. 
Therefore, unemployment is a common result of liver cirrhosis that reflects 
negatively on the patients' economic status. In the current study about 39% 
(130/333) reported that liver cirrhosis was the cause of their inability to work, and 
80% (321/401) said that they had financial difficulties. Similarly, van der Plas et al. 
(2003) showed that patients with advanced stage of cirrhosis had a higher 
probability of financial limitations due to liver disease. Furthermore, HRQOL (SF-
12) of chronic HCV patients at different stages of disease was predicted by 
depression, use of interferon, fatigue, joint pain and problems in financial affairs 
(Gutteling et al. 2006). In the current study one of the patients experienced job loss 
and difficulties in finding a job due to viral hepatitis.  
‘I was working in a cheese factory and now I do not work because I have HBV and 
as you know it can spread by food and to work in this job I need a certificate of free 
from infectious disease…I have energy to work but what I can do and who will give 
me work while I have this disease…I always sit in my home not doing anything 
else’ Man 49 years. 
Chronic disease is a stressor that can interfere with an individual's social and work 
roles; therefore these types of stressors need continuous psychological adaptation 
(Cohen and Wills 1985; Tijhuis et al. 1995) and economic support in the form of 
providing medical treatment and healthcare services free or at low cost. In this 
study, 79.8% of patients reported that medication fees were shared between the 
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patients and the state of insurance, while only 1.7% had full insurance that covered 
their medical care. This may be because the majority of the patients were workers, 
farmers, housewives or unemployed. According to the report of the Ministry of 
Health and Population and the National Committee for the Control of Viral Hepatitis 
in Egypt, The ‘Egyptian constitution enshrines free medical care as a basic right for 
all citizens, and though access to primary healthcare is fairly widespread, this ideal 
has yet to be fully realized’ (Dalglish 2008, p. 10). Therefore, there is an urgent 
need to reform healthcare policy in Egypt to provide these patients with full health 
insurance.  
9.2.2.1 Biophysical Factors  
Association between biophysical factors and perceived HRQOL was evaluated 
using these variables: disease stage, number of comorbidities, and number of 
complications, as a widely used indicator of health status in clinical setting (Wilson 
and Cleary 1995). Only disease stage and comorbidities were negatively 
associated with physical health domains (PCS) (section 6.3.4.1). However, none of 
the medical variables was associated with mental health domains (MCS) (section 
6.3.4.2). This finding is consistent with previous liver disease studies (Arguedas et 
al. 2003; Fritz and Hammer 2009). In patients with mixed disease stages, disease 
severity was associated with PCS but not MCS (Sobhonslidsuk et al. 2006; Haag et 
al. 2008).  
In this study, the commonly reported comorbidities were medical comorbidities (see 
table 6-2), number of comorbidities was associated with only PCS. This finding is 
consistent with previous studies (Hauser et al. 2004; Hsu et al. 2009). For example, 
using the stepwise multiple regression analysis, number of medical comorbidities 
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was significantly associated with only PCS, while the presence of psychiatric 
comorbidities, assessed by the HADS, was associated with MCS (Hauser et al. 
2004). 
In this study the cause of disease was classified into three groups: viruses (B or C), 
mixed (viruses and bilharzias) or others causes. About 92% of participants had viral 
hepatitis with or without bilharzias. Inconsistencies in criteria used to categorise 
causes of disease make it difficult to compare findings between studies. However, 
the current study's results are similar to some previous studies. For example, 
Kalaitzakis et al. (2008) found that mental and physical health did not significantly 
differ by cause of cirrhosis (hepatocellular, cholestatic, alcoholic and hepatitis C 
cirrhosis). Kim et al. (2006) also found that there was no significant difference in 
QOL by cause of liver cirrhosis (HCV, HBV and alcohol).  
On the other hand, using different classifications, Afendy et al. (2009) investigated 
whether the cause of cirrhosis (i.e. alcoholic liver disease, autoimmune hepatitis, 
viral hepatitis, non-alcoholic fatty liver disease and cholestatic liver disease) is 
associated with the HRQOL. The results showed that the non-alcoholic fatty liver 
disease (NAFLD) and alcoholic liver disease were significantly associated with poor 
physical health. However, NAFLD, autoimmune hepatitis and cholestatic liver 
disease were significantly associated with poor mental health domains (Afendy et 
al. 2009). The possible reason for this discrepancy may be due to the method of 
classifying the cause of liver disease. Also, in the current study there may be a lack 
of statistical power to differentiate between patients according to cause of cirrhosis  
due to small number of people with other causes compared to people viruses (B or 
C) and mixed (viruses and bilharzias). Therefore, it is recommended that future 
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studies examine whether the cause of cirrhosis is related to HRQOL by measuring 
this association using an adequate sample size for each cause and a common valid 
classification strategy.  
9.2.3 Social Support 
Social environment has been hypothesised to be an important factor in the 
individual’s perceived HRQOL. Supportive family and friends can improve the 
patient’s physical, social and role functioning (Wilson and Cleary 1995). However, 
no previous study was found that examined the association between perceived 
social support and HRQOL in liver disease and cirrhotic patients. Therefore, the 
MSPSS was used for the first time in these participants to examine this association.  
The regression analysis disclosed that perceived spouse and family support are 
positively associated with MCS, but not with PCS, suggesting that spouse and 
family support have more  influence on mental health domains than physical health 
domains. Theoretically, it has been hypothesised that a supportive family can 
improve the patient’s physical, social and role functioning (Wilson and Cleary 
1995). However, in this study perceived social support was significantly associated 
with only mental health. These findings are consistent with research conducted 
among patients with other chronic disease. For example, using another social 
support questionnaire (Interview Schedule for Social Interaction, 50 items assess 
perceived availability and adequacy of social support), for people with cardiac 
disease, Arestedt et al. (2012) found that social support was associated specifically 
with mental but not with physical health domains (SF-12). In a study with a 12 
months follow up investigating the impact of perceived social support on HRQOL in 
people with chronic heart failure, Bennett et al. (2001) found that an increase in 
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social support significantly predicted improvement in perceived HRQOL. A 
decrease in emotional and informational support significantly predicted an increase 
in hospital admissions due to different causes; increasing positive social interaction 
decreased hospital admissions due to cardiac problems (Bennett et al. 2001). 
Perceived higher social support decreased symptoms of depression among cardiac 
patients (Frasure-Smith et al. 2000). Also, in patients with head and neck cancer, 
perceived higher social support was associated with better mental health domains 
(SF-36) and lower symptoms of depression (Beck Depression Inventory); however 
social support was not associated with physical health (Karnell et al. 2007). 
According to the Buffer and Main effect theory (Cohen and Wills 1985), social 
support can prevent the occurrence of stressors; modify the patient’s perceptions of 
their illness; and enhance coping skills that can reflect on the patient’s health. Low 
social support may increase mortality or morbidity in different groups (Vandervoort 
1999; Lyyra and Heikkinen 2006), suggesting that increased social support has a 
positive influence on health outcomes.  
9.2.4 Symptoms Experience 
This is the first study that has investigated a full range of physical and psychosocial 
symptoms (using LDSI-2.0) and their association with HRQOL among liver cirrhotic 
patients in Egypt. Symptom severity was significantly associated with physical and 
mental health, suggesting that patients with high symptom severity were more likely 
to report poor HRQOL. The results support the model of HRQOL, where symptom 
is an essential determinant of health status (Wilson and Cleary 1997). The results 
also are consistent with several studies that examined associations between 
severity of various symptoms and HRQOL. Somatic symptoms (i.e. muscle cramps, 
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pruritus) (Marchesini et al. 2001), psychiatric symptoms (i.e. depression and 
anxiety) (Haag et al. 2008), gastrointestinal symptoms (Kalaitzakis et al. 2006), and 
symptoms of fatigue, joint pain, abdominal pain and decreased appetite (Gutteling 
et al. 2006) were associated with HRQOL in patients with chronic liver disease or 
cirrhosis. Patients with high severity of symptoms are more likely to have poor 
HRQOL.  
In a large cross-sectional survey of 544 Italian cirrhotic patients, Marchesini et al. 
(2001) entered many of the independent variables in a logistic regression analysis 
such as marital status, disease severity, recent hospitalisation, liver disease 
complications and comorbidities, and symptom severity of muscles cramps and 
pruritus during the last month. They found that severity of muscle cramps 
significantly predicted mental and physical health. However, disease severity and 
recent hospitalisation predicted physical health only (Marchesini et al. 2001). 
Therefore, the current study findings are consistent with previous studies that 
suggest that severity of symptoms is an important factor in explaining perceived 
physical and mental health domains in cirrhotic patients. However, symptom 
severity explained 28.7% of the variation in physical health and 43.6% of the 
variation in MCS, suggesting that symptom severity contributed more in explaining 
MCS than PCS of cirrhotic patients in Egypt. There is no similar study to compare 
these results with.  
In this study, hindrances in daily life due to symptoms were not significantly 
associated with any aspect of HRQOL. The total score of the LDSI-2.0 (items 
measuring hindrance of symptoms) was used to find the association between 
hindrance of symptoms and HRQOL. In other identified studies that used LDSI-2.0 
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(such as van der Plas et al. 2004), the researchers used the items separately to 
find their association with HRQOL. Therefore, there is no similar study to compare 
with. However, van der Plas et al. (2004) found that both severity and hindrance of 
symptoms was associated with HRQOL, with hindrance of symptoms having a 
higher influence on HRQOL than severity of symptoms. It is worth noting that van 
der Plas et al. (2004) conducted their study among a general liver disease 
population from the Dutch Liver Association (DLA), with most participants on-
cirrhotic (42.5%), which means they were more likely to be engaged in social 
activities. For instance, van der Plas and colleagues (2004) compared the 
participants from clinical settings who had compensated and decompensated 
disease stage with participants from the DLA. They found that symptom severity 
and hindrance were significantly associated with HRQOL among clinical and DLA 
participants. However, the liver disease DLA population had a higher prevalence of 
symptom hindrance than the clinical population. Therefore, they suggest that DLA 
participants may not be representative of a clinical population of chronic liver 
patients. In this PhD study, all the participants had cirrhosis with most of them 
housewives or unemployed, and they were recruited from inpatients and 
outpatients clinics. This means that these participants were more likely to be 
experiencing severity of symptoms than hindrance of daily activities due to 
symptoms (see tables 7-1 and 7-2), as they may not have been fully engaged in 
daily and social activities. In van der Plas et al.'s (2004) study, the frequency of 
reporting hindrance of symptoms was higher than severity of symptoms (see table 
9-4). Therefore, it is recommended that the two different dimensions of symptoms 
should be measured, that is severity and hindrance. van der Plas et al. (2004, p. 
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1477) state that ‘this supports the value of including symptom severity items as well 
as symptom hindrance items in the disease-specific questionnaire’.  
SECTION II: SYMPTOMS EXPERIENCE AND ITS ASSOCIATED FACTORS 
Theoretically, symptoms experience means: (1) including a person's perception of 
whether s/he observes any change in feeling or behaviour, (2) evaluating symptom 
severity, its effect on daily life, cause and method of treatment from a person’s 
perception and (3) physiological, psychological, socio-cultural and behavioural 
response of the person to this symptom (Dodd et al. 2001). It was not possible to 
address overall symptoms experience in depth in this study. Thus, “symptoms 
experience” reflects symptom severity and distress from the patient's perception 
using LDSI-2.0.  
The second aim of this study was to explore and describe experienced symptoms 
(prevalence, severity and hindrance) in Egyptian cirrhotic patients and to identify 
and evaluate factors associated with symptoms severity and symptoms hindrance 
(distress). 
Table 9-3: Research questions and key findings  
Discussed points Research questions  Key findings 
Overall symptoms 
experience of 
cirrhotic patients  
 The mean of the LDSI-2.0 total score 
was 46.16 ± SD (20.75) with a median 
of 49. The mean score of symptoms 
severity was 32.61 ± SD (13.15) and 
symptoms hindrance was 13.54 ± SD 
(8.54), the high score indicates the 
severity and hindrance of symptoms.   
Prevalence of 
symptom severity 
and hindrance 
 
2.1 What symptoms do 
patients with liver cirrhosis 
experience? 
 
 
 
 
 
 
The majority of the patients had one or 
more of a wide range of physical and 
psychosocial symptoms. Joint pain, 
decreased appetite, memory problems, 
difficulty of using time effectively, 
financial difficulties and muscle cramp, 
difficulty in sleeping at night were the 
most frequently reported symptoms. 
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2.2 Which of the reported 
symptoms limit the daily 
activities?  
 
Joint pain, depression and decreased 
appetite were the main hindrances. 
Muscle cramp and difficulty in sleeping 
at night were additional hindrances 
symptoms.  
Factors 
associated with 
symptoms 
experience: 
severity and 
distress using 
multivariate 
analysis 
2.7 What are the factors 
associated with 
symptoms experience?  
Model 1: the regression model 
significantly explained 19.6% of the 
variations in overall symptoms severity. 
Six variables significantly associated 
with symptoms severity: gender, marital 
status, perceived spouse support, 
employment status, perceived family 
support and number of liver disease 
complications. Females, unemployed 
and married with increased liver disease 
complications and patients with a low 
perceived social support were more 
likely to experience high severity of 
symptoms.  
Model 2: the regression model 
significantly explained 14% of the 
variation in hindrance of daily activities 
due to symptoms (distress). Three 
variables significantly associated with 
symptoms hindrance: gender, perceived 
spouse support and number of liver 
cirrhosis complications.  
Gender, number of liver cirrhosis 
complications and perceived social 
support from spouse significantly 
associated with symptoms severity as 
well as hindrance of symptoms. Gender 
(females) and perceived spouse support 
(low) made the strongest contribution in 
explaining increasing severity of 
symptoms and hindrance of daily 
activities due to symptoms.   
 
9.3 SYMPTOMS EXPERIENCE OF EGYPTIAN CIRRHOTIC PATIENTS  
Self-reporting of experienced symptoms and their characteristics is the gold 
standard for studying symptoms (Dodd et al. 2001). LDSI-2.0 assesses symptoms 
in general as disease specific HRQOL and provides two subscales to examine 
symptoms severity and hindrance. The sum score of all relevant items was used 
(Gutteling et al. 2008) to assess general severity but not general hindrance of 
symptoms.  
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In the current study, two general subscales were used independently to assess the 
two summary dimensions of symptoms experience: severity and hindrance. The 
use of this tool is a new contribution that confirms its simplicity and feasibility for 
assessing overall symptoms severity and distress. The mean score of symptoms 
severity was higher than the mean score of symptoms distress, suggesting that 
patients were more likely to report severity of experienced symptoms than 
hindrance of symptoms. One explanation may be that because most of the patients 
were housewives, unemployed and admitted in the hospitals, their hindrance of 
symptoms is lower than severity. Alternatively, this result may relate to the ability of 
patients to cope with symptoms, which does not bother their daily life. Further 
research is required to identify coping strategies among these patients and their 
associations with symptom experience.  
9.3.1 Prevalence of Severity and Hindrance of Symptoms  
Each person experiences symptoms (distressed or not) differently, with certain 
symptoms more stressful than others (Wilson and Cleary 1995). The developers of 
the LDSI-2.0 stated that 'single items have not been combined into multi-item 
scales, as we are of the opinion that in clinical practice results of separate symptom 
severity and symptom hindrance items are easier to interpret and more valuable for 
patient management' (van der Plas et al. 2004, p. 1470). In view of that, it was 
important to run further analysis to explore the prevalence of separate symptoms in 
terms of severity and distress on daily activities.  
More than two-thirds of patients reported joint pain, decreased appetite, worry, 
depression and sleepiness as well as muscle cramps and difficulty in sleeping at 
night, which were not measured by LDSI-2.0. However, joint pain, depression, 
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decreased appetite and worry made the biggest impact on their daily and social 
activities. These findings increase our insight into the most important symptoms 
that negatively can affect these patients’ daily life and may be treatable, such as 
depression and decreased appetite. Moreover, they support that a symptom is a 
multidimensional concept that should be measured from different dimensions such 
as severity and distress (Lenz et al. 1997). 
Teunissen et al. (2007) acknowledge that assessing symptom prevalence is 
important not only for clinical practice, as it enables healthcare providers to focus 
on the more prevalent symptoms, but also to anticipate problems that need more 
attention while developing care plans and directing healthcare policy. Also, studying 
symptom distress can provide important and complementary information to 
symptom severity to gain insight into symptoms experience and its impact on 
patients’ daily lives and social activities (Tishelman et al. 2007). 
The study by van der Plas et al. (2004) is the only one that examined and 
presented the frequency of severity and hindrance (distress) of symptoms using 
LDSI-2.0. Table 9-4 presents the frequency of severity and hindrance of symptoms 
in this study compared to the study by van der Plas et al. (2004). However, it is 
important to acknowledge that cultural aspects, such as beliefs and values unique 
to the individual's ethnicity and religion, can reflect the person's perception of 
symptoms (Dodd et al. 2001).  
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Table 9-4: Symptoms experience in Egyptian and Dutch liver disease and cirrhotic 
patients  
 
LDSI-2.0 items 
This study van der Plas et al.’s study 
(2004) 
Prevalence of 
people 
reported 
Symptom 
severity 
n% 
Prevalence of 
people reported 
hindrance of 
daily life due to 
symptom 
(Among 
symptomatic) 
% 
Prevalence of 
people 
reported 
Symptom 
severity 
n% 
Prevalence of 
people 
reported 
hindrance of 
daily life due 
to symptom 
(Among 
symptomatic) 
% 
Itch 210 (52.4) Activity: (25.7) 
Sleep: (31.2) 
451 (39.6) 50.5 
Joint pain 314 (78.3) 70.3 654 (57.5) 83.8 
Right abdominal 
pain 
259 (64.6) 51.9 451 (39.3) 63.1 
Sleepiness during 
the day 
290 (72.3) 53.1 817 (71.2) 85.1 
Worry about the 
family situation  
300 (74.8) 57.6 578 (50.5) 66.6 
Decreased appetite 303 (75.6) 59.1 370 (32.3) 71.4 
Depression 291 (72.6) 61.3 544 (47.5) 77.6 
Jaundice 109 (27.2) 16.2 113 (9.9) 41.1 
 
The current study found that the frequency of reported symptoms was higher in 
Egyptian than in Dutch patients at mixed stages of liver disease. However, it is the 
most frequently reported symptoms in both Egyptian and Dutch patients were joint 
pain and worry about the family situation. This suggests that regardless of cultural 
differences, liver disease affects patients’ physiologically by affecting their 
musculoskeletal system resulting in joint pain and psychologically resulting in worry 
about their families’ situation. However, both groups experienced other symptoms 
differently. This finding supports the model of HRQOL outcomes that hypothesises 
that reporting of symptoms is influenced by a number of cultural characteristics 
(Wilson and Cleary 1995).  
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Depression and joint pain were the most reported hindrance symptoms for daily 
activities among Egyptians and Dutch. However, Egyptian patients reported that 
decreased appetite was one of the most reported hindrance symptoms to their daily 
activities, while Dutch patients reported sleepiness during the day. This suggests 
that while there are common symptoms shared between liver disease patients 
across countries, other symptoms may differ from one country to other.  
The literature review revealed that depression (Girgrah et al. 2003; Kim et al. 2006) 
was the most commonly studied and supported symptom among liver disease 
patients with more than half of cirrhotic patients suffering from depression (Bianchi 
et al. 2005). Thus, routine assessment and treatment of depression among cirrhotic 
patients in Egypt is urgently needed. Kraus et al. (2000) showed that recently 
diagnosed liver disease patients without advanced cirrhosis had significantly lower 
depression and anxiety symptoms and higher problem solving skills than 
longstanding ones (> 5 years). In a longitudinal study of American cirrhotic patients 
on a waiting list for liver transplantation, Singh et al. (1997) found that mortality was 
higher among depressed than non-depressed patients. Therefore, it is 
recommended that liver disease patients should be regularly assessed for 
depression, anxiety and inappropriate coping styles (Kraus et al. 2000). 
The literature review has showed that pathophysiological bone changes due to liver 
disease is common among cirrhotic patients, which may be related to joint pain. 
Gallego-Rojo et al. (1998) studied 35 viral cirrhotic men to determine the 
prevalence of osteoporosis. Compared to a matched controlled healthy group, it 
was found that liver cirrhotic patients had a lower bone mass density and 
prevalence of osteoporosis was high (53%). Similarly, in a cohort study among 
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cirrhotic patients due to viral or alcoholic disease, Cijevschi et al. (2005) studied 
150 gender-balanced patients to determine the prevalence of osteoporosis using 
the Dual Energy X-ray Absorptiometry-DXA. It was found that 38% had 
osteoporosis or osteopenia and the low Body Mass Index was used as the high 
predictive risk factor.  
In this study, decreased appetite was one of the most commonly reported 
symptoms. However, some of the patients unexpectedly mentioned that they 
decreased their food intake because they were afraid of liver disease 
complications. This suggests that some patients perceived that eating itself, not the 
type of food, was a risk factor for developing complications. This means that some 
of the Egyptian cirrhotic patients may not have sufficient information about an 
appropriate diet and how to self-manage. Therefore, opening the channel of 
communication about silent symptoms will help to provide supportive health 
information that can reflect positively on the patients' symptoms experience and to 
enhance their QOL. Constant et al. (2005) showed that patients who reported 
physicians as the source of their information were more likely to have a lower 
perceived disease severity than patients who reported other sources of information 
such as significant others and television.  
In addition, some patients reported difficulty in sleeping at night and muscle cramps 
as additional experienced symptoms that were not measured by the LDSI-2.0. They 
also reported these symptoms hindered their daily activities.  
‘The muscle cramp wakes me up from sleeping’ Man 39 years. 
‘Muscle cramp affects my life to a high extent, one day I was driving, my leg 
cramped then I stopped till the cramp was relieved’ Man 55 years. 
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These results are consistent with the Marchesini et al. (2001) study, which found 
that 36% of cirrhotic patients reported muscle cramps, which was also a key factor 
associated with perceived poor physical and mental health. The literature review 
shows that cirrhotic patients have a higher prevalence of muscle cramps than a 
healthy control group, and pathophysiological changes such as the presence of 
ascites are predictive factors (Angeli et al. 2003). The literature has also shown that 
cirrhotic patients have more sleeping disorders such as daytime sleepiness, 
insomnia and frequent nocturnal awakening, although there was no significant 
relationship between sleeping problems and clinical and laboratory parameters 
(Mostacci et al. 2008). Therefore, further studies are required to develop a 
symptom management program to teach patients how to manage their symptoms 
effectively in order to improve their health status as well as their QOL.  
9.4 FACTORS ASSOCIATED WITH SYMPTOMS EXPERIENCE 
According to the theory of unpleasant symptoms (Lenz et al. 1997) and the 
conceptual model of HRQOL outcomes (Wilson and Cleary 1995) many 
biophysiological, psychosocial and situational factors can predict symptom 
experience. In this study, multiple linear regression analysis found that being 
female, increasing number of liver disease complications and low perceived social 
support from spouse were associated with increasing severity and hindrance of 
symptoms. While, being unemployed, married and with low perceived support from 
family were significantly associated with increased severity of symptoms only. The 
results are consistent with the hypothesis of the model of HRQOL that suggests 
that reporting of symptoms is influenced not only by biophysiological factors but 
also by the demographic as well as cultural background of the patient (Wilson and 
Cleary 1995).  
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To the best of my knowledge, this is the first study that has examined factors 
associated with symptoms experience using a multiple regression analysis and has 
investigated the relationship between social support and overall symptoms 
experience. Therefore, it was difficult to compare these findings with other studies. 
However, assessing symptom experience by using bivariate analysis and different 
questionnaires among cirrhotic patients in Korea, Kim et al. (2006 and 2006a) 
found that the overall score of symptoms experience was not associated with age, 
gender and cause of disease. However, disease stage was associated with the 
overall score of symptoms experience and there was a significant difference 
between men and women in reporting individual symptoms.  
Erim et al. (2010) investigated depression symptoms (using Beck Depression 
Inventory) among HCV non-cirrhotic patients and found that women were more 
likely to have depression than men. In other chronic diseases, Teunissen et al. 
(2007) conducted a systematic literature review of 44 studies with 25,074 patients 
with incurable cancer; six of these studies assessed gender differences in symptom 
prevalence. There was a significant gender difference in all of these studies, with 
dysphagia and insomnia being more common among males and nausea and 
vomiting in females (Teunissen et al. 2007). In line with this, this study found that 
there was a significant gender difference in reporting particular symptoms; for 
example, women were more likely to report depression and joint pain and men to 
report decreased sexual activity. These findings not only support the validity and 
sensitivity of the Arabic LDSI-2.0, but also highlight the symptoms that are 
commonly experienced by Egyptian cirrhotic men and women. These results could 
be the foundation for developing a future symptoms management program.  
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This study's findings also show that perceived adequacy of social support is 
associated with symptoms experience. This finding is new and it contributes to 
understanding the relationship between perceived social support and symptom 
experience among these patients. Social support particularly from spouse was 
negatively associated with severity and hindrance of symptoms (disease specific 
HRQOL). However, perceived family support was associated only with severity of 
symptoms. This is a logical finding as the majority of the participants were married 
and the supporting role of the spouse can decrease the burden of daily life due to 
symptoms. However, this result in general supports the assumption of the model of 
HRQOL outcomes, in that when the patient has a surrounding supportive 
environment (spouse, family or friends) symptom burden will decrease and the 
patients’ HRQOL will improve.  
Interestingly, the study found that perceived social support from spouse and family 
was significantly associated with only the psychosocial domains of generic HRQOL; 
mental health domains (SF-36).It is well established that lack of social support can 
cause psychological symptoms such as anxiety or depression, which may have a 
negative influence on health status (Cohen and Wills 1985). Karnell et al. (2007) 
showed that with decreasing social support there was an increase in the severity of 
depressive symptoms among patients with head and neck cancer. Social support 
has also been found to be significantly related to patients’ survival rate. For 
instance, several longitudinal studies have shown that high social support, 
especially perceived emotional support, is strongly related to improved 
psychological and physical health outcomes as well as to a decrease in mortality 
rate (Brummett et al. 2005; Lyyra and Heikkinen 2006). Staniute et al. (2011) have 
therefore suggested that healthcare providers should pay more attention to patients 
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with low social support during the development of a rehabilitation program. 
Therefore, perceived social support may be essential in perceiving better mental 
health and symptom experience among these patients.  
Interestingly, in this PhD study, the number of liver cirrhosis complications did 
explain some variance in symptoms severity (14.4%) and hindrance (16.9%), 
although disease stage could not. Several liver disease complications were 
dentified in the Egyptian cirrhotic patients, with most of these patients had more 
than two of liver disease complications (see tables 6-2 and 6-11).  
Interestingly, when HRQOL was stratified by disease stage, it was found that only 
two domains of physical health significantly were poorer among decompensated 
than compensated (PF and RP). However, when HRQOL was stratified by number 
of liver cirrhosis complications, the four domains of physical health were poorer 
among patients with 3-4 complications than with 1-2 (see tables 6-11 and 6-12).  
Therefore, disease stage was significantly associated with generic physical health 
(SF-36), although it was not associated with disease specific HRQOL (LDSI-2.0). 
However, the number of liver disease complications was significantly associated 
with symptom experience (disease specific HRQOL) but not with generic HRQOL. 
This finding is logical as having more than one complication such as ascities and 
oesophageal bleeding at once can cause several mixed symptoms. In fact, the 
relationship between biophysiological variables and symptom experience is likely to 
be very complex (Wilson and Cleary 1995).Therefore, further future research 
aiming to evaluate the association between type of liver cirrhosis complications and 
generic and disease specific HRQOL will be helpful to understand this relationship. 
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SECTION III: SOCIAL SUPPORT AND ITS ASSOCIATED FACTORS 
Social support has been found to be essential for enhancing coping skills for people 
with chronic disease. Social support has three dimensions: emotional, 
informational, and instrumental (Williams et al. 2004). Coping also has three 
dimensions: emotion focused (thoughts/actions intended to control negative 
feelings), problem focused (direct actions intended to alter threatening 
circumstances), and perception focused (thoughts intended to control the meaning 
of threatening circumstances) (Vilhjalmsson 1993). Therefore, it was essential to 
study how patients with cirrhosis perceive their social support in general and from 
different sources. Social support has been found to be related to an individual's 
demographic characteristics (Zimet et al. 1990). Finding antecedent factors for 
perceived social support provides insight into people who are more likely to report 
low support. Thus, vulnerable groups should be considered during the development 
of self-management and intervention programs.  
Therefore, the third aim of this study was to explore and describe how cirrhotic 
patients in Egypt perceive social support from spouse, family and friends and to 
evaluate factors associated with general perceived social support. Table 9-5 
presents the major research questions and the key findings. 
Table 9-5: Research questions and key findings  
Discussed points Research questions Findings 
Perceived social 
support among liver 
cirrhotic patients 
 
3.1. How do patients with liver 
cirrhosis in Egypt 
perceive the available 
social support? 
The perceived social support 
score was relatively high, with 
the support from a spouse rating 
the highest. 
Perceptions of Social 
Support from Spouse, 
Family and Friends  
 
3.2. Do patients with liver 
cirrhosis perceive 
adequacy of social 
support from spouse, 
family and friends? 
 
More than half of the married 
patients perceived that their 
spouses (husband or wife) 
provided them with different 
kinds of support. More than half 
of the sample perceived that 
320 
 
their families did not really try to 
help them although they gave 
emotional help and support. 
Support from friends was 
perceived as the lowest source 
of support. More than half of the 
patients reported that they could 
not count on their friends during 
hard times, although they could 
share their joys and sorrows 
with their friends. 
Factors associated 
with perceived social 
support using 
multivariate test  
3.5 What are the factors 
associated with perceived 
adequacy of social 
support among liver 
cirrhotic patients in 
Egypt? 
 
 
The regression model 
significantly explained 10.9% of 
the variation in perceived social 
support. Four variables 
associated significantly with 
overall perceived social support: 
gender, age, marital status and 
employment status. Being 
females, unmarried, 
unemployed and elderly patients 
were more likely to perceive low 
social support. Gender (13.5%) 
and marital status (13.6%) made 
the strongest contribution to 
explain social support. 
 
9.5 PERECIVED SOCIAL SUPPORT AMONG EGYPTIAN CIRRHOTIC 
PATIENTS   
Perceived social support score was relatively high, with the support from a spouse 
rating the highest. This suggests that patients perceive the spouse as the master 
source of social support followed by family and friends respectively.  
In Egyptian society, the family is the central source of support for singles; while for 
married people, the spouse is the central support. The majority of the participants 
were married (77.3%) therefore, it was logical to find that spousal support was the 
main source of support. This finding is consistent with a study that examined 
perceived social support among Arab immigrant married women in the US (Aroian 
et al. 2010). Furthermore, in a study of Arab American adolescents, Ramaswamy et 
al. (2009) found that family was the main source of support, followed by friends. 
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This finding reflects the importance of spouse and family as key sources of support 
for Arabic people in or out of home. Similarly, in a cross-sectional study of 240 
postpartum women in Uganda, Nakigudde et al. (2009) showed that perceived 
support from a significant other (spouse) followed by family were the highest 
sources of support, while support from friends was low. In a study by Zimet et al. 
(1990), three groups: pregnant women, adolescents and paediatric residents in a 
training course were compared using MSPSS. It was found that married women 
perceived support from a significant other (i.e. husband, partner or friend) to be 
higher than single women, while there was no significant difference in terms of 
support from family and friends between the two groups. This supports the 
association that a spouse may be the central source of support for married people.  
9.5.1 Perceptions of Social Support from Spouse, Family and Friends  
This study found that more than half of the married patients perceived that their 
spouses (husband or wife) provided them with different kinds of support; they were 
there when needed and cared about their feelings. However, more than half of the 
sample perceived that their families did not really try to help them and were not 
willing to help them make decisions although they gave them emotional help and 
support. Therefore, it seems that type of support may be a significant factor 
requiring further research, as this study aimed to study the general perceived 
support from the surrounding people.  
On the other hand, support from friends was perceived as the lowest source of 
support. More than half of the patients reported that they could not count on their 
friends during hard times, and that they would not help them, although they could 
share their joys and sorrows with them. This suggested that ‘the availability of 
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someone with whom to have a good time may be less beneficial to the health of a 
chronic disease patient than the availability of someone to help with daily chores’ 
(Sherbourne and Hays 1990, p. 329). For instance, Lindsey et al. assessed 
structural and functional social support in Egyptian cancer patients in 1985. They 
found that the reported social support network was n = 591, 57.5% were families 
and 15.8% were friends. This suggests that few friends but many families are 
included in the Egyptian cancer patients' network. Also, spouses were perceived to 
provide more support than families, while friends provided less (Lindsey et al. 
1985). Thus, family and spouse support is the main source of support among 
chronically ill patients in Egyptian  
9.6 FACTORS ASSOCIATED WITH PERCEIVED SOCIAL SUPPORT  
Identifying actors that could be associated with perceived social support was 
important, as it has not been done in in Egypt. However, using the model of Wilson 
and Cleary (1995) could not help to understand the relationship between 
demographic and medial variables and perceived social support. This is a limitation 
in the model of HRQOL. However, this is an area where it could be improved. 
Furthermore, no study could be found to compare these findings to. The results 
show that marital status, gender, age and employment status are significantly 
associated with perceived social support. Unmarried people, females, the 
unemployed and elderly cirrhotic patients are vulnerable groups with perceived low 
social support. However, in a study of elderly patients with chronic heart failure 
(mean age 79 years) in Sweden, Arestedt et al. (2012) showed that men, living 
alone, had financial problems and in advanced disease stage had low availability or 
adequacy of social support. Consistently, the results of this study support findings 
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of studies that used MSPSS and investigated the association between marital 
status and perceived support, particularly from a significant other. For example, 
Zimet et al. (1990) compared perceived support from three sources between 
married and single people, and found that married people reported significantly 
higher support from a significant other than singles, and there was no significant 
difference according to the support from family or friends. Similarly, in 445 Dutch 
and Danish cardiac patients, Pedersen et al. (2009) showed that having a partner 
was associated with perceived high support. 
In this study, cirrhotic women in Egypt were more likely to perceive low social 
support. There is conflicting evidence in the literature about the nature of the 
relationship between gender and perceived social support (Norris et al. 2008). For 
example elderly women with chronic heart failure reported significantly better social 
support especially availability of attachment compared to man (Arestedt et al. 
2012). Also, women with cancer in Sweden reported significantly higher social 
support than men (Bertero 2000).  
On the other hand, several studies showed a significant association between 
gender and perceived social support. For instance, Staniute et al. (2011) 
investigated the association between social support and HRQOL among 560 
patients in Palanga (Lithuania) with coronary artery disease. They found that 
perceived social support had a significant effect on the HRQOL in patients with 
coronary artery disease, especially in females. Also, in a recent longitudinal cohort 
study (baseline and 12 month follow up) Norris et al. (2008) investigated 2394 
people in Canada undergoing catheterization for coronary artery disease. After 
adjustment for all the variables, the results showed that women reported 
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significantly more depressive symptoms, physical limitations, and treatment 
dissatisfaction, as well as lower social support and QOL than men at baseline and 
at 12 months (Norris et al. 2008).  
It is difficult to interpret the discrepancy in findings related to gender and social 
support. However, there are two suggested explanations: first, the type of 
participant characteristics (e.g. age and cause of disease) and the social support 
questionnaires were different in their structure and conceptualization. Second, the 
cultural background may affect patients' perception and experience with illness. For 
example, Egyptian women with rheumatoid arthritis, compared to Dutch women, 
experienced significantly higher loneliness, depression and anxiety. They also 
reported a higher need for help with their daily and household activities (El-
Mansoury et al. 2008). In line with that, Bosworth et al. (2000) showed that women 
received less assistance with household duties from informal caregivers, while men 
got more support from their spouses than women. Men were more likely to involve 
their spouses in their recovery, resuming work and keeping physically fit were 
important to them. Women reported that they had less social support up to one 
year after a myocardial infarction than men (Bosworth et al. 2000).  
Therefore, our findings confirm previous studies in terms of lower perceived social 
support among women with chronic disease, when comparing men and women’s 
HRQOL. Egyptian cirrhotic women were more likely to report depression, joint pain, 
decreased memory, decreased appetite, abdominal pain and difficulty to manage 
time (using LDSI-2.0). All these symptoms hinder their daily activities and social 
contacts. The majority of women in this study were housewives, suggesting little 
chance of developing friendships, which may cause them to require more support 
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from husband and families; however the level of the provided support may not be 
sufficient to meet their needs.  
Liver disease is most commonly due to HCV, which may have a negative impact on 
the relationship between spouses, particularly their intimacy (Blasiole et al. 2006) 
and their social activities. The following quotes are from female patients those 
participated in this study: 
 During completing the LDSI-2.0 a woman responded to that item ‘My sexual 
interest has decreased since I know I have a liver disease’ (item 10), and said that 
‘the disease has not decreased it but increased it, because I feel I need my 
husband now more than before but he is always away and neglects me and even 
refuses to touch me when I ask him to help me to stand up from the floor’ Women 
50 years and has ascities. 
‘I am not concerned about the disease and I am not worried about it, but the 
problem is my husband who does not look after me or support me. All the time he 
says bad words to me; like you are ill, and you are useless, it is better to burn 
yourself to die’ Women 50 years. 
‘My husband eats out of the home and does not eat any food I prepare, also he 
says bad words that hurt me, every time he says look, other ladies are healthy and 
you are not, look at yourself’ Women 50 years has ascities. 
‘Me and my husband sleep in separate rooms since we have known I have the 
virus C and there is no sexual relation for 4 years till now, also he does not touch 
me, he is afraid of infection’ Women 40 years. 
‘My husband married another woman when he knew I am infected with HBV and 
lives with his new wife in other flat. I asked him to remain married (not divorce me) 
for my children’s sake because there is not anyone who can care for them’ Women 
34 years. 
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‘I become weak and my children go away from me because I am frequently 
admitted to hospital and this makes me so sad and depressed. I do not know how 
they eat or are cared for while I am in the hospital. My husband goes to work every 
day and leaves them alone in the flat even when I am back at home I cannot do 
anything; I feel fatigue all the time, my husband is young and strong and I cannot 
give him his rights and this makes him to quarrel with me how can I solve this 
problem and what can I do’ Women 37 years. 
Therefore, a qualitative study is required to examine the impact of liver disease on 
the partner relationship and on the patients’, partners’ and children’s HRQOL in 
order to find a supportive management method. 
The study found that the level of perceived support decreased with increasing age. 
This finding is inconsistent with a study of HCV non-cirrhotic German patients, 
using the Social Support Questionnaire (F-SOZU) where age and gender were not 
associated with social support (Erim et al. 2010). The difference in cultural 
background and disease stage may be the cause for the inconsistency in findings.  
9.6.1  Disease Stage and Perceived Social Support 
This study's findings show that there is a statistically significant difference in 
perceived social support from families of patients with decompensated and 
compensated cirrhosis. Patients at an advanced stage of cirrhosis are more likely 
to gain higher social support from their family than patients in an early stage of 
cirrhosis. This suggests that with increasing disease severity there is increasing 
family support. These findings support previous studies of patients with chronic 
HCV which found that patients with a chronic physical illness are more likely to 
receive equal or higher levels of support than healthy people (Erim et al. 2010). 
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On the other hand, this PhD study showed that there was no significant difference 
in perceived social support from spouse or friends according to disease stage. The 
reason for these findings is unclear. However, a possible explanation may be that 
according to the culture of Egyptian people the family and spouse are usually the 
main source of support particularly during illness; but friends may support 
emotionally. However, their effect may not be as strong as the family and spouse. 
For example, in this study more than half of the patients reported that their friends 
did not really try to help them (57.9%), they cannot count on their friends when 
things go wrong (65.6%) and they cannot talk about their problems with their 
friends (56.4%). However, in regression analysis, disease stage was not 
significantly associated with perceived social support.  
9.7 FINDINGS’ IMPLICATIONS  
9.7.1 Implication for Theory  
One of the strengths of this study is the use of the conceptual model of HRQOL 
outcomes by Wilson and Cleary (1995) for the first time for patients with liver 
cirrhosis. It helped to direct this study in terms of selecting the studied concepts, 
defining these concepts theoretically and operationally and directing data analysis. 
This study helped to confirm the practicality and feasibility of using this model to 
explore factors associated with HRQOL. Similarly, Sousa and Kwok (2006) found 
that ‘this model places concepts in a context and will be useful to guide the 
development of new theories. This model, as described and tested, could be used 
as a tool to assess interventions and organizational performance within the new 
paradigm’ (p. 735). 
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Using regression analysis, two models were developed to find the factors 
associated with physical and mental HRQOL. The results showed that symptoms 
severity made the strongest contribution in explaining both aspect of HRQOL, PCS 
(28.7%) and MCS (43.6%). Social support from a spouse and family was 
significantly (p ≤ 0.04) associated with MCS only; and they explained 13.5% and 
9.7% of the variation in MCS respectively. These findings support the conclusion 
that symptoms are the greatest associated factor with HRQOL. Furthermore, social 
support was significantly associated with HRQOL and symptoms experience as 
hypothesised by the model. Diagram 9-1 summaries the study results, and the 
relationships between the studied concepts that confirm the hypotheses of the 
HRQOL conceptual model outcomes.  
The HRQOL conceptual model outcomes by Wilson and Cleary (1995) was 
investigated before, using Structural Equation Modeling, and fitted well with clinical 
data. For example, the pathways hypotheses were tested by Henderson et al. 
(2012) and showed that social support significantly predicted symptom status, while 
symptom status and social support significantly predicted general health 
perceptions and overall QOL. Also, environmental factors such as income 
significantly predicted symptom status and general health perceptions.  
 
 
 
 
329 
 
Diagram 9-1: Summary of the relationship between the studied concepts 
 
 
 
 
 
 
 
 
 
Note: F: Family support, S: Spouse support, dummy code of disease stage: 0 decompensated, 
1 compensated 
 
 
In a recent study of patients with HIV, Sousa and Kwok (2006) tested the HRQOL 
model outcomes. They found that with increasing symptom status there was poorly 
perceived functional health, where symptom status explained 49.0% of the variance 
in functional health. Also, patients who experienced more symptoms and less 
functional health had low perceived general health. Following the pathway of the 
model, they found that patients who experienced increased symptom status and 
had poor perceived general health were likely to report poor QOL. For instance, in 
patients with renal failure and on haemodialysis, Kring (2008) found that symptoms 
of anxiety and depression, general health perception, and level of albumin 
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significantly predicted QOL, while gender, age, marital status and income level did 
not, suggesting a need to explore other contributing factors to explain QOL. 
Generally, this means that the pathways from symptom status to general health 
perception to overall QOL are reliable and can give valid results consistent with the 
original theoretical model of Wilson and Cleary (1995); and symptom status is the 
factor most associated with HRQOL.  
In this study, although regression models could significantly explain PCS and MCS, 
81% of the variation in PCS and 68.3% of the variation in MCS could not be 
explained. Therefore, these results suggest that there must be other factors that 
have an influence on HRQOL that need to be investigated in future research.  
9.7.2 Implications for Practice  
Sousa and Williamson stated that ‘Nursing continues to struggle to identify 
outcomes that measure quality of care. Traditional outcomes, such as morbidity 
and mortality, do not provide sufficient information about quality of patient care’ 
(2003, p. 572). This study’s findings are important as they increase our insight into 
HRQOL and experienced symptoms. These findings contribute to healthcare 
professionals’ understanding of how patients perceive their health status and the 
psychosocial factors that influence their perception. Thus, improvement of patients’ 
perception of their physical and mental health domains will be through managing 
symptoms and satisfying their psychosocial needs. Managing symptoms is the core 
of nursing practice. Therefore, healthcare professional, and nurses in particular, are 
responsible to develop symptom management programs to meet patients’ 
psychosocial needs.  
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Smith et al. (1994) conducted a meta-analysis using randomized experimental and 
controlled studies to investigate the effectiveness of symptom management 
intervention in cancer patients. Results showed that symptom management 
interventions were effective in relieving symptoms such as pain, nausea, vomiting 
and anxiety. Thus, symptom management programs will be helpful to decrease 
peoples’ suffering and improve their perception of their physical and mental health. 
Also, in a randomised control study, Lorig et al. (1999) investigated the 
effectiveness of a designed self-management program in changing health 
behaviours, health status, and health service utilization over a six-month period in 
952 patients with chronic heart and lung diseases. Findings showed that groups 
who received the self-management programs, experienced improvements in 
weekly minutes of exercise, cognitive symptom management, communication with 
physicians, self-reported health, as well as decreases in reporting disability, and 
social/role activity limitations. Moreover, hospitalizations (admission and staying) 
decreased. The researchers summarised that the intervention program was 
designed to meet the patients’ needs and it was feasible and beneficial for these 
patients, including those with comorbidity. 
Understanding how patients perceive their HRQOL as well as determining its 
associated factors such as symptoms and social support is clinically valuable for 
several reasons. Firstly, healthcare professionals, particular nurses, will develop a 
prioritised symptom management program according to the main experienced 
symptoms. Secondly, social support has been found to influence patients’ 
perceptions about severity of symptoms and mental health domains. Thus, nurses 
should encourage involvement of the patient’s family in any nursing intervention, 
particularly in symptom management programs that can enhance these patients 
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mental health domains and decrease being troubled by experienced symptoms. 
Family support can be enhanced by increasing their understanding about the 
patient’s health condition and his/her psychosocial needs that need to be fulfilled by 
the family. Hence, in Egypt it is important to acknowledge the patient’s family in the 
healthcare policy and healthcare delivery system by providing support services and 
resources that make them more responsive to patients’ needs. 
Involving these patients in peer support groups and getting support from others in 
their communities will enhance their health status; it was argued that as 
“inadequate social support without effective intervention may result in negative 
outcomes” (Bertero 2000, p. 94). Therefore, patient-management and family-
management programs are urgently needed not only for patients but also for their 
families to satisfy their needs and enhance their capabilities to support and care for 
patients. This will happen if there is effective communication between patients, 
families and their healthcare providers, as well as by improving health literacy 
regarding their disease and enhancing their coping skills.  
Interaction between patients and healthcare professionals was considered an 
essential aspect for therapeutic relationships. The literature showed that 
communication with patients about their experienced symptoms had a positive 
influence on their health outcomes. Jackson (2005) conducted a survey in 500 
people attending a primary care clinic. They were interviewed pre and post 
clinicians’ visit in order to find the association between patient-clinician 
communication and the influence on symptom relief and functional health. Results 
showed that when discussion about experienced symptoms took place, patients 
were more satisfied with the provided care, less likely to worry after a visit, and had 
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greater symptom improvement two weeks post-visit. This suggests that discussions 
about symptoms can help to improve patients' health outcomes and symptoms 
experience as well as increase their satisfaction with healthcare.  
Self-management or self-care interventions have been found to be beneficial in 
health outcomes of patients with chronic diseases such as heart failure, cancer and 
asthma. However, their impacts on patients with chronic liver disease or cirrhosis 
are uncertain and need research. For example, Grady (2008) reviewed seventeen 
randomised controlled trials (RCTs), and four longitudinal studies (pre/post or 
repeated measures design) that evaluated the effect of self-care on QOL in 
patients with heart failure. They found that nine RCTs showed significant 
improvement in the intervention group’s QOL compared with the control group or 
those that received usual care. All four longitudinal studies also showed significant 
improvements in QOL from baseline to follow-up. Jovicic et al. (2006) also 
systematically reviewed six RCTs to determine the effectiveness of self-
management interventions on health outcomes (health-related quality of life and 
hospital readmission and mortality rates) in a total of 857 patients with heart failure. 
They demonstrated that self-management significantly improved adherence to 
prescribed medical advice and decreased rates of hospital readmissions although 
its effect on mortality rate and QOL was not significant.  
The only identified quasi-experimental study that was conducted among Iranian 
cirrhotic patients demonstrated that a self-care educational intervention could 
significantly improve abdominal symptoms, fatigue, systemic symptoms, activity, 
worry and emotional domains, without significant changes in disease severity. 
However, HRQOL of the control group who did not receive the intervention 
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significantly declined three months later in domains of activity, worry and emotional 
status (Zandi et al. 2005). Studying symptoms experience and involving patients in 
their care plans by asking them their educational needs are essential step before 
developing self-care intervention programs to improve these patients’ HRQOL. 
Lorig and Holman (2003) argue that self-management education is a problem-
based approach that must be developed on the basis of patients’ needs and 
perceived problems. For example, assessing the patients’ major concerned 
symptoms can help in developing effective self-management programs that are 
based on patients’ needs. In this study, the majority of patients reported that 
depression, decreased appetite and joint pain limit their daily activities. Therefore, 
developing self-care or self-management interventions that aim to improve patients’ 
ability to cope with these kinds of symptoms are needed. 
Patients with chronic disease usually make daily decisions about how to self-
manage their illness. Thus, collaboration between the patient and healthcare 
professional has become an essential paradigm of providing and enhancing self-
management interventions. Self-management interventions complement traditional 
methods of care by supporting patients to be active members in managing their 
chronic condition. Traditional patient education offers only information and technical 
skills, while self-management education teaches problem-solving skills 
(Bodenheimer et a. 2002).  
9.7.3 Implications for Research 
There is a shortage of valid HRQOL measures in Arabic that can be used in 
research studies or in clinical settings. This study contributed to current knowledge 
by translating and validating the disease specific HRQOL questionnaire (LDSI-2.0) 
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that is simple and easily understood by patients, even those who are illiterate. The 
psychometric properties of LDSI-2.0 were confirmed and published to be available 
for future use. Also, the psychometric properties of SF-36 and MSPSS were 
investigated. The results supported the validity of these tools and their reliability 
among patients with cirrhosis in Egypt, and they can also be used in future 
research or clinical practice.  
In this study, symptoms severity have been identified as the key factor associated 
with perceived HRQOL in Egyptian cirrhotic patients, it explained about 41% of the 
variance in MCS and 29% of the variance in PCS. Therefore, this study is the 
foundation for developing future research in symptom management. Self-
management is a patient concern and uses a problems-based approach. Future 
studies into intervention programs that aim to improve patients’ symptom 
experience or perceived HRQOL using a self-management educational program 
are warranted.  
9.8 RECOMMENDATIONS  
9.8.1 Recommendations for Improving Healthcare Practice in Egypt 
There is growing concern to solve the problem of spreading liver disease as a 
national health problem in Egypt. In 2008, the Egyptian Ministry of Health launched 
a National Control Strategy for treating and preventing viral hepatitis, including the 
opening of 20 national treatment reference centres providing antiviral hepatitis for 
free to those with national health insurance or who cannot pay (Guerra et al. 2012). 
There is a need to develop medical research that focuses on the treatment of viral 
hepatitis (Dalglish 2008), and to construct specific liver disease institutes.  
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The medical model as the main approach for providing healthcare services has 
contributed to some extent to improve health. By preventing HBV through 
obligatory anti-HBV vaccinations for children and optional vaccinations for adults, 
providing physical examination, continuous routine check-ups for hemodynamic 
parameters and tumour markers as well as trying to provide free or low cost 
medicine for patients with viral hepatitis and cirrhosis. However, according to this 
study's findings, cirrhotic patients in Egypt have poor HRQOL, which means that 
the available healthcare services may not be enough to enhance satisfaction 
regarding their health status. Bowling (2005) maintains that a medical model is no 
longer enough; particularly in cases of chronic or life threatening diseases . 
Therefore, it is recommended that ‘The best measure of quality is not how well or 
how frequently a medical service is given, but how closely the result approaches 
the fundamental objectives of prolonged life, relieving distress, restoring function 
and preventing disability’ (Ware et al. 2008, p.3).  
Increasing the quality of healthcare is a growing interest globally. Thus, sufficient 
and qualified healthcare providers, nurses in particular, are considered the 
backbone of the healthcare system worldwide (Ma et al. 2012). In Egypt, the 
nursing sector faces many challenges; a shortage of nurses in general and 
qualified nurses in particular (Farag 2008). The ratio of nurse to population is 
estimated to be 33.5 nurses per 10,000 people, which is too low to provide 
adequate care (WHO 2008). A brief background explanation will help to understand 
why the quality of nursing in Egypt is so low.  
Three types/levels of nurses’ education are currently available in Egypt: (1) 
Secondary school nursing education (low level), who account for 94% of the current 
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nurses in Egypt, (2) Technical institutes of health (two years of nurses’ education 
after secondary school), resulting in a high nursing Diploma, which account for 
about 0.5% of nurses in Egypt, and (3) University nursing education (four years of 
nurses’ education after secondary school plus one year internship in clinical 
settings), resulting in a baccalaureate of nursing sciences; which account for about 
1.0% of nurses in Egypt (Farag 2008; Ma et al. 2012).. 
The majority of qualified nurses prefer to work in private hospitals, a teaching 
career or migrate to countries where nurses are paid more (Farag 2008). 
Therefore, the majority of current nurses in the public health sector, which is the 
major sector in Egypt, are without a basic standard of nursing qualification. That 
means they do not have the ability to make decisions regarding the patient's health 
or care. There is a growing concern to reform the nursing sector in Egypt to provide 
healthcare services that meet the patients' needs. The reform process is still being 
implemented as it aims to increase the number of qualified nurses by improving the 
quality of university nursing education and by increasing the number of admitted 
students and to stop secondary school nursing (Ma et al. 2012). However, the 
reform has faced several obstacles such as financial restrictions and stakeholder 
resistance (Bossert and El Rabbat 2012).   
Nurses have an important role in supporting patients and their families to adjust to 
the disease and use available healthcare resources effectively to improve their 
QOL. Thus, supporting patients to engage in their daily activities as far as possible 
can be achieved by providing self-management programs. Healthcare policy should 
support nurses by providing continuous development programs, and establishing 
evidence based infrastructure. Improving people’s health cannot be achieved 
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without continuous support from the national healthcare system. Healthcare policy 
makers need to develop strategic plans of investment for improving current nurses' 
performance and equipping them with the needed resources. For example in the 
one of the developed Western countries, the Scottish Government (2010, p. 41) 
states that in their healthcare strategy for improving the National Health Service 
(NHS) in Scotland ‘...important changes in culture and approach will be required to 
ensure that staff are equipped and supported...’. Therefore continuous upgrading of 
the healthcare system through staff development and training together with the 
provision of resources is important for increasing the quality of healthcare services. 
The main responsibility of healthcare policy makers is to improve the map of 
healthcare services to direct healthcare providers' actions and performance, 
particularly for the care of liver disease patients. Delivering high quality healthcare 
that produces better health outcomes for patients requires qualified staff with skills 
and knowledge that makes them competent to deliver high quality care. Ware et al. 
(2008, p. 3) state that ‘clinical investigators evaluating new treatments and 
technologies and practicing physicians and other providers trying to achieve the 
best possible patients outcomes began to use the information about functional 
status, well-being, and other important health outcomes. Policy analysts also began 
to utilize this information to compare the costs and benefits of competing ways of 
organizing and financing healthcare services, as did managers of healthcare 
organisations seeking to produce the best value for each healthcare dollar’.  
In Egypt, the Executive Committee for Accreditation and Quality (ECAQ) was 
established in 2006, with the aim to update the standards of accreditation, assess 
and survey facilities, increase quality awareness, provide training, and develop 
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performance improvement projects. Accordingly, a strategic plan was developed in 
2006 to improve the quality of healthcare services under the supervision of the 
ECAQ. However, Professor El Hosseiny, the Head of ECAQ and Consultant for the 
Egyptian Minister of Health (MOH) reported that many challenges in the application 
of accreditation standards have been identified. The main problem was staff 
resistance to change especially in the areas of: (1) working as a team, (2) 
delivering care as an integrated team and (3) following standard procedures (El 
Hosseiny 2010).  
Furthermore, many cultural problems challenged the ECAQ's aims; such as 
changing the concept of physician-centred to patient-centred care, accepting the 
idea of continuous performance evaluation, staff turnover due to the fact that 
preparing for accreditation requires more effort and problems of staff 
communication (among doctors, nurses and patients). Therefore, ECAQ asserted 
that there is still a need for more effort and work to increase the commitment of 
policy makers and all healthcare providers and to enhance the concept of patient 
first in healthcare provision (El Hosseiny 2010). It is strongly recommended that 
healthcare providers, social scientists and policy makers in Egypt work in harmony 
to improve the national healthcare system, while taking patients’, families’ and 
healthcare professionals’ experience into consideration, for their mutual benefit.  
Although patient-centeredness is one of the ECAQ aims in Egypt (El Hosseiny 
2010), the list of national indicators to analyse and evaluate quality of healthcare 
does not include assessment of patients, family or healthcare professionals’ 
satisfaction. In Scotland, the healthcare quality strategy is built on listening to 
people’s experience of care and using this information to improve healthcare 
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services (The Scottish Government 2010). Thus, a person-centered approach with 
communication not only between healthcare professionals but also with patients 
and their family is at the heart of a quality healthcare strategy. Patient reported 
outcomes, patient experience of access, self-assessed general health and 
healthcare experience are some of the quality outcomes measures. Thus, peoples’ 
experience was used to develop a quality healthcare strategy generally for NHS 
Scotland (The Scottish Government 2010), and specifically for liver care (NHS Liver 
Care 2013)  
Involving patients in the processes of decision making during the development of a 
care plan would help to develop a self-management program that satisfies patients’ 
needs. Patients are the greatest source of information to help healthcare providers 
to decide whether a goal is achieved. However, patient experience regarding their 
disease or the medical intervention provided has not been routinely collected in 
clinical practice (Ware et al. 2008), particularly in public hospitals in Egypt where 
the majority of patients receive healthcare services.  
Continuous ignorance of the psychosocial needs of people with liver cirrhosis may 
cause them to experience ‘stigma and discrimination; lack of adequate healthcare 
and rehabilitation services; and inaccessible transport, buildings and information’ as 
reported by WHO in disabilities and rehabilitation (2012b). According to the 
recommendations of the WHO, governments and authorities have the responsibility 
to provide services to meet peoples’ needs, develop national specific programmes 
for those who are in need, and adopt a national improvement strategy and action 
plan. Furthermore, lay people should be involved in the development of services to 
cover patient needs and expectations, as well as understanding barriers to 
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receiving appropriate care. They should be involved in the design and 
implementation of programs and strategic plans as lay persons (WHO 2012b). 
To enhance the mental health of patients, healthcare providers in Egypt, 
particularly physicians and nurses, need to be aware of the importance of engaging 
the patient’s family in the care plan. Social support can influence patients' health 
outcomes as well as the care plan. In a study of US patients with diabetes or heart 
failure to assess the influence of family support and family-related barriers to their 
self-care Rosland, et al. (2010) found that about two-thirds of patients had 
supportive family involvement in self-care. Patients with high social support were 
more likely to report high adherence to self-care programs. Therefore, it is highly 
recommended to enhance the social support to people with liver cirrhosis in Egypt 
by developing effective intervention programs. 
9.8.2 Recommendations for Future Research 
Replicating this study with a large sample of patients at different stages of chronic 
liver disease (non-cirrhosis, compensated and decompensated cirrhosis) using a 
longitudinal approach to investigate the predictive factors of HRQOL and symptoms 
experience are needed in order to confirm the hypotheses of the model of Wilson 
and Cleary (1995) as well as to develop causal relationships. Although this study 
used quantitative questions, some patients gave qualitative comments to "explain" 
their answer, which increased the understanding of patients’ suffering. Therefore, a 
qualitative approach is recommended to explore why cirrhotic patients in Egypt, 
particularly females, have lower perceived social support and higher severity of 
some symptoms, such as depression, than men. 
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The majority of the studies of HRQOL of liver disease patients that were conducted 
in different countries have a norm-based sample of a healthy population that was 
used as a comparative group, particularly for SF-36 (Younossi et al. 2001; Hauser 
et al. 2004; Karaivazoglou et al. 2010). There are also HRQOL databases, which 
have been used to track liver disease patients' HRQOL (Afendy et al. 2009; Liu et 
al. 2012). However, the SF-36 has not been tested with the Egyptian general 
population's HRQOL, which may be less than the norm-based standard in Western 
countries. Moriarty et al. (2003, p. 2) insisted that ‘continuous monitoring of 
population HRQOL gives public health agencies current health data they need to 
assess, protect, and promote population health. Tracking population HRQOL over 
time also helps identify health disparities, evaluate progress on achieving broad 
health goals, and inform healthy public policy’. Therefore, there is a need in the 
near future to create a database in Egypt about the general population’s HRQOL 
and patients' generic and disease specific HRQOL. This should be available for 
routine clinical care as well as for future research to study and track HRQOL of 
patients with liver disease and other chronic illnesses.  
There are different sources of support: (1) natural or primary support provided by 
family and (2) professional support provided by healthcare professionals (Lanza 
and Revenson 1993). Perceived social support from healthcare providers has not 
been investigated in patients with liver disease or cirrhosis in Egypt or other chronic 
illnesses. Lindsey et al. (1985) assessed structural and functional social support 
using the Norbeck Social Support Questionnaire in Egyptian cancer patients. 
Results showed that no participant reported a healthcare provider; therapist or 
counsellor in their social network, while only two listed a religious person. This 
suggests that Egyptian patients may not recognise that healthcare professionals 
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are a source of support. Therefore it may be useful to explore how cirrhotic or liver 
disease patients in general perceive the availability and adequacy of support from 
their healthcare provider and the types of social support available. Types of social 
support in general have been explored in people with other chronic diseases; 
however, they have not been investigated in patients with liver disease or cirrhosis, 
particularly in Egypt. Types of support can be helpful in identifying the needed 
intervention, for example, for a lack of information the healthcare provider may give 
effective support.  
Although the association between social support and physical and mental health 
has been supported theoretically (Cohen and Wills 1985; Tijhuis et al. 1995; Hlebec 
et al. 2009) it still needs more empirical investigation in patients with chronic 
diseases in Egypt, particularly those with liver disease, to understand the 
mechanisms of social support, and whether types of social support from different 
sources are associated with HRQOL. 
9.9 STRENGTHS AND LIMITATIONS OF THE STUDY  
9.9.1 Study Design  
This study is cross-sectional, which makes it difficult to report causal relationships 
between variables. However, Seers and Critelton (2001), and Ligthelm et al. (2007) 
acknowledged that a well-designed cross-sectional study can play a vital role in 
supporting evidence-based practice for patient management. Getting information 
from the population at a single point in time is seen as a reasonable strategy for 
pursuing descriptive and exploratory research projects (Ruane 2005) in order to 
develop future hypotheses. However, future longitudinal studies are recommended 
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to identify causal relationships between the studied independent and dependent 
factors such as social support, symptoms experience and HRQOL.  
The cross-sectional nature of this study also made it impossible to explore how 
patients perceived their health over time to evaluate health transition status. The 
data for this study were collected between June-August 2011, the same year as the 
Egyptian revolution (January 2011). Therefore, the results may have been 
influenced by this as community change can affect an individual's perception of 
their health, particularly mental health. Therefore, there is a need to repeat this 
study and to conduct longitudinal research to determine whether there is stability in 
perceived general health over time and whether the perception of health status is 
different according to patients' satisfaction with the healthcare they received. 
9.9.2 Sample and Sampling Strategy  
Although, probability (randomization) sampling  is the best way to give every 
individual a chance to take part in the study and to decrease the chances of 
sampling errors (Meadows 2003), this method is sometimes impossible when 
facilities and resources to develop a random table for recruitment is missing. Bruce 
et al. (2008, p. 139) insisted that ‘where time and resources are very short, or there 
is no structured way of contacting people for a given study, it may be satisfactory to 
use what is known as a convenience sample’. A convenience sample is a 
commonly used method in nursing research because it saves time and money, and 
is useful in overcoming insufficient resources (Nieswiadomy 2008). The time 
restriction of the data collection period (three months) and insufficient resources to 
develop a sampling frame made it impossible to randomly select the participants. 
345 
 
For this reason, a nonprobability (convenience) sampling method was used to 
recruit the sample.  
The convenience sampling method is usually criticised as a limitation in 
generalising the research findings, because it may not be representative of the 
general population of interest. However, the current study sample is thought to be 
representative of people with liver cirrhosis in Egypt. The sample was collected 
from three specialized well-known hospitals caring for liver disease people, which 
patients from different regions in Egypt and socioeconomic status attend for 
treatment. Four hundred and one patients with heterogeneous demographic and 
socioeconomic status participated in this study. There was an excellent response 
rate (96.6%), which decreases the chance of selection bias. Specific inclusion and 
exclusion criteria helped to select the representative sample of patients with liver 
cirrhosis but without cancer, or advanced hepatic encephalopathy, who may need a 
different approach of care.  
9.9.2.1  Participants' Characteristics  
A total of 401 patients with compensated and decompensated cirrhosis were 
recruited for this study, where 56.6% were females, 63.6% resident in urban areas, 
77.3% married, 44.4% housewives, 54.5% illiterate and mean age 53.25 years (22-
76 years). In previous liver disease surveys in both Egypt (Darwish et al. 2001; 
Strickland et al. 2002; Schwarzinger et al. 2004; Basal et al. 2011) and western 
other countries (Marchesini et al. 2001; Kim et al. 2006; Les et al. 2009) more men 
were recruited than women because liver disease is reported to be higher among 
males (WHO 2006). However, this study sample represents cirrhotic patients in 
Egypt in terms of socio-demographic and medical characteristics.  
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It was found that most participants in previous Egyptian surveys were males, 
married, illiterate and between 35-39.6 years (Darwish et al. 2001; Strickland et al. 
2002; Schwarzinger et al. 2004). This study is quite different, as the mean age was 
higher and the number of females larger. This may be because the previous 
Egyptian studies were conducted only with HCV patients, mainly without cirrhosis 
and the majority were farmers and manual labourers from rural areas or Upper 
Egypt (Darwish et al. 2001; Strickland et al. 2002; Schwarzinger et al. 2004). The 
current study was conducted in Cairo, so the majority of participants came from 
urban areas, and the participants were patients diagnosed with cirrhosis due to 
various causes.  
In a recent quasi-experimental study of Egyptian patients with liver disease, Abdel-
Wahhab et al. (2011) investigated the impact of new medical treatment in two 
groups of patients: liver cirrhosis and hepatic carcinoma (HCC). The results were 
similar to the current study; the mean age of the cirrhotic group was 47.8, while the 
HCC group was 52.3. The percentage of men in the two groups was 42.3% and 
44.4% respectively, which is lower than the females. In addition, the number of 
patients living in urban areas was 61.1% in the liver cirrhotic patients group, which 
was higher than the patients with hepatic carcinoma (46.2%). In Kalaitzakis et al. 
(2006) study, the mean age of the cirrhotic Swedish participants was 57.2 and 61% 
were men. The mean age of non-cirrhotic patients was 48, and 50 for patients with 
advanced cirrhosis, the majority (67%) were married and women were more than 
half of the participants (van der Plas et al. 2003). Therefore, this sample is quite 
representative of cirrhotic patients in terms of socio-demographic characteristics 
such as age, education, marital status, type of occupation and employment status.  
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Regarding the medical characteristics of the participants, this study's results 
showed that comorbidities were common in cirrhotic patients. A number of patients 
reported one or more medical comorbidities, most often diabetes and hypertension. 
This study's findings are consistent with previous studies which found that medical 
comorbidities, such as diabetes mellitus, hypertension…etc. were the most 
common comorbidities of cirrhotic patients (Marchesini et al. 2001; Kalaitzakis et al. 
2006; Firtz and Hammer 2009; Les et al. 2010; Basal et al. 2011). For example, 
Mabrouk et al. (2012) retrospectively studied HRQOL of patients getting liver 
transplants and compared them to patients on the waiting list for transplantation. 
They found that 45.6% of the liver transplant patients had diabetes and 25.2% had 
hypertension, and in non-transplant patients, diabetes was 48% and hypertension 
was 28%. These findings suggest that the current study is representative of 
cirrhotic patients in Egypt and the most common comorbidities are diabetes and 
hypertension.  
According to the report of the Ministry of Health and Population and National 
Committee for the Control of Viral Hepatitis in Egypt, viral hepatitis is the main 
cause of liver cirrhosis and is a major health problem facing Egypt (Dalglish 2008). 
In this study, the common cause of cirrhosis was HCV. Similarly, in a recent study 
HCV was identified as the major cause of liver cirrhosis (>77%) in liver transplant 
and no-transplant patients in Egypt (Mabrouk et al. 2012), however, ‘Egyptian 
patients may also be co-infected with Schistosomiasis, a pathogen that also harms 
the liver and accelerates the course of liver disease’ (Dalglish 2008, p. 9). Also, a 
group of patients in this study had both viral hepatitis (B or C) and Schistosomiasis. 
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Although the current study lacked laboratory data to confirm the stage of cirrhosis 
using the Child-Pugh score, endoscopy reports, ultrasound and/or CT images were 
used to identify complications such as ascites and varices and medical records 
were reviewed to find significant comorbidities. Medical comorbidities and number 
of hospitalizations were self-reported by some patients, because their medical 
records did not show this data. However, several studies have demonstrated the 
accuracy and validity of self-reported medical history by patients (Dominguez et al. 
2007; Vinay et al. 2011). In conclusion, we argue that the study sample represents 
cirrhotic patients in Egypt in terms of socio-demographic and medical 
characteristics.  
9.9.2.2  Setting and Method of Data Collection  
About 100 hospitals in Egypt are prepared to provide healthcare for patients with 
advanced liver disease, although there are about 400 specialist liver disease 
hospitals (Dalglish 2008). To recruit a large heterogeneous sample, patients were 
recruited from three liver disease specialist hospitals in the biggest city in Egypt 
(Cairo) from different sectors: teaching institute (NHTMRI), teaching hospital 
(Section 2 in Kaser El-Ani) and private hospital (CDYCDLR).  
The majority of the participants (85%) were approached by the researcher. One of 
my colleagues in the Faculty of Nursing-Cairo University assisted me in recruiting 
the others. To avoid data collection biases the assistant was trained in the method 
of recruitment and completing the questionnaire. A training protocol (Appendix 4-
17) was developed and there was training on clinical settings with real examples.  
The majority of the participants preferred to be interviewed alone. Interviewing the 
patients without family attendance was helpful to avoid their effect on the patients’ 
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perception of their health status. For instance, two of the participants agreed to be 
interviewed with their relative in attendance and the family member tried to answer 
on behalf of the patient. For example, when asking the patients item 1 in SF-36 
which is related to general health perception, the daughter and wife of these two 
patients responded rapidly that s/he could not do anything and their health is so 
poor. Thus, it was observed that the patient's family perceived his/her health status 
as poor, although the patient perceived it as fair or good. As a result, it was difficult 
to complete the interview; therefore, it was essential to agree that attending family 
member avoid responses during the interview. Based on that, it may be useful to 
conduct future research to find whether or not there is a significant difference 
between the patients and their families' perception of the patients’ HRQOL.  
9.9.3 Quality and Limitations of Instruments   
9.9.3.1  Generic HRQOL: SF-36 
Over the last few years interest in using generic and disease specific measures of 
HRQOL has rapidly increased in health research (Bowling 2001). Hauser et al. 
(2004) recommended that HRQOL should be measured by generic and disease 
specific instruments. Therefore both disease specific (LDSI-2.0) and generic (SF-
36) measures of HRQOL were used in this study for first time. 
SF-36 is a short validated generic HRQOL tool in Arabic and can be completed 
within 20 minutes. Bao et al. (2007) stated that the SF-36 is a cheap and 
convenient generic HRQOL tool, which can be used in developing countries, to 
provide complementary and useful clinical data. However, its validity was not tested 
in liver disease Egyptian patients although it is widely used. Therefore, it was 
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essential to test its psychometric properties in the studied sample. The results 
confirmed its validity and internal reliability (see section 8.4).  
9.9.3.2 Disease Specific HRQOL: LDSI-2.0 
LDSI-2.0 is a short tool that can be completed in 10 minutes; it can assess the 
severity and hindrance of symptoms. LDSI-2.0 was translated into Arabic for this 
study and its convergent and divergent validity was established among 38 cirrhotic 
patients in Egypt (Youssef et al. 2012). A further analysis for testing the tool’s 
construct validity using the main sample size (n=401) was done. Factor analysis 
found that the Arabic LDSI-2.0 is valid and has high internal consistency and 
reliability. This suggests that the LDSI-2.0 is a feasible tool that can be used in 
clinical settings (see section 8.2). The LDSI-2.0 has been used before in clinical 
settings in the Netherlands and its applicability in tracking patients’ health status 
was statistically significant (Gutteling et al. 2008; Gutteling et al. 2008a). However, 
there is a need for future studies to confirm the psychometric properties of the 
LDSI-2.0 in different stages of liver disease and its feasibility in clinical practice 
among people with mixed liver disease stages.  
9.9.3.3 Perceived General Health: Item 1 in SF-36 
It was planned to investigate the relationship between perceived general health and 
HRQOL, but because the scale (perceived general health) is an item in the SF-36, 
it proved to be difficult to expose this relationship. Smith et al. (1999) conducted a 
meta-analysis study to find the difference between QOL and health status. The 
standard question "in general, would you say your health is excellent, very good, 
good, fair or poor?" was the widely used measure to assess the patients' 
perception of general health (Smith et al. 1999). Item 1 in SF-36 had the same 5 
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point ordinal scale ranging from excellent to poor. Therefore, it was apparent that 
item 1 in SF36 was the most appropriate scale to use to assess the general health 
perception among cirrhotic patients in Egypt. However, because the item is 
involved in the PCS of the SF-36 it was difficult to include it in the regression 
analysis as an independent factor to find the association between perceived 
general health and HRQOL to avoid singularity. 
Singularity is a statistical problem that occurs if one independent variable is a 
combination of another independent variable and entered in the regression 
analysis, because it will develop poor regression results (Pallant 2007). Therefore, 
there is a need to develop a valid tool to assess the perceived general health in 
liver disease patients in Egypt to use in future research.  
9.9.3.4 Perceived adequacy of Social Support: MSPSS 
No identified studies have assessed perceived social support in liver disease 
patients using the MSPSS. Hence, this study was the first to use this tool in liver 
disease and cirrhotic patients to assess their social support perception. The 
psychometric properties of MSPSS were tested with Arabic immigrant women in 
the US (Aroian et al. 2010); however, it has not been examined in liver disease 
patients in Egypt or elsewhere. Hence, it was important to test its validity and 
internal reliability to check its properties in cirrhotic patients. The findings 
established that the MSPSS is valid and reliable in cirrhotic patients in Egypt (see 
section 8.3). 
While completing the MSPSS no particular problem related to clarity and 
understandability was found by participants. For instance, the patients did not ask 
for further clarification during the completion of the MSPSS and it took less than six 
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minutes to complete. However, future research is required to investigate its retest 
reliability, which was not examined due to the constraints of time.  
Although the MSPSS could explore how patients in this study perceived the 
available support from different sources: spouse, family and friends, it could not 
decide the type of available support, and this was the only limitation in MSPSS. 
Social support has been identified as ‘a multi-faceted concept that has been difficult 
to conceptualise, define and measure’ (Hupcey 1998, p. 1231). Therefore, a 
recommendation for future research is to evaluate different types of social support 
using a valid tool combined with the MSPSS, in order to help to recognise some of 
these patients’ needs. 
9.10 CONCLUSION  
It is important to acknowledge that using a cross-sectional design makes it 
impossible to determine the direction of causality of any identified associations. 
However, the study is unique as it is the first study to investigate and explore 
HRQOL, symptoms experience and perceived social support of liver cirrhotic 
patients in Egypt. It is the only study to have been conducted among liver cirrhotic 
patients in the Middle East and particularly in Egypt to evaluate and analyse the 
factors associated with HRQOL, symptoms experience and perceived social 
support. Regarding the first aim of this study, results showed that liver cirrhotic 
patients in Egypt have poor perceived HRQOL in all domains of SF-36. Symptoms 
severity has been identified as the main factor associated with perceived HRQOL. 
Therefore, treating symptoms may improve these patients’ HRQOL and decrease 
their physical, psychological and social suffering. Social support was also found to 
be an important factor associated with perceived symptoms severity and hindrance 
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of symptoms. This suggests that engaging the patients’ family in the care plan will 
decrease these patients’ burden and increase their HRQOL.  
Regarding the second aim of this study, results showed that liver cirrhotic patients 
in Egypt have  relatively high severity of symptoms. The majority of participants 
reported one or more of a wide range of symptoms: joint pain, decreased appetite, 
memory problems and difficulty of using time effectively were some of the most 
frequent reported symptoms. Joint pain, depression and decreased appetite were 
the symptoms that influenced their daily activities most. Gender, number of liver 
cirrhosis complications and perceived social support from spouse associated 
significantly with symptoms severity as well as hindrance of symptoms. Therefore, 
healthcare providers should consider these factors during the development of 
symptoms management programs of cirrhotic patients.  
Regarding the third aim, the perceived social support score was relatively high 
among patients with liver cirrhosis in Egypt, with the support from a spouse rating 
the highest. Marital status made the strongest contribution, followed by gender, to 
explain social support. Singles, females, unemployed and elderly patients were 
more likely to perceive low social support. Therefore, these patients were found to 
be a vulnerable group who need further attention from  healthcare providers to 
develop a care plan, particularly a self-care program that may need involving the 
patient’s family.  
In summary, symptoms are a treatable factor that can be managed; however so far 
few studies are concerned with developing intervention programs that aim to 
improve these patients’ HRQOL. Hence, there is a need for future studies to 
alleviate these patients' symptoms in order to improve their HRQOL. This study has 
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contributed to knowledge by finding some of the psychosocial factors that may 
affect HRQOL of liver cirrhotic people in Egypt. However, there may be other 
important associated factors, although the regression model could significantly 
explain the HRQOL. Accordingly, further research in liver cirrhotic patients in Egypt 
is urgently needed to explore other factors that are associated with or predict 
perceived HRQOL such as self-efficacy and coping style that have not been 
investigated before among patients with cirrhosis.  
Finally, based on this study results we recommend that for clinical practice and 
future research: 
 
 Different dimensions of symptom experience should be measured: severity 
and hindrance. 
 Liver disease patients should be regularly assessed for symptom experience 
to identify treatable symptoms such as depression and decreased appetite. 
 Future intervention studies that aim to develop programs to relieve treatable 
symptoms and enhance social support are recommended.  
 Nurses should involve the patient’s family in any plan of care.  
 Enhancing social support to people with liver cirrhosis in Egypt by 
developing effective intervention programs is required. 
 Healthcare providers in Egypt, particularly physicians and nurses, need to 
be aware of the importance of engaging the patient’s family in the care plan. 
 Future studies to confirm the psychometric properties of the LDSI-2.0 in 
different stages of liver disease and its feasibility in clinical practice among 
people with mixed liver disease stages need to be developed. 
 A valid tool to assess perceived general health in liver disease patients in 
Egypt to use in future research needs to be developed. 
 There is a need to design future studies to examine whether the cause of 
cirrhosis is related to HRQOL by measuring this association using an 
adequate sample size for each cause and a common classification strategy.  
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 Further research is recommended to explore additional predictive factors of 
HRQOL and symptoms experience, such as coping strategy and self-
efficacy. 
 Longitudinal studies are recommended to identify causal relationships 
between the studied independent and dependent factors such as social 
support, symptoms experience and HRQOL 
 Future studies are recommended to explore why cirrhotic patients in Egypt, 
particularly females, have lower perceived social support and higher severity 
of some symptoms, such as depression, than men. 
 There is a need to create a database in Egypt about the general 
population’s HRQOL and patients' generic and disease specific HRQOL. 
This should be available for routine clinical care as well as for future 
research to study and track HRQOL of patients with liver disease and other 
chronic illnesses.  
 It may be useful to explore how cirrhotic or liver disease patients in general 
perceive the availability and adequacy of support from their healthcare 
provider and the types of social support available. 
 There is a need for further studies to investigate the type of social support 
and its relation with HRQOL among liver cirrhotic patients. 
 Testing the mediation effect of social support in the relationship between 
symptoms experience and perceived HRQOL should be evaluated in future 
research. 
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APPENDICES LIST 
Appendix 3-1: Search process  
(1) MEDLINE via web of knowledge (search ended at April 2012) 
Number of search Key-terms Result 
# 1 MeSH Heading=((((quality of life *) OR health related quality of life 
*) OR functional status *) OR health status *) OR well-being *)  
Databases=MEDLINE Timespan=All Years 
Lemmatization=On    
153438 
# 2 MeSH Heading=((liver cirrhosis *) OR liver disease *) OR 
hepatitis *)  
Databases=MEDLINE Timespan=All Years 
Lemmatization=On    
184020 
# 3 MeSH Heading=((liver disease *) OR liver cirrhosis *) OR 
((hepatits *) NOT fatty liver *) NOT alcohol *))  
Databases=MEDLINE Timespan=All Years 
Lemmatization=On    
65430 
# 4 #1 AND #3  
Databases=MEDLINE Timespan=All Years 
Lemmatization=On    
309 
# 5 MeSH Heading=(((symptom *) OR fatigue *) OR pain *) OR 
depression *)  
Databases=MEDLINE Timespan=All Years 
Lemmatization=On    
271214 
# 6 #5 AND #3 
Databases=MEDLINE Timespan=All Years 
Lemmatization=On    
259 
# 7 MeSH Heading=(((social support *) OR social network *) OR 
psychosocial support *) OR support system *)  
Databases=MEDLINE Timespan=All Years 
Lemmatization=On    
43627 
# 8 #7 AND #3 
Databases=MEDLINE Timespan=All Years 
Lemmatization=On    
9 
# 9 #7 AND #5 AND #3  
Databases=MEDLINE Timespan=All Years 
Lemmatization=On    
 
0 
# 10 #7 AND #5 AND #3 AND #1  
Databases=MEDLINE Timespan=All Years 
Lemmatization=On    
0 
Total number of papers 
that reviewed from 
MEDLINE   
309+259+9= 577 
 
 
 
 
2 
 
(2) CINAHL and PsycINFO (via Health Source) (search ended at April 2012) 
Number of 
search 
 
Key-terms Limiters/Expanders 
Result 
S1 
quality of life OR health 
related quality of life OR 
functional status OR health 
status  
Limiters - Exclude MEDLINE 
records  
Search modes - 
Boolean/Phrase 
109610 
S2 liver disease OR liver 
cirrhosis OR hepatitis NOT 
fatty liver NOT alcohol NOT 
transplantation NOT 
primary biliary cirrhosis 
Limiters - Exclude MEDLINE 
records  
Search modes - 
Boolean/Phrase  
23851 
S3 
symptom OR fatigue OR 
pain OR depression  
Limiters - Exclude MEDLINE 
records  
Search modes - 
Boolean/Phrase  
538237 
S4 
social support  OR social 
network OR psychosocial 
support OR support system 
Limiters - Exclude MEDLINE 
records  
Search modes - 
Boolean/Phrase  
93166 
S5 
 
S1 and S2  
Limiters - Exclude MEDLINE 
records  
Search modes - 
Boolean/Phrase  
461  
 
 
S6 
 
S2 and S3  
Limiters - Exclude MEDLINE 
records  
Search modes - 
Boolean/Phrase  
1711 
S7 
 
S2 and S4 
Limiters - Exclude MEDLINE 
records  
Search modes - 
Boolean/Phrase  
121 
Total number  461+1711+121= 2293 
 
 
(3) ASSIA Databases Applied Social Sciences Index and Abstracts 
Number of 
search 
Key-terms Result 
S1 su.EXACT(("Alcohol related liver cirrhosis" OR "Liver 
cirrhosis") OR "Hepatomegaly" OR "Chronic liver diseases" OR 
("Cholestasis" OR "Chronic liver diseases" OR "Hepatocellular 
cancer" OR "Hepatomegaly" OR "Liver diseases" OR 
"Obstetric cholestasis")) 
130148 
S2 su.EXACT(("Perceived social support" OR "Social support")) 
OR su(Support System)  
3542 
S3 (symptom OR fatigue OR pain OR psychological status OR 49541 
3 
 
depression) 
S4 health related quality of life or quality of life or health status or 
functional health or mental health or functional status 
50792 
S5 S1 AND S4 21 
S6 S1 AND S3 33 
S7 S1 AND S2 0 
Total  21 + 33 = 54 
 
(4)Search strategy used in Google scholar: search limitations (1990-2012), English study 
First search 
http://scholar.google.co.uk/scholar?q=quality+of+life+and+chronic+liver+disease+or+hepatitis+
C+in+Egypt&btnG=&hl=en&as_sdt=0%2C5&as_ylo=1990&as_yhi=2012 
Second search 
http://scholar.google.co.uk/scholar?q=fatigue+or+pain+or+depression+and+chronic+liver+dise
ase+or+hepatitis+C+in+Egypt&btnG=&hl=en&as_sdt=0%2C5&as_ylo=1990&as_yhi=2012 
Search libraries of these sites in Egypt: 
Centre l ibrary of Cairo University, 
National l iver institute, 
Academy of Scientific Research and Technology and  
Arab Journal of Gastroenterology.   
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Appendix 3-2: Quality appraisal form  
Study  Reporting  
 
External validity 
(generalisability 
Internal validity (bias) 
1. No.  
2. Yes 
 
1. No  
2. Unable to determine  
3. Yes   
- not applicable  
1. No 
2. Unable to determine 
3. Yes 
- not applicable 
Cleary 
described 
the study's 
aim, 
hypotheses 
or research 
questions 
Clearly 
described 
the main 
outcome 
Clearly 
described 
participants 
characteristics 
Clearly 
described 
the key 
findings 
Participants 
are 
representative 
of the entire 
population 
Healthcare 
resources in 
setting of data 
collection  
representative 
of the 
treatment that 
majority of 
patients 
receive 
Used valid 
and reliable 
measurement 
Used 
appropriate 
statistical data 
analysis (e.g. 
nonparametric 
methods used 
for small 
sample size) 
Recruited 
study and 
control 
from the 
same 
population 
Used 
appropriate 
sampling 
method 
(e.g. 
random 
selection 
for 
intervention 
study) 
Reported 
number and 
characteristics 
of participants 
who lost 
during follow-
up or 
response rate 
Reported 
power 
analysis or 
method of 
sample 
calculation 
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Appendix 3-3:Methodological characteristics  of 41 studies  investigating HRQOL in liver disease or c irrhotic patients   
Author/country Design, Sampling method, Year of data 
collection, Method of data collection, 
theoretical framework  
Sample size, Setting   Demographic characteristics of 
the participants  
Afendy et al. 2009 
USA 
Databases cohort study, Databases cohort 
sample, USA cohort: 1996-2008, Italian cohort: 
July-December 1998, self-completion, NA 
1103 (number of patients with 
cirrhosis =69%) 
 
Mean age 54.2±12.0, 40% females.  
Arguedas et al. 2003 
USA 
Cross-section, consecutive, January-
September 2001, interview, NA 
160 patients at liver mixed stage 
(Child-Pugh A-c), one transplant 
clinic in university hospital  
Mean age 51.7±10, 64% males, 85% 
Caucasians 
Bailey et al. 2009 
USA 
Cross-section, convenience, NA, self-
completed in the hospital or by phone, NA  
126 patients with chronic HCV, 
one tertiary centre, 93% response 
rate 
Mean age 53.1±9.4 (27-78), 50.8% 
females, mean education 14 (7-22) 
years 
Bao et al. 2007 
China 
NA (seems cross-section comparative study), 
NA, December 2003-February 2006, self-
completing, NA 
126: 20 chronic HBV, 106 with 
cirrhosis, two hospitals (out and 
inpatients)  
Cirrhotic patients: Mean age 
45.4±7.2, 69% males, mean 
education 11.3±2.3 years 
Basal et al. 2011 
Egypt 
Cross-section, Convenience, June-December 
2010, interview, NA   
200 patients with HCV: 27 Child-
A, 173 Child-B, three clinics in 
three regions: Tanta, Assuite, 
Monofia 
39% aged 50-60 years, 71.5% 
males, 73.5% were married, the 
sample was divided into males and 
females: 56.6% of men and 63.2% of 
women lived in rural area, 39.2% of 
men were farmer, 36.8% of women 
were housewives, above 51% of both 
their income was not enough. 33.6% 
males and 42.1% females had 
secondary school education, 56.6% 
males and 63.2% females live in rural 
area. 
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Author/country Design, Sampling method, Year of data 
collection, Method of data collection, 
theoretical framework  
Sample size, Setting   Demographic characteristics of 
the participants  
Bianchi et al. 2005 
Italy 
NA, (seems cross-section), consecutive, 
January-December 2002, self-report and 
interview to check completion, NA 
165 cirrhotic patients, one 
university hospital  
 
age 37-87 years (median 65), 51.5% 
males 
Dan et al. 2006 
USA 
Databases cohort study (Retrospective 
survey), cohort sample completed the 
questionnaires between 1997-2005 during 
clinic visit, self-completion, NA 
140 patients at mixed disease 
stage (38% had cirrhosis) 
Mean age 49.4±11.2, 42% females, 
Fritz and Hammer 2009 
Australia 
NA (seems cross-section), consecutive, 
December 2001- December 2002, self-
reported, NA 
75 cirrhotic patients, one tertiary 
centre (out and inpatient) 
 
Mean age 57±1.4 (24-82), 42 males, 
91% secondary education or above, 
17 working, 36 benison 
Girgrah et al. 2003 
Canada 
NA (seems cross-section, NA, July 1998-
December 1999, self-reported, NA 
30 patients with cirrhosis, liver 
clinic of the general hospital  
 
Mean age 54±4, 93.3% males  
Gutteling et al. 2006 
Netherlands 
 NA (seems cross-section survey), cohort 
samples were selected from databases and 
received questionnaires by emails. October-
February 2000, self-report, NA 
1175 patients at mixed disease 
stages, Dutch liver patient 
association (DLA)  
Age 48±12, 42.3% males  
Haag et al. 2008 
Germany 
Prospective (seems cross-section), 
consecutive, NA, self-completed, NA 
204 patients with chronic liver 
disease (100 had cirrhosis), two 
tertiary centres (outpatient) 
Mean age 52.7±13.9, 51% men, 
100% Caucasians   
 
Hauser et al. 2004 
Germany 
NA (seems cross-section), consecutive, 
August 2002-August 2003, self-completed 
during outpatients visit or hospital stay, YES 
(biopsychosocial model of HRQOL in chronic 
gastrointestinal disease, did not mention how it 
was applied ), NA  
88 patients with chronic HCV at 
mixed stage, one tertiary referral 
centre  
Mean age 48.6%±14.6, 50% 
females, 70.5% with partner, 20.7% 
unemployed, 18.4% housewives or 
houseman, 39.8% in work, 52.3% 
were regular smokers, 25.0% had ≥ 2 
alcoholic drink/day. 
Hilsabeck et al. 2005 
USA 
NA (seems cross-section), consecutive, NA 
self-report, NA 
94 (38 with cirrhosis), one tertiary 
liver care centre 
Mean age 46.2±7.6, 57 males, 68% 
married, mean education 13.4 ±2.4 
years, 78% married, 72% 
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Author/country Design, Sampling method, Year of data 
collection, Method of data collection, 
theoretical framework  
Sample size, Setting   Demographic characteristics of 
the participants  
Caucasians, 61% genotype 1  
Hsu et al. 2009 
Canada 
NA (seems cross-section/Comparative study, 
convenience, 1
st
 January 2006—1
st
 June 2007, 
self-completion, NA 
271 patients with chronic HCV, 
197 non-cirrhosis, 17 CC, 57 DC, 
a tertiary care clinic (five 
hospitals)  
Mean age 49.7±8.6, 62.4% males, 
51.3% married, 89.7% white 
ethnicity, 20.3% lower high education 
Jover et al. 2005 
Spain 
Cross-section, consecutive, January 2001-
September 2002 administer by doctors, NA  
46 with cirrhosis (20 alcoholic 
cirrhosis) 
Mean age 58.8±9 (41-73), 69.5% 
men 
Kalaizakis et al. 2006 
Sweden 
Cross-section, consecutive, NA, self-
completion, NA  
128 patients with cirrhosis, one 
university hospital (in and 
outpatient), 90% response rate   
Mean age 57.2±11.5, 61% males 
Kalaizakis et al. 2008 
Sweden 
Cross-section, consecutive, NA, NA 156 with cirrhosis, one 
gastroenterology clinic (in and 
outpatient), 87% response rate 
Alcoholic cirrhosis (n=55): age 60±8, 
78%males,76% outpatients, 
HCV cirrhosis (n=32): age 54±7, 72% 
males, 84% outpatients, cholestatic 
cirrhosis (n=29): age 54±4, 69% 
males, 86% outpatients    
Karaivazoglou et al. 2010 
Greece 
Cross-section, consecutive, May 2004-
Septamber 2006, self-reported, NA 
84 patients viral hepatitis, 
HBV=45 and HCV=39, one 
hepatology unit  
Mean age 46±16.7 (19-78), 65.5% 
men, mean of education 8.8±4.4 
years,  
Kim et al. 2006 
Korea 
Cross-section survey, NA (seems 
consecutive), September 27-November 25 
2003, interview, NA  
129 cirrhotic patients (82.2% 
HBV), two university hospitals (in 
and outpatients clinics), 77.2% 
response rate  
Mean age 53.6±9.28, 80.6% men, 
90.7% married, 67.5% had higher 
education 50.4% unemployed  
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Author/country Design, Sampling method, Year of data 
collection, Method of data collection, 
theoretical framework  
Sample size, Setting   Demographic characteristics of 
the participants  
Les et al. 2010 
Spain 
Cross section, consecutive, 2004-2007, self-
completion, NA 
212 with cirrhosis, one tertiary 
clinic (outpatient) 
Mean age 61.5±10.9, 74% males 
Liu et al. 2012 
Japan 
Databases cohort study / stratified random 
sample from the main data in databases, Data 
available from a cross-sectional survey from 
2008-2009 in databases, self-completing, NA 
HCV group=312 for unmatched 
comparison. HCV group after 
developing matching with control 
group they become= 306, national 
survey  
306 HCV patients: 
mean age 60.64.±12.08, 44.38% 
females, 73.70% married, 46.93% 
college education, 46.82% employed, 
57.45% had national insurance 
Marchesini et al. 2001 
Italy 
Cross-sectional survey, Recruiting all patients 
who regular fellow up in outpatient clinic 
through 6 months, till December 1998, self-
completion and interview to avoid missing 
data, NA 
544 with cirrhosis, tertiary clinic 
(in and outpatients) 
 
Age 50±11, , 64% males, 51% had 
primary school  
Moyer et al. 2003 
Michigan 
Survey, consecutive, October 1999-May 2000, 
self-completing, NA 
214 with HCV : 
91 say not knowing, 123 divided 
into optimists (79.6%) and 
pessimists (6.5%), one tertiary 
university clinic (outpatient),  
Mean age 46.9±7.9, (20-69), 59.3% 
males, 69.9% married. 
Schwarzinger et al. 2004 
Egypt 
Cohort survey, NA (seems convenience), May-
December 2002, interview, NA  
146 HCV, Community, response 
rate 78% 
Participants were not aware of their 
HCV status, mean age 39.6%±12.3, 
43.1% females, 86.3% married, 
74.7% farmers, 60.3% illiterate 
Singh et al. 1997 
USA 
Prospective: 100 days for all participants, 18 
months for patients after transplantation, 
consecutive, 1991-1994, self-completion, NA  
81 with cirrhosis waiting for 
transplantation, one newly liver 
transplant centre   
Median age 47 (22-68 years), 80 
males  
Sobhonslidsuk et al. 2006 
Thailand 
Cross-section, NA (seems consecutive), 1
st
 
January -30
th
 June 2004, self-completion and 
interview with illiterate, NA 
250 patients with chronic liver 
disease, 23.6% Child-A, 22.4% 
Child-B/C, gastroenterology clinic  
Mean age 49.1±8.5, 64% males, 
29.8% single, 26.4%, unemployed, 
36.6%.reported  financial burden  
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Author/country Design, Sampling method, Year of data 
collection, Method of data collection, 
theoretical framework  
Sample size, Setting   Demographic characteristics of 
the participants  
Sumskiene et al. 2006 
Lithuania 
Survey, NA, 2001-2002, NA, NA 131 with cirrhosis different 
causes, one gastroenterology 
clinic (inpatient) 
Age: 17.6% <40years, 51.1% 40-60 
years, 31.3% > 60 years. 51.9% men 
Svirtlih et al. 2008 
Serbia 
Prospective (seems cross-section) study, 
consecutive, January 2005-December 2006, 
self-completion, NA 
227 patients with chronic liver 
disease (43 cirrhosis) 
 
Mean age 39±11.3  (16-66 years), 
64.3% 
Bondini et al. 2007 
USA 
Retrospective, cohort sample, NA, self-
completing, NA  
128 patients from Databases with 
viral hepatitis: B =68, C=60 and 
PBC=18  
 
HBV: mean age 44.2±12.9, 35% 
females, 29% cirrhosis 
HCV: mean age 47.3±8.3, 31% 
females, 38% cirrhosis  
PBC: mean age 57.9±9.6, 100% 
women 
Taliani et al. 2007 
Italy 
Prospective (6 months follow up), consecutive 
divided into three groups, NA structured 
interview and self-completing (based on type 
of data), NA 
264: patients with recent 
diagnosis of HCV and divided into 
three groups: untreated, treated 
and did not respond and treated 
and relapsed  (cirrhosis was in 5 
untreated   and 2 in treated), 14 
academic centres at 8 cities 
Mean age 43.8±11.4 (20-69), 64.4% 
males 
Teixeira et al. 2005 
Brazil 
Cross-section, NA , NA, self-completion, NA 103 (63 cirrhotic  and 40 non-
cirrhotic) 
Cirrhotic group: age 46±9.2, men 
64.4%, Non cirrhotic group: age 
37±10.8, males 60%  
Teixeira et al. 2006 
Brazil 
Survey (6 month follow up only for the group 
was on antiviral therapy), July 2001-May 2003, 
administer by physician, NA 
120 (5 had cirrhosis), on hospital 
(outpatient) 
 
Mean age 38.6±11 (20-62), 63.3% 
males 
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Author/country Design, Sampling method, Year of data 
collection, Method of data collection, 
theoretical framework  
Sample size, Setting   Demographic characteristics of 
the participants  
Teuber et al. 2008 
Germany 
Cross-section,  NA, self-completion, NA 215 chronic hepatitis C (16.7% 
severe fibrosis or cirrhosis), on 
university hospital (outpatient), 
power of sample calculated (at 
least 200 required) 
Mean age 46.7±13.4 (19-79), 57% 
men, disease duration 6±5.6 (1-32 
years) 
Toda et al. 2005 
Japan 
NA, NA, answered the questionnaires during 
clinical visit, NA  
117, chronic viral hepatitis (45.3% 
cirrhosis), one hospital 
(outpatient) 
Age 50 year 19%, 50-59 year 28%, 
>60 year 53%,  
van de Plas et al. 2003 
Netherlands 
Survey, selected from databases of liver 
disease association and received email to 
complete the tools, October 2000, self-
completion, NA 
1175 cohort sample of patients 
with chronic liver disease.  
489 non-cirrhosis, 391 CC, 84 
DC, Dutch liver patient 
association (DLA), 80% response 
rate 
G1: non-cirrhosis (489) , mean age 
48±12, 43.8% males, 73.9% married  
G2: CC (391), mean age 49±14, 
41.4% males, 75.1% married  
G3: DC, mean age 50±12, 42.9% 
males, 67.9%. married  
van der Plas et al. 2004 
Netherlands 
Survey, consecutive, patients received 
questionnaire by email, October 2000, self-
completed, NA 
1175: 42.5% non-cirrhotic 34% 
CC, 7.3% DC, 16.2% liver 
transplant, DLA 
 
 
Mean age48±12, 57.7% males, 74% 
married. 90.7% secondary or higher 
education,   
van der Plas et al. 2007 
Netherlands 
Observational study, patients received 
questionnaire by email, October 2000, self-
completed, NA 
918 patients with mixed stages 
and causes of disease 
(48.7% non-cirrhosis, 42.1%) CC, 
9.2% DC), DLA, about 80% 
response rate 
 
Mean age 49±13, 58.5% women, 
74.5% married, 52.4% secondary 
education of above 
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Author/country Design, Sampling method, Year of data 
collection, Method of data collection, 
theoretical framework  
Sample size, Setting   Demographic characteristics of 
the participants  
Wilson et al. 2010 
USA 
Cross-section, consecutive, 2004-2005, self-
completing, NA  
65 of patients had HCV, 39% 
grade IV fibrosis, one 
gastroenterology clinic 
(outpatient). 
66% males, 55% married, 
Wunsch et al. 2011 
Poland 
NA, consecutive, January September 2008, 
self-completion, NA 
77 with cirrhosis, one tertiary 
clinic (in and outpatient) 
 
Mean age 52.8±13.1, (22-84 y), 61% 
males, 
Younossi et al. 2001 
USA 
Cross-section, convenience, August 1997-
February 1999, self-completion, NA 
353 patients with different causes 
of liver disease, 35% Child-A, 
61.6% Child-B/C, cirrhosis, one 
liver disease clinic,  
G1 chronic viral hepatitis (n=133), 
mean age 46±9, 64.7% males  
G2 chronic cholestatic (n=126), 
mean age 54±11, 30.2% males, 
G3 Hepatocellular disease (n=94), 
mean age 52±13, 59.6% males  
Zandi et al. 2005 
Iran 
Quasi-experimental study control, Longitudinal 
cases register method random assignment to 
divide the sample into 20 control and 20 study 
groups, 2002, NA  
 
40 with cirrhosis, one hepatitis 
centre, 
 
Experimental group: mean age 
40.8±12.5/(18-65), 50% males, 85% 
married, 90% primary, secondary 
and higher education, 40% work: 
laborer, 30% employee, 20% 
housewife 
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Appendix 4-3: Information sheet (The main study-English) 
 
1. Title of research study 
Health-related quality of life and symptoms experience of patients with liver cirrhosis in 
Egypt 
2. Invitation for taking part in research study 
Would you like to take part in a research study? 
 
 Before you decide, it is important for you to understand why the research is 
being done and what it will involve. 
 
 Please take time to read/understand the following information sheet carefully 
and discuss it with the researcher or others if you wish. Please ask if there is anything 
that is not clear or if you would like more information. 
3. Introduction about liver cirrhosis:  
Liver cirrhosis is a chronic disease that leads to impaired liver functions as a result from 
fibrosis and scarring formation. Till now there is no definite management for curing 
patients from cirrhosis. Patients have only to keep taking prescribed medications and 
follow up with their doctor to prevent disease complications and stop cirrhosis to 
progress. 
4. Background about the study research: 
This study is part of a research project for my PhD study. 
This research is looking at what patients with liver cirrhosis think about their health status 
and what symptoms that they have and how these symptoms affect their daily activities 
and social life. 
15 
 
 The research is funded by the Egyptian government and is part of my 
PhD study which I am doing at Department of Nursing and Midwifery, University of 
Stirling, UK. 
The study will be conducted for three years 
 It is up to you to decide whether or not to take part. 
5. What will happen to the participants?  
I am interested in exploring what patients with liver cirrhosis think about their health 
status and what are symptoms that they have and how these symptoms affect their 
daily activities and social life.  
Therefore, I will interview a sample of patients (at least 200) with liver cirrhosis disease 
to complete the following four questionnaires: 
 
1) A background questionnaire that contains questions such as where you live, whether 
you work and your medical history with liver disease. 
2) A questionnaire to assess if you experience any symptoms associated with your liver 
disease and how these may affect your everyday activities.  
3) A questionnaire to assess what you think about your health status. 
4) A questionnaire to assess what you think about your family support.  
I will interview you for about one hour and this will take place in the hospital 
before or after consultation with the consultant (for out-patient) or in the patients' room 
(for admitted patients). 
If you like, you can ask a relative or friend to be present during the interview.  
I just will take notes about what you are saying to complete the questionnaires.  
There will be a private room for conducting the interview to maintain privacy.  
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You can ask me to stop to take a rest at any point during the interview.  
6. Volunteer participation 
If you would like to participate you will be asked to sign a consent form. You will be given 
a copy of the signed consent form to keep.  
If you change your mind at any time about being involved, you can tell me to 
stop and you can withdraw from the study and withdraw your consent without having to 
say why.  
Stopping will not affect your care. 
7. Results of the study and confidentiality 
 
 The results of the study will be collected together and written in my PhD 
thesis (report) which will be ready in 2012. You will not be identified in the report.  
All data will be kept confidential and I will make sure that you cannot be 
identified from any data collected. I will put a code, not your name, on the questionnaire. 
Also, nobody can see your medical records except me to collect your medical data. All 
your personal information will be stored in a locked filing cabinet and will be treated as 
confidential. 
I hope that this study will explore what patients with liver cirrhosis think 
about their health status and what symptoms they have and how these symptoms affect 
their daily life.  This will   help healthcare providers in the future to develop appropriate 
intervention programs to decrease symptoms severity and improve patients’ health 
status. 
 
 8. Medical research ethical approval  
17 
 
The Research Ethics Committee (REC) in Department of Nursing and Midwifery, 
University of Stirling, UK has examined the proposal and has raised no objections from 
the point of view of medical ethics. The research also has been approved by responsible 
institutes in Egypt whose role is to check that research is properly conduc ted and the 
interests of those taking part are adequately protected. 
If you would like to talk to someone about the study, please contact Prof. Khairia Elsawy 
on 0102572350 (professor of nursing in Faculty of Nursing, Cairo University) who will be 
happy to discuss it with you. 
Thank you for taking time to consider taking part in this study. If you would like to 
find out more about it, please contact me. 
Naglaa Fathy Afifi Youssef 
PhD student, Department of Nursing and Midwifery  
University of Stirling - United Kingdom 
I can be contacted in any of the following ways:  
 Telephone: 0181725189; I am available all the day.  
 Email:  nagla.elshamy@gamil.com 
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 بحثية -وثيقة إعلام للمشاركة فى دراسة
 صفحة معلومات للمشاركين في البحث 
 
 
  . عنوان الدراسة1
 نوعية الحياة الصحية و خبرة الآعراض لمرضى التليف الكبدى بمصر
  . دعوة للمشاركة في الدراسة:2
 يدعوك الباحث للمشاركة في هذه الدراسة البحثية
 
 
 سة البحثية؟ه الدراذهل تود المشاركة فى ه
 
رجاء إستغرق وقتا كافيا لدراسة هذه المعلومات ولا تتردد في توجيه أي اسئلة  للباحث إذا ماكان هناك أي شئ 
 غير واضح لك. 
 
 
 مقدمة للمريض: -3
تليف الكبد هو مرض نتج عن تحول خلايا الكبد الطبيعية الى الياف و تكون ندبات مما ينتج عنه خلل فى اداء 
ظائفه بصورة طبيعية. حتى الان ليس هناك علاج جذرى لمرض التليف الكبدى. العلاج الحالى يعتمد على الكبد لو
المتابعة الدورية مع الطبيب و اخذ الادوية الموصوفة من قبل الطبيب المعالج لتقليص فرص تطور المرض و 
 تقليل المضاعفات و الاعراض المصاحبة للمرض.
 
 ي ستجري والغرض من اجرائها. شرح موجز للدراسة الت4
 هذه الدراسة هى جزاء من مشروعى البحثى المقدم للحصول على درجة الدكتوراة 
الصحية و الاعراض التى يعانى منها و شدة  عن حالته مريض التليف الكبدى هذا البحث يهدف الى معرفة مفهوم
 الاجتماعية. هذه الاعراض و مدى تاثرها على انشطة المريض اليومية و على حالته
 و لك الحرية فى الاختيار بالموافقة او الرفض للمشاركة فى الدراسة
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 . وصف البحث:5 
مريض من مرضى التليف الكبدى فى مصر. سيتم اختيار المشاركين  220عدد المشاركين فى البحث على الاقل 
     .قسام الداخليةالذين تنطبق عليهم شروط المشاركة من العيادات الخارجية و الا
 : سوف يتم مقابلة المرضى المشاركين فى هذه الدراسة مره واحدة فقط
مددة المقابلدة بالتقريدب سداعة  .اثناء هذه المقابلة سيقوم الباحث بملىء الأستمارات البحثية (عددادهم اربدع اسدتمارات
 و سيكون مكان المقابلة داخل المستشفى 
 داخل المستشفى)  آخر يوماو فى  ع المريض (قبل او بعد الاستشارة الطبيةسيكون موعد المقابلة بلاتفاق م
المطلوب من المشارك طوال فترة الدراسة هو الموافقة على المشاركة فى الدراسة ثم الاجابة على الاسئلة 
 المطروحة.
 يمكنك أن تطلب مني أن أتركك لتأخذ قسطا من الراحة في أي لحظة خلال المقابلة.
 
 
دراسة البحثية هى دراسة خارجية بتمويل من الحكومة المصرية للحصول على الدكتوراه من جامعة هذه ال
   استرلنج باللملكة المتحدة البريطانيه. 
 سنوات 3مدة الدراسة 
 
 
 
 . وصف الهدف النهائي للبحث:6
ا مرضى التليف الكبدى الهدف من هذه الدراسة هو معرفة نوعية الحياة الصحية و شدة الاعراض التى يعانى منه
 فى مصر ومدى تاثيرها على انشطة المريض اليومية و على حالته
 
 
 . الاشتراك التطوعي:7
يمكن للمريض عدم الاشتراك او الانسحاب من الدراسة في اي وقت بدون ابداء اسباب و دون أن يؤثر ذلك علي 
 علاجه أو علاقتة مع الاطباء المعالجين او الممرضات. 
 
 حماية بيانات: -8
لن يستخدم اسم المريض وسوف يشار اليه برمز وستظل هويته غير معلنة في ايه نتائج ولكن سوف يسمح لفريق 
 البحث (الباحث الاساسى فقط) في الإطلاع علي الملف الطبى.
 02
 
 
 
 
 نتائج الدراسة: -9
 0020ف تكون جاهزة للمناقشة بعام نتائج الدراسة سوف يتم تجمعها و كتابتها فى رسالة الدكتوراة التى سو
اتمنى هذه الدراسة ان تساعد فى كشف اسباب معانة مرض التليف الكبدى مع المرض حتى تساعد معطى 
 الرعاية الصحية (الطبيب و الممرضة) ايجاد طرق علاجية لتخفيف معانتهم.
 
 لجنة أخلاقيات البحث العلمى: -01
جامعة استرلنج, اسكتلند,  -لجنة أخلاقيات البحث العلمى بكلية التمريض هذا البحث تمت الموافقة عليه من قبل
المملكة المتحدةالبريطانية والتي تدقق بأن كل الشروط التي تتعلق بسلامتك وحقوقك محترمة و محفوظة طول 
  2020/9/8 مدة الدراسة. وقد أعطيت الموافقة علي هذا البحث بتاريخ 
  
 ث:يمكنك الإتصال بالباح -11 
مها صلاح (كلية  ةبدكتور في  حالة احتياجك لمعرفة المزيد عن الدراسة و مناقشاتها  يمكنك الاتصال 
  3838082002جامعة القاهرة) على هذا الرقم -التمريض
 بالباحث او 
 اسم الباحث: نجلاء فتحى عفيفى يوسف
 يةالمملكة المتحدة البريطان-جامعة استرلنج-طالبة دكتوراة, قسم التمريض
 
   
  4511055610 الهاتف:
 اي وقت  يمكنك الاتصال فى وقت الأتصال:
 البريد الالكترونى: moc.liamg@ymahsle.algan 
و لديك الحق  إذا وافقت علي الإنضمام الي هذا البحث سوف تعطى الباحث موافقة كتابية بالموافقة على المشاركة
قعها.و  يمكنك الاتصال برقم الهاتف السابق في اى وقت اذا ما كانت في الاحتفاظ بنسخة من هذه الوثيقة بعد أن تو
 لديك اسئلة
 شكرا" لمشاركتك فى هذه الدراسة 
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Appendix 4-5: Informed consent (The main study-English) 
 
The study title: “Health-related quality of life and symptoms experience of patients with liver 
cirrhosis in Egypt” 
Please answer the following questions with yes (√) or no (X) to be sure you understood the 
content of the information sheet. 
 
 
I have read/informed well the information sheet  
 
 
I have had the chance to ask questions and talk about 
the research study 
 
 
 
I have been informed and understand it is voluntary 
participation 
 
 
 
I have been informed that I can withdraw from the study 
at any time without saying why 
 
 
 
I have been informed and understand the data and my 
confidentiality will be protected 
I agree to see my medical document 
 
 
I have taken copy of the informed consent 
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I am happy to take part in the above study   
 
Do you have any other question before giving your 
consent 
 
Participant's name:…………………...........Signature:……………………….. 
[by a person independent of the research]…………………………………… 
To be used if participant is unable to sign because of physical disability……: 
Name:……………………………………Signature:………………………….. 
Name of person taking consent:………………………Signature:………………… 
Date:……………………………………. 
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 وثيقة قبول ( موافقة) على الاشتراك فى دراسة بحثية  
 عنوان الدراسة البحثية 
 برة الاعراض لمرضى التليف الكبدى بمصرالحياة الصحية و خ نوعية
 للتاكد من انك قد فهمت كل المعلومات الخاصة بالبحث )х( او لا) √( ه الاسئلة بنعم ذمن فضلك اجب على ه
 لديك الحق في الاحتفاظ بنسخة من هذه الوثيقة بعد أن توقعها.
 
 
 
 أعلمت بشكل صحيح بالدراسة البحثية المقترحة.  
 
  ة من صفحة معلومات المريض.إستلمت نسخ
 
 اتيحة لى الفرصة للاستفسار عن الدراسة 
 اوافق على ان تطلع على ملفى الطبى
 
اعلمت بان إشتراكي تطوعي تماما ًولدي الحق في سحب موافقتي في أي وقت بدون أبداء تفسير أو اسباب 
 ولن يوثر ذلك علي علاقتي مع طبيبي المعالج او الممرضة.
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علمت بان البيانات والمعلومات التي ستجمع منى اوعني ستكون سرية ويتم التصرف فيها طبقا لقانون ا
                                            حماية المعلومات الخاصة بالآشخاص فيما يتعلق بالبيانات الشخصية.
     
 
 أوافق علي المشاركة في الدراسة البحثية التى تحت عنوان
  نوعية الحياة الصحية و خبرة الاعراض لمرضى التليف الكبدى بمصر
 جامعة استرلنج بالمملكة المتحدة البريطانية -والمسجلة بقسم التمريض
 
 إستلمت نسخة من وثيقة الموافقة (قبول الاشتراك)
 
 هل هناك اى سوال تود الاستفسار عنه قبل اعطاء الموافقة
 ...................................................................................أسم المريض: .......... 
 / /  التاريخ:.............................................. توقيع المريض:
 أسم وكيل المريض فى حالة عدم القراءة والكتابة:..................................................
 /   /  التاريخ:....................قيع وكيل المريض:....................................تو
 
 /          /   توقيع الباحث:.....................................التاريخ:
 
 هذه الوثيقة أعدت مع الاخذ في الاعتبار لكلا من:
جمعية الطبية العالمية الثامن عشر الذي عقد بهلسنكي بفنلندا إعلان الرابطة العالمية والمتبني من مؤتمر ال
 2222وفي السادس من اكتوبر  6661؛  6961؛ 3961؛  5761. والذي روجع اعوام 4661في يونيو 
  )  ten.amw.www (اعلان هلسنكى 9222, في ادنبرة اسكتلندا
  7661سبتمبر   59/53/HCI/BMPC ريرية الجيدة للمارسة الس  PCG-HCIتوجيهات 
التوجيهات الاخلاقية العالمية للبحث الطبي الحيوي المتضمن ادمين مجلس للمنظمات العالمية من العلوم 
   2222عام والذي روجع  2661) جنيف عام  SMOIC ( -الطبية
البحوث الطبية الحيوية  : التوجيهات العلمية للجنة الاخلاقية لمراجعة OHW( (منظمة الصحة العالمية 
  .2222جنيف عام 
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Appendix 4-7: Background data sheet (English) 
 
Participants’ Code………………………. 
Place of data collection (Setting) 
1. Outpatient   2. Inpatient  
 
A. Individual characteristics (Socio-demographic data and economic status) 
Age:  ………………… 
Gender:  
1. Male  2. Female 
Marital status 
1. Single 2. Married. 3. Widowed 4. Divorced 
Educational level: 
1. Illiterate  
2. Can read and write 
3. Primary or preparatory school 
4. Secondary school or Diploma 
5. Higher education 
Place of residence:  
1. Rural 
2. Urban  
Socio-economic status: 
Type of work/job 
1. Employee  2. Worker  3. Housewife  4. Farmer 
Current employment status   
1. Employed   2. Unemployed 
Reason for unemployment 
2. The liver disease…………………….. 
3. Other ……………………………………………… 
House occupied 
1. Own  2. Rented 
Who pay for your medications? ---------------------------------- 
 
B.  Medical and clinical data 
Complication of liver disease that you have in year 2010-2011: 
1. Splenomegaly  
2. Ascites  
3. Oesophageal varices without bleeding  
4. Oesophageal varices with bleeding  
5. Encephalopathy 
6. Other ......................  
Disease stage/severity  
26 
 
1. Compensate cirrhosis  2. Decompensate cirrhosis 
Cause of liver disease ………………. 
 
Note: These data from the patients’ medical records  
Previous hospital admission due to liver disease:   
1. No   
2. Yes 
1. Number of admission……………………………..   
2. Cause of hospital admission……………………….. 
Comorbidity  
1. Number of comorbidity….............................. 
2. Types of comorbidity: 1.       2.   3. 
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  فية و الطبيةاستبيان البيانات الديموجرا
  :....................كود المريض المشارك بالبحث
 مكان تجميع البيانات
 اقسام داخلية. 0  عيادة خارجية .0
 اولا" البيانات الديموجرافية
 -------------------السن
 ؟ النوع/الجنس
 . أنثى0                      . ذكر 0      
  الحالة الاجتماعية  
 . مهجوره5    . مطلق 4          . أرمل3       . متزوج 0     الزواج)  ىق ل(لم يسب . اعزب0 
 التعليم ىمستو 
 (لا يمكن القراءة والكتابة)  ى. أم0
 اعداديه) –(ابتدائيه  فقط القراءة والكتابةيمكن . 0
 . المدارس الثانوية أو الدبلوم 3
 . التعليم العالي4
 ..................................... اجابه اخرى....................5
 (المحافظة)............................................................ مكان الاقامة
 حضر. 0  ريف .0
  الحالة الاجتماعية والاقتصادية
 نوع العمل  
  ة..................................................وظيفال 
  ية وظيفال الحالةا 
 لا تعمل. 0  عملت .0
  عدم العملسبب  
  .....................................................على المعاش -ى (ربة منزلأخر . اسباب2  مرض الكبد
  لا .0            . نعم0 ؟تعيش فيههل تملك المنزل الذي 
  دوية ؟لاثمن ألك الذي يدفع  من
  قرار على نفقة الدولة. 3الاقارب او الاهل     . 0 انا          . 0
  ............................................ ذكاة او جمعيات خيرية5(النص بالنص او كله)       التأمينانا و  .4
 ثانيا. البيانات الطبية
 ما هي المضاعفات الناجمة عن مرض الكبد ألتى يعانى منها المريض خلال عام2122 -1122؟ 
 0. تضخم الطحال 
 0. استسقاء 
 3. دوالي المريء النزيف
 4. مرض الكبد الدماغى 
 5. الصفراء
 ما هي شدة / مرحلة تليف الكبد؟ 
 0 تليف الكبد تعويضى
 0. تليف الكبد غير تعويضى
 سبب مرض الكبد (فيرس س, ب, بلهارسيا.....................................)
 ملحوظة: هذه البيانات من ملف المريض الطبى
  لكبد؟دخول المستشفى بسبب مرض ال سبق لك ه
  . لا 0
  . نعم 0
  ........................................................................... ؟بسبب مرض الكبد المستشفىمرات دخولك  ما هو عدد
  .......  ........................... ؟ مثال على ذلك النزيففى كل مرة" المستشفى ب دخولاسبا
  ؟هاعاني منتما هي الأمراض الأخرى التي  
  ......................................3......................................0..........................................0
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Appendix 4-9: SF-36v2 (English) 
 
Your Health and Well-Being 
This survey asks for your views about your health. This information will help keep 
track of how you feel and how well you are able to do your usual activities. Thank you 
for completing this survey! 
For each of the following questions, please tick the one box that best describes  your answer. 
1. In general, would you say your health is: 
Excellent Very good Good Fair Poor 
     
   1    2    3    4    5 
2. Compared to one year ago, how would you rate your health in general now? 
Much better 
now than one 
year ago 
Somewhat 
better 
now than one 
year ago 
About the 
same as 
one year ago 
Somewhat 
worse 
now than one 
year ago 
Much worse 
now than one 
year ago 
     
   1    2    3    4    5 
 
 
     
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
 ▼  ▼  ▼  
 a Vigorous activities, such as running, lifting  
heavy objects, participating in strenuous sports ............................  1..............  2..............  3 
 b Moderate activities, such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf....................................  1..............  2..............  3 
 c Lifting or carrying groceries..........................................................  1..............  2..............  3 
 d Climbing several flights of stairs ..................................................  1..............  2..............  3 
 e Climbing one flight of stairs .........................................................  1..............  2..............  3 
 f Bending, kneeling, or stooping .....................................................  1..............  2..............  3 
 g Walking more than a mile ............................................................  1..............  2..............  3 
 h Walking several hundred yards....................................................  1..............  2..............  3 
3.  The following questions are about activities you might do during a typical day.  Does 
your health now limit you in these activities?  If so, how much? 
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4. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your physical 
health? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
 ▼  ▼  ▼  ▼  ▼  
 a Cut down on the amount of  
  time you spent on work or  
  other activities ....................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 b Accomplished less than you  
  would like ..........................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 c Were limited in the kind of  
  work or other activities ........................  1 ..............  2 ..............  3 ..............  4 .............  5 
 d Had difficulty performing the 
  work or other activities (for  
  example, it took extra effort).................  1 ..............  2 ..............  3 ..............  4 .............  5 
5. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
 ▼  ▼  ▼  ▼  ▼  
 a Cut down on the amount of  
  time you spent on work or  
  other activities ....................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 b Accomplished less than you  
  would like ..........................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 c Did work or other activities 
  less carefully than usual ......................  1 ..............  2 ..............  3 ..............  4 .............  5 
 
6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbours, or 
groups? 
Not at all Slightly Moderately Quite a bit Extremely 
▼  ▼  ▼  ▼  ▼  
   1    2    3    4    5 
 
 
 i Walking one hundred yards .........................................................  1..............  2..............  3 
 j Bathing or dressing yourself ........................................................  1..............  2..............  3 
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7. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very severe 
▼  ▼  ▼  ▼  ▼  ▼  
   1    2    3    4    5    6 
 
 
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
▼   ▼  ▼  ▼  
   1    2    3    4    5 
 
 
9. These questions are about how you feel and how things have been with you during 
the past 4 weeks.  For each question, please give the one answer that comes closest to 
the way you have been feeling.  How much of the time during the past 4 weeks… 
 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
▼  ▼  ▼  ▼  ▼  
   1    2    3    4    5 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
 ▼  ▼  ▼  ▼  ▼  
 a Did you feel full of life? ........................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 b Have you been very nervous? ..............  1 ..............  2 ..............  3 ..............  4 ..............  5 
 c Have you felt so down in the  
dumps that nothing could  
cheer you up?.....................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 d Have you felt calm and   
peaceful?............................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 e Did you have a lot of energy?...............  1 ..............  2 ..............  3 ..............  4 ..............  5 
 f Have you felt downhearted   
and low? ............................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 g Did you feel worn out? ........................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 h Have you been happy?........................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 i Did you feel tired? ...............................  1 ..............  2 ..............  3 ..............  4 ..............  5 
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11. How TRUE or FALSE is each of the following statements for you? 
 Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
 ▼  ▼  ▼  ▼  ▼  
 a I seem to get ill more 
easily than other people ......................  1 ..............  2 .............  3...............  4 ..............  5 
 b I am as healthy as  
anybody I know ..................................  1 ..............  2 .............  3...............  4 ..............  5 
 c I expect my health to  
get worse ...........................................  1 ..............  2 .............  3...............  4 ..............  5 
 d My health is excellent .........................  1 ..............  2 .............  3...............  4 ..............  5 
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 صحتك وعافيتك
 
 
ومدى قدرتك على القيام  ما تشعر بهستساعد هذه المعلومات على تتبع   يستفسر هذا الاستبيان عن آرائك في صحتك.
 شكًرا لك على ملء هذا الاستبيان! بأنشطتك المعتادة.
 في المربع الذي يحدد إجابتك أفضل تحديد وذلك لكل سؤال على حدة. ضع علامة برجاء و
 :هل يمكنك القول أن صحتك ة،بصفة عام .1
 معتلة متوسطة جيدة جيدة جًدا ممتازة
     
 5    4    3    2    1   
 
 ؟في الوقت الحاليم صحتك بصفة عامة كيف تقي   ،بالسنة الماضية بالمقارنة .2
 كثيًرا ضل أف
ن من السنة الآ
 الماضية
أفضل إلى حد ما 
ن من السنة الآ
 الماضية
 تقريًبا مثلما 
 كانت السنة الماضية
إلى حد ما أسوأ 
ن من السنة الآ
 الماضية
 أسوأ كثيًرا 
ن من السنة الآ
 الماضية
     
 5    4    3    2    1   
 
ممارستك  من تقي دهل صحتك الآن تتناول الأسئلة التالية الأنشطة التي قد تمارسها خلال أي يوم من أيامك العادية.  .3
 إذا كانت الإجابة بنعم، فإلى أي مدى؟ لهذه الأنشطة؟
 
 نعم، تقّيدها   
 كثيًرا
 نعم، تقّيدها 
 قليلاً 
دها لا، لا تقي ّ
 إطلاقًا
    
 ورفع الأشياء الثقيلة  العدومثل  ،قويةأنشطة  ا
  3 ................ 2  .................1 ............................................والمشاركة في الرياضات المجهدة
 ، مثل تحريك منضدة أو دفع أنشطة متوسطة ب
  3 ................ 2  .................1 ............................... أو ركوب دراجة مكنسة كهربائية أو السباحة
  3 ................ 2  .................1 ............................................................. رفع بقالة أو حملها ج
  3 ................ 2  .................1 ...................................................... طوابق عدةلصعود السلم  د
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  3 ................ 2  .................1 ...................................................... واحدصعود السلم لطابق  ه
  3 ................ 2  .................1 .................................................. الانحناء أو الركوع أو الميل  و
  3 ................ 2  .................1 ................................................... يزيد عن كيلومترالسير لما  ز
  3 ................ 2  .................1 ...................................................عدة مئات من الأمتارالسير  ح
  3 ................ 2  .................1 ................................................................. مائة مترالسير  ط
  3 ................ 2  .................1 ..................................................الاستحمام أو ارتداء الملابس ي
 
أي أنشطة يومية  في ، كم من الوقت مررت بأي من المتاعب التالية في عملك أوالماضيةالأسابيع الأربع خلال  .4
 حالتك الصحية البدنية؟لنتيجة معتادة أخرى 
 طوال  
 الوقت
 معظم 
 الوقت
 بعض 
 الوقت
 قليل من 
 الوقت
 لم يحدث
 
 الذي تقضيه في العمل أو  لوقتتخفيض ا ا
 5  ............. 4  ............... 3  .............. 2  .............. 1  ....................................... من الأنشطة.غيره  
 5  ............. 4  ............... 3  .............. 2  .............. 1  ....................................... مما تود أنجزت أقل ب
 العمل  نوعيةحدث انحصار في  ج
 5  ............. 4  ............... 3  .............. 2  .............. 1  .................................... أو غيره من الأنشطة. 
 العمل أو أداء في  صعوبةلاقيت  د
 غيره من الأنشطة (مثلاً، بذلت فيه  
 5  ............. 4  ............... 3  .............. 2  .............. 1  ..............................................جهًدا إضافيًا) 
 
يومية أنشطة أي  في، كم من الوقت مررت بأي من المتاعب التالية في عملك أو لأسابيع الأربع الماضيةاخلال  .5
 (مثل الشعور بالاكتئاب أو القلق)؟ نتيجة لأي مشكلات نفسيةمعتادة أخرى 
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 طوال  
 الوقت
 معظم 
 الوقت
 بعض 
 الوقت
 قليل من 
 الوقت
 لم يحدث
 
 ه في العمل أو الذي تقضي الوقتتخفيض  ا
 5  ............. 4  ............... 3  .............. 2  .............. 1  ........................................ غيره من الأنشطة 
 5  ............. 4  ............... 3  .............. 2  .............. 1  ....................................... مما تود أنجزت أقل ب
 أديت العمل أو غيره من الأنشطة  ج
 5  ............. 4  ............... 3  .............. 2  .............. 1  ..................................... بعناية أقل من المعتاد 
 
على أنشطتك  أو مشاكلك النفسية ة، إلي أي مدي أثرت حالتك الصحية البدنيالأسابيع الأربع الماضيةخلال  .6
 الاجتماعية العادية مع أسرتك أو أصدقائك أو جيرانك أو التجمعات التي تنتمي إليها؟
 لم يحدث 
 مطلقًاأثر 
حدث بدرجة  حدث بدرجة طفيفة
 متوسطة
حدث بدرجة كبيرة  حدث بدرجة كبيرة
 جًدا
     
 5    4    3    2    1   
 
 
 ؟الأسابيع الأربع الماضيةالذي شعرت به خلال  البدنيما مقدار الألم  .7
 حاد جًدا حاد متوسط طفيف طفيف جًدا لا شيء
      
 6    5    4    3    2    1   
 
 
على عملك المعتاد (بما في ذلك كل من عملك خارج المنزل وأعمال  الألم، كم أثر الأسابيع الأربع الماضيةخلال  .8
 المنزل)؟
حدث بدرجة  حدث بدرجة طفيفة لم يحدث أثر مطلقًا
 متوسطة
حدث بدرجة كبيرة  حدث بدرجة كبيرة
 جًدا
     
 5    4    3    2    1   
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ب على كل من ينرجو أن تج .الأسابيع الأربع الماضيةهذه الأسئلة تتناول شعورك و كيفية سير الأمور معك خلال  .9
 ...الأسابيع الأربع الماضيةكم المدة خلال  طريقة شعورك.الأسئلة التالية بالإجابة الأقرب إلى 
 
 
 
في أنشطتك الإجتماعية (مثل  حالتك الصحية البدنية أو النفسية، كم من الوقت أثرت الأسابيع الأربع الماضيةخلال  .11
 زيارة الأصدقاء أو الأقارب إلخ)؟
 لم يحدث قليل من الوقت لوقتبعض ا معظم الوقت طوال الوقت
     
  5   4     3    2    1   
 
 
 
 طوال  
 الوقت
 معظم 
 الوقت
 بعض 
 الوقت
 قليل من 
 الوقت
 لم يحدث
 
 5  .............. 4  .............. 3  .............. 2  .............. 1  ....................هل كنت تشعر أنك مليء بالحيوية؟   ا
 5  .............. 4  .............. 3  .............. 2  .............. 1  .................................... هل كنت عصبيًا جًدا؟ ب
 هل كنت تشعر أنك مغتم لدرجة  ج
 5  .............. 4  .............. 3  .............. 2  .............. 1  ........................ نه لا شيء يستطيع أن يسعدك؟أ
 5  .............. 4  .............. 3  .............. 2  .............. 1  .......................هل كنت تشعر بالهدوء والسكينة؟ د
 5  .............. 4  .............. 3  .............. 2  .............. 1  .......................... هل كان لديك كثير من الطاقة؟  ه
 5  .............. 4  .............. 3  .............. 2  .............. 1  ..................... هل كنت تشعر بالحزن والاكتئاب؟  و
 5  .............. 4  .............. 3  .............. 2  .............. 1  ...................... هل كنت تشعر بأنك منهك القوى؟  ز
 5  .............. 4  .............. 3  .............. 2  .............. 1  .......................................... هل كنت سعيًدا؟  ح
 5  .............. 4  .............. 3  .............. 2  .............. 1  ............................... هل كنت تشعر بالإرهاق؟  ط
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11.  أطخ وأ ةحص ىدم املك ؟كل ةبسنلاب ةيلاتلا تارابعلا نم 
  حيحص 
اًمامت 
 حيحص 
اًبلاغ 
 لا 
فرعأ 
 أطخ 
اًبلاغ 
خ أط 
اًمامت 
      
ا  ًلايلق لهسأ ةروصب ضرمأ يننأ ودبي 
.نيرخلآا نم...............................................  1 ...........  2 ............ 3............  4 ...........  5 
ب  ةحص لثم ةديج يتحصأ صخش ي 
هفرعأ.......................................................  1 ...........  2 ............ 3............  4 ...........  5 
ج يتحص ءوست نأ عقوتأ....................................  1 ...........  2 ............ 3............  4 ...........  5 
د ةزاتمم يتحص .............................................  1 ...........  2 ............ 3............  4 ...........  5 
 
 
 ًركشلأا هذه ىلع ةباجلإا ىلع ا!ةلئس 
 
SF-36v2™ Health Survey  2007 Health Assessment Lab, Medical Outcomes Trust and 
QualityMetric Incorporated. All rights reserved. SF-36
®
 is a registered trademark of Medical 
Outcomes Trust. (SF-36v2™ Health Survey Standard, Egypt (Arabic). 
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Appendix 4-11: Permission of QualityMetric Incorporated  
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Appendix 4-12: Method of interpreting outcome of SF-36v2, adapted from 
(ware and Gandek 1998 and Ware et al. 2000)  
Score under the average  
NBS (50) 
Norm-based standard (NBS)  Score above the average 
NBS (50) 
Difficult in performing different 
types of physical activities due to 
health limitation  
1 Physical functioning (PF) 
Performing different levels 
of physical activities without 
health limitation 
Difficult in performing work or daily 
activities because of physical 
health problems  
2 Role limitation due to 
physical problems (RP) Performing work or daily 
activities without physical 
health problems  
Experience severe pain and 
extremely difficult in performing 
daily activities due to pain  
3 Bodily Pain (BP) 
No pain or experience of 
limitation in activities due to 
pain  
Report general health as poor 
4 General Health (GH) 
Report general health as 
excellent  
Feeling tired and worn out all of the 
time 
5 Vitality (VT) 
Feeling of full happiness 
and energy all of the time  
Frequent difficult in performing  
social activities due to  physical 
and emotional problems 
6 Social Functioning (SF) 
Performing social activities 
without limitation result 
from physical or emotional 
problems  
Difficult in performing work or daily 
activities because of emotional 
health problems 
7 Role Limitation Due To 
Emotional Problems (RE) Performing work or daily 
activities without emotional 
problems 
Feeling nervous and depression all 
of the time 
8 Mental Health (MH) 
Feeling peaceful, calm and 
happy all the time 
Experience limitation in self-care, 
physical, social and role activities, 
feeling severe body pain, tiredness 
and perceived poor general health 
Physical Component Summary 
(PCS) 
No physical health 
problems, limitations, 
feeling high energy, 
excellent general health 
perception  
Feeling  psychological distress, 
social and role activities limitation 
due to due to emotional problems 
and perceived poor general health   
Mental Component Summary 
(MCS) 
No psychological distress, 
no problems in performing 
usual social and role 
activities due to emotional 
problems and perceived 
excellent general health   
 
 
Domains & Component summary 
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Appendix 4-13: LDSI-2.0 (English) 
Item   
1A To what extent in the past week: did you have 
itch? 
Not at all  To a high extent   
1B To what extent in the past week: has itch 
hampered you in your work or daily activities 
Not at all  To a high extent   
1C To what extent in the past week: has itch 
hampered you in your sleep? 
Not at all  To a high extent   
2A To what extent in the past week: did you have 
joint pain? 
Not at all  To a high extent   
2B To what extent in the past week: has joint pain 
hampered you in your work or daily activities? 
Not at all  To a high extent   
3A To what extent in the past week: did you have 
pain in the right upper belly? 
Not at all  To a high extent   
3B To what extent in the past week: has pain in 
the right upper belly hampered you in your 
work or daily activities? 
Not at all  To a high extent   
4A To what extent in the past week: were you 
sleepy during the day? 
Not at all  To a high extent   
4B To what extent in the past week: has 
sleepiness hampered you in your work or daily 
activities? 
Not at all  To a high extent   
5A To what extent in the past week: did you worry 
about the impact your liver disease may have 
on your home/family situation? 
Not at all  To a high extent   
5B To what extent in the past week: did you worry 
about the impact your liver disease may have 
on your home/family situation, hamper you in 
your work or daily activities?  
Not at all  To a high extent   
6A To what extent in the past week: did you have 
a decreased appetite?  
Not at all  To a high extent   
6B To what extent in the past week: did decrease 
appetite hamper you? 
Not at all  To a high extent   
7A To what extent in the past week: did you feel 
depressed due to your disease? 
Not at all  To a high extent   
7B To what extent in the past week: did 
depression due to your disease hamper you in 
your work, daily activities and/or social 
contacts? 
Not at all  To a high extent   
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8 To what extent in the past week: were you 
afraid that possible liver disease complications 
would develop? 
Not at all  To a high extent   
9A To what extent in the past week: did your skin 
turn yellow? 
Not at all  To a high extent   
9B To what extent in the past week: did 
yellowness of your skin hamper you in your 
work, daily activities and/or social contacts? 
Not at all  To a high extent   
EXTRA  ITEMS 
10 Since I have a liver disease I have difficulty 
remembering things. For example: things, 
which happened recently, where I have left 
things and appointments I have made. 
Not at all  To a high extent   
11 Due to my liver disease my personality has 
changed. 
Not at all  To a high extent   
12 My liver disease is a hindrance to my financial 
affairs. For example: with respect to 
mortgaging or insuring. 
Not at all  To a high extent   
13 My liver disease forces me to use my time 
differently than I really want. 
Not at all  To a high extent   
14 My sexual interest has decreased since I know 
I have a liver disease. 
Not at all  To a high extent   
15 My sexual activity has decreased since I know 
I have a liver disease. 
Not at all  To a high extent   
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Appendix 4-14: MSPSS (English)  
Items Very 
Strongly 
Disagre
e 
Strongly 
Disagre
e 
Mildly 
Disagree 
Neither 
agree 
nor 
disagree 
Mildly 
Agree 
Strongly 
Agree 
Very 
Strongly  
Agree 
1. There is a special 
person who is around 
when I am in need 
1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
2. There is a special 
person with whom I 
can share my joys and 
sorrows 
1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
3. My family really tries 
to help me 1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
4. I get the emotional 
help and support I 
need from my family 
1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
5. I have a special 
person who is a real 
source of comfort to 
me 
1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
6. My friends really try to 
help me 1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
7. I can count on my 
friends when things go 
wrong 
1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
8. I can talk about my 
problems with my 
family 
1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
9. I have friends with 
whom I can share my 
joys and sorrows 
1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
10.There is a special 
person in my life who 
cares about my 
feelings 
1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
11.My family is willing to 
help me make 
decisions 
1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
12. I can talk about my 
problems with my 
friends 
1 □ 2□ 3□ 4□ 5□ 6□ 7□ 
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  نحن مهتمين عن شعورك تجاه البيانات التالية. ِاْقَرأْي كلّ بيان بعناية. أَشِيري إلى كيف تَشعرين حول كلّ بيان. 
 
       لا توافقين) إذا كنَت 0ضعي دائرة حول رقم واحد (     
                           )  اذا كنت محايدة 0ضعي دائرة حول رقم اثنين (
                         ) اذا كنت توافقين.3ضعي دائرة حول رقم ثلاثة (
  ) اذا كان لا ينطبق عليك (ارملة، مطلقة، او منفصلة)99ضعي دائرة حول رقم (                        
 
 
  لا توافقين محايدة توافقين  طبقلا ين
  1 2 3 99
 
 .1 َزْوجي بجانبي عندما أكون محتاجة له..................................    0 0 3 99
 
 .2 أَشارَك فَرحتي و أحزاني مع َزْوجي....................................    0 0 3 99
 
 .3 تَُساِعَدني......................  تَُحاِولُ عائلتي (سوى َزْوجي) أن   0 0 3 
 
   
 3
 
 0
 
 0
 .4  أَحصل على المساعدة العاطفيّة و الدعم الذي ِاْحتَاَجه من   
  عائلتي (سوى َزْوجي) ...................................................     
  
 .5   .............  َزْوجي هو مصدر حقيقي للراحة لّي....................... 0 0 3 99
 
 .6 يَُحاِولُ أَْصِدقائي مساعدتي...........................................    0 0 3 
 
 .7 أَْعتَِمَد على أَْصِدقائي عندما تسوء الامور معي........................    0 0 3 
 
 .8 ...............أَتََحدَّ َث عن مشاكلي مع عائلتي (سوى َزْوجي).........   0 0 3 
 
 .9 عندي أَْصِدقاء أَشارَك فَرحتي و أحزاني معهم........................    0 0 3 
 
 .01 يَْهتَمُّ َزْوجي بمشاعري....................................................  0 0 3 99
 
 .11 ات.........عائلتي (سوى َزْوجي) راغبة أن تَُساِعَدني لاتخاذ قََرار َ  0 0 3 
 
 .21 أَتََحدَّ َث عن مشاكلي مع أَْصِدقائي.......................................   0 0 3 
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Appendix 4-16: Permission to use MSPSS 
(1) Professor Aroian permission 
 
From: Karen Aroian <karoian@mail.ucf.edu> 
Sent: 28 June 2010 15:10 
To: Naglaa Youssef 
Subject: Re: Multidimensional scale of perceived social support in Arabic 
Attachments: MSPSS.docx  
Naglaa,  
You have my permission to use the Arab version but be sure to credit Dr. Zimit as the author of 
the original version. Also, please note, we adapted the Arab version so that special person on 
the original is "husband" on the Arab version. This should meet your needs but I want to make 
sure you are informed.  I also want the Arab version to be properly referenced to me (Aroian) 
and for you to let me know how it performed in your study. The Arab version is attached. RE: 
time to complete the measure; my guess is 10 minutes at the most. Best wishes.  
Karen  
Karen Aroian, Professor 
Karen Aroian karoian@mail.ucf.edu 
 
(2) Professor Zimet permission 
From: Zimet, Gregory D <gzimet@iupui.edu> 
Sent: 17 January 2012 01:32 
To: Naglaa Youssef 
Subject: RE: Permission to use MSPSS 
Dear Naglaa Youssef,  
You have my permission to use the MSPSS in your research.  
I hope your research goes well. 
Sincerely yours, 
Gregory D. Zimet, PhD 
Professor of Pediatrics & Clinical Psychology 
Section of Adolescent Medicine 
Indiana University School of Medicine 
Health Information & Translational Sciences 
410 W. 10th Street, HS 1001 
Indianapolis, IN  46202 
USA 
Phone: +1-317-274-8812 
Fax:     +1-317-274-0133 
e-mail: gzimet@iupui.edu 
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Appendix 4-17: Training protocol for data collection assistant  
1. Contents outlines of the protocol 
2. Introduction  
3. Process that was used to identify data collection assistant 
4. What criteria that data collection assistant should have to be eligible for 
helping? 
5. Objectives of training data collection assistant  
6. The main objectives of these training sessions 
7. Content that will cover 
8. Tips to keep the team work 
9. Objectives of the training program and how it will achieve 
10. List of documents 
11. Interview procedures 
The document content is available but to save space it was not attached. Then you can 
ask the researcher to obtain it 
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Appendix 5-1: Permission for LDSI-2.0 tool to be translated into Arabic  
(1) Doctor Robert A. de Man permission 
From:   R.A. de Man [r.deman@erasmusmc.nl] 
Sent:   21 May 2010 21:40 
To:     Sally Wyke 
Cc:     'b.hansen@erasmusmc.nl'; Naglaa Youssef; Ashley Shepherd 
Subject:        Re: Permission to translate and use LDSI 2.0  
 
Dear dr. Wyke, 
The LDSI has not been translated in arabic. 
The questionaire is in the public domain so we give you permission to use 
it and wish you lots of succes with the planned studies. 
Kind regards, 
sincerely yours, 
Robert A. de Man 
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Appendix 5-2: Information sheet (Pilot study-English) 
 
1. Title of research study 
Pilot study to test the Arabic liver disease symptoms questionnaire    
2. Invitation for taking part in research study 
 
 
Would you like to take part in a pilot research study? 
Before you decide, it is important for you to understand why the pilot study is being done 
and what it will involve. 
Please take time to read/understand the following information sheet carefully 
and discuss it with the researcher or others if you wish. Please ask if there is anything 
that is not clear or if you would like more information. 
3. Introduction about liver cirrhosis:  
Liver cirrhosis is a chronic disease that leads to impaired liver functions as a result from 
fibrosis and scarring formation. Till now there is no definite management for curing 
patients from cirrhosis. Patients have only to keep taking prescribed medications and 
follow up with their doctor to prevent disease complications and stop cirrhosis to 
progress. 
4. Background about this pilot study: 
This pilot study is looking at testing the use of a questionnaire that has been translated 
into Arabic from English. I want to see if the questionnaire is easy to use or if during 
translation the questions are unclear for the Arabic speaker.  
 The pilot study is part of my PhD study research which I am doing at the 
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University of Stirling in the UK. The research study is funded by Egyptian government.  
The research study will be conducted for three years.  
It is up to you to decide whether or not to take part. 
5. What will happen to the participants?  
This is a pilot study to test a liver disease symptom questionnaire that is used for 
assessing the symptoms among patients with liver disease and how these symptoms 
affect these patients’ daily activities and their social life. This questionnaire has recently 
been translated from English to Arabic in order to assess health-related quality of life 
and symptoms experience of patients with liver cirrhosis in Egypt.  
I am interested in finding out whether the questionnaire is easily understood by 
participants and whether all the questions are clear.  
Therefore, I will interview a sample of at least 30 patients with liver cirrhosis  
I will ask questions to find out your thoughts about this questionnaire. Also, I will 
complete three questionnaires: 
1) A background questionnaire that contains questions such as where you live, whether 
you work and your medical history with liver disease. 
 2) A questionnaire to assess if you experience any symptoms associated with your liver 
disease and how these may affect your everyday activities.  
3) A questionnaire to assess what you think about your health status.  
I will interview you for about one hour and this will take place in the hospital  
before or after consultation with the consultant (for out-patients) or in the patients' room 
(for admitted patients). 
I need to interview you again for approximately 20 minutes to complete one of the 
questionnaires that mentioned before within the next three days after the first interview. 
You have the ability to refuse to attend the second interview. 
If you like, you can ask a relative or friend to be present during the interview.  
I just will take notes about what you are saying and complete the questionnaires.  
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There will be a private room for conducting the interview to maintain 
privacy.  
You can ask me to stop to take a rest at any point during the interview.  
 
 
  
6. Volunteer participation 
If you would like to participate you will be asked to sign a consent form. You will be given 
a copy of the signed consent form to keep. 
 
 
If you change your mind at any time about being involved, you can tell me 
to stop and you can withdraw from the study and withdraw your consent without having to 
say why.  
Stopping will not affect your care. 
 
 7. Results of the study and confidentiality 
The results of the study will be collected together and written in my PhD thesis (report) 
which will be ready in 2012. You will not be identified in the report.  
All data will be kept confidential and I will make sure that you cannot be 
identified from any data collected. I will put a code, not your name, on the questionnaire. 
Also, nobody can see your medical records except me to collect your medical data. All 
your personal information will be stored in a locked filing cabinet and will be treated as 
confidential. 
 
 
8. Medical research ethical approval  
The Research Ethics Committee (REC) in the Department of Nursing and Midwifery, 
University of Stirling, UK has examined the proposal and has raised no objections from 
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the point of view of medical ethics. The pilot study also has been approved by 
responsible institutes in Egypt whose role is to check that research is properly conducted 
and the interests of those taking part are adequately protected. 
If you would like to talk to someone about the study, please contact Prof. Khairia Elsawy 
on 0102572350 (professor of nursing in Faculty of Nursing, Cairo University) who will be 
happy to discuss it with you. 
Thank you for taking time to consider taking part in this study. If you would like to find out 
more about it, please contact me. 
Naglaa Fathy Afifi Youssef 
PhD student, Department of Nursing and Midwifery  
University of Stirling - United Kingdom 
I can be contacted in any of the following ways:  
 Telephone: 0181725189; I am available all the day.  
 Email:  nagla.elshamy@gmail.com 
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 تجريبيةبحثية   وثيقة إعلام للمشاركة فى دراسة
 صفحة معلومات للمشاركين في البحث
 
 
  عنوان الدراسة .1
 دراسة تجريبية لاختبار استبيان مؤشر أعراض مرض الكبد 2.2 المترجم الي العربيه
 
  . دعوة للمشاركة في الدراسة:2
 يدعوك الباحث للمشاركة في هذه الدراسة البحثية
 
 
 ه الدراسة البحثية؟ذد المشاركة فى ههل تو
 
 
رجاء إستغرق وقتا كافيا لدراسة هذه المعلومات ولا تتردد في توجيه أي اسئلة  للباحث إذا ماكان هناك أي شئ غير 
 واضح لك. 
 
 
 مقدمة للمريض: -3
عنه خلل فى اداء الكبد تليف الكبد هو مرض نتج عن تحول خلايا الكبد الطبيعية الى الياف و تكون ندبات مما ينتج 
لوظائفه بصورة طبيعية. حتى الان ليس هناك علاج جذرى لمرض التليف الكبدى. العلاج الحالى يعتمد على 
المتابعة الدورية مع الطبيب و اخذ الادوية الموصوفة من قبل الطبيب المعالج لتقليص فرص تطور المرض و تقليل 
 المضاعفات و الاعراض المصاحبة للمرض.
 
 . شرح موجز للدراسة التي ستجري والغرض من اجرائها4
 هذه الدراسة التجريبيه هى جزاء من مشروعى البحثى المقدم للحصول على درجة الدكتوراة 
" التي تم   2.0مؤشر أعراض مرض الكبد " يالمسمما إذا كانت الاستبيان هدف الى معرفة دراسة التجريبية تهذه ال
يسهل فهمها من قبل المشاركين في الاستبيان وأيضا ما إذا كانت جميع الأسئلة  الى العربيةترجمتها من الانكليزية 
 واضحة. 
يتم استخدام ا الاستبيان لتقييم الأعراض التي يعاني منها مرضي تليف الكبد وكيف تؤثر هذه الأعراض علي  
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 أنشطتهم اليومية وحياتهم الاجتماعية. 
 افقة او الرفض للمشاركة فى الدراسةو لك الحرية فى الاختيار بالمو
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 . وصف البحث:5 
مريض من مرضى التليف الكبدى فى مصر. سيتم اختيار المشاركين  20عدد المشاركين فى البحث على الاقل 
     .الذين تنطبق عليهم شروط المشاركة من العيادات الخارجية و الاقسام الداخلية
 : مرتينالمرضى المشاركين فى هذه الدراسة  سوف يتم مقابلة
  سيقوم الباحث بملىء الأستمارات البحثية  ولي:في المقابله الا
 هناك ثلاثة استبيانات سيتم ملئها: 
 ) استبيان البيانات الديموجرافيه مثل التاريخ المرضى, السن. 1
 اليومية.  همنشاطات الكبد وكيف تؤثر على ي) استبيان لتقييم الأعراض المصاحبة لمرض0 
 ) استبيان لتقييم ما رأيك في صحتك 0
 مدة المقابلة بالتقريب ساعة و سيكون مكان المقابلة داخل المستشفى 
 داخل المستشفى)  آخر يوماو فى  سيكون موعد المقابلة بلاتفاق مع المريض (قبل او بعد الاستشارة الطبية
الموافقة على المشاركة فى الدراسة ثم الاجابة على الاسئلة المطلوب من المشارك طوال فترة الدراسة هو 
 و رائيك حول هذا الاستبيان.  المطروحة
و سديكون مكدان دقيقده   20مددة المقابلدة بالتقريدب  واحدده,بحثيدة  هسيقوم الباحث بملدىء اسدتمار في المقابله الثانيه: 
 المريضسيكون موعد المقابلة بلاتفاق مع و المقابلة داخل المستشفى 
 في المقابله الثانيهلاتشارك يمكنك ا
 إذا أردت ، يمكنك ان تطلب من قريب أو صديق ليكون حاضرا خلال المقابلة. 
 سوف اكتب ملاحظات حول ما تقوله ولا استكمال الاستبيانات. 
 
 وسيكون هناك غرفة خاصة لإجراء المقابلة للحفاظ على خصوصية المريض المشارك
 
 ي أن أتركك لتأخذ قسطا من الراحة في أي لحظة خلال المقابلة.يمكنك أن تطلب من
 
هذه الدراسة البحثية هى دراسة خارجية بتمويل من الحكومة المصرية للحصول على الدكتوراه من جامعة استرلنج 
   باللملكة المتحدة البريطانيه. 
 سنوات 0مدة الدراسة 
 . وصف الهدف النهائي للبحث:6 
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"  التي  2.0مؤشر أعراض مرض الكبد "ما إذا كانت اداة الاستبيان هو معرفة دراسة التجريبية ال الهدف من هذه 
يسهل فهمها من قبل المشاركين في الاستبيان وأيضا ما إذا كانت جميع  تم  ترجمتها  من الانكليزية الى العربية
 الأسئلة واضحة. 
 
 
 . الاشتراك التطوعي:7
ك او الانسحاب من الدراسة في اي وقت بدون ابداء اسباب و دون أن يؤثر ذلك علي يمكن للمريض عدم الاشترا
 علاجه أو علاقتة مع الاطباء المعالجين او الممرضات. 
 
 حماية بيانات: -8
معلنة في ايه نتائج ولكن سوف يسمح لفريق  لن يستخدم اسم المريض وسوف يشار اليه برمز وستظل هويته غير
 البحث (الباحث الاساسى فقط) في الإطلاع علي الملف الطبى.
 
 نتائج الدراسة: -9
 0120نتائج الدراسة سوف يتم تجمعها و كتابتها فى رسالة الدكتوراة التى سوف تكون جاهزة للمناقشة بعام 
 
 لجنة أخلاقيات البحث العلمى: -01
جامعة استرلنج, اسكتلند,  -ث تمت الموافقة عليه من قبل لجنة أخلاقيات البحث العلمى بكلية التمريضهذا البح
المملكة المتحدةالبريطانية والتي تدقق بأن كل الشروط التي تتعلق بسلامتك وحقوقك محترمة و محفوظة طول مدة 
    2120/9/8الدراسة. وقد أعطيت الموافقة علي هذا البحث بتاريخ 
 
 يمكنك الإتصال بالباحث: -11
في  حالة احتياجك لمعرفة المزيد عن الدراسة و مناقشاتها  يمكنك الاتصال  بدكتورة خيرية الصاوئ على 
  او بالباحث  2100510212هذا الرقم 
 اسم الباحث: نجلاء فتحى عفيفى يوسف
 طالبة دكتوراة, قسم التمريض 
 نيةجامعة استرلنج, المملكة المتحدة البريطا
 
   
 9815271810 الهاتف:
 وقت الأتصال: يمكنك الاتصال فى اي وقت 
 البريد الالكترونى: moc.liamg@ymahsle.algaN 
و لديك الحق  إذا وافقت علي الإنضمام الي هذا البحث سوف تعطى الباحث موافقة كتابية بالموافقة على المشاركة
قعها.و  يمكنك الاتصال برقم الهاتف السابق في اى وقت اذا ما كانت في الاحتفاظ بنسخة من هذه الوثيقة بعد أن تو
 لديك اسئلة
 شكرا" لمشاركتك فى هذه الدراسة 
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Appendix 5-4: Informed consent (Pilot study-English) 
 
 
Pilot study to test the Arabic liver disease symptoms questionnaire  
  
Please answer the following questions with yes (√) or no (X) to be sure you understood the 
content of the information sheet. 
 
 
 
I have read/informed well the information sheet  
 
 
I have had the chance to ask questions and talk about 
the research study 
 
 
 
I have been informed and understand it is voluntary 
participation 
 
 
 
I have been informed that I can withdraw from the study 
at any time without saying why 
 
 
 
I have been informed and understand the data and my 
confidentiality will be protected 
 
 
 
I have taken copy of the informed consent 
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I am happy to take part in the above pilot study  
 
 
 
I am happy to take part in the second interview in the 
above pilot study 
 
 
Do you have any other question before giving your 
consent 
 
Participant's name:…………………...........Signature:……………………….. 
To be used if participant is unable to sign  
Name:……………………………………Signature:………………………….. 
Name of person taking consent:………………………Signature:………………………..  
Date:……………………………………. 
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 بحثية تجريبيةوثيقة قبول (موافقة) على الاشتراك فى دراسة 
 تجريبيةعنوان الدراسة البحثية 
 الي العربيه المترجم 2.0مؤشر أعراض مرض الكبد  استبيانراسة تجريبية لاختبار د
    ثللتاكد من انك قد فهمت كل المعلومات الخاصة بالبح )х( او لا) √( ه الاسئلة بنعم ذمن فضلك اجب على ه
 لديك الحق في الاحتفاظ بنسخة من هذه الوثيقة بعد أن توقعها.
 
 أعلمت بشكل صحيح بالدراسة البحثية المقترحة.  
 
 إستلمت نسخة من صفحة معلومات المريض.
 
 اتيحة لى الفرصة للاستفسار عن الدراسة 
 
أي وقت بدون أبداء تفسير أو اسباب  اعلمت بان إشتراكي تطوعي تماما ًولدي الحق في سحب موافقتي في
 ولن يوثر ذلك علي علاقتي مع طبيبي المعالج او الممرضة.
 
اعلمت بان البيانات والمعلومات التي ستجمع منى اوعني ستكون سرية ويتم التصرف فيها طبقا لقانون 
  حماية المعلومات الخاصة بالآشخاص فيما يتعلق بالبيانات الشخصية
 
  المشاركة في الدراسة البحثية التى تحت عنوان أوافق علي
  الي العربيه المترجم 2.2مؤشر أعراض مرض الكبد  استبيانراسة تجريبية لاختبار د  
 جامعة استرلنج بالمملكة المتحدة البريطانية -والمسجلة بقسم التمريض
 75
 
 
 أوافق علي المشاركة في المقابله الثانيه
  الطبى اوافق على ان تطلع على ملفى
 
 إستلمت نسخة من وثيقة الموافقة (قبول الاشتراك)
 
 هل هناك اى سوال تود الاستفسار عنه قبل اعطاء الموافقة
 
 أسم المريض: ..........................................................................
 / /    تاريخ:ال  .................................... توقيع المريض:
 أسم وكيل المريض فى حالة عدم القراءة والكتابة:.........................................
 /       / ....................................التاريخ: توقيع وكيل المريض:
 .........اسم الباحث:......................................................................
 /   /   توقيع الباحث:.....................................التاريخ:
 
 هذه الوثيقة أعدت مع الاخذ في الاعتبار لكلا من:
إعلان الرابطة العالمية والمتبني من مؤتمر الجمعية الطبية العالمية الثامن عشر الذي عقد بهلسنكي بفنلندا 
 2222وفي السادس من اكتوبر  6661؛  6961؛ 3961؛  5761م . والذي روجع اعوا4661في يونيو 
 ten.amw.wwwفي ادنبرة اسكتلندا 
  7661سبتمبر   59/53/HCI/BMPC للمارسة السريرية الجيدة   PCG-HCIتوجيهات 
نظمات العالمية من العلوم التوجيهات الاخلاقية العالمية للبحث الطبي الحيوي المتضمن ادمين مجلس للم
  3661) جنيف عام  SMOICالطبية (
منظمة الصحة العالمية : التوجيهات العلمية للجنة الاخلاقية لمراجعة البحوث الطبية الحيوية جنيف عام 
  .2222
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Prof. Sharazad 
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Prof. of Medical-Surgical 
Nursing (Adult nursing) 
Faculty of Nursing, British 
University, Egypt 
Prof. Kairia El-Sawia Prof. of Medical- Surgical 
Nursing (Adult nursing) 
Medical Unit, Faculty of Nursing, 
Cairo University, Egypt 
Dr. Naglaa Zayd 
Lecturer of Tropical Medicine, 
Consultant of Hepatology and 
Gastroenterology, Researcher  
Department of Tropical Medicine 
Gastroenterology and Liver 
Diseases, 
Kasr El Aini, Egypt 
Faculty of Medicine, Cairo 
University, Egypt 
Ali Alshraifeen  PhD student in the UK School of Nursing, Midwifery and 
Health, University of Stirling 
Nahla Hassan MPhil student in the UK School of Languages, Cultures 
and Religions, University of 
Stirling 
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Appendix 5-7: Guidance sheet for assess ing face and content validity of the LDSI-2.0  
The questionnaire of Liver disease symptom Index 2.0 (LDSI-2.0) has been translated from English to Arabic to use among patients with liver disease in 
Egypt. I would like to know your feedback about the questionnaire (LDS1-2.0) to what extent the English and Arabic versions are similar and its items 
appropriate to Egyptian people. Please read each question in the following table and answering it by giving your point of view during comparing between the 
two versions (Arabic and English Copies) by selecting from that scale: 
1. Strongly agree    2. Agree    3. Disagree    4. Strongly disagree 
 
    
LDSI’s 
items  
Is the translation 
similar in two 
versions?  
 
The item has to be 
modified?  
How? write your 
notes 
Is the item valid to the target 
cultural context (Egypt)?  
i.e.it gather information about 
symptoms among patients with 
liver disease in Egypt 
Is the concept valid in 
the target culture 
(Egyptian)?  
i.e. depression, pain, 
within the tool 
Is the phrasing 
clear in Arabic 
and English 
versions? 
Additional  
comment  
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Appendix 5-8: Observation sheet to evaluate feasibility of the Arabic LDSI-2.0  
Participant’s code:        Date: 
1. How long did it take to complete the LDSI-2.0 from the patient? (Administration time) 
o 0-5 minutes  
o 6-10 minutes 
o 11-15 minutes 
o 16-20 minutes 
o 20 minutes + 
2. Write (√) if the answer is Yes or write (X) if the answer is No 
Tools’ 
items 
Difficult and Missing items  Researcher’s 
comment 
Did patient 
provide a specific 
answer? 
Did patient give an 
open ended 
answer? 
 
Researcher asks: What do you 
mean by this answer? (in case 
the patients gave open ended 
answer)  
Did patient give a miss 
understood answer again? 
Did patient need 
clarification? 
Did patients cannot 
understand the item 
completely?  
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  )cibarA( 0.2-ISDL :9-5 xidneppA
  2.2مؤشر أعراض مرض الكبد 
 استبيان
الاستبيان يستفسر عن شدة الاعراض التى تشعر بها و تعانى منها و الى اى مدى هذه الاعراض تؤثر على عملك او انشطتك اليومية او  هذا
 وف تقوم بتحديد الإجابة التي تنطبق عليك. جميع الاسئلة متصلة بالاسبوع الماضي.سالاجتماعية. 
 على سبيل المثال :
 بألم؟  شعرت: إلى أي مدى في الاسبوع الماضي:  1البند 
 إلى حد كبير     4 3 0 0 لم يحدث على الإطلاق  2
 ؟ فى أنشطتك اليومية : إلى أي مدى في الاسبوع الماضي: أعاقك الألم في عملك أو 2البند 
 إلى حد كبير     4 3 0 0 الإطلاق يحدث علىلم   2
 
  لم يحدث على الإطلاق   0  4إلى حد كبير    2.2مؤشر أعراض مرض الكبد 
  أ) إلى أي مدى في الأسبوع الماضي:0(
  عانيت من حكة / هرش بجسمك؟
  لم يحدث على الإطلاق   إلى حد كبير  
  دى في الأسبوع الماضي:ب) إلى أي م0(
 اعاقتك الحكة /الهرش بجسمك في عملك أو أنشطتك اليومية؟
  لم يحدث على الإطلاق   إلى حد كبير  
  ج) إلى أي مدى في الأسبوع الماضي:0(
 اعقتك الحكة /الهرش بجسمك اثناء النوم؟
  لم يحدث على الإطلاق   إلى حد كبير  
  الماضي: أ) إلى أي مدى في الأسبوع0(
 عانيت من ألم في المفاصل؟
  لم يحدث على الإطلاق   إلى حد كبير  
  ب) إلى أي مدى في الأسبوع الماضي:0(
 اعاقك ألم المفاصل في عملك أو فى أنشطتك اليومية؟
  لم يحدث على الإطلاق   إلى حد كبير  
  أ) إلى أي مدى في الأسبوع الماضي:3(
  العلوي الأيمن من البطن؟ عانيت من ألم في الجانب
  لم يحدث على الإطلاق   إلى حد كبير  
  ب) إلى أي مدى في الأسبوع الماضي:3(
اعاقك ألالم في الجانب العلوي الأيمن من البطن في عملك أوفى 
 انشطتك اليومية؟
  لم يحدث على الإطلاق   إلى حد كبير  
  أ) إلى أي مدى في الأسبوع الماضي:4(
  لنوم يغلبك أثناء النهار؟كان ا
  لم يحدث على الإطلاق   إلى حد كبير  
  ب) إلى أي مدى في الأسبوع الماضي:4(
 اعاقك النوم أثناء النهار في عملك أوفى أنشطتك اليومية؟
  لم يحدث على الإطلاق   إلى حد كبير  
  أ) إلى أي مدى في الأسبوع الماضي:5(
الكبد الذي تعاني منه على الوضع  كنت قلقا ًبشاْن تأثير مرض
 العائلى/ اسرتك؟
  لم يحدث على الإطلاق   إلى حد كبير  
  ب) إلى أي مدى في الأسبوع الماضي:5(
 (القلق من تاثير مرض الكبد على حياتك العائلية )أعاقك القلق  
 في عملك أو فى أنشطتك اليومية؟
  لم يحدث على الإطلاق   إلى حد كبير  
  أ) إلى أي مدى في الأسبوع الماضي:6(
  كان لديك ضعف فى الشهية؟ 
  لم يحدث على الإطلاق   إلى حد كبير  
  ب) إلى أي مدى في الأسبوع الماضي:6(
  أعاقك ضعف الشهية الذي تعاني منه؟ 
  لم يحدث على الإطلاق   إلى حد كبير  
  أ) إلى أي مدى في الأسبوع الماضي:7(
  بسبب مرضك؟(الحزن الشديد) تئاب شعرت بالاك 
  لم يحدث على الإطلاق   إلى حد كبير  
  لم يحدث على الإطلاق   إلى حد كبير    ب) إلى أي مدى في الأسبوع الماضي:7(
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أعاقك الاكتئاب بسبب مرضك في عملك، أنشطتك اليومية و/أو  
 علاقاتك الاجتماعية؟
  ) إلى أي مدى في الأسبوع الماضي:8(
  شعرت بالخوف من احتمال تطور مضاعفات مرض الكبد؟ 
  لم يحدث على الإطلاق   إلى حد كبير  
  أ) إلى أي مدى في الأسبوع الماضي:9(
  )؟صفراءتغير لون جلدك الى الاصفر ( 
  لم يحدث على الإطلاق   إلى حد كبير  
  ب) إلى أي مدى في الأسبوع الماضي:9(
ك في عملك، أنشطتك اليومية و/أو أعاقك اصفرار لون جلد 
 علاقاتك الاجتماعية؟
  لم يحدث على الإطلاق   إلى حد كبير  
)  بسبب أنك تعاني من مرض الكبد فإنك تجد صعوبة في تذكر الأشياء 20(
، على سبيل المثال: الأشياء التي وقعت حديثا،ً وكذلك الأماكن التي تركت 
  . فقت عليهافيها الأشياء والمواعيد التي ات
  الى اى مدى منذ ان اصبت بمرض الكبد اصبحت تنسى) ( 
  لم يحدث على الإطلاق   إلى حد كبير  
  لم يحدث على الإطلاق   إلى حد كبير    بسبب مرض الكبد. (طباعك)) الى اى مدى تغيرت شخصيتك 00(
لمالية ) الى اى مدى يمثل مرض الكبد الذي تعاني منه إعاقة لشئونك ا00(
 (مثال: مصاريف البيت). 
  لم يحدث على الإطلاق   إلى حد كبير  
) الى اى مدى مرض الكبد الذي تعاني منه يجبرك على استغلال وقتك 30(
  (يمنعك من استغلال وقتك)  بطريقة مختلفة عما تريده في الواقع
  لم يحدث على الإطلاق   إلى حد كبير  
) منذ (الجنسيةهتمامك/ رغبتك  للعلاقة الزوجية ) الى اى مدى قل ا 40(
 علمك بانك تعاني من مرض كبدي.
  لم يحدث على الإطلاق   إلى حد كبير  
) منذ الجنسية) الى اى مدى قل نشاطك/ممارستك للعلاقة الزوجية (50(
 علمك بانك تعاني من مرض كبدي
  لم يحدث على الإطلاق   إلى حد كبير  
  ى اعراض اخرى تعانى منها؟هل هناك ا
  --------------------------------------------------------ما هى؟
  ----------------------------------------------شدتها؟ مدىو الى اى 
  -----------------------أعاقتك في عملك، أنشطتك اليومية و/أو علاقاتك الاجتماعية؟ مدىو الى اى 
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